start-ver=1.4
cd-journal=joma
no-vol=27
cd-vols=
no-issue=5
article-no=
start-page=2308
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260228
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Aerobic Exercise Attenuates Epidermal Hyperplasia in an Obesity-Associated Psoriasiform Dermatitis Model
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Obesity is an important risk factor for psoriasis, and clinical studies indicate that exercise interventions can improve disease severity. However, the mechanisms by which exercise influences psoriatic pathogenesis remain insufficiently understood. To investigate the effects of aerobic exercise on obesity-associated psoriasis, wild-type mice were fed a high-fat diet (HFD) for 7 weeks to induce obesity and subsequently underwent moderate-intensity treadmill running for 3 weeks. Psoriasiform dermatitis was induced by daily topical application of imiquimod (IMQ) to the skin for five consecutive days. HFD increased body weight, epididymal fat mass, and serum cholesterol. HFD-fed mice developed more severe IMQ-induced psoriatic skin changes compared with normal diet-fed mice. Treadmill exercise modestly reduced body weight gain and attenuated epidermal hyperplasia in HFD-fed mice. In contrast, inflammatory cytokine expression, including Tnfa, Il17a, and Il23a, showed modest increases in the skin of HFD-fed exercised mice, which did not parallel the improvement in epidermal hyperplasia. Overall, these findings indicate that while obesity exacerbates psoriasiform dermatitis, aerobic exercise ameliorates epidermal hyperplasia in obese mice without corresponding changes in inflammatory cytokine expression in the skin, suggesting that exercise may influence psoriatic skin changes through multiple metabolic and immunological pathways.
en-copyright=
kn-copyright=

en-aut-name=MatsudaYoshihiro
en-aut-sei=Matsuda
en-aut-mei=Yoshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MorizaneShin
en-aut-sei=Morizane
en-aut-mei=Shin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakezakiDaiki
en-aut-sei=Takezaki
en-aut-mei=Daiki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SakamotoYuma
en-aut-sei=Sakamoto
en-aut-mei=Yuma
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=BabaNobuyasu
en-aut-sei=Baba
en-aut-mei=Nobuyasu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=IsekiMasanori
en-aut-sei=Iseki
en-aut-mei=Masanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KawakamiYoshio
en-aut-sei=Kawakami
en-aut-mei=Yoshio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=ShiomiTatsushi
en-aut-sei=Shiomi
en-aut-mei=Tatsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MukaiTomoyuki
en-aut-sei=Mukai
en-aut-mei=Tomoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Immunology and Molecular Genetics, Kawasaki Medical School
kn-affil=

affil-num=5
en-affil=Department of Immunology and Molecular Genetics, Kawasaki Medical School
kn-affil=

affil-num=6
en-affil=Department of Immunology and Molecular Genetics, Kawasaki Medical School
kn-affil=

affil-num=7
en-affil=Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Pathology, Kawasaki Medical School
kn-affil=

affil-num=9
en-affil=Department of Immunology and Molecular Genetics, Kawasaki Medical School
kn-affil=
en-keyword=psoriasis
kn-keyword=psoriasis
en-keyword=obesity
kn-keyword=obesity
en-keyword=aerobic exercise
kn-keyword=aerobic exercise
en-keyword=imiquimod
kn-keyword=imiquimod
en-keyword=high-fat diet
kn-keyword=high-fat diet
END

start-ver=1.4
cd-journal=joma
no-vol=18
cd-vols=
no-issue=7
article-no=
start-page=810
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260326
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effect of Universal Adhesives on Resin Cement?Fiber Post?Core Materials
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This study evaluated eleven resin cements used as core build-up materials by examining the following properties: (a) push-out force between root dentin and the fiber post; (b) pull-out force between the fiber post and the core build-up material; (c) shear bond strength of the resin cement to root dentin; (d) flexural strength of the resin cement; and (e) flexural modulus of elasticity of the resin cement. The purpose of this investigation was to clarify the relationships between recently available universal adhesives, core build-up materials, resin cements, and fiber posts. All experiments were performed at two evaluation periods: after 1 day of water storage (Base) and after 20,000 thermocycles (TC 20k). For the push-out test, simulated post spaces were prepared in single-rooted human premolars. The specimens were sectioned perpendicular to the long axis into 2 mm-thick slices and then subjected to push-out testing to assess the bond strength of the dentin?resin cement?fiber post complex. No significant differences in bonding performance were found between Base and TC 20k. These findings suggest that universal adhesives used for pretreatment of multiple substrates in fiber post cementation can provide not only strong but also durable adhesion over time.
en-copyright=
kn-copyright=

en-aut-name=IrieMasao
en-aut-sei=Irie
en-aut-mei=Masao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OkadaMasahiro
en-aut-sei=Okada
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MaruoYukinori
en-aut-sei=Maruo
en-aut-mei=Yukinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=AkiyamaKenraro
en-aut-sei=Akiyama
en-aut-mei=Kenraro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YoshiharaKumiko
en-aut-sei=Yoshihara
en-aut-mei=Kumiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TsujimotoAkimasa
en-aut-sei=Tsujimoto
en-aut-mei=Akimasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MatsumotoTakuya
en-aut-sei=Matsumoto
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Biomaterials, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Dental Biomaterials, Graduate School of Dentistry, Tohoku University
kn-affil=

affil-num=3
en-affil=Department of Prosthodontics, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Occlusal and Oral Functional Rehabilitation, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Health Research Institute, National Institute of Advanced Industrial Science and Technology
kn-affil=

affil-num=6
en-affil=Department of Operative Dentistry, School of Dentistry, Aichi Gakuin University
kn-affil=

affil-num=7
en-affil=Department of Biomaterials, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=bonding performance
kn-keyword=bonding performance
en-keyword=universal adhesive
kn-keyword=universal adhesive
en-keyword=fiber post
kn-keyword=fiber post
en-keyword=luting materials
kn-keyword=luting materials
en-keyword=root dentin
kn-keyword=root dentin
END

start-ver=1.4
cd-journal=joma
no-vol=27
cd-vols=
no-issue=2
article-no=
start-page=831
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260114
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Porphyromonas gingivalis Vesicles Control Osteoclast?Macrophage Lineage Fate
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Porphyromonas gingivalis (Pg), a keystone pathogen of chronic periodontitis, releases outer membrane vesicles (OMVs) that act as nanoscale vehicles to disseminate virulence factors within periodontal tissues and systemically beyond the oral cavity. Although Pg-OMVs are increasingly recognized as critical mediators of host?pathogen interactions, their effects on the differentiation and function of monocyte?macrophage/osteoclast lineage cells remain unclear. Here, we examined the impact of Pg-OMVs on the differentiation of RAW264.7 monocyte/macrophage-like cells into osteoclasts (OC) and/or macrophages (MΦ) in the presence of receptor activator of nuclear factor-κB ligand (RANKL). OMVs were isolated from Pg W83 and applied to RANKL-primed RAW264.7 cells using three distinct stimulation schedules: (1) simultaneous treatment with Pg-OMVs and RANKL at Day 0; (2) RANKL priming at Day 0 followed by Pg-OMV stimulation at Day 1; and (3) RANKL priming at Day 0 followed by Pg-OMV stimulation at Day 3. In all schedules, cells were cultured for 7 days from the initial RANKL exposure. Remarkably, simultaneous exposure to Pg-OMVs and RANKL (Schedule 1) markedly suppressed osteoclastogenesis (OC-genesis) while promoting M1 macrophage polarization. In contrast, delayed Pg-OMV stimulation of RANKL-primed cells (Schedules 2 and 3) significantly enhanced OC-genesis while reducing M1 polarization. These schedule-dependent effects were consistent with altered expression of osteoclastogenic markers, including dc-stamp, oc-stamp, nfatc1, and acp5. Importantly, a monoclonal antibody against OC-STAMP counteracted the Pg-OMV-induced upregulation of OC-genesis in Schedules 2 and 3. Furthermore, levels of Pg-OMV phagocytosis were inversely correlated with osteoclast formation. Finally, co-stimulation with RANKL and Pg-OMVs (Schedule 1) enhanced macrophage migratory capacity, whereas delayed stimulation with Pg-OMVs (Schedules 2 and 3) did not. Collectively, these findings indicate that Pg-OMVs exert stage-specific effects on the OC/MΦ lineage: stimulation at early stages of RANKL priming suppresses OC-genesis and promotes M1 polarization, whereas stimulation at later stages enhances OC-genesis without inducing M1 differentiation. Thus, Pg-OMVs may critically influence the fate of the OC/MΦ unit in periodontal lesions, contributing to disease progression and tissue destruction.
en-copyright=
kn-copyright=

en-aut-name=LeonElizabeth
en-aut-sei=Leon
en-aut-mei=Elizabeth
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NakamuraShin
en-aut-sei=Nakamura
en-aut-mei=Shin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ShindoSatoru
en-aut-sei=Shindo
en-aut-mei=Satoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=PastoreMaria Rita
en-aut-sei=Pastore
en-aut-mei=Maria Rita
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KumagaiTomoki
en-aut-sei=Kumagai
en-aut-mei=Tomoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HeidariAlireza
en-aut-sei=Heidari
en-aut-mei=Alireza
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=AbdolahiniaElaheh Dalir
en-aut-sei=Abdolahinia
en-aut-mei=Elaheh Dalir
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=UedaTomoya
en-aut-sei=Ueda
en-aut-mei=Tomoya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MemidaTakumi
en-aut-sei=Memida
en-aut-mei=Takumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=Duran-PinedoAna
en-aut-sei=Duran-Pinedo
en-aut-mei=Ana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=Frias-LopezJorge
en-aut-sei=Frias-Lopez
en-aut-mei=Jorge
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=HanXiaozhe
en-aut-sei=Han
en-aut-mei=Xiaozhe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=ChenXin
en-aut-sei=Chen
en-aut-mei=Xin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=HuangShengyuan
en-aut-sei=Huang
en-aut-mei=Shengyuan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=CaoGuoqin
en-aut-sei=Cao
en-aut-mei=Guoqin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=RuizSunniva
en-aut-sei=Ruiz
en-aut-mei=Sunniva
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=PotempaJan
en-aut-sei=Potempa
en-aut-mei=Jan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=KawaiToshihisa
en-aut-sei=Kawai
en-aut-mei=Toshihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

affil-num=1
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=2
en-affil=Department of Periodontics and Endodontics, Division of Dentistry, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=4
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=5
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=6
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=7
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=8
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=9
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=10
en-affil=Department of Oral Biology, College of Dentistry, University of Florida
kn-affil=

affil-num=11
en-affil=Department of Oral Biology, College of Dentistry, University of Florida
kn-affil=

affil-num=12
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=13
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=14
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=15
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=16
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=17
en-affil=Department of Oral Immunology and Infectious Diseases, School of Dentistry, University of Louisville
kn-affil=

affil-num=18
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University, Fort Lauderdale, FL 33314, USA
kn-affil=
en-keyword=Porphyromonas gingivalis
kn-keyword=Porphyromonas gingivalis
en-keyword=outer membrane vesicle
kn-keyword=outer membrane vesicle
en-keyword=periodontitis pathogenesis
kn-keyword=periodontitis pathogenesis
en-keyword=macrophage polarization
kn-keyword=macrophage polarization
en-keyword=osteoclastogenesis
kn-keyword=osteoclastogenesis
en-keyword=OC/MΦ unit
kn-keyword=OC/MΦ unit
END

start-ver=1.4
cd-journal=joma
no-vol=27
cd-vols=
no-issue=7
article-no=
start-page=3143
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260330
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=CXCR2-Dependent Infiltration of Tumor-Associated Neutrophils Is Linked to Enhanced CD8+ T Cell Effector Function and Reduced Lung Metastasis in 4T1 Breast Cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Triple-negative breast cancer (TNBC) is characterized by prominent neutrophil infiltration; however, its significance remains controversial. Here, we investigated the role of neutrophil chemoattractant receptors in TNBC progression and metastasis. In contrast to wild-type (WT), Fpr1?/?, and Fpr2?/? mice, neutrophils were almost completely absent in 4T1 tumors from Cxcr2?/? mice, indicating a dominant role for CXCR2 in the recruitment of tumor-associated neutrophils, leading us to use Cxcr2?/? mice for further studies. Primary tumor growth was comparable between WT and Cxcr2?/? mice, whereas lung metastasis was significantly increased in Cxcr2?/? mice, with reduced expression of inflammatory cytokines, chemokines and cytotoxic molecules, including granzyme B and perforin, in primary tumors and metastatic lungs of Cxcr2?/? mice. In vitro, WT, but not Cxcr2?/?, neutrophils enhanced CD8+ T cell activation, partly via ICAM-1, and directly induced tumor cell death, supporting their anti-tumor function. To assess clinical relevance, transcriptomic data were analyzed. High neutrophil infiltration combined with elevated CXCR2 expression, and to a lesser extent CXCR1 expression, was associated with improved prognosis in patients with basal-like BC that largely overlaps with TNBC. Collectively, these findings suggest that CXCR2-mediated neutrophil recruitment exerts protective, anti-tumor effects and may represent a new prognostic marker for TNBC patients.
en-copyright=
kn-copyright=

en-aut-name=LiTiantian
en-aut-sei=Li
en-aut-mei=Tiantian
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YoshimuraTeizo
en-aut-sei=Yoshimura
en-aut-mei=Teizo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TianMiao
en-aut-sei=Tian
en-aut-mei=Miao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NishidaGakushi
en-aut-sei=Nishida
en-aut-mei=Gakushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=LiChunning
en-aut-sei=Li
en-aut-mei=Chunning
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FujisawaMasayoshi
en-aut-sei=Fujisawa
en-aut-mei=Masayoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=OharaToshiaki
en-aut-sei=Ohara
en-aut-mei=Toshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MatsukawaAkihiro
en-aut-sei=Matsukawa
en-aut-mei=Akihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=8
en-affil=Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=breast cancer
kn-keyword=breast cancer
en-keyword=neutrophils
kn-keyword=neutrophils
en-keyword=CD8+ T cells
kn-keyword=CD8+ T cells
en-keyword=chemokines
kn-keyword=chemokines
en-keyword=chemokine receptors
kn-keyword=chemokine receptors
en-keyword=tumor microenvironment
kn-keyword=tumor microenvironment
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Suppression of salt-enhanced apoplastic flow by salicylic acid in rice
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Salinity enhances apoplastic flow, resulting in an increment of Na+ uptake and a lower K+/Na+ ratio. Salicylic acid (SA) plays an important role in improving salinity tolerance in plants. The effect of exogenous SA on apoplastic flow in salt-treated rice seedlings was studied using an apoplastic tracer, 8-hydroxy-1,3,6-pyrenetrisulphonic acid (PTS) in light. Application of NaCl at 25 mM to the hydroponic solution significantly increased PTS uptake, while 25 mM NaCl did not affect seedling growth. Application of 25 mM NaNO3 increased PTS uptake to the same degree. Salinity significantly increased sodium (Na+) content but had no significant effect on potassium (K+) content, resulting in a lower K+/Na+ ratio. The application of SA at 0.05 mM and 0.1 mM to the hydroponic solution reduced Na-enhanced PTS uptake. Salicylic acid at 0.05 mM and 0.1 mM significantly reduced Na+ content and slightly increased K+ content in the shoots of rice seedlings, resulting in a higher K+/Na+ ratio. However, SA at up to 0.1 mM did not increase SA contents in shoots under salt stress. These results suggest that exogenous SA reduces Na+ uptake by suppressing Na+-enhanced apoplastic flow in rice seedlings. These findings provide insight into modulation of Na+ transport pathways from roots to shoots by SA and may allow us to utilize brackish water for rice cultivation and to improve salt-tolerant rice through suppression of salt-enhanced apoplastic flow by chemicals such as salicylic acid.
en-copyright=
kn-copyright=

en-aut-name=GalibMd. Asadulla Al
en-aut-sei=Galib
en-aut-mei=Md. Asadulla Al
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ZhaoMaoxiang
en-aut-sei=Zhao
en-aut-mei=Maoxiang
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NakamuraToshiyuki
en-aut-sei=Nakamura
en-aut-mei=Toshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakamuraYoshimasa
en-aut-sei=Nakamura
en-aut-mei=Yoshimasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HiraiYoshihiko
en-aut-sei=Hirai
en-aut-mei=Yoshihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NakashimaYoshitaka
en-aut-sei=Nakashima
en-aut-mei=Yoshitaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MunemasaShintaro
en-aut-sei=Munemasa
en-aut-mei=Shintaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MoriIzumi C.
en-aut-sei=Mori
en-aut-mei=Izumi C.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MurataYoshiyuki
en-aut-sei=Murata
en-aut-mei=Yoshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=3
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=4
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=5
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=6
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=7
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=8
en-affil=Institute of Plant Science and Resources, Okayama University
kn-affil=

affil-num=9
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=
en-keyword=Apoplastic flow
kn-keyword=Apoplastic flow
en-keyword=Salicylic acid
kn-keyword=Salicylic acid
en-keyword=Rice
kn-keyword=Rice
en-keyword=Salinity
kn-keyword=Salinity
en-keyword=Trisodium-8-hydroxy-1,3,6-pyrenetrisulphonic acid
kn-keyword=Trisodium-8-hydroxy-1,3,6-pyrenetrisulphonic acid
END

start-ver=1.4
cd-journal=joma
no-vol=14
cd-vols=
no-issue=
article-no=
start-page=30309
end-page=30326
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=2026
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Self-Adaptive Framework for Deploying Machine Learning Systems Without Ground-Truth Data at Runtime
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=In recent years, the practical application of machine learning technology has rapidly progressed, accelerating its adoption across various fields. In this context, studies into the effective operation of machine learning systems in real-world environments have become essential. In actual operational settings, the distribution of input data often changes over time, leading to a significant decline in the predictive performance of models. Additionally, the lack of ground-truth data for test data during operation can sometimes make adaptation through retraining difficult. This study proposes a framework that autonomously adapts to changes in input data distribution, even in environments where ground-truth data for test data is unavailable during operation. This framework analyzes the distribution of input data and selects the appropriate predictive model based on the state of the distribution. To ensure optimal model selection, the framework employs two complementary approaches: 1) dynamically switching between multiple pre-trained models with different feature sets according to environmental changes and 2) building ensemble models based on the distribution of the test data. These approaches enable the framework to autonomously adapt to shifts in data distribution, even in operational settings where ground-truth data is unavailable. Evaluation experiments using both simulated and real-world data assessed the predictive performance of the proposed method through metrics such as R2, RMSE, and MAE. Compared to conventional single model predictions, the proposed method consistently demonstrated higher accuracy. These results indicate that the proposed approach effectively adapts to data distribution shifts in operational environments where ground-truth data is unavailable.
en-copyright=
kn-copyright=

en-aut-name=FurukawaKento
en-aut-sei=Furukawa
en-aut-mei=Kento
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NakagawaHiroyuki
en-aut-sei=Nakagawa
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TsuchiyaTatsuhiro
en-aut-sei=Tsuchiya
en-aut-mei=Tatsuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Graduate School of Information Science and Technology, Osaka University
kn-affil=

affil-num=2
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=3
en-affil=Graduate School of Information Science and Technology, Osaka University
kn-affil=
en-keyword=Self-adaptive systems
kn-keyword=Self-adaptive systems
en-keyword=frameworks
kn-keyword=frameworks
en-keyword=machine learning
kn-keyword=machine learning
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=3-4
article-no=
start-page=456
end-page=439
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Suizidteilnahme und Einwilligung zum Mord
kn-title=自殺関与と同意殺人
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=ShiotaniT.
en-aut-sei=Shiotani
en-aut-mei=T.
kn-aut-name=塩谷毅
kn-aut-sei=塩谷
kn-aut-mei=毅
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学学術研究院社会文化科学学域
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=3-4
article-no=
start-page=494
end-page=457
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=2024 Irish D?il ?ireann Election: An Analysis of NEDS 2024 Data
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=NarihiroT.
en-aut-sei=Narihiro
en-aut-mei=T.
kn-aut-name=成廣孝
kn-aut-sei=成廣
kn-aut-mei=孝
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学学術研究院社会文化科学学域
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=3-4
article-no=
start-page=586
end-page=496
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The Possibility of a Japanese Approach to Standards of Judicial Review
kn-title=日本独自の違憲審査基準論の可能性
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=ItoT.
en-aut-sei=Ito
en-aut-mei=T.
kn-aut-name=伊藤健
kn-aut-sei=伊藤
kn-aut-mei=健
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学学術研究院社会文化科学学域
END

start-ver=1.4
cd-journal=joma
no-vol=16
cd-vols=
no-issue=
article-no=
start-page=15
end-page=29
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260328
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Critical Reading Instruction of Expository Text that Promotes Reflecting: Practice for First-year Student at High School
kn-title=説明的文章の指導における「内省」を促す批判的読み ―高等学校１年生を対象として―
en-subtitle=
kn-subtitle=
en-abstract=　Critical reading is an essential skill at present time and is included in government guidelines for teaching. Although recent research on teaching critical reading has been conducted, there have been criticisms that lack of consideration of content value and understanding context within society. There are also calls for critical reading that focuses on the perspective of “reflect” . Therefore, this paper developed a lesson that encourages students not only critically read the text, but also critically consider (reflect on) their own ideas. As a measure to achieve this, incorporated activities such as comparing two teaching materials that contained multiple social perceptions, exchanging opinions from opposing perspectives, writing an evaluation of the materials, and having the students themselves evaluate their own writing (their own reading). Analysis of the students’ writings shows that, while some students didn’ t reach conscious reflection, about 60% of students’ writings showed changes. And then it suggests that the methods used were effective.
kn-abstract=　批判的読みは，現代では欠かせない能力であり，学習指導要領にも明記されている。近年，批判的読みの指導に関する研究がなされているものの，内容的な価値の検討や社会的な文脈のなかで捉えることが希薄だとする指摘や，「反省性」という観点に着目した批判的読みを求める声もある。そこで，本稿では，文章そのものを批判的に読むだけでなく，自身の持っている考えをも批判的に捉える（内省する）ことを促す授業を開発した。その手立てとして，複数の社会認識が存在する二つの教材の読み比べたうえで，対立する立場からの意見交換を行うことや，教材に対する評価の記述，その記述（自己の読み）を学習者自身が評価するといった活動を取り入れた。学習者の記述の分析からは，意識的な内省に至らなかった学習者も見受けられたものの，約６割の学習者の記述には変容が見られ，用いた手立ては効果があったと推測できることを指摘した。
en-copyright=
kn-copyright=

en-aut-name=SAISHOYumi
en-aut-sei=SAISHO
en-aut-mei=Yumi
kn-aut-name=最相有未
kn-aut-sei=最相
kn-aut-mei=有未
aut-affil-num=1
ORCID=

en-aut-name=IKEDAMasafumi
en-aut-sei=IKEDA
en-aut-mei=Masafumi
kn-aut-name=池田匡史
kn-aut-sei=池田
kn-aut-mei=匡史
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Graduate School of Education (Professional Degree Corse), Okayama University
kn-affil=岡山大学大学院教育学研究科

affil-num=2
en-affil=Faculty of Education, Okayama University
kn-affil=岡山大学学術研究院教育学域
en-keyword=反省性 (reflectiveness)
kn-keyword=反省性 (reflectiveness)
en-keyword=情意的性向 (affective disposition)
kn-keyword=情意的性向 (affective disposition)
en-keyword=複数テクスト (multiple texts)
kn-keyword=複数テクスト (multiple texts)
en-keyword=「現代の国語」 (“Contemporary Japanese Language”)
kn-keyword=「現代の国語」 (“Contemporary Japanese Language”)
en-keyword=生物多様性 (biodiversity)
kn-keyword=生物多様性 (biodiversity)
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=3
article-no=
start-page=84
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260225
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Purpose Immune checkpoint inhibitor (ICI)-based combination therapy is a standard first-line treatment for metastatic renal cell carcinoma (mRCC), with combinations such as nivolumab plus cabozantinib (Nivo?+?Cabo) and pembrolizumab plus lenvatinib (Pem?+?Len) demonstrating favorable oncologic outcomes. However, no direct comparisons between these two regimens have been conducted. This study aimed to compare the safety and oncologic outcomes of Nivo?+?Cabo and Pem?+?Len in patients with mRCC.<br>
Methods This retrospective study included 185 patients with mRCC treated with Nivo?+?Cabo (n?=?81) or Pem?+?Len (n?=?104) between January 2018 and June 2025 across multiple institutions. The primary outcome was a comparison of treatment-related adverse events (TrAEs). Oncologic outcomes, including objective response rate (ORR), progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS), were compared using one-to-one propensity score matching.<br>
Results Any-grade TrAEs occurred in 90% of patients in the Nivo?+?Cabo group and 92% in the Pem?+?Len group (p?=?0.6). Severe TrAEs (grade???3) were more frequent in the Pem?+?Len group (44%) than in the Nivo?+?Cabo group (30%, p?=?0.048). Tyrosine kinase inhibitor dose reduction and treatment discontinuation rates were similar between groups. In the matched cohort (Nivo?+?Cabo: n?=?74; Pem?+?Len: n?=?74), ORRs were comparable (66% vs. 71%, p?=?0.6). With a median follow-up of 17 months, no significant differences were observed in PFS (p?=?0.4), CSS (p?=?0.9), or OS (p?=?0.5).<br>
Conclusions Nivo?+?Cabo and Pem?+?Len demonstrated similar oncologic efficacy as first-line treatments for mRCC. However, Pem?+?Len was associated with more severe TrAEs. Careful toxicity management and shared decision-making are essential when selecting ICI-based combinations.
en-copyright=
kn-copyright=

en-aut-name=YanagisawaTakafumi
en-aut-sei=Yanagisawa
en-aut-mei=Takafumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MoriKeiichiro
en-aut-sei=Mori
en-aut-mei=Keiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KawadaTatsushi
en-aut-sei=Kawada
en-aut-mei=Tatsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KatayamaSatoshi
en-aut-sei=Katayama
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TsujinoTakuya
en-aut-sei=Tsujino
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MaenosonoRyoichi
en-aut-sei=Maenosono
en-aut-mei=Ryoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ToyodaShingo
en-aut-sei=Toyoda
en-aut-mei=Shingo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=NukayaTakuhisa
en-aut-sei=Nukaya
en-aut-mei=Takuhisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MorinakaHirofumi
en-aut-sei=Morinaka
en-aut-mei=Hirofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TamuraKeita
en-aut-sei=Tamura
en-aut-mei=Keita
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=FukuokayaWataru
en-aut-sei=Fukuokaya
en-aut-mei=Wataru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=UrabeFumihiko
en-aut-sei=Urabe
en-aut-mei=Fumihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=MurakamiMasaya
en-aut-sei=Murakami
en-aut-mei=Masaya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=BekkuKensuke
en-aut-sei=Bekku
en-aut-mei=Kensuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=TakaharaKiyoshi
en-aut-sei=Takahara
en-aut-mei=Kiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=FujitaKazutoshi
en-aut-sei=Fujita
en-aut-mei=Kazutoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=AzumaHaruhito
en-aut-sei=Azuma
en-aut-mei=Haruhito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=ArakiMotoo
en-aut-sei=Araki
en-aut-mei=Motoo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=InamotoTeruo
en-aut-sei=Inamoto
en-aut-mei=Teruo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=KomuraKazumasa
en-aut-sei=Komura
en-aut-mei=Kazumasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=KimuraTakahiro
en-aut-sei=Kimura
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

affil-num=1
en-affil=Department of Urology, The Jikei University School of Medicine
kn-affil=

affil-num=2
en-affil=Department of Urology, The Jikei University School of Medicine
kn-affil=

affil-num=3
en-affil=Department of Urology, Comprehensive Cancer Center, Medical University of Vienna
kn-affil=

affil-num=4
en-affil=Department of Urology, Comprehensive Cancer Center, Medical University of Vienna
kn-affil=

affil-num=5
en-affil=Department of Urology, Osaka Medical and Pharmaceutical University
kn-affil=

affil-num=6
en-affil=Department of Urology, Osaka Medical and Pharmaceutical University
kn-affil=

affil-num=7
en-affil=Department of Urology, Faculty of Medicine, Kindai University
kn-affil=

affil-num=8
en-affil=Department of Urology, Fujita-Health University School of Medicine
kn-affil=

affil-num=9
en-affil=Department of Urology, Kawasaki Medical School
kn-affil=

affil-num=10
en-affil=Department of Urology, Hamamatsu Medical University
kn-affil=

affil-num=11
en-affil=Department of Urology, The Jikei University School of Medicine
kn-affil=

affil-num=12
en-affil=Department of Urology, The Jikei University School of Medicine
kn-affil=

affil-num=13
en-affil=Department of Urology, The Jikei University School of Medicine
kn-affil=

affil-num=14
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=15
en-affil=Department of Urology, Fujita-Health University School of Medicine
kn-affil=

affil-num=16
en-affil=Department of Urology, Faculty of Medicine, Kindai University
kn-affil=

affil-num=17
en-affil=Department of Urology, Osaka Medical and Pharmaceutical University
kn-affil=

affil-num=18
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=19
en-affil=Department of Urology, Hamamatsu Medical University
kn-affil=

affil-num=20
en-affil=Department of Urology, Kawasaki Medical School
kn-affil=

affil-num=21
en-affil=Department of Urology, The Jikei University School of Medicine
kn-affil=
en-keyword=Metastatic renal cell carcinoma
kn-keyword=Metastatic renal cell carcinoma
en-keyword=Immune checkpoint inhibitor
kn-keyword=Immune checkpoint inhibitor
en-keyword=Pembrolizumab
kn-keyword=Pembrolizumab
en-keyword=Lenvatinib
kn-keyword=Lenvatinib
en-keyword=Nivolumab
kn-keyword=Nivolumab
en-keyword=Cabozantinib
kn-keyword=Cabozantinib
END

start-ver=1.4
cd-journal=joma
no-vol=15
cd-vols=
no-issue=1
article-no=
start-page=35
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260124
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A case of tubulointerstitial nephritis with infiltration of neutrophils and interleukin-17-positive cells associated with Beh?et’s disease
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Beh?et’s disease (BD) is a non-infectious inflammatory condition characterized by neutrophilic infiltration. In addition to primary symptoms, including oral and genital ulcers, ocular involvement, and skin lesions, BD can also affect various organs. However, renal involvement, particularly in tubulointerstitial nephritis, has rarely been described. Herein, a rare case of acute tubulointerstitial nephritis in a patient clinically diagnosed with BD is reported. The renal lesion presented with other symptoms of BD and fever, and was considered to be BD-related due to the presence of neutrophilic infiltration and its responsiveness to BD-directed therapy. Alterations in T-helper (Th) 1, Th2, and Th17 cytokine profiles are associated with BD activity. Interleukin (IL)-17 plays a central role in neutrophil activation, and recent studies have demonstrated a strong correlation between IL-17A levels and BD activity. In the present case, elevated serum IL-17A levels and infiltration of IL-17A-positive cells into the renal tissue reflected an active phase of BD and a BD-associated renal lesion.
en-copyright=
kn-copyright=

en-aut-name=UchidaNaruhiko
en-aut-sei=Uchida
en-aut-mei=Naruhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TanakaKeiko
en-aut-sei=Tanaka
en-aut-mei=Keiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KubotaNatsuki
en-aut-sei=Kubota
en-aut-mei=Natsuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KatsuyamaTakayuki
en-aut-sei=Katsuyama
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TanabeKatsuyuki
en-aut-sei=Tanabe
en-aut-mei=Katsuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=UchidaHaruhito A.
en-aut-sei=Uchida
en-aut-mei=Haruhito A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=WadaJun
en-aut-sei=Wada
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=Tubulointerstitial nephritis
kn-keyword=Tubulointerstitial nephritis
en-keyword=Beh?et’s disease
kn-keyword=Beh?et’s disease
en-keyword=Neutrophils
kn-keyword=Neutrophils
en-keyword=Interleukin-17
kn-keyword=Interleukin-17
en-keyword=T-helper (Th) 1/Th2/Th17  cytokines
kn-keyword=T-helper (Th) 1/Th2/Th17  cytokines
END

start-ver=1.4
cd-journal=joma
no-vol=16
cd-vols=
no-issue=1
article-no=
start-page=8840
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260317
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Tribolium castaneum with longer duration of tonic immobility have more variations corresponding to the human Parkinson’s disease genomic region
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Parkinson’s disease (PD) is a common neurodegenerative syndrome characterized by the loss of dopaminergic neurons and is also a progressive neurodegenerative disorder that is characterized by dopamine deficiency. We established strains artificially selected for longer and shorter durations of tonic immobility, an antipredator behavior that has received much attention recently, in the red flour beetle, Tribolium castaneum, a model insect species for molecular analyses different from Drosophila melanogaster. Previous studies have shown that the long strains (L-strain) have significantly lower levels of dopamine expression in the brain than the short strains (S-strain) and that they have an abnormal pattern of locomotor activity. Furthermore, previous studies have shown that administering dopamine to L-strain beetles reduces the duration of tonic immobility. Transcriptome analysis of brain and thorax of the L- and S-strains also showed differences in mRNA expression of genes involved in dopamine synthesis and tyrosine metabolism. These results indicate that the phenotype and molecular basis of the L-strain are similar to those of Parkinson’s syndrome symptoms. In order to establish a link between T. castaneum and PD, we compared the DNA sequences of the L- and S-strains to human genes affecting dopaminergic pathways. The DNA comparison revealed many mutated regions in these genes in the L-strain. We discuss the relationship between dopaminergic pathway genes and PD-like phenotypes across humans, Drosophila, and the red flour beetle.
en-copyright=
kn-copyright=

en-aut-name=TanakaKeisuke
en-aut-sei=Tanaka
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SasakiKen
en-aut-sei=Sasaki
en-aut-mei=Ken
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YajimaShunsuke
en-aut-sei=Yajima
en-aut-mei=Shunsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MiyatakeTakahisa
en-aut-sei=Miyatake
en-aut-mei=Takahisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=NODAI Genome Research Center, Tokyo University of Agriculture
kn-affil=

affil-num=2
en-affil=Graduate School of Agriculture, Tamagawa University
kn-affil=

affil-num=3
en-affil=NODAI Genome Research Center, Tokyo University of Agriculture
kn-affil=

affil-num=4
en-affil=Faculty of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=9
cd-vols=
no-issue=3
article-no=
start-page=e72040
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202603
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effects of Overload on Imiquimod‐Induced Psoriasis Model Mice: A Basic Experimental Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background and Aim: Psoriasis is a skin disorder complicated by arthritis and enthesitis. The cytokines interleukin (IL)-17, IL-23, and tumor necrosis factor (TNF)-α are reportedly key effectors of psoriasis. Additionally, gamma delta (γδ) T cells exacerbate inflammation by producing inflammatory cytokines such as IL-17 and TNF-α. However, details regarding the mechanisms linking pathogenesis and mechanical stress remain unclear. This study aimed to investigate the effect of strenuous exercise on the pathology of psoriasis using mouse models of imiquimod (IMQ)-induced psoriasis.<br>
Methods: Twenty mice were randomly assigned to four groups: IMQ???TRED? (control), IMQ???TRED+ (treadmill running mice), IMQ?+?TRED? group (IMQ treated mice), and IMQ?+?TRED+ group (IMQ treated and treadmill running mice). The tissue sections from back skin and thymus were immunostained with antibodies against IL-17, IL-23, and γδ T cells. Shoulder sections were stained using hematoxylin and eosin, and Toluidine Blue and Picrosirius Red. Additionally, the shoulder tissue sections were immunostained with antibodies against TNF-α and matrix metalloproteinase (MMP)-13. Serum cytokine level was measured to evaluate systemic inflammation.<br>
Results: Strenuous exercise exacerbated pathological changes associated with psoriasis, including increased γδ T cell infiltration and upregulated IL-17 and IL-23 expression in the skin, as well as enhanced γδ T cell development and IL-17 expression in the thymus. Although strenuous exercise did not further worsen the modified PASI scores, histological and immunological markers of inflammation were significantly enhanced. Serum levels of TNF-α and IL-17 were significantly elevated in IMQ-induced psoriasis model mice. Moreover, pathological changes induced by strenuous exercise were observed in the enthesis, including angiogenesis and upregulated expression of TNF-α and MMP-13.<br>
Conclusion: This study revealed that strenuous exercise exacerbates pathological changes in IMQ-induced psoriasis model mice.
en-copyright=
kn-copyright=

en-aut-name=FurutaniTomoki
en-aut-sei=Furutani
en-aut-mei=Tomoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SaitoTaichi
en-aut-sei=Saito
en-aut-mei=Taichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=IkedaAsahi
en-aut-sei=Ikeda
en-aut-mei=Asahi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MashimaKenta
en-aut-sei=Mashima
en-aut-mei=Kenta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YukihiroNatsumi
en-aut-sei=Yukihiro
en-aut-mei=Natsumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KusakabeSatoki
en-aut-sei=Kusakabe
en-aut-mei=Satoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NakamichiRyo
en-aut-sei=Nakamichi
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YoshidaAki
en-aut-sei=Yoshida
en-aut-mei=Aki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=NishidaKeiichiro
en-aut-sei=Nishida
en-aut-mei=Keiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=OzakiToshifumi
en-aut-sei=Ozaki
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Orthopaedic Surgery, Section of Medicine, Division of Medicine, Dentistry, and Pharmaceutical Sciences, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Okayama University Medical School Faculty of Medicine
kn-affil=

affil-num=4
en-affil=Okayama University Medical School Faculty of Medicine
kn-affil=

affil-num=5
en-affil=Okayama University Medical School Faculty of Medicine
kn-affil=

affil-num=6
en-affil=Okayama University Medical School Faculty of Medicine Okayama Japan
kn-affil=

affil-num=7
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Locomotive Pain Center, Okayama University Hospital
kn-affil=

affil-num=10
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=
en-keyword=enthesis
kn-keyword=enthesis
en-keyword=psoriasis
kn-keyword=psoriasis
en-keyword=strenuous exercise
kn-keyword=strenuous exercise
END

start-ver=1.4
cd-journal=joma
no-vol=24
cd-vols=
no-issue=1
article-no=
start-page=146
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260115
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=MMP-3 cleavage of Lamin A induces pro-migratory nuclear deformity, nucleophagy, and their autophagic secretion with extracellular vesicles in metastatic cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteinases that cleave a plethora of substrates, including components of the extracellular matrix and cell-surface-associated proteins, as well as intracellular targets. MMPs have also been found in extracellular vesicles (EVs), such as exosomes. MMP-3 promotes tumor growth, epithelial-to-mesenchymal transition, genome instability, migration, invasion, and metastasis of cancer cells, and nuclear MMP-3 controls gene transcription. Intranuclear proteolysis by MMPs may significantly alter cancer progression. However, the nuclear substrates of MMP-3 have not been well investigated. In this study, we performed proteomic analyses to identify the nuclear substrates and EV proteins regulated by MMP-3. While rabidly metastatic colon cancer (LuM1) three-dimensionally cultured tumoroids secreted EVs containing 30 protein types, including Lamin A (LMNA), MMP-3, fibronectin (FN1), HSPA8 (Hsc70), β-actin (ACTB), and vimentin (VIM), CRISPR/Cas9-based knockout of MMP-3 reduced the secretion of these proteins in EVs. Notably, EV-bound cleaved Lamin secretion was confirmed by immunoelectron microscopy. Also, MMP-3 formed proteolytic dimers via its hemopexin-like repeat domains in nuclei. Many nuclear MMP-3-binding proteins, including Lamin A/C, histones, topoisomerases, and hnRNPs, were screened by co-immunoprecipitation followed by proteomics. Proteolytic MMP-3 overexpression generated a C-terminal 30-kDa fragment of Lamin A, whose cleavage site was defined via structural analysis. MMP-3 digestion of Lamin A induced nuclear deformity (atypia) required for cell migration in confined space. The cleaved Lamin A and MMP-3 were transported with autophagosomes (LC3B+), nucleophagosomes, and amphisomes (CD63?+?LC3B+) and co-secreted with EVs. Proteolytic MMP-3 also induced nuclear speckles of Lamin A, suggesting their roles in transcription and splicing. Clinical analysis revealed that high expressions of MMP3 and LMNA were significantly seen in head and neck squamous cell carcinoma (HNSC) than in the other 16 cancer types, and predicted poor prognosis of patients suffering from HNSC, pancreatic, rectum and lung adenocarcinomas at specific stages. Immunohistochemistry revealed that nuclear MMP-3 and cleaved Lamin were significantly higher expressed in stage IV metastatic HNSC cases than in stage I non-metastatic cases. Taken together, MMP3-cleavage of Lamin A induces nuclear deformity, nucleophagy, and their autophagic co-secretion with EVs in metastatic cancer. Also, high expression of MMP-3 and secretion of Lamin A can predict poor prognosis in multiple cancer types at specific stages.
en-copyright=
kn-copyright=

en-aut-name=EguchiTakanori
en-aut-sei=Eguchi
en-aut-mei=Takanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TahaEman A.
en-aut-sei=Taha
en-aut-mei=Eman A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NakanoKeisuke
en-aut-sei=Nakano
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TiwariVikas
en-aut-sei=Tiwari
en-aut-mei=Vikas
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TakebeKatsuki
en-aut-sei=Takebe
en-aut-mei=Katsuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=InoueTomohiro
en-aut-sei=Inoue
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=XingLizi
en-aut-sei=Xing
en-aut-mei=Lizi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=SogawaChiharu
en-aut-sei=Sogawa
en-aut-mei=Chiharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OkamotoKuniaki
en-aut-sei=Okamoto
en-aut-mei=Kuniaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=CalderwoodStuart K.
en-aut-sei=Calderwood
en-aut-mei=Stuart K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Biochemistry, Faculty of Science, Ain Shams University
kn-affil=

affil-num=3
en-affil=Department of Oral Pathology and Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Council of Scientific & Industrial Research-Indian Institute of Toxicological Research
kn-affil=

affil-num=5
en-affil=Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=8
en-affil=Department of Food and Health Sciences, Faculty of Environmental Studies, Hiroshima Institute of Technology
kn-affil=

affil-num=9
en-affil=Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=10
en-affil=Division of Molecular and Cellular Biology, Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School
kn-affil=
en-keyword=Lamin A (LMNA)
kn-keyword=Lamin A (LMNA)
en-keyword=Matrix metalloprotease (MMP)
kn-keyword=Matrix metalloprotease (MMP)
en-keyword=Proteolysis
kn-keyword=Proteolysis
en-keyword=Extracellular vesicle (EV)
kn-keyword=Extracellular vesicle (EV)
en-keyword=Exosome
kn-keyword=Exosome
en-keyword=Autophagy
kn-keyword=Autophagy
en-keyword=Amphisome
kn-keyword=Amphisome
en-keyword=Proteome
kn-keyword=Proteome
en-keyword=Nuclear deformity
kn-keyword=Nuclear deformity
en-keyword=Migration
kn-keyword=Migration
en-keyword=Metastatic cancer
kn-keyword=Metastatic cancer
en-keyword=Head and neck squamous cell carcinoma
kn-keyword=Head and neck squamous cell carcinoma
en-keyword=Colorectal cancer
kn-keyword=Colorectal cancer
END

start-ver=1.4
cd-journal=joma
no-vol=12
cd-vols=
no-issue=1
article-no=
start-page=27
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260203
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Association between the incidence of infusion-related reactions by obinutuzumab and the dose of corticosteroid as premedication: a multicenter retrospective cohort study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Premedication with corticosteroids is recommended for prophylaxis against infusion-related reactions (IRRs) caused by obinutuzumab despite a lack of solid evidence regarding the dose of corticosteroids.<br>
Methods The incidence rates of IRR in the high-dose and low-dose corticosteroid groups were investigated and compared using Student’s t-test.Univariable and multivariable logistic regression analyses were performed on patients to explore the risk of developing IRRs with obinutuzumab.<br>
Results The incidence of IRRs in the high-dose and low-dose corticosteroid groups at the initial administration of obinutuzumab was 27.0% (41/152) and 48.4% (31/64), respectively, indicating that the high-dose group had a lower incidence of IRRs (p?=?0.002). The incidence of IRRs at the initial administration of obinutuzumab was significantly associated with the administration of first-generation histamine 1 receptor antagonist (OR?=?3.31, 95% CI: 1.16?9.47; reference: second-generation histamine 1 receptor antagonist), hydrocortisone (OR?=?7.21, 95% CI: 1.57?33.15; reference: dexamethasone), and methylprednisolone (OR?=?3.99, 95% CI :1.13?14.10; reference: dexamethasone), although no association was found with the lower dose of corticosteroids.<br>
Conclusions Although no association was found between corticosteroid dosage and IRR when considering multiple factors, dexamethasone may be a better option than hydrocortisone or methylprednisolone for preventing IRR. Additionally, second-generation H1-receptor antagonists may be a better option than first-generation drugs. Certain combinations of premedications may influence infusion reaction incidence.
en-copyright=
kn-copyright=

en-aut-name=OhtsuboTatsuya
en-aut-sei=Ohtsubo
en-aut-mei=Tatsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YamamotoKazuhiro
en-aut-sei=Yamamoto
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MatumotoSaori
en-aut-sei=Matumoto
en-aut-mei=Saori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ItoKaori
en-aut-sei=Ito
en-aut-mei=Kaori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SasaYuzuka
en-aut-sei=Sasa
en-aut-mei=Yuzuka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TomishimaKosuke
en-aut-sei=Tomishima
en-aut-mei=Kosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=DoteSatoshi
en-aut-sei=Dote
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MakiharaKatuya
en-aut-sei=Makihara
en-aut-mei=Katuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=WakasugiYoshinori
en-aut-sei=Wakasugi
en-aut-mei=Yoshinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=MitsuieTsutomu
en-aut-sei=Mitsuie
en-aut-mei=Tsutomu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=YamagiwaKouhei
en-aut-sei=Yamagiwa
en-aut-mei=Kouhei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=SatoKazuo
en-aut-sei=Sato
en-aut-mei=Kazuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=HasegawaHiroki
en-aut-sei=Hasegawa
en-aut-mei=Hiroki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=UoshimaNobuhiko
en-aut-sei=Uoshima
en-aut-mei=Nobuhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=KitahiroYumi
en-aut-sei=Kitahiro
en-aut-mei=Yumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=TomoganeKanji
en-aut-sei=Tomogane
en-aut-mei=Kanji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

affil-num=1
en-affil=Department of Pharmacy, Japanese Red Cross Kyoto Daini Hospital
kn-affil=

affil-num=2
en-affil=Department of Integrated Clinical and Basic Pharmaceutical Sciences, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Pharmacy, Japanese Red Cross Osaka Hospital
kn-affil=

affil-num=4
en-affil=Faculty of Pharmacy, Meijo University
kn-affil=

affil-num=5
en-affil=Department of Pharmacy, Kindai University Hospital
kn-affil=

affil-num=6
en-affil=Department of Pharmacy, Japanese Red Cross Kyoto Daiichi Hospital
kn-affil=

affil-num=7
en-affil=Department of Pharmacy, Kyoto-Katsura Hospital
kn-affil=

affil-num=8
en-affil=Department of Pharmacy, Yodogawa Christian Hospital
kn-affil=

affil-num=9
en-affil=Department of Pharmacy, Shiga University of Medical Science Hospital
kn-affil=

affil-num=10
en-affil=Department of Pharmacy, Japanese Red Cross Otsu Hospital
kn-affil=

affil-num=11
en-affil=Department of Pharmacy, Saiseikai Shiga Hospital
kn-affil=

affil-num=12
en-affil=Department of Pharmacy, Japan Baptist Hospital
kn-affil=

affil-num=13
en-affil=Department of Pharmacy, Rakuwakai Otowa Hospital
kn-affil=

affil-num=14
en-affil=Department of Hematology, Japanese Red Cross Kyoto Daini Hospital
kn-affil=

affil-num=15
en-affil=Department of Pharmacy, Kobe University Hospital
kn-affil=

affil-num=16
en-affil=Department of Pharmacy, Japanese Red Cross Kyoto Daini Hospital
kn-affil=
en-keyword=Obinutuzumab
kn-keyword=Obinutuzumab
en-keyword=Infusion-related reaction
kn-keyword=Infusion-related reaction
en-keyword=Premedication
kn-keyword=Premedication
en-keyword=Corticosteroids
kn-keyword=Corticosteroids
en-keyword=Histamine 1 receptor antagonists
kn-keyword=Histamine 1 receptor antagonists
END

start-ver=1.4
cd-journal=joma
no-vol=28
cd-vols=
no-issue=1
article-no=
start-page=32
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260102
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Real-world comparative effectiveness of sarilumab versus Janus kinase inhibitors as monotherapy in rheumatoid arthritis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Sarilumab (SAR), an interleukin-6 receptor inhibitor (IL-6Ri), and Janus kinase inhibitors (JAKi) are approved options for rheumatoid arthritis (RA) when methotrexate (MTX) cannot be used. Real-world evidence for MTX-free monotherapy remains limited.<br>
Methods: We conducted a multicenter retrospective cohort study of RA patients receiving SAR or JAKi as MTX-free monotherapy. To reduce confounding, 1:1 propensity score matching was performed in the overall cohort (n?=?252, 126 per group) and separately within treatment-line strata: Phase 2 first-line biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs: 45 per group), Phase 3 second-line b/tsDMARDs (53 per group), and Phase 3???third-line b/tsDMARDs (47 per group). Outcomes over 12 months included drug retention, change in Clinical Disease Activity Index (CDAI), glucocorticoid (GC) tapering and discontinuation, low disease activity (LDA, CDAI???10), and safety profiles. Predictors of LDA were evaluated with logistic regression. This multicenter real-world.<br>
Results: Across matched strata by prior b/tsDMARDs, retention and CDAI change did not differ significantly between SAR and JAKi through 12 months. When classified by cause, adverse events (AEs)-related discontinuation was higher with JAKi, yielding lower AE-specific retention. Both groups demonstrated GC sparing overtime, with a greater increase in GC discontinuation for SAR than for JAKi in Phase 2. Baseline predictors of achieving LDA at 12 months included higher C-reactive protein (CRP) and platelet count (Plt) in both groups, with additional associations of younger age and lower hemoglobin (Hb) in the SAR. In safety analyses, overall AEs were less frequent with SAR than with JAKi, driven by lower risks of infection including herpes zoster, while other categories were similarly infrequent.<br>
Conclusion: SAR and JAKi showed no statistically significant differences in 12-month retention or disease control in MTX-free monotherapy settings. Higher CRP and Plt with lower Hb, particularly in younger patients, identified better response to SAR and support biomarker guided selection between IL-6Ri and JAKi. In Phase 2, GC discontinuation with SAR suggests a practical strategy to reduce AEs while maintaining efficacy. Prospective studies should validate these findings and define actionable thresholds.
en-copyright=
kn-copyright=

en-aut-name=NozakiYuji
en-aut-sei=Nozaki
en-aut-mei=Yuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KishimotoKazuya
en-aut-sei=Kishimoto
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ItamiTetsu
en-aut-sei=Itami
en-aut-mei=Tetsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TomitaDaisuke
en-aut-sei=Tomita
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=WadaYumiko
en-aut-sei=Wada
en-aut-mei=Yumiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KotaniTakuya
en-aut-sei=Kotani
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TakeuchiTohru
en-aut-sei=Takeuchi
en-aut-mei=Tohru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HidakaToshihiko
en-aut-sei=Hidaka
en-aut-mei=Toshihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HinoShoichi
en-aut-sei=Hino
en-aut-mei=Shoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=MiyamotoToshiaki
en-aut-sei=Miyamoto
en-aut-mei=Toshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=MiyakeHirofumi
en-aut-sei=Miyake
en-aut-mei=Hirofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=HattaKazunari
en-aut-sei=Hatta
en-aut-mei=Kazunari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=MamotoKenji
en-aut-sei=Mamoto
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=YamadaYutaro
en-aut-sei=Yamada
en-aut-mei=Yutaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=OkanoTadashi
en-aut-sei=Okano
en-aut-mei=Tadashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=OkanoTakaichi
en-aut-sei=Okano
en-aut-mei=Takaichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=SaegusaJun
en-aut-sei=Saegusa
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=HoritaMasahiro
en-aut-sei=Horita
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=NishidaKeiichiro
en-aut-sei=Nishida
en-aut-mei=Keiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=KinoshitaKoji
en-aut-sei=Kinoshita
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=RaiShinya
en-aut-sei=Rai
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

affil-num=1
en-affil=Department of Hematology and Rheumatology, Kindai University Faculty of Medicine
kn-affil=

affil-num=2
en-affil=Department of Hematology and Rheumatology, Kindai University Faculty of Medicine
kn-affil=

affil-num=3
en-affil=Department of Hematology and Rheumatology, Kindai University Faculty of Medicine
kn-affil=

affil-num=4
en-affil=Department of Hematology and Rheumatology, Kindai University Faculty of Medicine
kn-affil=

affil-num=5
en-affil=Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University
kn-affil=

affil-num=6
en-affil=Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University
kn-affil=

affil-num=7
en-affil=Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University
kn-affil=

affil-num=8
en-affil=Rheumatology Center, Miyazaki Zenjinkai Hospital
kn-affil=

affil-num=9
en-affil=Department of Rheumatology and Clinical Immunology, Izumi City General Medical Center
kn-affil=

affil-num=10
en-affil=Miyamoto Internal Medicine and Rheumatology Clinic
kn-affil=

affil-num=11
en-affil=Department of General Internal Medicine, Tenri Hospital
kn-affil=

affil-num=12
en-affil=Department of General Internal Medicine, Tenri Hospital
kn-affil=

affil-num=13
en-affil=Department of Orthopaedic Surgery, Graduate School of Medicine, Osaka Metropolitan University
kn-affil=

affil-num=14
en-affil=Center for Senile Degenerative Disorders (CSDD), Osaka Metropolitan University Graduate School of Medicine
kn-affil=

affil-num=15
en-affil=Center for Senile Degenerative Disorders (CSDD), Osaka Metropolitan University Graduate School of Medicine
kn-affil=

affil-num=16
en-affil=Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine
kn-affil=

affil-num=17
en-affil=Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine
kn-affil=

affil-num=18
en-affil=Department of Orthopaedic Surgery, Faculty of Medical Development Field, Okayama University
kn-affil=

affil-num=19
en-affil=Locomotive Pain Center, Faculty of Medical Development Field, Okayama University
kn-affil=

affil-num=20
en-affil=Department of Hematology and Rheumatology, Kindai University Faculty of Medicine
kn-affil=

affil-num=21
en-affil=Department of Hematology and Rheumatology, Kindai University Faculty of Medicine
kn-affil=
en-keyword=Rheumatoid arthritis
kn-keyword=Rheumatoid arthritis
en-keyword=Methotrexate
kn-keyword=Methotrexate
en-keyword=Biological DMARDs
kn-keyword=Biological DMARDs
END

start-ver=1.4
cd-journal=joma
no-vol=12
cd-vols=
no-issue=1
article-no=
start-page=e006392
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202601
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Dental infection is associated with early relapse in patients with ANCA-associated vasculitis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Objectives Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is a systemic autoimmune disease where infections can trigger relapses. Dental infections, being common and associated with systemic inflammation, may play a role in AAV relapse, though their impact remains unclear. We aimed to evaluate the association between severe dental infections and early relapse in patients with AAV.<br>
Methods This retrospective cohort study included patients newly diagnosed with AAV between January 2011 and July 2022. Patients with severe dental infections requiring tooth extraction were placed in the dental infection group, while the remaining patients were assigned to the control group. The primary outcome was defined as either vasculitis relapse or all-cause mortality within 1 year of treatment initiation. Adjusted HRs (aHRs) and 95% CIs were estimated using Cox proportional hazards models.<br>
Results A total of 93 patients were enrolled with a median age of 74 years. 41 patients (44.1%) had severe dental infections in this cohort. Over the 1-year follow-up period, 13 patients experienced a relapse and two died, resulting in a composite event rate of 20.9 per 100 person-years. Dental infection was independently associated with the composite outcome (aHR, 3.78 (95% CI 1.13 to 12.66); p=0.031). Exploratory analysis indicated that composite outcome rates were similar regardless of tooth extraction among patients with dental infections.<br>
Conclusions Severe dental infections were associated with increased risk of early relapse or mortality in AAV. These findings highlight the importance of early dental evaluation in AAV management.
en-copyright=
kn-copyright=

en-aut-name=NawachiShoichi
en-aut-sei=Nawachi
en-aut-mei=Shoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KatsuyamaTakayuki
en-aut-sei=Katsuyama
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MiyawakiYoshia
en-aut-sei=Miyawaki
en-aut-mei=Yoshia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=Sakamoto-TokunagaMoe
en-aut-sei=Sakamoto-Tokunaga
en-aut-mei=Moe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KubotaNatsuki
en-aut-sei=Kubota
en-aut-mei=Natsuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TerajimaYuya
en-aut-sei=Terajima
en-aut-mei=Yuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MatsumotoKazuya
en-aut-sei=Matsumoto
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HiroseKei
en-aut-sei=Hirose
en-aut-mei=Kei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=NakadoiTakato
en-aut-sei=Nakadoi
en-aut-mei=Takato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=Hirata-WatanabeManami
en-aut-sei=Hirata-Watanabe
en-aut-mei=Manami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KatayamaYu
en-aut-sei=Katayama
en-aut-mei=Yu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=HayashiKeigo
en-aut-sei=Hayashi
en-aut-mei=Keigo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=WatanabeHaruki
en-aut-sei=Watanabe
en-aut-mei=Haruki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=KatsuyamaEri
en-aut-sei=Katsuyama
en-aut-mei=Eri
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=Takano-NarazakiMariko
en-aut-sei=Takano-Narazaki
en-aut-mei=Mariko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=TsujiShigetomo
en-aut-sei=Tsuji
en-aut-mei=Shigetomo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=MatsumotoYoshinori
en-aut-sei=Matsumoto
en-aut-mei=Yoshinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=SadaKen-Ei
en-aut-sei=Sada
en-aut-mei=Ken-Ei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=WadaJun
en-aut-sei=Wada
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

affil-num=1
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=12
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=13
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=14
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=15
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=16
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=17
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=18
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=19
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=12
cd-vols=
no-issue=
article-no=
start-page=e79545
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260302
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Prescription Support Practice for Pharmacy Students: Pre-Post Educational Intervention Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: In the field of team-based care, pharmacists are vital for optimizing medication therapy. However, many medical professionals lack the opportunity to learn how to propose prescription changes with precision.<br>
Objective: This study aimed to address this knowledge gap by developing and assessing a new educational program for pharmacy students focused on prescription support and interprofessional collaboration.<br>
Methods: We recruited 191 fifth-year pharmaceutical students during the 2022‐2024 academic years. The program featured a 7-day intensive curriculum that included learning how to assist with prescriptions, analyzing clinical data, and engaging in role-playing exercises. A web-based questionnaire and a paper test were used to evaluate students’ awareness and knowledge both before and after the program. Statistical analyses were performed to verify the significance of changes; we utilized the Wilcoxon signed-rank test for the ordinal data derived from the specific behavioral objectives and 2-tailed paired t tests for the interval data from the knowledge tests. The magnitude of change was quantified using r for Wilcoxon tests and Cohen dz for 2-tailed t tests, with 95% CI calculated to ensure the stability and reliability of the observed results.<br>
Results: Analysis of the primary outcome specific behavioral objectives revealed statistically significant effects across all items (Wilcoxon signed-rank test; P<.001). Effect sizes (r=0.505‐0.835) ranged from moderate to large, with particularly large effects observed in identifying contents issue (r=0.835, 95% CI 0.126-0.330; P<.001). Knowledge test scores showed significant improvement in the following 3 subjects: pharmacology (r=?0.504, 95% CI ?0.215 to 0.127; P<.001), organic chemistry (r=0.254, 95% CI ?0.148 to ?0.193; P=.004), and communication (r=0.221, 95% CI ?0.151 to ?0.190; P=.01). No significant changes were observed in pathology or pharmacokinetics.<br>
Conclusions: This program provides strong evidence that practical, hands-on learning with hospital pharmacists helps improve pharmacy students’ professional skills and optimize pharmaceutical therapies in interprofessional care. By teaching pharmacists to effectively propose prescription changes, the program equips them to become integral members of interprofessional care, ultimately leading to optimized pharmaceutical care for patients.
en-copyright=
kn-copyright=

en-aut-name=AizawaFuka
en-aut-sei=Aizawa
en-aut-mei=Fuka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YagiKenta
en-aut-sei=Yagi
en-aut-mei=Kenta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HigashionnaTsukasa
en-aut-sei=Higashionna
en-aut-mei=Tsukasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HamanoHirofumi
en-aut-sei=Hamano
en-aut-mei=Hirofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TakahashiShimon
en-aut-sei=Takahashi
en-aut-mei=Shimon
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ShinomiyaKazuaki
en-aut-sei=Shinomiya
en-aut-mei=Kazuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=NiimuraTakahiro
en-aut-sei=Niimura
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=GodaMitsuhiro
en-aut-sei=Goda
en-aut-mei=Mitsuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KawadaKei
en-aut-sei=Kawada
en-aut-mei=Kei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=IshizawaKeisuke
en-aut-sei=Ishizawa
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital
kn-affil=

affil-num=2
en-affil=Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University
kn-affil=

affil-num=3
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University
kn-affil=

affil-num=6
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Department of Pharmaceutical Care and Clinical Pharmacy, Tokushima Bunri University
kn-affil=

affil-num=8
en-affil=Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital
kn-affil=

affil-num=9
en-affil=Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University
kn-affil=

affil-num=10
en-affil=Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University
kn-affil=

affil-num=11
en-affil=Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital
kn-affil=
en-keyword=academic detailing
kn-keyword=academic detailing
en-keyword=pharmaceutical clinical practice
kn-keyword=pharmaceutical clinical practice
en-keyword=prescription support
kn-keyword=prescription support
en-keyword=professional education
kn-keyword=professional education
en-keyword=Interprofessional care
kn-keyword=Interprofessional care
END

start-ver=1.4
cd-journal=joma
no-vol=16
cd-vols=
no-issue=2
article-no=
start-page=199
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260128
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Targeting the Gut in Sepsis: Therapeutic Potential of Medical Gases
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Sepsis is a life-threatening condition characterized by a dysregulated host response to infection, often resulting in multiorgan dysfunction. Among affected systems, the gastrointestinal tract plays a central role in sepsis progression by promoting systemic inflammation through impaired barrier function, immune imbalance, and microbiome alterations. Recent research has identified selected medical gases and gasotransmitters as promising therapeutic candidates for preserving gut integrity in sepsis. In particular, hydrogen, carbon monoxide, and hydrogen sulfide exhibit antioxidative, anti-inflammatory, and cytoprotective properties. These gases act through defined molecular pathways, including activation of Nrf2, inhibition of NF-κB, and preservation of tight junction integrity, thereby supporting intestinal barrier function. In addition, they influence immune cell phenotypes and autophagy, with indirect effects on the gut microbiome. Although most supporting evidence derives from preclinical models, translational findings and emerging safety data highlight the potential of gut-targeted gas-based strategies. This review summarizes current mechanistic and translational evidence for gut-protective medical gases in sepsis and discusses their integration into future organ-specific and mechanism-based therapeutic approaches.
en-copyright=
kn-copyright=

en-aut-name=YumotoTetsuya
en-aut-sei=Yumoto
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ObaraTakafumi
en-aut-sei=Obara
en-aut-mei=Takafumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NaitoHiromichi
en-aut-sei=Naito
en-aut-mei=Hiromichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakaoAtsunori
en-aut-sei=Nakao
en-aut-mei=Atsunori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=carbon monoxide
kn-keyword=carbon monoxide
en-keyword=gastrointestinal tract
kn-keyword=gastrointestinal tract
en-keyword=gut
kn-keyword=gut
en-keyword=hydrogen
kn-keyword=hydrogen
en-keyword=hydrogen sulfide
kn-keyword=hydrogen sulfide
en-keyword=sepsis
kn-keyword=sepsis
en-keyword=septic shock
kn-keyword=septic shock
END

start-ver=1.4
cd-journal=joma
no-vol=411
cd-vols=
no-issue=1
article-no=
start-page=22
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251127
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The impact of liver transection depth on surgical difficulty in robotic versus laparoscopic limited liver resection (TAKUMI-5)
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Purpose Although robotic liver resection (RLR) has gained popularity worldwide, limited liver resection remains the mainstay of RLR. This study aimed to investigate the effect of parameters, including liver transection depth (LTD), on surgical difficulty in limited RLR compared with limited laparoscopic liver resection (LLR).<br>
Methods This retrospective study included 105 patients who underwent limited RLR (n?=?56) or LLR (n?=?49) at our institution between January 2018 and December 2024. After comparing outcomes of RLR and LLR, multivariate analyses were performed to examine effect of LTD on surgical difficulty (defined as prolonged operative time). Moreover, outcomes stratified by LTD cut-off values were compared between the groups.<br>
Results Median LTD was similar between groups (RLR vs. LLR: 2.6 vs. 2.6 cm, P?=?0.77). LTD was significantly correlated with operative time for both procedures (RLR, R? = 0.07, P?=?0.042; LLR, R? = 0.08, P?=?0.046). Multivariate analyses demonstrated that LLR (odds ratio, 6.9; P?<?0.001) and LTD (odds ratio, 2.0; P?=?0.004) were significant risk factors of surgical difficulty. Among patients with deeper LTD (>?2.5 cm), the RLR group had significantly shorter operative time (145 vs. 231 min, P?<?0.001), less blood loss (nil vs. 100 mL, P?=?0.006), and a higher rate of textbook outcomes (76.7% vs. 42.3%, P?=?0.01).<br>
Conclusion This study investigated impact of LTD on surgical outcomes in patients who underwent limited RLR compared to those who underwent limited LLR. LTD may be a useful parameter for estimating surgical difficulty in limited RLR. Moreover, robotic surgery may be favorable for deeper and limited liver resections.
en-copyright=
kn-copyright=

en-aut-name=FujiTomokazu
en-aut-sei=Fuji
en-aut-mei=Tomokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TakagiKosei
en-aut-sei=Takagi
en-aut-mei=Kosei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YasuiKazuya
en-aut-sei=Yasui
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ItoAtene
en-aut-sei=Ito
en-aut-mei=Atene
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NishiyamaTakeyoshi
en-aut-sei=Nishiyama
en-aut-mei=Takeyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NagaiYasuo
en-aut-sei=Nagai
en-aut-mei=Yasuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YokoyamaShohei
en-aut-sei=Yokoyama
en-aut-mei=Shohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=3
en-affil=Department of Gastroenterological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=4
en-affil=Department of Gastroenterological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=5
en-affil=Department of Gastroenterological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=6
en-affil=Department of Gastroenterological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=7
en-affil=Department of Gastroenterological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=8
en-affil=Department of Gastroenterological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=
en-keyword=Robotic surgery
kn-keyword=Robotic surgery
en-keyword=Laparoscopic surgery
kn-keyword=Laparoscopic surgery
en-keyword=Limited liver resection
kn-keyword=Limited liver resection
en-keyword=Textbook outcome
kn-keyword=Textbook outcome
END

start-ver=1.4
cd-journal=joma
no-vol=27
cd-vols=
no-issue=10
article-no=
start-page=e70269
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202510
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=D3 lymph node dissection in colon cancer patients aged 90?years and over: Is it justified? A multi‐institutional retrospective study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Aim: The oncological benefit of D3 lymph node dissection (D3 LND) for colon cancer in patients aged ?90?years remains unclear. This study aimed to evaluate the impact of D3 LND on outcomes in this specific, vulnerable population.<br>
Method: This retrospective cohort study evaluated 166 patients aged ?90?years with pathological Stages II?III colon cancer undergoing non-D3 or D3 LND from a multicentre database (2011?2022). Postoperative complications, overall survival and cancer-specific survival were compared between LND groups using propensity score-weighted analyses.<br>
Results: D3 LND group had significantly more females and laparoscopic procedures. Operation time was longer, and blood loss was lower in the D3 LND group. Postoperative complications and severe complications were significantly fewer, and postoperative hospital stay was shorter in the D3 LND group. The number of harvested lymph nodes and distal margin was significantly higher in the D3 group. While unadjusted analysis showed better overall survival with D3 LND (p?<?0.001), adjusted cancer-specific survival showed no significant difference (p?=?0.10). Adjusted mortality risk was significantly higher in the non-D3 group (p?=?0.001).<br>
Conclusion: In nonagenarian colon cancer patients, D3 LND is safe and feasible without increasing complications, but lacks survival benefit. Careful consideration is warranted, and high-quality D2 LND must be consistently ensured when limited surgery is chosen.
en-copyright=
kn-copyright=

en-aut-name=TeraishiFuminori
en-aut-sei=Teraishi
en-aut-mei=Fuminori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TakanagaSatoe
en-aut-sei=Takanaga
en-aut-mei=Satoe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=InadaRyo
en-aut-sei=Inada
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MitsuhashiToshiharu
en-aut-sei=Mitsuhashi
en-aut-mei=Toshiharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=ToshimaToshiaki
en-aut-sei=Toshima
en-aut-mei=Toshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OhtaniTsuyoshi
en-aut-sei=Ohtani
en-aut-mei=Tsuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YoshidaRyosuke
en-aut-sei=Yoshida
en-aut-mei=Ryosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=ShojiRyohei
en-aut-sei=Shoji
en-aut-mei=Ryohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=Setouchi Colorectal Neoplasm Registration study group collaborators
en-aut-sei=Setouchi Colorectal Neoplasm Registration study group collaborators
en-aut-mei=
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=4
en-affil=Center for Innovative Clinical Medicine, Medical Development Field, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Surgery, Kagawa Rosai Hospital
kn-affil=

affil-num=6
en-affil=Department of Surgery, Saiseikai Okayama Hospital
kn-affil=

affil-num=7
en-affil=Department of Surgery, Okayama Rosai Hospital
kn-affil=

affil-num=8
en-affil=Department of Gastroenterological Surgery, Okayama University Hospital
kn-affil=

affil-num=9
en-affil=Department of Gastroenterological Surgery, Okayama University Hospital
kn-affil=

affil-num=10
en-affil=
kn-affil=
en-keyword=colon cancer
kn-keyword=colon cancer
en-keyword=lymph node dissection
kn-keyword=lymph node dissection
en-keyword=nonagenarian
kn-keyword=nonagenarian
en-keyword=postoperative complication
kn-keyword=postoperative complication
en-keyword=survival benefit
kn-keyword=survival benefit
END

start-ver=1.4
cd-journal=joma
no-vol=70
cd-vols=
no-issue=3
article-no=
start-page=329
end-page=336
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251224
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Prevalence and Modifiable Risk Factors of Dementia in People With Down Syndrome: Cross‐Sectional Study of Japan in Collaboration With the Intellectual Diversity for Goodness Research Consortium (INDIGO‐2019)
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: People with Down syndrome (DS) have a strong genetic predisposition to Alzheimer's disease (AD). However, the clinical burden and associated risk factors in diverse, non-Western populations remain less understood. This study aimed to investigate the prevalence of dementia in Japanese adults with DS and to identify modifiable clinical factors associated with dementia.<br>
Methods: This cross-sectional multicentre study surveyed 133 adults with DS (mean age 50.1?years) residing in 45 welfare facilities across Japan in 2019. Dementia was diagnosed by a consensus panel of physicians using established criteria (DSM-5, ICD-10, DC-LD) after comprehensive assessments, including the Japanese version of the Dementia Screening Questionnaire for Individuals with Intellectual Disabilities (DSQIID-J). Logistic regression analysis was performed to identify factors independently associated with dementia.<br>
Results: Forty-six participants (34.6%) were diagnosed with dementia. The prevalence rose sharply with age: 0% in their 30s, 30.8% in their 40s, 31.6% in their 50s and 65.5% in their 60s. After adjusting for covariates, older age, female sex, dyslipidaemia and visual impairment were independently associated with dementia.<br>
Conclusions: This study, the largest of its kind in Asia, confirms a high prevalence of dementia in institutionalized Japanese adults with DS. Crucially, this study is the first to identify dyslipidaemia and visual impairment as independent and potentially modifiable risk factors in this population. These findings highlight tangible targets for clinical interventions aimed at mitigating dementia risk in people with DS.
en-copyright=
kn-copyright=

en-aut-name=TakenoshitaShintaro
en-aut-sei=Takenoshita
en-aut-mei=Shintaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TeradaSeishi
en-aut-sei=Terada
en-aut-mei=Seishi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=InoueTomokazu
en-aut-sei=Inoue
en-aut-mei=Tomokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KurozumiTaku
en-aut-sei=Kurozumi
en-aut-mei=Taku
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TakakiManabu
en-aut-sei=Takaki
en-aut-mei=Manabu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KuwanoRyozo
en-aut-sei=Kuwano
en-aut-mei=Ryozo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=SuemitsuShigeru
en-aut-sei=Suemitsu
en-aut-mei=Shigeru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Neuropsychiatry, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Neuropsychiatry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Asahigawaso Research Institute, Social Welfare Corporation Asahigawaso
kn-affil=

affil-num=4
en-affil=Asahigawaso Research Institute, Social Welfare Corporation Asahigawaso
kn-affil=

affil-num=5
en-affil=Department of Neuropsychiatry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Asahigawaso Research Institute, Social Welfare Corporation Asahigawaso
kn-affil=

affil-num=7
en-affil=Asahigawaso Research Institute, Social Welfare Corporation Asahigawaso
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=52
cd-vols=
no-issue=1
article-no=
start-page=72
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260227
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Preferential sacral fracture sites in fragility fractures of the pelvis type IVb and comparison of internal fixation methods: CT-based morphological mapping and finite element analysis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Purpose Fragility fractures of the pelvis (FFP) classified as Rommens-Hoffman type IVb are associated with spinopelvic dissociation and are generally considered to require surgical intervention. This study aimed to clarify the localization patterns of FFP type IVb and compare the biomechanical stability of different internal fixation techniques.<br>
Methods In this retrospective study, morphologic mapping of sacral fracture lines was performed in 36 patients with FFP type IVb. Based on the mapping results, a finite element (FE) model of FFP type IVb was developed to evaluate the biomechanical stability of ilio-sacral screw (ISS) fixation, trans-sacral screw (TSS) fixation, spinopelvic fixation (SPF; On each side, L5 pedicle screw was connected to two iliac screws with a rod, and the bilateral constructs were linked using a cross-connector.), and bilateral triangular fixation (one TSS at S1 combined with SPF mentioned above) using finite element analysis (FEA).<br>
Results Morphologic mapping showed that the sacrum fracture transverse line tended to pass between the S1-2 transverse lines. Although bilateral triangular fixation and SPF provided the highest stability in both U-type and H-type fractures, a TSS for U-type and two TSSs for H-type also demonstrated comparable levels of stability. ISS-based methods showed greater displacements.<br>
Conclusion TSS-based fixation may provide stability comparable to bilateral triangular fixation and SPF in FFP type IVb, with less invasiveness when anatomy permits. Further studies are needed to optimize treatment strategies for this complex injury.
en-copyright=
kn-copyright=

en-aut-name=NaniwaShuichi
en-aut-sei=Naniwa
en-aut-mei=Shuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YorimitsuMasanori
en-aut-sei=Yorimitsu
en-aut-mei=Masanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HasegawaTsubasa
en-aut-sei=Hasegawa
en-aut-mei=Tsubasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=AndoTeruhiko
en-aut-sei=Ando
en-aut-mei=Teruhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OkudaRyuichiro
en-aut-sei=Okuda
en-aut-mei=Ryuichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FukuokaShiro
en-aut-sei=Fukuoka
en-aut-mei=Shiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MochizukiYusuke
en-aut-sei=Mochizuki
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YamakawaYasuaki
en-aut-sei=Yamakawa
en-aut-mei=Yasuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=NakaharaRyuichi
en-aut-sei=Nakahara
en-aut-mei=Ryuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=HanakawaShiro
en-aut-sei=Hanakawa
en-aut-mei=Shiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=OzakiToshifumi
en-aut-sei=Ozaki
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Orthopaedic Surgery, Section of Medicine, Division of Medicine, Dentistry and Pharmaceutical Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Musculoskeletal Traumatology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University,
kn-affil=

affil-num=3
en-affil=Department of Orthopaedic Surgery, Section of Medicine, Division of Medicine, Dentistry and Pharmaceutical Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Orthopaedic Surgery, Section of Medicine, Division of Medicine, Dentistry and Pharmaceutical Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Orthopaedic Surgery, Section of Medicine, Division of Medicine, Dentistry and Pharmaceutical Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Orthopaedic Surgery, Kagawa Prefectural Central Hospital
kn-affil=

affil-num=7
en-affil=Department of Emergency Health Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=8
en-affil=Department of Orthopaedic Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=9
en-affil=Department of Musculoskeletal Health Promotion, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=10
en-affil=Department of Orthopaedic Surgery, Okayama Saidaiji Hospital
kn-affil=

affil-num=11
en-affil=Department of Orthopedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=Fragility fractures of the pelvis
kn-keyword=Fragility fractures of the pelvis
en-keyword=Spinopelvic dissociation
kn-keyword=Spinopelvic dissociation
en-keyword=Finite element analysis
kn-keyword=Finite element analysis
en-keyword=Internal fixation
kn-keyword=Internal fixation
END

start-ver=1.4
cd-journal=joma
no-vol=27
cd-vols=
no-issue=1
article-no=
start-page=16
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260221
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Compound heterozygosity of a novel missense variant and exonic deletion in hypomyelinating leukodystrophy 15
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Hypomyelinating leukodystrophy 15 (HLD15) results from biallelic pathogenic variants in EPRS1, but exonic deletions have not been reported. We describe a 40-year-old woman with mild intellectual disability, ataxia, dystonia, and MRI showing hypomyelination. Whole-exome sequencing identified a heterozygous missense variant in the prolyl-tRNA synthetase domain of EPRS1 (c.3430 C?>?G; p.Leu1144Val, NM_004446.3), without second variant. Whole-genome sequencing revealed a heterozygous 220-bp deletion spanning exon 15 (c.1743-30_1932del), and segregation analysis confirmed compound heterozygosity. RT-PCR from lymphoblastoid cells demonstrated exon-15 skipping leading to a frameshift (p.Asn582Serfs*10) and nonsense-mediated decay, leaving predominant expression of the paternally inherited missense allele. These findings support loss-of-function for the deletion and classify c.3430 C?>?G as likely pathogenic under ACMG/AMP criteria (PM1, PM2, PM3, PP3). This case represents the first exonic deletion reported in EPRS1. The relatively mild, adult-onset phenotype broadens both mutational and clinical spectra of HLD15 and highlights the importance of structural-variant anal
en-copyright=
kn-copyright=

en-aut-name=MitsutakeAkihiko
en-aut-sei=Mitsutake
en-aut-mei=Akihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MatsukawaTakashi
en-aut-sei=Matsukawa
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OrimoKenta
en-aut-sei=Orimo
en-aut-mei=Kenta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=UedaKunihiro
en-aut-sei=Ueda
en-aut-mei=Kunihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SekiTomonari
en-aut-sei=Seki
en-aut-mei=Tomonari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ShiioYasushi
en-aut-sei=Shiio
en-aut-mei=Yasushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MitsuiJun
en-aut-sei=Mitsui
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=IshiuraHiroyuki
en-aut-sei=Ishiura
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MoriHarushi
en-aut-sei=Mori
en-aut-mei=Harushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TsujiShoji
en-aut-sei=Tsuji
en-aut-mei=Shoji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=TodaTatsushi
en-aut-sei=Toda
en-aut-mei=Tatsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan Department of Neurology
kn-affil=

affil-num=2
en-affil=Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan Department of Neurology
kn-affil=

affil-num=3
en-affil=Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan Department of Neurology
kn-affil=

affil-num=4
en-affil=Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan Department of Neurology
kn-affil=

affil-num=5
en-affil=Department of Neurology, Tokyo Teishin Hospital
kn-affil=

affil-num=6
en-affil=Department of Neurology, Tokyo Teishin Hospital
kn-affil=

affil-num=7
en-affil=Department of Precision Medicine Neurology, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=8
en-affil=Department of Neurology, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=9
en-affil=Department of Radiology, School of Medicine, Jichi Medical University,
kn-affil=

affil-num=10
en-affil=Institute of Medical Genomics, International University of Health and Welfare
kn-affil=

affil-num=11
en-affil=Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan Department of Neurology
kn-affil=
en-keyword=Hypomyelinating leukodystrophy
kn-keyword=Hypomyelinating leukodystrophy
en-keyword=EPRS1
kn-keyword=EPRS1
en-keyword=Structural variant
kn-keyword=Structural variant
en-keyword=Exon deletion
kn-keyword=Exon deletion
en-keyword=Nonsense?mediated decay
kn-keyword=Nonsense?mediated decay
en-keyword=Whole?genome sequencing
kn-keyword=Whole?genome sequencing
END

start-ver=1.4
cd-journal=joma
no-vol=414
cd-vols=
no-issue=
article-no=
start-page=578885
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202605
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Immuno-deficient features of thymoma-associated myasthenia gravis patients with hypogammaglobulinemia: A condition comparable to Good's syndrome
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Good's syndrome (GS) is a rare immunodeficiency disorder associated with thymoma, characterized by hypogammaglobulinemia and recurrent infections; however, its clinical significance in thymoma-associated myasthenia gravis (TAMG) remains unclear. We retrospectively reviewed 30 patients with TAMG admitted to our center between January 2010 and March 2022. We defined GS-like immunodeficiency as serum IgG below the institutional cutoff of 861 mg/dL and a history of two or more infections requiring antimicrobial treatment; 11 patients (36.7%) met this definition. Compared with the remaining patients, the GS-like group had higher incidences of malignancy (45.5% vs. 5.3%, p = 0.016) and autoimmune diseases other than MG (36.4% vs. 5.3%, p = 0.047), lower peripheral lymphocyte counts (median 1100/μL vs. 2200/μL, p = 0.0051), and more frequent airflow obstruction defined by one second to forced vital capacity ratio of less than 70% (60.0% vs. 5.3%, p = 0.0026). Five deaths occurred in the GS-like group, and none in the other; median survival from the first antimicrobial-treated infection was 5.0 years. These findings imply that TAMG patients with GS-like immunodeficiency have a worse prognosis, underscoring the need for close monitoring and timely adjustments of MG management. (189 words).
en-copyright=
kn-copyright=

en-aut-name=NakashimaSaki
en-aut-sei=Nakashima
en-aut-mei=Saki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SakuishiKaori
en-aut-sei=Sakuishi
en-aut-mei=Kaori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HaraManato
en-aut-sei=Hara
en-aut-mei=Manato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KawasakiReiko
en-aut-sei=Kawasaki
en-aut-mei=Reiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KakumotoToshiyuki
en-aut-sei=Kakumoto
en-aut-mei=Toshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=IshiuraHiroyuki
en-aut-sei=Ishiura
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TodaTatsushi
en-aut-sei=Toda
en-aut-mei=Tatsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Neurology, Graduate School of Medicine, the University of Tokyo
kn-affil=

affil-num=2
en-affil=Department of Neurology, Teikyo University Chiba Medical Center
kn-affil=

affil-num=3
en-affil=Department of Neurology, Graduate School of Medicine, the University of Tokyo
kn-affil=

affil-num=4
en-affil=Department of Neurology, Graduate School of Medicine, the University of Tokyo
kn-affil=

affil-num=5
en-affil=Department of Neurology, Graduate School of Medicine, the University of Tokyo
kn-affil=

affil-num=6
en-affil=Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Neurology, Graduate School of Medicine, the University of Tokyo
kn-affil=
en-keyword=Good's syndrome
kn-keyword=Good's syndrome
en-keyword=Thymoma-associated myasthenia gravis
kn-keyword=Thymoma-associated myasthenia gravis
en-keyword=Hypogammaglobulinemia
kn-keyword=Hypogammaglobulinemia
en-keyword=Immunodeficiency
kn-keyword=Immunodeficiency
en-keyword=Prognosis
kn-keyword=Prognosis
END

start-ver=1.4
cd-journal=joma
no-vol=23
cd-vols=
no-issue=1
article-no=
start-page=120
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251124
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Comparison of clinical practices during the transitional and young adult phases between patients with oligoarticular/polyarticular juvenile idiopathic arthritis and those with rheumatoid arthritis in Japan
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Juvenile idiopathic arthritis (JIA) is a chronic inflammatory condition that frequently persists into adulthood, posing long-term challenges in disease control and quality of life. However, clinical management during the transitional and young adult phases remains insufficiently characterized, especially in comparison with adult-onset rheumatoid arthritis (RA). This study aimed to compare disease activity, medication use, and treatment practices between patients with oligoarticular/polyarticular JIA and those with RA, focusing on individuals aged 16?30 years.<br>
Methods Data were derived from two nationwide multicenter databases in Japan?NinJa (National Database of Rheumatic Diseases in Japan) for RA and CoNinJa (a pediatric counterpart of NinJa) for JIA. A total of 176 JIA and 152 RA patients, all aged 16?30 years, were analyzed. Clinical parameters, disease activity indices, and medication profiles were compared using the Mann?Whitney U test and Fisher’s exact test.<br>
Results Compared to RA patients, JIA patients demonstrated significantly lower disease activity (median SDAI 0.6 vs. 2.4) and higher remission rates, particularly Boolean remission (70% vs. 44%) (p?<?0.001). MTX usage was less frequent in JIA (49% vs. 68%, p?<?0.001), whereas biologic use was notably more common (69% vs. 38%, p?<?0.001), with 31% involving off-label prescriptions. Among patients in CDAI remission, biologic monotherapy was observed more frequently in JIA (29% vs. 7%, p?<?0.001). Discontinuation of MTX was most commonly attributed to disease improvement (58%) or gastrointestinal intolerance (nausea, 29%). Subcutaneous tocilizumab, though unapproved for JIA in Japan, had the lowest discontinuation rate (4%), suggesting favorable tolerability.<br>
Conclusions Despite an overlap in age, patients with JIA and RA exhibit distinct disease characteristics and therapeutic patterns. These differences underscore the need to expand approved treatment options for JIA, promote equitable access to biologics, and strengthen transitional care frameworks. Further research is warranted to explore long-term outcomes, reproductive health considerations, and socioeconomic barriers that influence treatment continuity in young adults with childhood-onset arthritis.
en-copyright=
kn-copyright=

en-aut-name=MoriSho
en-aut-sei=Mori
en-aut-mei=Sho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ShabanaKosuke
en-aut-sei=Shabana
en-aut-mei=Kosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MatsuiToshihiro
en-aut-sei=Matsui
en-aut-mei=Toshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NozawaTomo
en-aut-sei=Nozawa
en-aut-mei=Tomo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SugitaYuko
en-aut-sei=Sugita
en-aut-mei=Yuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TomiitaMinako
en-aut-sei=Tomiita
en-aut-mei=Minako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NakagishiYasuo
en-aut-sei=Nakagishi
en-aut-mei=Yasuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YamasakiYuichi
en-aut-sei=Yamasaki
en-aut-mei=Yuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=UmebayashiHiroaki
en-aut-sei=Umebayashi
en-aut-mei=Hiroaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=YashiroMasato
en-aut-sei=Yashiro
en-aut-mei=Masato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=IwataNaomi
en-aut-sei=Iwata
en-aut-mei=Naomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=YasumuraJunko
en-aut-sei=Yasumura
en-aut-mei=Junko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=WakiguchiHiroyuki
en-aut-sei=Wakiguchi
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=YamamotoTakeshi
en-aut-sei=Yamamoto
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=TakezakiShunichiro
en-aut-sei=Takezaki
en-aut-mei=Shunichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=OkuraYuka
en-aut-sei=Okura
en-aut-mei=Yuka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=YokoyamaTadafumi
en-aut-sei=Yokoyama
en-aut-mei=Tadafumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=ShimizuMasaki
en-aut-sei=Shimizu
en-aut-mei=Masaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=HirayamaMasahiro
en-aut-sei=Hirayama
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=TohmaShigeto
en-aut-sei=Tohma
en-aut-mei=Shigeto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=OkamotoNami
en-aut-sei=Okamoto
en-aut-mei=Nami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=MoriMasaaki
en-aut-sei=Mori
en-aut-mei=Masaaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

affil-num=1
en-affil=Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine
kn-affil=

affil-num=2
en-affil=Department of Pediatrics, Osaka Medical and Pharmaceutical University
kn-affil=

affil-num=3
en-affil=Department of Rheumatology Research, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital
kn-affil=

affil-num=4
en-affil=Department of Pediatrics, Graduate School of Medicine, Yokohama City University
kn-affil=

affil-num=5
en-affil=Department of Pediatrics, Osaka Medical and Pharmaceutical University
kn-affil=

affil-num=6
en-affil=Department of Allergy and Rheumatology, Chiba Children’s Hospital
kn-affil=

affil-num=7
en-affil=Department of Pediatric Rheumatology, Hyogo Prefectural Kobe Children’s Hospital
kn-affil=

affil-num=8
en-affil=Department of Pediatrics, Kagoshima University Hospital
kn-affil=

affil-num=9
en-affil=Department of General Pediatrics, Miyagi Children’s Hospital
kn-affil=

affil-num=10
en-affil=Department of Pediatrics, Okayama University Hospital
kn-affil=

affil-num=11
en-affil=Department of Infection and Immunology, Allergy and Immunology Center, Aichi Children’s Health and Medical Center
kn-affil=

affil-num=12
en-affil=Department of Pediatrics, Hiroshima University Graduate School of Biomedical and Health Sciences
kn-affil=

affil-num=13
en-affil=Department of Pediatrics, Yamaguchi University Graduate School of Medicine
kn-affil=

affil-num=14
en-affil=Department of Pediatrics, Chiba University Graduate School of Medicine
kn-affil=

affil-num=15
en-affil=Department of Pediatrics, Faculty of Medicinea and Graduate School of Medicine, Hokkaido University
kn-affil=

affil-num=16
en-affil=Center for Pediatric Allergy and Rheumatology, KKR Sapporo Medical Center
kn-affil=

affil-num=17
en-affil=Department of Pediatrics, Kanazawa University
kn-affil=

affil-num=18
en-affil=Department of Pediatrics, Perinatal and Maternal Medicine, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo
kn-affil=

affil-num=19
en-affil=Department of Pediatrics, Mie University Graduate School of Medicine
kn-affil=

affil-num=20
en-affil=Department of Rheumatology, National Hospital Organization Tokyo National Hospital
kn-affil=

affil-num=21
en-affil=Department of Pediatrics, Osaka Medical and Pharmaceutical University
kn-affil=

affil-num=22
en-affil=Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine
kn-affil=
en-keyword=Juvenile idiopathic arthritis
kn-keyword=Juvenile idiopathic arthritis
en-keyword=Rheumatoid arthritis
kn-keyword=Rheumatoid arthritis
en-keyword=Disease activity
kn-keyword=Disease activity
en-keyword=Biologics
kn-keyword=Biologics
en-keyword=Methotrexate
kn-keyword=Methotrexate
END

start-ver=1.4
cd-journal=joma
no-vol=7
cd-vols=
no-issue=2
article-no=
start-page=e70170
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Safety and efficacy of Rez?m water vapour energy therapy in BPH patients receiving antithrombotic therapy: A Japanese single‐centre experience
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Objectives: The objective of this study is to evaluate the safety and efficacy of Rez?m water vapour energy therapy (WAVE) in Japanese patients with benign prostatic hyperplasia (BPH) continuing antithrombotic therapy and to validate the Okayama University Modified Clavien-Dindo classification (OU-mCD) for perioperative hematuria.<br>
Patients and Methods: We retrospectively analysed 80 consecutive patients who underwent WAVE from August 2023 to July 2024, including 37 (46.2%) continuing antithrombotic therapy perioperatively. Hematuria within 30?days was graded using conventional Clavien-Dindo classification and the OU-mCD, a novel classification focusing on intervention necessity. We assessed clinically significant hematuria (Grade ? Ib), catheter-free rate, prostate volume reduction and haemoglobin change.<br>
Results: Clinically significant hematuria occurred in 21.6% (8/37) of patients continuing antithrombotic therapy versus 4.7% (2/43) without (p?=?0.038). All 10 Grade ? Ib cases occurred during hospitalization with the catheter in place and were managed conservatively with continuous bladder irrigation (median 1 day); none required transfusion or surgical reintervention. Only one patient required temporary drug discontinuation. Treatment efficacy did not differ by antithrombotic status: 86.2% achieved PVR?<?50?ml with 44% mean prostate volume reduction. Multivariate analysis identified antithrombotic therapy as the sole independent risk factor for Grade ? Ib hematuria (OR 5.46, 95% CI 1.06?28.16, p?=?0.042).<br>
Conclusion: WAVE can be safely performed with continued antithrombotic therapy. Whereas Grade ?Ib hematuria occurred in 25% of antiplatelet/anticoagulant users (vs. 5% without), 75% had no significant bleeding, and all complications were managed conservatively without transfusion. The OU-mCD provides precise complication stratification. These findings suggest outpatient procedures may be feasible with appropriate patient selection.
en-copyright=
kn-copyright=

en-aut-name=MoriwakeTakatoshi
en-aut-sei=Moriwake
en-aut-mei=Takatoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TominagaYusuke
en-aut-sei=Tominaga
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KatayamaSatoshi
en-aut-sei=Katayama
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KakuHaruki
en-aut-sei=Kaku
en-aut-mei=Haruki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TsuboiIchiro
en-aut-sei=Tsuboi
en-aut-mei=Ichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YoshinagaKasumi
en-aut-sei=Yoshinaga
en-aut-mei=Kasumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YamanoiTomoaki
en-aut-sei=Yamanoi
en-aut-mei=Tomoaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KawadaTatsushi
en-aut-sei=Kawada
en-aut-mei=Tatsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=SadahiraTakuya
en-aut-sei=Sadahira
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=IwataTakehiro
en-aut-sei=Iwata
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=NishimuraShingo
en-aut-sei=Nishimura
en-aut-mei=Shingo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=BekkuKensuke
en-aut-sei=Bekku
en-aut-mei=Kensuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=KatayamaYasuhiro
en-aut-sei=Katayama
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=ArakiMotoo
en-aut-sei=Araki
en-aut-mei=Motoo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

affil-num=1
en-affil=Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=8
en-affil=Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=9
en-affil=Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=10
en-affil=Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=11
en-affil=Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=12
en-affil=Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=13
en-affil=Department of Urology, Okamura Isshindo Hospital
kn-affil=

affil-num=14
en-affil=Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=benign prostatic hyperplasia
kn-keyword=benign prostatic hyperplasia
en-keyword=hematuriaantithrombotic therapy
kn-keyword=hematuriaantithrombotic therapy
en-keyword=Japanese
kn-keyword=Japanese
en-keyword=OU-mCD
kn-keyword=OU-mCD
en-keyword=water vapour energy therapy
kn-keyword=water vapour energy therapy
END

start-ver=1.4
cd-journal=joma
no-vol=8
cd-vols=
no-issue=11
article-no=
start-page=e2543107
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251112
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non?Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Importance  Brain metastases reduce overall survival rates of patients with non?small cell lung cancer (NSCLC); patients with epidermal growth factor receptor 2 (ERBB2 [formerly HER2])?mutant NSCLC are more likely to have baseline brain metastases. Trastuzumab deruxtecan (T-DXd) is an approved ERBB2-directed treatment for previously treated unresectable or metastatic ERBB2-mutant NSCLC.<br>
Objective  To assess the clinical effectiveness and safety of T-DXd 5.4 mg/kg and 6.4 mg/kg doses in patients with previously treated ERBB2-mutant metastatic NSCLC with or without untreated or previously treated stable brain metastases.<br>
Design, Setting, and Participants  This post hoc secondary analysis pooled patients from the DESTINY-Lung01 (data cutoff date: December 3, 2021) and DESTINY-Lung02 (data cutoff date: December 23, 2022) clinical trials by T-DXd dose (5.4 mg/kg and 6.4 mg/kg). DESTINY-Lung01 was a multicenter, open-label, 2-cohort, nonrandomized phase 2 study, while DESTINY-Lung02 was a dose-blinded, multicenter, 2-cohort, randomized phase 2 study. Participants had a previously treated ERBB2-mutant metastatic NSCLC with or without untreated or previously treated stable brain metastases at baseline. All statistical analyses were performed from April 2023 to October 2024.<br>
Intervention  Patients received a T-DXd dose of either 5.4 mg/kg or 6.4 mg/kg intravenously every 3 weeks.<br>
Main Outcome and Measure  Systemic and intracranial effectiveness by blinded independent central review using RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1, sites of progression, and safety.<br>
Results  This analysis included 102 patients in the T-DXd 5.4-mg/kg dose group (65 females [64%]; median [range] age, 57.5 [37.0-83.0] years and 59.5 [30.0-79.0] years in patients with and without brain metastases, respectively) and 141 patients in the T-DXd 6.4-mg/kg dose group (94 females [67%]; median [range] age, 62.5 [29.0-88.0] years and 59.0 [27.0-83.0] years in patients with and without brain metastases, respectively). In each group, 31% (32 of 102) and 38% (54 of 141) of patients, respectively, had baseline brain metastases and 53% (17 of 32) and 44% (24 of 54), respectively, received prior brain metastasis treatment. In patients with and without brain metastases, systemic confirmed objective response rates (ORRs) were 47% (15 of 32; 95% CI, 29%-65%) and 50% (35 of 70; 95% CI, 38%-62%), respectively, with the T-DXd 5.4-mg/kg dose, and 50% (27 of 54; 95% CI, 36%-64%) and 59% (51 of 87; 95% CI, 48%-69%) with the T-DXd 6.4-mg/kg dose. Median progression-free survival was 7.1 (95% CI, 5.5-9.7) months in the T-DXd 5.4-mg/kg dose group and 7.1 (95% CI, 4.5-9.6) months in the T-DXd 6.4-mg/kg dose group of patients with baseline brain metastases. Among patients with measurable baseline brain metastases, intracranial confirmed ORRs were 50% (7 of 14; 95% CI, 23%-77%) with the T-DXd 5.4-mg/kg dose and 30% (9 of 30; 95% CI, 15%-49%) with the T-DXd 6.4-mg/kg dose. At both doses, the safety profile of T-DXd was generally manageable, regardless of baseline brain metastases, favoring the T-DXd 5.4 mg/kg dose.<br>
Conclusions and Relevance  In this secondary analysis, T-DXd at the approved dose of 5.4 mg/kg showed antitumor activity in patients with previously treated ERBB2-mutant metastatic NSCLC with or without brain metastases. This finding supports T-DXd 5.4 mg/kg use in this population.
en-copyright=
kn-copyright=

en-aut-name=J?nnePasi A.
en-aut-sei=J?nne
en-aut-mei=Pasi A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=PlanchardDavid
en-aut-sei=Planchard
en-aut-mei=David
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=GotoKoichi
en-aut-sei=Goto
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SmitEgbert F.
en-aut-sei=Smit
en-aut-mei=Egbert F.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=de LangenAdrianus Johannes
en-aut-sei=de Langen
en-aut-mei=Adrianus Johannes
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=GotoYasushi
en-aut-sei=Goto
en-aut-mei=Yasushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NinomiyaKiichiro
en-aut-sei=Ninomiya
en-aut-mei=Kiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KuboToshio
en-aut-sei=Kubo
en-aut-mei=Toshio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=P?rolMaurice
en-aut-sei=P?rol
en-aut-mei=Maurice
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=FelipEnriqueta
en-aut-sei=Felip
en-aut-mei=Enriqueta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=HayashiHidetoshi
en-aut-sei=Hayashi
en-aut-mei=Hidetoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=NakagawaKazuhiko
en-aut-sei=Nakagawa
en-aut-mei=Kazuhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=ShimizuJunichi
en-aut-sei=Shimizu
en-aut-mei=Junichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=NagasakaMisako
en-aut-sei=Nagasaka
en-aut-mei=Misako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=PereiraKaline
en-aut-sei=Pereira
en-aut-mei=Kaline
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=TaguchiAyumi
en-aut-sei=Taguchi
en-aut-mei=Ayumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=AliAhmed
en-aut-sei=Ali
en-aut-mei=Ahmed
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=KarnoubMaha
en-aut-sei=Karnoub
en-aut-mei=Maha
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=YonemochiRie
en-aut-sei=Yonemochi
en-aut-mei=Rie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=LeungDavid
en-aut-sei=Leung
en-aut-mei=David
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=LiBob T.
en-aut-sei=Li
en-aut-mei=Bob T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

affil-num=1
en-affil=Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute
kn-affil=

affil-num=2
en-affil=Department of Medical Oncology, Thoracic Cancer Group, Gustave Roussy, Medical Oncology
kn-affil=

affil-num=3
en-affil=Department of Thoracic Oncology, Nation Cancer Center Hospital East
kn-affil=

affil-num=4
en-affil=Department of Pulmonary Diseases, Leiden University Medical Center
kn-affil=

affil-num=5
en-affil=Department of Thoracic Oncology, Netherlands Cancer Institute
kn-affil=

affil-num=6
en-affil=Department of Thoracic Oncology, National Cancer Center Hospital
kn-affil=

affil-num=7
en-affil=Center for Comprehensive Genomic Medicine, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Center for Clinical Oncology, Okayama University Hospital
kn-affil=

affil-num=9
en-affil=Department of Medical Oncology, Centre L?on B?rard
kn-affil=

affil-num=10
en-affil=Department of Medical Oncology, Vall d’Hebron University and Vall d’Hebron Institute of Oncology
kn-affil=

affil-num=11
en-affil=Department of Medical Oncology, Kindai University Faculty of Medicine
kn-affil=

affil-num=12
en-affil=Department of Medical Oncology, Kindai University Faculty of Medicine
kn-affil=

affil-num=13
en-affil=Department of Thoracic Oncology, Aichi Cancer Center
kn-affil=

affil-num=14
en-affil=Division of Hematology-Oncology, Department of Medicine, University of California Irvine
kn-affil=

affil-num=15
en-affil=Daiichi Sankyo Inc
kn-affil=

affil-num=16
en-affil=Daiichi Sankyo Co Ltd
kn-affil=

affil-num=17
en-affil=Daiichi Sankyo Europe GmbH
kn-affil=

affil-num=18
en-affil=Daiichi Sankyo Inc
kn-affil=

affil-num=19
en-affil=Daiichi Sankyo Inc
kn-affil=

affil-num=20
en-affil=Daiichi Sankyo Inc
kn-affil=

affil-num=21
en-affil=Thoracic Oncology and Early Drug Development Service, Global Research Program, Memorial Sloan Kettering Cancer Center
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=20
cd-vols=
no-issue=12
article-no=
start-page=1814
end-page=1828
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202512
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02?A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Introduction: Trastuzumab deruxtecan (T-DXd) demonstrated strong and durable responses in patients with previously treated HER2 (ERBB2) mutant (HER2m) metastatic NSCLC (mNSCLC) in the DESTINY-Lung02 primary analysis (December 23, 2022, data cutoff). This final analysis evaluated T-DXd efficacy and safety after 8 additional months of follow-up, including clinically relevant subgroups and patient-reported outcomes.<br>
Methods: DESTINY-Lung02 was a randomized, dose-blinded, multicenter, phase 2 trial. Patients with previously treated HER2m mNSCLC were randomized 2:1 to receive T-DXd 5.4 or 6.4 mg/kg once every 3 weeks. Primary end point was confirmed objective response rate by blinded independent central review.<br>
Results: As of August 25, 2023, 102 and 50 patients had received T-DXd 5.4 or 6.4 mg/kg, respectively. Median follow-up (Q1?Q3) was 15.8 (8.2?20.7) months and 16.5 (9.4?20.8) months, respectively. Confirmed objective response rate (95% confidence interval) was 50.0% (51/102; 39.9%?60.1%) and 56.0% (28/50; 41.3%?70.0%), respectively. Safety profile was acceptable and generally manageable. Accordingly, median treatment duration (Q1?Q3) was 7.7 (3.7?14.4) months and 8.3 (2.8?13.1) months; drug-related grade 3 or higher treatment-emergent adverse events occurred in 39.6% (40/101) and 60.0% (30/50), with nausea most common (67.3% [68/101], 82.0% [41/50]). Adjudicated drug-related interstitial lung disease occurred in 14.9% (15/101) and 32.0% (16/50), mostly grade 1 or 2 with one grade 5 in each arm. Health-related quality of life was preserved for the duration of T-DXd treatment while sample size was sufficient for analysis, with no adverse effects on health-related quality of life observed at either dose.<br>
Conclusions: T-DXd demonstrated strong and durable responses at both doses, with no clinically significant changes in toxicity. The approved 5.4-mg/kg dose demonstrated a more favorable benefit-risk profile, including lower adjudicated drug-related interstitial lung disease incidence.<br>
ClinicalTrials.gov identifier: NCT04644237
en-copyright=
kn-copyright=

en-aut-name=J?nnePasi A.
en-aut-sei=J?nne
en-aut-mei=Pasi A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=GotoYasushi
en-aut-sei=Goto
en-aut-mei=Yasushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KuboToshio
en-aut-sei=Kubo
en-aut-mei=Toshio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NinomiyaKiichiro
en-aut-sei=Ninomiya
en-aut-mei=Kiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KimSang-We
en-aut-sei=Kim
en-aut-mei=Sang-We
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=PlanchardDavid
en-aut-sei=Planchard
en-aut-mei=David
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=AhnMyung-Ju
en-aut-sei=Ahn
en-aut-mei=Myung-Ju
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=SmitEgbert
en-aut-sei=Smit
en-aut-mei=Egbert
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=Johannes de LangenAdrianus
en-aut-sei=Johannes de Langen
en-aut-mei=Adrianus
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=P?rolMaurice
en-aut-sei=P?rol
en-aut-mei=Maurice
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=Pons-TostivintElvire
en-aut-sei=Pons-Tostivint
en-aut-mei=Elvire
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=NovelloSilvia
en-aut-sei=Novello
en-aut-mei=Silvia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=HayashiHidetoshi
en-aut-sei=Hayashi
en-aut-mei=Hidetoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=ShimizuJunichi
en-aut-sei=Shimizu
en-aut-mei=Junichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=KimDong-Wan
en-aut-sei=Kim
en-aut-mei=Dong-Wan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=PereiraKaline
en-aut-sei=Pereira
en-aut-mei=Kaline
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=ChengFu-Chih
en-aut-sei=Cheng
en-aut-mei=Fu-Chih
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=TaguchiAyumi
en-aut-sei=Taguchi
en-aut-mei=Ayumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=ChengYingkai
en-aut-sei=Cheng
en-aut-mei=Yingkai
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=DuntonKyle
en-aut-sei=Dunton
en-aut-mei=Kyle
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=AliAhmed
en-aut-sei=Ali
en-aut-mei=Ahmed
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=GotoKoichi
en-aut-sei=Goto
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

affil-num=1
en-affil=Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute
kn-affil=

affil-num=2
en-affil=Department of Thoracic Oncology, National Cancer Central Hospital
kn-affil=

affil-num=3
en-affil=Center for Clinical Oncology, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Center for Comprehensive Genomic Medicine, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Oncology Department, Asan Medical Center, Seoul, and University of Ulsan College of Medicine, Ulsan
kn-affil=

affil-num=6
en-affil=Department of Medical Oncology, Thoracic Cancer Group, Gustave Roussy, and Faculty of Medicine, Paris-Saclay University
kn-affil=

affil-num=7
en-affil=Department of Hematology and Oncology, Samsung Medical Center Sungkyunkwan, and University School of Medicine
kn-affil=

affil-num=8
en-affil=Department of Pulmonary Diseases, Leiden University Medical Center
kn-affil=

affil-num=9
en-affil=Department of Thoracic Oncology, Netherlands Cancer Institute
kn-affil=

affil-num=10
en-affil=Department of Medical Oncology, L?on Berard Centre
kn-affil=

affil-num=11
en-affil=Centre Hospitalier Universitaire Nantes, Nantes University
kn-affil=

affil-num=12
en-affil=Department of Oncology, University of Turin, Turin, and Azienda Ospedaliero-Universitaria San Luigi Gonzaga
kn-affil=

affil-num=13
en-affil=Department of Medical Oncology, Kindai University Hospital
kn-affil=

affil-num=14
en-affil=Department of Thoracic Oncology, Aichi Cancer Center Hospital
kn-affil=

affil-num=15
en-affil=Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Hospital
kn-affil=

affil-num=16
en-affil=Daiichi Sankyo
kn-affil=

affil-num=17
en-affil=Daiichi Sankyo
kn-affil=

affil-num=18
en-affil=Daiichi Sankyo
kn-affil=

affil-num=19
en-affil=Daiichi Sankyo
kn-affil=

affil-num=20
en-affil=Daiichi Sankyo UK
kn-affil=

affil-num=21
en-affil=Daiichi Sankyo Europe GmbH
kn-affil=

affil-num=22
en-affil=Department of Thoracic Oncology, National Cancer Center Hospital East
kn-affil=
en-keyword=HER2-directed therapy
kn-keyword=HER2-directed therapy
en-keyword=HER2-mutant
kn-keyword=HER2-mutant
en-keyword=HER2-targeted
kn-keyword=HER2-targeted
en-keyword=Non?small cell lung cancer
kn-keyword=Non?small cell lung cancer
en-keyword=Trastuzumab deruxtecan
kn-keyword=Trastuzumab deruxtecan
END

start-ver=1.4
cd-journal=joma
no-vol=88
cd-vols=
no-issue=5
article-no=
start-page=1003
end-page=1015
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251222
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Claudin-18 expression in gastric type adenocarcinoma and HPV-associated adenocarcinoma of the uterine cervix
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Aims: Claudin-18 (CLDN18) is both a marker for the gastric phenotype and a therapeutic target. However, little is known about its immunoexpression in endocervical adenocarcinomas (ECAs), particularly as detected using the clone 43-14A antibody, or about the gene expression of its isoforms in ECAs.<br>
Methods and results: We examined CLDN18, HIK1083, p16 and Rb expression by immunohistochemistry and high-risk human papillomavirus (HR-HPV) mRNA by in situ hybridization (ISH) in 121 ECAs, including 35 HPV-independent adenocarcinomas (gastric type [GAS], n?=?24; non-GAS, n?=?11) and 86 HPV-associated ECAs. We also analysed mRNA expression of the CLDN18.1 (lung type) and CLDN18.2 (gastric type) isoforms by quantitative polymerase chain reaction (qPCR) in selected cases. CLDN18 positivity was detected in 8/24 (33%) GASs, 0/11 (0%) non-GASs and 2/86 (2%) HPV-associated ECAs, with positivity defined as staining in ?75% of tumour cells, as in gastric cancer. When a 5% cut-off was used, CLDN18 positivity was detected in 22/24 (92%) GASs, 0/11 (0%) non-GASs and 6/86 (7%) HPV-associated ECAs; CLDN18 expression was thus significantly associated with GAS histology (P?<?0.0001). Among the 6 cases of HPV-associated ECAs with CLDN18 expression (ranging from 5% to 80%), the histological patterns included a mix of usual and mucinous features in 4 cases, pure usual type in 1 and villoglandular variant in 1. Otherwise features such as p16 overexpression and the Rb partial loss pattern were consistent with those of HPV-associated ECAs. Six of 22 (27%) CLDN18-positive GASs were also positive for p16, but their other features?such as CLDN18 expression and the Rb preserved pattern?were the same as in p16 negative GASs. Expression of CLDN18.2 mRNA but not CLDN18.1 mRNA was confirmed in both GASs and HPV-associated ECAs.<br>
Conclusions: CLDN18 (43-14A) emerged as a potential diagnostic and therapeutic marker for GAS. A minor subset of HPV-associated ECAs also can be immunoreactive for CLDN18 and express CLDN18.2 mRNA, suggesting divergent gastric phenotypic differentiation. The caution is that GAS and HPV-associated ECAs can share overlapping histological features and similar expression of CLDN18 and p16.
en-copyright=
kn-copyright=

en-aut-name=YasutakeNobuko
en-aut-sei=Yasutake
en-aut-mei=Nobuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YokawaYuki
en-aut-sei=Yokawa
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TanakaTakehiro
en-aut-sei=Tanaka
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MishimaRiri
en-aut-sei=Mishima
en-aut-mei=Riri
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KomamizuMisato
en-aut-sei=Komamizu
en-aut-mei=Misato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KugaRyosuke
en-aut-sei=Kuga
en-aut-mei=Ryosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=JiromaruRina
en-aut-sei=Jiromaru
en-aut-mei=Rina
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KawatokoShinichiro
en-aut-sei=Kawatoko
en-aut-mei=Shinichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=SonodaKenzo
en-aut-sei=Sonoda
en-aut-mei=Kenzo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=YahataHideaki
en-aut-sei=Yahata
en-aut-mei=Hideaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KatoKiyoko
en-aut-sei=Kato
en-aut-mei=Kiyoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=OdaYoshinao
en-aut-sei=Oda
en-aut-mei=Yoshinao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=YamamotoHidetaka
en-aut-sei=Yamamoto
en-aut-mei=Hidetaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

affil-num=1
en-affil=Department of Gynecology and Obstetrics, Graduate School of Medical Sciences, Kyushu University
kn-affil=

affil-num=2
en-affil=Department of Pathology and Oncology, Graduate School of Medicine, Dentistry &amp; Pharmaceutical Science, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Pathology and Oncology, Graduate School of Medicine, Dentistry &amp; Pharmaceutical Science, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Pathology and Oncology, Graduate School of Medicine, Dentistry &amp; Pharmaceutical Science, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Gynecology and Obstetrics, Graduate School of Medical Sciences Kyushu University  Fukuoka Japan
kn-affil=

affil-num=6
en-affil=Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University
kn-affil=

affil-num=7
en-affil=Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University
kn-affil=

affil-num=8
en-affil=Department of Medicine and Clinical Science, Kyushu University Beppu Hospital
kn-affil=

affil-num=9
en-affil=Department of Gynecology, Kyushu University Beppu Hospital
kn-affil=

affil-num=10
en-affil=Department of Gynecology and Obstetrics, Graduate School of Medical Sciences, Kyushu University
kn-affil=

affil-num=11
en-affil=Department of Gynecology and Obstetrics, Graduate School of Medical Sciences, Kyushu University
kn-affil=

affil-num=12
en-affil=Department of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University
kn-affil=

affil-num=13
en-affil=Department of Pathology and Oncology, Graduate School of Medicine, Dentistry &amp; Pharmaceutical Science, Okayama University
kn-affil=
en-keyword=claudin-18
kn-keyword=claudin-18
en-keyword=endocervical adenocarcinoma
kn-keyword=endocervical adenocarcinoma
en-keyword=gastric type
kn-keyword=gastric type
en-keyword=human papillomavirus
kn-keyword=human papillomavirus
en-keyword=p16
kn-keyword=p16
END

start-ver=1.4
cd-journal=joma
no-vol=17
cd-vols=
no-issue=7
article-no=
start-page=e87334
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250705
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The Challenge of Diagnosing Scirrhous Gastric Cancer by Endoscopic Biopsy: A Case Report
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Scirrhous gastric cancer, also known as linitis plastica, is a rare and aggressive subtype of gastric carcinoma that poses significant diagnostic challenges due to its submucosal infiltration and often normal-appearing mucosa. We report a case involving a 30-year-old Japanese woman who presented with a six-month history of epigastric pain and postprandial vomiting. Initial endoscopic examination revealed erythema and mucosal swelling, with limited antral distensibility and resistance during duodenal intubation. Despite 12 mucosal biopsies, histopathological examination revealed no evidence of malignancy. Given the strong clinical and endoscopic suspicion of scirrhous gastric cancer, additional deep sections and immunohistochemical staining were performed. These revealed scattered signet-ring cell carcinoma and poorly differentiated adenocarcinoma, with positive immunostaining for p53 and Ki67. The patient underwent total gastrectomy, and the diagnosis of scirrhous gastric cancer was confirmed on the resected specimen. This case highlights the importance of a high index of clinical suspicion, close collaboration between endoscopists and pathologists, and the utility of ancillary diagnostic tools, such as immunohistochemistry, in identifying subepithelial gastric malignancies that may be missed on conventional biopsy.
en-copyright=
kn-copyright=

en-aut-name=IkedaYuka
en-aut-sei=Ikeda
en-aut-mei=Yuka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=IwamuroMasaya
en-aut-sei=Iwamuro
en-aut-mei=Masaya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YoshinoTadashi
en-aut-sei=Yoshino
en-aut-mei=Tadashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TanakaTakehiro
en-aut-sei=Tanaka
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=IkedaNobumasa
en-aut-sei=Ikeda
en-aut-mei=Nobumasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OtsukaMotoyuki
en-aut-sei=Otsuka
en-aut-mei=Motoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Internal Medicine, Clinic IkedaDepartment of Internal Medicine, Clinic Ikeda
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Pathology, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Pathology, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Internal Medicine, Clinic Ikeda
kn-affil=

affil-num=6
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=
en-keyword=endoscopic biopsy
kn-keyword=endoscopic biopsy
en-keyword=esophagogastroduodenoscopy
kn-keyword=esophagogastroduodenoscopy
en-keyword=immunohistochemistry
kn-keyword=immunohistochemistry
en-keyword=linitis plastica
kn-keyword=linitis plastica
en-keyword=scirrhous gastric cancer
kn-keyword=scirrhous gastric cancer
END

start-ver=1.4
cd-journal=joma
no-vol=9
cd-vols=
no-issue=2
article-no=
start-page=e70154
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260217
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Mitrofanoff Appendicovesicostomy With Boari Flap for Complete Female Urethral Transection: A Case Report
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Introduction: Female urethral complete transection caused by pelvic trauma is extremely rare, and no standard management has been established when urethral reconstruction is not feasible.<br>
Case Presentation: A woman in her twenties sustained an open pelvic fracture with perineal injury due to a traffic accident. Complete urethral transection was identified, and a suprapubic cystostomy was placed. After staged vaginal reconstruction and bladder function evaluation, a Mitrofanoff appendicovesicostomy was performed. Because the appendix was not enough to reach the umbilicus, a Boari flap was created to compensate for the length. Urodynamic evaluation showed improvement from a preoperative high-pressure bladder to increased compliance postoperatively, though pharmacological management was still required. Postoperatively, the patient achieved stable clean intermittent catheterization without complications.<br>
Conclusion: The Mitrofanoff procedure can be an effective option in female urethral injuries where reconstruction is impossible. The addition of a Boari flap may expand its applicability by overcoming conduit length limitations.
en-copyright=
kn-copyright=

en-aut-name=MoriKohei
en-aut-sei=Mori
en-aut-mei=Kohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=IwataTakehiro
en-aut-sei=Iwata
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KawadaTatsushi
en-aut-sei=Kawada
en-aut-mei=Tatsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SadahiraTakuya
en-aut-sei=Sadahira
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TominagaYusuke
en-aut-sei=Tominaga
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KatayamaSatoshi
en-aut-sei=Katayama
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NishimuraShingo
en-aut-sei=Nishimura
en-aut-mei=Shingo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=BekkuKensuke
en-aut-sei=Bekku
en-aut-mei=Kensuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=YamasakiYuichiro
en-aut-sei=Yamasaki
en-aut-mei=Yuichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=ArakiMotoo
en-aut-sei=Araki
en-aut-mei=Motoo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Urology, Kanagawa Children's Medical Center
kn-affil=

affil-num=10
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=Boari flap
kn-keyword=Boari flap
en-keyword=female urethral transection
kn-keyword=female urethral transection
en-keyword=Mitrofanoff
kn-keyword=Mitrofanoff
END

start-ver=1.4
cd-journal=joma
no-vol=12
cd-vols=
no-issue=5
article-no=
start-page=25-00095
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=2025
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Examining OpenFOAM-based LES analysis in terms of inviscid energy conservation and viscous turbulence decay
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The present study examines an OpenFOAM-based LES analysis from the viewpoints of inviscid energy conservation and viscous turbulence decay. The Smagorinsky model is employed as the sub-grid scale (SGS) model, and a two-dimensional periodic analytical solution and a three-dimensional periodic Taylor-Green vortex (TGV) are employed to represent inviscid flows. The analytical relationship for the kinetic energy K, dK/dt = 0, with t as the dimensionless time, is utilized to validate the OpenFOAM results. For the viscous flow case, the TGV flow in a three-dimensional periodic cubic domain is adopted, and its turbulence kinetic energy distribution is compared with that obtained by a spectral method to examine the analysis. The OpenFOAM-based analysis exhibits energy conservation error in flows that should ideally conserve energy. For the two-dimensional flow, this error decreases with increasing grid resolution N. However, in the three-dimensional flow, the error does not improve even with higher N. In the three-dimensional TGV flow, the turbulence kinetic energy predicted by OpenFOAM exhibits a strong agreement with that from the spectral method when a standard constant value of the Smagorinsky model is employed and the mesh is sufficiently refined. Conversely, for a condition of relatively coarse mesh, the decay characteristics of turbulent kinetic energy deviate from those of the spectral method, and a higher constant value of the Smagorinsky model than the default value becomes necessary to reproduce comparable results. These results suggests that even in LES simulations where highly accurate conservation laws are not satisfied, adjusting the model constants so that the predicted values match experimental or numerical reference data can improve the apparent reliability of the turbulent kinetic energy in the decaying turbulence.
en-copyright=
kn-copyright=

en-aut-name=SUZUKIHiroki
en-aut-sei=SUZUKI
en-aut-mei=Hiroki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TANAKAKento
en-aut-sei=TANAKA
en-aut-mei=Kento
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KOUCHIToshinori
en-aut-sei=KOUCHI
en-aut-mei=Toshinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=3
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=
en-keyword=Turbulent flows
kn-keyword=Turbulent flows
en-keyword=Numerical simulation
kn-keyword=Numerical simulation
en-keyword=Large-eddy simulation
kn-keyword=Large-eddy simulation
en-keyword=Energy conservation
kn-keyword=Energy conservation
en-keyword=Decaying turbulence
kn-keyword=Decaying turbulence
END

start-ver=1.4
cd-journal=joma
no-vol=32
cd-vols=
no-issue=16
article-no=
start-page=9663
end-page=9677
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251011
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Development of sulfation for cellulose pulp to change its fiber morphology and appearance to transparent in water
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Cellulose pulp (CP) is composed mainly of cellulose which is one of the most useful and sustainable natural polymers. Cellulose-based materials, such as completely dispersed nanofibers and water-soluble cellulose, are transparent in water. Additionally, chemical modification of CP has been employed as a pretreatment for the preparation of nanofibers and to impart absorption properties derived from anionic functional groups. However, little is known about chemically modified CPs comprising micron-scale fibers that are transparent in water.In this study, we synthesized transparent sulfated cellulose pulp (TSCP) that exhibits good dispersion stability, high transparency in water, and highly swollen fiber structures. The sulfation method involved heating sulfamic acid and urea supported on CP. TSCP synthesized using a sulfamic acid amount relative to CP (Q) of 18.5, a molar ratio of urea to sulfamic acid (R) of 0.80, and a reaction temperature of 140 °C exhibited the highest total light transmittance (94.7%) in water, a degree of polymerization (535), and amount of sulfate groups (1.73 mmol/g). Polarization microscopy confirmed that most TSCP fibers swelled in water along the fiber width direction. The structure of hydrous-state TSCP was further confirmed using low-vacuum scanning electron microscopy. The maximum fiber width of the swollen TSCP reached 122 μm, which was approximately six times than that of CP. The crystallinity was equivalent to that of the original CP with a Cellulose I-type crystalline structure. This transparent, hydrous-state TSCP, comprising predominantly swollen CP fibers, demonstrates potential for applications as a transparent material.
en-copyright=
kn-copyright=

en-aut-name=NishimuraAyato
en-aut-sei=Nishimura
en-aut-mei=Ayato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=UchidaTetsuya
en-aut-sei=Uchida
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=
en-keyword=Cellulose pulp
kn-keyword=Cellulose pulp
en-keyword=Sulfation
kn-keyword=Sulfation
en-keyword=Transparent
kn-keyword=Transparent
en-keyword=Swollen fiber structure
kn-keyword=Swollen fiber structure
en-keyword=Microscopy
kn-keyword=Microscopy
en-keyword=Refractive index
kn-keyword=Refractive index
END

start-ver=1.4
cd-journal=joma
no-vol=61
cd-vols=
no-issue=2
article-no=
start-page=444
end-page=451
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Interactive Effects of Maximum Daytime and Minimum Nighttime Temperatures on Spinach Growth and Physiological Characteristics
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=High temperatures restrict spinach growth, and the plant’s growth and physiological responses to heat remain poorly understood. It remains unclear whether high daytime or elevated nighttime temperatures have a more negative impact on spinach growth. In addition, the interaction effect of maximum daytime and minimum nighttime temperatures on spinach growth remains unknown. This study was conducted to address these issues. Spinach was grown in controlled environments under four temperature treatments: 30 and 20 °C (T30/20), 30 and 25 °C (T30/25), 35 and 20 °C (T35/20), and 35 and 25 °C (T35/25). These treatments represent the maximum daytime temperature and minimum nighttime temperature, respectively, and were maintained for 45 days. Plant growth characteristics were monitored, and the physiological responses to temperature regimes were assessed. The results show that compared with T30/20, dry matter production decreased by 15.4% with increased nighttime temperature (T30/25), decreased by 42.3% with increased daytime temperature (T35/20), and decreased by 57.7% when both daytime and nighttime temperatures were increased (T35/25). However, there was no statistically significant interaction effect (P > 0.05) between daytime maximum and nighttime minimum temperatures on plant biomass production variables. In comparison with T30/20, the T35/25 treatment increased significantly plant stomatal conductance, stomatal apertures, transpiration rate, and leaf temperature during heat waves. The T35/25 treatment also decreased the quantum efficiency in light compared with the other treatments. Plant biomass production did not improve with the T35/20 and T35/25 treatments, likely as a result of a decoupling of photosynthesis and stomatal conductance during heat waves. Overall, these results reveal that maximum daytime and minimum nighttime temperatures exert additive effects on spinach growth.
en-copyright=
kn-copyright=

en-aut-name=SambaNethone
en-aut-sei=Samba
en-aut-mei=Nethone
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=AkasakaHisao
en-aut-sei=Akasaka
en-aut-mei=Hisao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YasubaKen-ichiro
en-aut-sei=Yasuba
en-aut-mei=Ken-ichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=GotoTanjuro
en-aut-sei=Goto
en-aut-mei=Tanjuro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=Hikawa-EndoMinori
en-aut-sei=Hikawa-Endo
en-aut-mei=Minori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MiyamaYoko
en-aut-sei=Miyama
en-aut-mei=Yoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Faculty of Food and Agricultural Sciences, Fukushima University
kn-affil=

affil-num=2
en-affil=The United Graduate School of Agricultural Sciences, Iwate University, Iwate, 020-8550, Japan; and Iwate Agricultural Research Center, Kenpoku Agricultural Research Institute
kn-affil=

affil-num=3
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=4
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=5
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=6
en-affil=Faculty of Food and Agricultural Sciences, Fukushima University, Fukushima, 960-1296, Japan; and The United Graduate School of Agricultural Sciences, Iwate University
kn-affil=
en-keyword=photosynthesis
kn-keyword=photosynthesis
en-keyword=quantum efficiency
kn-keyword=quantum efficiency
en-keyword=stomatal aperture
kn-keyword=stomatal aperture
en-keyword=stomatal conductance
kn-keyword=stomatal conductance
en-keyword=transpiration
kn-keyword=transpiration
END

start-ver=1.4
cd-journal=joma
no-vol=29
cd-vols=
no-issue=1
article-no=
start-page=146
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250719
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Safety and feasibility of D3 lymph node dissection in oldest-old patients undergoing colorectal cancer surgery: a multi-institutional, retrospective analysis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Colorectal cancer (CRC) is a significant health burden, with lymph node dissection (LND) playing a critical role in staging and guiding treatment. However, the optimal extent of LND for the oldest-old population (aged???90 years) remains undefined because of insufficient targeted clinical data. This study aimed to compare the short-term outcomes of D3 versus non-D3 LND in Stage II?III CRC in oldest-old patients.<br>
Methods This retrospective cohort study utilized data from the Setouchi Colorectal Neoplasm Registration database, including 282 oldest-old patients with CRC treated between 2011 and 2022. Patients were stratified into D3 and non-D3 LND groups, with inverse-probability-weighted regression adjustment implemented to address potential confounding factors. Postoperative complications and hospital stays were analyzed using regression models and descriptive statistics.<br>
Results D3 LND resulted in significantly higher lymph node harvests in both Stage II and Stage III patients (p?<?0.01). There were no significant differences in overall or major postoperative complications between D3 and non-D3 groups. Hospital stays were comparable for Stage II patients but shorter for Stage III patients in the D3 group (p?<?0.01). Complication rates ranged from 28% to 47.7%, with surgical site infections and pneumonia being the most common.<br>
Conclusions D3 LND can be safely performed in oldest-old patients with CRC without increasing postoperative complications or extending hospital stays. These findings support the feasibility of extensive LND in this age gr
en-copyright=
kn-copyright=

en-aut-name=InadaR.
en-aut-sei=Inada
en-aut-mei=R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TeraishiF.
en-aut-sei=Teraishi
en-aut-mei=F.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MitsuhashiT.
en-aut-sei=Mitsuhashi
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TakanagaS.
en-aut-sei=Takanaga
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=ToshimaT.
en-aut-sei=Toshima
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OhtaniT.
en-aut-sei=Ohtani
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YoshidaR.
en-aut-sei=Yoshida
en-aut-mei=R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HoriN.
en-aut-sei=Hori
en-aut-mei=N.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=ShigemitsuK.
en-aut-sei=Shigemitsu
en-aut-mei=K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=YamamotoS.
en-aut-sei=Yamamoto
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KubotaT.
en-aut-sei=Kubota
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=OkanoY.
en-aut-sei=Okano
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=NobuhisaT.
en-aut-sei=Nobuhisa
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=TaniguchiF.
en-aut-sei=Taniguchi
en-aut-mei=F.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=IshikawaW.
en-aut-sei=Ishikawa
en-aut-mei=W.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=ShojiR.
en-aut-sei=Shoji
en-aut-mei=R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=MatsudaT.
en-aut-sei=Matsuda
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=UmeokaT.
en-aut-sei=Umeoka
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=FujiwaraT.
en-aut-sei=Fujiwara
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=Setouchi Colorectal Neoplasm Registration Study Group Collaborators
en-aut-sei=Setouchi Colorectal Neoplasm Registration Study Group Collaborators
en-aut-mei=
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

affil-num=1
en-affil=Department of Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Surgery, Kagawa Rosai Hospital
kn-affil=

affil-num=6
en-affil=Department of Surgery, Saiseikai Okayama Hospital
kn-affil=

affil-num=7
en-affil=Department of Surgery, Okayama Rosai Hospital
kn-affil=

affil-num=8
en-affil=Department of Surgery, Tottori Municipal Hospital
kn-affil=

affil-num=9
en-affil=Department of Surgery, Tsuyama Chuo Hospital
kn-affil=

affil-num=10
en-affil=Department of Surgery, Okayama City Hospital
kn-affil=

affil-num=11
en-affil=Department of Surgery, Kobe Red Cross Hospital
kn-affil=

affil-num=12
en-affil=Department of Surgery, Onomichi City Hospital
kn-affil=

affil-num=13
en-affil=Department of Surgery, Himeji Red Cross Hospital
kn-affil=

affil-num=14
en-affil=Department of Surgery, National Hospital Organization Iwakuni Clinical Center
kn-affil=

affil-num=15
en-affil=Department of Surgery, Fukuyama City Hospital
kn-affil=

affil-num=16
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=17
en-affil=Department of Surgery, Matsuda Hospital
kn-affil=

affil-num=18
en-affil=Department of Surgery, Matsuyama City Hospital
kn-affil=

affil-num=19
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=20
en-affil=
kn-affil=
en-keyword=Lymph node dissection
kn-keyword=Lymph node dissection
en-keyword=Colorectal cancer
kn-keyword=Colorectal cancer
en-keyword=Oldest-old patients
kn-keyword=Oldest-old patients
en-keyword=Postoperative complication
kn-keyword=Postoperative complication
END

start-ver=1.4
cd-journal=joma
no-vol=18
cd-vols=
no-issue=3
article-no=
start-page=e105012
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=2026310
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Rare Association of Congenital Glaucoma and Retinitis Pigmentosa: A 22-Year Follow-Up Case
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Primary congenital glaucoma is a rare congenital disease with a genetic background that shows high intraocular pressure due to ocular outflow anomalies. Retinitis pigmentosa is a predominant form of inherited retinal disorders. In this study, we present the case of a patient with primary congenital glaucoma in association with retinitis pigmentosa. A four-month-old female baby was brought to the emergency department due to corneal opacity in the left eye. The intraocular pressure measured by a hand-held applanation tonometer was 40 mmHg in the right eye and 36 mmHg in the left eye. She was otherwise healthy and diagnosed with primary congenital glaucoma. She immediately underwent trabeculotomy ab externo in both eyes under general anesthesia, and the intraocular pressure was lowered to 15 mmHg in the right eye and 12 mmHg in the left eye three weeks later. At the age of nine months, she was found to have retinal degeneration along the upper and lower vascular arcades of the fundus in both eyes and was diagnosed with retinitis pigmentosa. At the age of one year and 10 months, the visual acuity was measured at 0.2 in the right eye and 0.2 in the left eye for the first time by a preferential looking procedure. The intraocular pressure was 9 mmHg in both eyes under sedation, and she did not use any topical medication. At the age of three years and three months, the uncorrected visual acuity and best-corrected visual acuity with myopic astigmatism correction were 0.1 and 0.15, respectively, in the right eye and 0.6 and 0.7, respectively, in the left eye. Occlusion therapy with an eye patch over the left eye for one hour daily was started. At the age of four years and 10 months, the best-corrected visual acuity was 0.7 in both eyes. At the age of six years, occlusion therapy was discontinued, and full-correction glasses were prescribed, based on cycloplegic refraction. The visual acuity in the right eye decreased to 0.3 at the age of 11 years and further to 0.1 at the age of 12 years, while the visual acuity in the left eye remained 0.8. Afterwards, she maintained a visual acuity of 0.1 in the right eye and 0.8 in the left eye until the age of 22 years. An incidental presence of primary congenital glaucoma in this patient led to the detection of retinitis pigmentosa in earlier years and allowed long-term follow-up for 22 years. Even though genetic testing was not performed for this patient, the abnormal function of primary cilia, designated as ciliopathy, might explain the co-occurrence of primary congenital glaucoma and retinitis pigmentosa.
en-copyright=
kn-copyright=

en-aut-name=MatsuoToshihiko
en-aut-sei=Matsuo
en-aut-mei=Toshihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Ophthalmology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=
en-keyword=ciliopathy
kn-keyword=ciliopathy
en-keyword=cycloplegic refraction
kn-keyword=cycloplegic refraction
en-keyword=full-correction glasses
kn-keyword=full-correction glasses
en-keyword=goldmann perimetry
kn-keyword=goldmann perimetry
en-keyword=occlusion therapy
kn-keyword=occlusion therapy
en-keyword=optical coherence tomography
kn-keyword=optical coherence tomography
en-keyword=photoreceptor ellipsoid zone
kn-keyword=photoreceptor ellipsoid zone
en-keyword=primary congenital glaucoma
kn-keyword=primary congenital glaucoma
en-keyword=retinitis pigmentosa
kn-keyword=retinitis pigmentosa
en-keyword=trabeculotomy
kn-keyword=trabeculotomy
END

start-ver=1.4
cd-journal=joma
no-vol=22
cd-vols=
no-issue=1
article-no=
start-page=98
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260119
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Genetic and phenotypic identities of Staphylococcus coagulans isolated from pustules of dogs with superficial bacterial folliculitis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Staphylococcus coagulans, formerly called Staphylococcus schleiferi subsp. coagulans is the second most common isolate from skin lesions of dogs with superficial bacterial folliculitis (SBF). However, the clinical significance of S. coagulans in pustules of canine SBF remains uncertain. This study aimed to investigate the prevalence and genotypic and phenotypic diversity of S. coagulans isolated from pustules in two dogs with SBF.<br>
Results Two dogs with SBF were included in this study. S. schleiferi/coagulans was isolated as the sole organism from three pustules in case #1, whereas it coexisted with S. pseudintermedius in two of seven pustules in case #2. S. pseudintermedius was the sole organism in the remaining five pustules in case #2. Whole genome sequences revealed that all isolates tested were annotated as S. coagulans. The isolates from the same pustules exhibited identical genotypic and phenotypic profiles, indicating clonal multiplication. S. coagulans isolated from different pustules exhibited similar yet distinct genotypic and phenotypic profiles.<br>
Conclusions S. coagulans with identical genetic and phenotypic profiles can be identified as the sole pathogen or coexist with S. pseudintermedius in the pustules of the same dogs with SBF.
en-copyright=
kn-copyright=

en-aut-name=OsumiTakafumi
en-aut-sei=Osumi
en-aut-mei=Takafumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ShinomiyaYuuki
en-aut-sei=Shinomiya
en-aut-mei=Yuuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=WanganuttaraThamonwan
en-aut-sei=Wanganuttara
en-aut-mei=Thamonwan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ImanishiIchiro
en-aut-sei=Imanishi
en-aut-mei=Ichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=ShimazakiYotaro
en-aut-sei=Shimazaki
en-aut-mei=Yotaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=IyoriKeita
en-aut-sei=Iyori
en-aut-mei=Keita
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ToyodaYoichi
en-aut-sei=Toyoda
en-aut-mei=Yoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=IdeKaori
en-aut-sei=Ide
en-aut-mei=Kaori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=UchiyamaJumpei
en-aut-sei=Uchiyama
en-aut-mei=Jumpei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NishifujiKoji
en-aut-sei=Nishifuji
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Animal Medical Center, Faculty of Agriculture, Tokyo University of Agriculture and Technology
kn-affil=

affil-num=2
en-affil=Department of Veterinary Medicine, Faculty of Agriculture, Tokyo University of Agriculture and Technology
kn-affil=

affil-num=3
en-affil=Department of Bacteriology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai
kn-affil=

affil-num=5
en-affil=Animal Medical Center, Faculty of Agriculture, Tokyo University of Agriculture and Technology
kn-affil=

affil-num=6
en-affil=1sec Co. Ltd.
kn-affil=

affil-num=7
en-affil=1sec Co. Ltd.
kn-affil=

affil-num=8
en-affil=Animal Medical Center, Faculty of Agriculture, Tokyo University of Agriculture and Technology
kn-affil=

affil-num=9
en-affil=Department of Bacteriology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=10
en-affil=Animal Medical Center, Faculty of Agriculture, Tokyo University of Agriculture and Technology
kn-affil=
en-keyword=Staphylococcus coagulans
kn-keyword=Staphylococcus coagulans
en-keyword=Staphylococcus pseudintermedius
kn-keyword=Staphylococcus pseudintermedius
en-keyword=Dog
kn-keyword=Dog
en-keyword=Superficial bacterial folliculitis
kn-keyword=Superficial bacterial folliculitis
en-keyword=Antimicrobial susceptibility
kn-keyword=Antimicrobial susceptibility
en-keyword=Disk diffusion test
kn-keyword=Disk diffusion test
END

start-ver=1.4
cd-journal=joma
no-vol=18
cd-vols=
no-issue=1
article-no=
start-page=123
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260119
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Streamlined Radiosynthesis of [18F]Fluproxadine (AF78): An Unprotected Guanidine Precursor Enables Efficient One-Step, Automation-Ready Labeling for Clinical Use
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background/Objectives: [18F]Fluproxadine (formerly [18F]AF78) is a PET radiotracer targeting the norepinephrine transporter (NET) with potential applications in cardiac, neurological, and oncological imaging. Its guanidine moiety, while essential for NET binding, presents major radiosynthetic challenges due to high basicity and the harsh deprotection conditions required for protected precursors. Previous methods relied on multistep procedures, strong acids, and complex purification, limiting clinical translation. This study aimed to develop a practical one-step radiosynthesis suitable for routine and automated production. Methods: A direct SN2-type nucleophilic [18F]fluorination was performed using an unprotected guanidine precursor to eliminate deprotection steps. Reaction parameters, including the base system, solvent composition, precursor concentration, and temperature, were optimized under conventional and microwave heating. Radiochemical conversion (RCC) and operational robustness were evaluated, and purification strategies were assessed for automation compatibility. Results: Direct [18F]fluorination using the unprotected precursor reduced the total synthesis time to 60?70 min. Optimal conditions employed a tert-butanol/acetonitrile (4:1) solvent system with K2CO3/Kryptofix222, affording RCC up to 33% under conventional heating. Microwave irradiation further improved efficiency, achieving RCC of up to 64% within 1.5 min at 140 °C. The method showed broad tolerance to variations in the base molar ratio and precursor concentration and enabled isocratic HPLC purification. Conclusions: This one-step radiosynthesis overcomes longstanding challenges in [18F]fluproxadine production by eliminating harsh deprotection and enabling high-yield, automation-ready synthesis, thereby improving clinical feasibility.
en-copyright=
kn-copyright=

en-aut-name=ChenXinyu
en-aut-sei=Chen
en-aut-mei=Xinyu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OhtaKaito
en-aut-sei=Ohta
en-aut-mei=Kaito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KimuraHiroyuki
en-aut-sei=Kimura
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YagiYusuke
en-aut-sei=Yagi
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SasakiTakanori
en-aut-sei=Sasaki
en-aut-mei=Takanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NoseNaoko
en-aut-sei=Nose
en-aut-mei=Naoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=AkehiMasaru
en-aut-sei=Akehi
en-aut-mei=Masaru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YamaneTomohiko
en-aut-sei=Yamane
en-aut-mei=Tomohiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=WernerRudolf A.
en-aut-sei=Werner
en-aut-mei=Rudolf A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=HiguchiTakahiro
en-aut-sei=Higuchi
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Nuclear Medicine, Faculty of Medicine, University of Augsburg
kn-affil=

affil-num=2
en-affil=Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Agency for Health, Safety and Environment, Kyoto University
kn-affil=

affil-num=4
en-affil=Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=8
en-affil=Department of Molecular Imaging Research, Kobe City Medical Center General Hospital
kn-affil=

affil-num=9
en-affil=Department of Nuclear Medicine, LMU Hospital, and German Cancer Consortium (DKTK), Partner Site Munich, Ludwig-Maximilians-University of Munich
kn-affil=

affil-num=10
en-affil=Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=norepinephrine transporter
kn-keyword=norepinephrine transporter
en-keyword=positron emission tomography
kn-keyword=positron emission tomography
en-keyword=[18F]AF78
kn-keyword=[18F]AF78
en-keyword=[18F]fluproxadine
kn-keyword=[18F]fluproxadine
en-keyword=radiolabeling
kn-keyword=radiolabeling
END

start-ver=1.4
cd-journal=joma
no-vol=27
cd-vols=
no-issue=5
article-no=
start-page=2113
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260224
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Fgf10 Gene Dosage from a Single Allele Is Insufficient for Forming Multilayered Epithelial Cells in the Murine Lacrimal Gland
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Mutations in the fibroblast growth factor 10 (FGF10) gene in humans cause aplasia of the lacrimal and salivary glands (ALSG). In patients with ALSG, heterozygous loss-of-function mutations are found, and FGF10 haploinsufficiency results in the absence of these secretory organs. Lacrimal glands (LGs) are formed through epithelial thickening, budding, and branching morphogenesis. To compare the variable phenotypes of the Fgf10+/? Harderian glands (HGs) previously reported, we examined the development of LGs in wild-type (WT), Fgf10+/?, and Fgf10-null mice. Pax6 immunostaining was performed to visualize the LG primordia from embryonic day 15.5 (E15.5) onwards. In situ hybridization of the genes encoding the epithelial receptor of FGF10, FGFR2b, and its other ligands was performed to determine their potential involvement in LG development. LG primordia were not observed in Fgf10+/? mice bilaterally at E16.5 or later stages. At E15.5, budding from the developing conjunctival epithelium (CE) was observed in a small fraction of the Fgf10+/? LG primordia. In contrast, the Fgf10-null CE failed to promote budding. Among Fgf1, Fgf3, Fgf7, Fgf10, and Fgf22, Fgf10 was expressed in the mesenchyme surrounding developing LG epithelial cells, whereas Fgf1 was expressed in the LG epithelium of WT mice. Fgf7 was initially expressed in the mesenchyme surrounding the nascent LG epithelium, but its expression subsequently became diffused. Thus, we conclude that among the FGFR2b ligands, initial LG formation is dependent on the mesenchymal factors FGF10 and FGF7, and FGF1 is likely to function as an epithelial factor in the LG primordia. A single allele of Fgf10 was found to be insufficient to support the budding process during LG morphogenesis.
en-copyright=
kn-copyright=

en-aut-name=IkedaShiori
en-aut-sei=Ikeda
en-aut-mei=Shiori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SatoKeita
en-aut-sei=Sato
en-aut-mei=Keita
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TajikaYuki
en-aut-sei=Tajika
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=FujitaHirofumi
en-aut-sei=Fujita
en-aut-mei=Hirofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=BandoTetsuya
en-aut-sei=Bando
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NohnoTsutomu
en-aut-sei=Nohno
en-aut-mei=Tsutomu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MiyaishiSatoru
en-aut-sei=Miyaishi
en-aut-mei=Satoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OhuchiHideyo
en-aut-sei=Ohuchi
en-aut-mei=Hideyo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Cytology and Histology, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Cytology and Histology, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Radiological Technology, Gumma Prefectural College of Health Sciences
kn-affil=

affil-num=4
en-affil=Department of Cytology and Histology, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Cytology and Histology, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Cytology and Histology, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Department of Legal Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=8
en-affil=Department of Cytology and Histology, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=fibroblast growth factor
kn-keyword=fibroblast growth factor
en-keyword=Fgf10
kn-keyword=Fgf10
en-keyword=Fgf1
kn-keyword=Fgf1
en-keyword=Fgf3
kn-keyword=Fgf3
en-keyword=Fgf7
kn-keyword=Fgf7
en-keyword=Fgf22
kn-keyword=Fgf22
en-keyword=Fgfr2b
kn-keyword=Fgfr2b
en-keyword=mouse
kn-keyword=mouse
en-keyword=lacrimal gland
kn-keyword=lacrimal gland
en-keyword=development
kn-keyword=development
END

start-ver=1.4
cd-journal=joma
no-vol=14
cd-vols=
no-issue=
article-no=
start-page=17960
end-page=17970
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=2026
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=FEM-Based Design and Characterization of a Millimeter-Scale Piezoelectric Resonance Force Sensor
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This paper presents a millimeter-scale piezoelectric effect-based force sensor that uses the change in its resonant frequency as the detection principle for high sensitivity and a wide measurement range. Such characteristics are suited for robot hand applications that not only detect small forces but also handle large payloads. We develop a methodology to estimate the relationship between applied force and resonant frequency shift by combining classical contact theory and finite element method (FEM) analysis. Although this relationship is non-linear, the designability of sensitivity and measurement range is demonstrated by the simulation. The simulation results based on the method are verified, showing good agreement with the experimental results. The static characteristics, including sensitivity, standard deviation, and resolution, are evaluated using prototype sensors with characteristic lengths ranging from 1 mm to 4 mm. The 4-mm model has a measurement range of 77 mN to 300 N, and the smallest model, which is one of the smallest force sensors suitable for practical implementation, has a measurement range of 9 mN to 20 N.
en-copyright=
kn-copyright=

en-aut-name=YamazakiAoto
en-aut-sei=Yamazaki
en-aut-mei=Aoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=AkidukiTakuma
en-aut-sei=Akiduki
en-aut-mei=Takuma
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HonnaAtsuo
en-aut-sei=Honna
en-aut-mei=Atsuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KitazakiMichiteru
en-aut-sei=Kitazaki
en-aut-mei=Michiteru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MashimoTomoaki
en-aut-sei=Mashimo
en-aut-mei=Tomoaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of Mechanical Engineering, Toyohashi University of Technology
kn-affil=

affil-num=2
en-affil=Department of Mechanical Engineering, Toyohashi University of Technology
kn-affil=

affil-num=3
en-affil=Riccoh Company Ltd.
kn-affil=

affil-num=4
en-affil=Department of Computer Science and Engineering, Toyohashi University of Technology
kn-affil=

affil-num=5
en-affil=Graduate School of Natural Science and Technology, Okayama University
kn-affil=
en-keyword=Force sensors
kn-keyword=Force sensors
en-keyword=piezoelectric effect
kn-keyword=piezoelectric effect
en-keyword=resonators
kn-keyword=resonators
en-keyword=transducers
kn-keyword=transducers
en-keyword=ultrasonics
kn-keyword=ultrasonics
END

start-ver=1.4
cd-journal=joma
no-vol=19
cd-vols=
no-issue=1
article-no=
start-page=13
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251208
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Pan-cancer profiling links C1orf50 to DNA repair and immune modulation in ovarian cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background C1orf50 encodes a small, evolutionarily conserved protein, the function of which remains unclear. Its significance across various human cancers, particularly its specific role in ovarian cancer within an immunogenomic context, is not yet fully understood. Utilizing The Cancer Genome Atlas and single-cell RNA sequencing (scRNA-seq) public datasets, we conducted a comprehensive profiling of C1orf50 across multiple cancer types, with a particular focus on ovarian cancer, to investigate its associations with copy-number status, genomic instability, tumor programs, and the immune microenvironment.<br>
Results Across cancer types, copy-number gain or amplification of C1orf50 was most frequent in ovarian cancer and closely tracked with higher messenger RNA levels. Higher C1orf50 expression was associated with a greater tumor mutational burden and homologous recombination deficiency, as indicated by gene-set patterns that suggested heightened cell-cycle and cellular stress responses accompanied by reduced oxidative phosphorylation, enrichment of regulatory T cells, and depletion of resting memory CD4 T cells. In ovarian cancer, focal events at chromosome 1p34.2 were accompanied by stepwise increases in C1orf50 expression by clinical stage and were linked to higher tumor mutational burden, homologous recombination deficiency, and greater loss of heterozygosity, together with more frequent gene alterations in BRCA1 or BRCA2. Immune composition clustered into profiles consistent with an immunosuppressive context in tumors with higher C1orf50 expression. The scRNA-seq data further revealed that cancer cells enhanced immune-suppressive interactions with various immune cell populations and diminished antigen-presentation signals. Analyses of genomic instability in ovarian cancer suggested mutational processes compatible with base-substitution patterns associated with cytidine deaminase activity and with insertion-deletion patterns characteristic of homologous recombination failure, while transcript-level patterns pointed to a broad downshift of canonical DNA repair activity with apparent compensatory adjustments in related pathways rather than a uniform change in any single pathway.<br>
Conclusions The overexpression of C1orf50 characterizes an aggressive immunogenomic phenotype in ovarian cancer, distinguished by genomic instability, impaired DNA repair mechanisms, and extensive immunosuppression. These findings indicate that C1orf50 warrants consideration as a potential biomarker and a prospective target for therapeutic investigation. Furthermore, they advocate for the progression to prospective validation and functional studies to ascertain its clinical significance.
en-copyright=
kn-copyright=

en-aut-name=RogachevskayaAnna
en-aut-sei=Rogachevskaya
en-aut-mei=Anna
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OtaniYusuke
en-aut-sei=Otani
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OhtsuAkira
en-aut-sei=Ohtsu
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ChinVanessa D.
en-aut-sei=Chin
en-aut-mei=Vanessa D.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=Pe?aTirso
en-aut-sei=Pe?a
en-aut-mei=Tirso
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=AraiSeiji
en-aut-sei=Arai
en-aut-mei=Seiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ToyookaShinichi
en-aut-sei=Toyooka
en-aut-mei=Shinichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=FujimuraAtsushi
en-aut-sei=Fujimura
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TanakaAtsushi
en-aut-sei=Tanaka
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School
kn-affil=

affil-num=2
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=3
en-affil=Harvard Medical School
kn-affil=

affil-num=4
en-affil=UMass Chan Medical School, UMass Memorial Medical Center
kn-affil=

affil-num=5
en-affil=Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School
kn-affil=

affil-num=6
en-affil=Department of Urology, Gunma University Graduate School of Medicine
kn-affil=

affil-num=7
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=8
en-affil=Department of Molecular Physiology, Faculty of Medicine, Graduate School of Medicine, Kagawa University
kn-affil=

affil-num=9
en-affil=Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School
kn-affil=
en-keyword=C1orf50
kn-keyword=C1orf50
en-keyword=Pan-cancer analysis
kn-keyword=Pan-cancer analysis
en-keyword=DNA repair
kn-keyword=DNA repair
en-keyword=Gene expression
kn-keyword=Gene expression
en-keyword=Tumor microenvironment
kn-keyword=Tumor microenvironment
en-keyword=Immune evasion
kn-keyword=Immune evasion
en-keyword=Single-cell RNA-seq
kn-keyword=Single-cell RNA-seq
END

start-ver=1.4
cd-journal=joma
no-vol=17
cd-vols=
no-issue=9
article-no=
start-page=4363
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=2026
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Gaseous CO2 electrolysis: latest advances in electrode and electrolyzer technologies toward abating CO2 emissions
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The conversion of CO2 into multicarbon (C2+) products via electrochemical reduction is considered a key technology for the sustainable production of fuels and chemicals. The performance of high-rate gaseous CO2 electrolysis is governed by interrelated factors such as the electrocatalysts, electrodes, electrolytes, and cell architectures. Despite the intensive focus on catalyst research, systematic studies addressing the other components remain scarce, leaving critical gaps in our understanding toward achieving higher performance in CO2 electrolysis systems. The nanoscale design of catalyst surface electronic structures and the macroscale design of electrodes and electrolyzer architectures both influence the overall activity of the electrochemical system. In designing macroscale components, it is necessary to establish benchmarks based on a comprehensive evaluation of CO2 emissions for the entire electrolysis process, because these parameters are directly linked to output metrics such as current density and cell voltage under practical operating conditions. This review summarizes recent advances in electrodes and electrolyzers, and through life-cycle assessment (LCA), evaluates key performance indicators (KPIs) for achieving negative emissions and assesses the current technology readiness of CO2 electrolysis.
en-copyright=
kn-copyright=

en-aut-name=KamiyaKazuhide
en-aut-sei=Kamiya
en-aut-mei=Kazuhide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NakasoneSora
en-aut-sei=Nakasone
en-aut-mei=Sora
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KuriharaRyo
en-aut-sei=Kurihara
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=InoueAsato
en-aut-sei=Inoue
en-aut-mei=Asato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=IrieHazuki
en-aut-sei=Irie
en-aut-mei=Hazuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NakahataShoko
en-aut-sei=Nakahata
en-aut-mei=Shoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NishinaYuta
en-aut-sei=Nishina
en-aut-mei=Yuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TaniguchiSatoshi
en-aut-sei=Taniguchi
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=NguyenThuy T. H.
en-aut-sei=Nguyen
en-aut-mei=Thuy T. H.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KataokaSho
en-aut-sei=Kataoka
en-aut-mei=Sho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Research Center for Solar Energy Chemistry, Graduate School of Engineering Science, The University of Osaka
kn-affil=

affil-num=2
en-affil=Research Center for Solar Energy Chemistry, Graduate School of Engineering Science, The University of Osaka
kn-affil=

affil-num=3
en-affil=Research Center for Solar Energy Chemistry, Graduate School of Engineering Science, The University of Osaka
kn-affil=

affil-num=4
en-affil=Research Center for Solar Energy Chemistry, Graduate School of Engineering Science, The University of Osaka
kn-affil=

affil-num=5
en-affil=Research Center for Solar Energy Chemistry, Graduate School of Engineering Science, The University of Osaka
kn-affil=

affil-num=6
en-affil=Research Center for Solar Energy Chemistry, Graduate School of Engineering Science, The University of Osaka
kn-affil=

affil-num=7
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=

affil-num=8
en-affil=Research Institute for Chemical Process Technology, National Institute of Advanced Industrial Science and Technology (AIST), Central 5
kn-affil=

affil-num=9
en-affil=Research Institute for Chemical Process Technology, National Institute of Advanced Industrial Science and Technology (AIST), Central 5
kn-affil=

affil-num=10
en-affil=Research Institute for Chemical Process Technology, National Institute of Advanced Industrial Science and Technology (AIST), Central 5
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=9
cd-vols=
no-issue=6
article-no=
start-page=1128
end-page=1136
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250531
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Surgery for Older Cancer Patients: Cross‐Organ Review and Good Practice Statement by the Japanese Geriatric Oncology Guideline Committee
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Although the number of older people is increasing, there is a lack of evidence and insufficient consensus regarding postoperative complications and survival in older cancer patients. In this study, we conducted a literature search and systematic review focusing on the outcomes after surgery for older cancer patients.<br>
Methods: Literature focusing on surgical treatment for older cancer patients was extracted from Japanese clinical practice guidelines for gastric cancer, lung cancer, colorectal cancer, liver cancer, and gynecological cancers (uterine body, uterine cervix, ovary, and external genitalia and vagina). Outcomes were reviewed, and committee members determined the strength of evidence on a four-point scale (A to D), with A being the highest and D being the lowest.<br>
Results: Older cancer patients tend to have a higher incidence of postoperative complications and postoperative syndromes, and their expected survival is generally shorter compared to non-older patients. When extensive surgeries such as para-aortic lymph node dissection and/or resection with other organs are performed for older cancer patients, the postoperative mortality rates tend to increase compared to non-older patients.<br>
Conclusion: Surgical treatments for older cancer patients tend to result in higher morbidity even when the patients are in good health status. Nevertheless, there is still a possibility that a certain fraction of the patients achieve treatment outcomes comparable to those of non-older patients. Therefore, surgical indication and procedure for older cancer patients should be carefully determined based on surgical invasiveness and patient tolerability.
en-copyright=
kn-copyright=

en-aut-name=TanakaChie
en-aut-sei=Tanaka
en-aut-mei=Chie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OfuchiTakashi
en-aut-sei=Ofuchi
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NinomiyaKiichiro
en-aut-sei=Ninomiya
en-aut-mei=Kiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=InoueDaisuke
en-aut-sei=Inoue
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SugimotoKen
en-aut-sei=Sugimoto
en-aut-mei=Ken
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MurofushiKeiko
en-aut-sei=Murofushi
en-aut-mei=Keiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=OkuyamaToru
en-aut-sei=Okuyama
en-aut-mei=Toru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=WatanukiShigeaki
en-aut-sei=Watanuki
en-aut-mei=Shigeaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=ImamuraChiyo
en-aut-sei=Imamura
en-aut-mei=Chiyo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=SakaiDaisuke
en-aut-sei=Sakai
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=SakuraiNaomi
en-aut-sei=Sakurai
en-aut-mei=Naomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=WatanabeKiyotaka
en-aut-sei=Watanabe
en-aut-mei=Kiyotaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=TamuraKazuo
en-aut-sei=Tamura
en-aut-mei=Kazuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=SaekiToshiaki
en-aut-sei=Saeki
en-aut-mei=Toshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=IshiguroHiroshi
en-aut-sei=Ishiguro
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=2
en-affil=Department of Surgery, Kyushu University Beppu Hospital
kn-affil=

affil-num=3
en-affil=Center for Comprehensive Genomic Medicine, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Obstetrics and Gynecology, University of Fukui
kn-affil=

affil-num=5
en-affil=Department of General Geriatric Medicine, Kawasaki Medical School
kn-affil=

affil-num=6
en-affil=Division of Radiation Oncology, Department of Radiology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
kn-affil=

affil-num=7
en-affil=Department of Psychiatry/Palliative Care Center, Nagoya City University West Medical Center
kn-affil=

affil-num=8
en-affil=National Center for Global Health and Medicine, National College of Nursing
kn-affil=

affil-num=9
en-affil=Advanced Cancer Translational Research Institute, Showa University
kn-affil=

affil-num=10
en-affil=Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine
kn-affil=

affil-num=11
en-affil=Cancer Solutions Co. Ltd
kn-affil=

affil-num=12
en-affil=Division of Medical Oncology, Department of Medicine, School of Medicine, Teikyo University
kn-affil=

affil-num=13
en-affil=NPO Clinical Hematology/Oncology Treatment Study Group
kn-affil=

affil-num=14
en-affil=Breast Oncology Service, Saitama Medical University International Medical Center
kn-affil=

affil-num=15
en-affil=Breast Oncology Service, Saitama Medical University International Medical Center
kn-affil=
en-keyword=cancer
kn-keyword=cancer
en-keyword=older patients
kn-keyword=older patients
en-keyword=surgery
kn-keyword=surgery
END

start-ver=1.4
cd-journal=joma
no-vol=53
cd-vols=
no-issue=5
article-no=
start-page=e2025GL119568
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260303
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Electrical Conductivity of Amorphous and Molten CaCO3 at High Pressures and Its Implications for Mantle Conductivity Anomalies
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Impedance spectrometry experiments have been conducted on CaCO3 up to 15 GPa and 2,100 K to identify its state under high pressure. The melting temperature of CaCO3 was also determined by the falling of a Re sphere observed via X-ray radiography. The phase transition from aragonite to the amorphous phase does not cause a leap in the Electrical conductivity (EC), while a drastic increase in the EC, by 1.5?2.0 log units, only occurs with the onset of melting. The EC of amorphous CaCO3 is comparable to other hydrous mantle minerals at similar pressure and temperature conditions. The required fraction of amorphous CaCO3 implies that it can be excluded from the potential origins responsible for the observed high EC anomalies in the upper mantle. If the conductivity anomalies are induced by the presence of carbonate, a low-degree melting of carbonate-bearing peridotite is anticipated.
en-copyright=
kn-copyright=

en-aut-name=ZhaoBin
en-aut-sei=Zhao
en-aut-mei=Bin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YoshinoTakashi
en-aut-sei=Yoshino
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ChenQi
en-aut-sei=Chen
en-aut-mei=Qi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YuTony
en-aut-sei=Yu
en-aut-mei=Tony
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=ZhangDongzhou
en-aut-sei=Zhang
en-aut-mei=Dongzhou
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ChenBin
en-aut-sei=Chen
en-aut-mei=Bin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=WangYanbin
en-aut-sei=Wang
en-aut-mei=Yanbin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Institute for Planetary Materials, Okayama University
kn-affil=

affil-num=2
en-affil=Institute for Planetary Materials, Okayama University
kn-affil=

affil-num=3
en-affil=Center for Advanced Radiation Sources, The University of Chicago
kn-affil=

affil-num=4
en-affil=Center for Advanced Radiation Sources, The University of Chicago
kn-affil=

affil-num=5
en-affil=Center for Advanced Radiation Sources, The University of Chicago
kn-affil=

affil-num=6
en-affil=School of Ocean and Earth Science and Technology, University of Hawaii at Manoa
kn-affil=

affil-num=7
en-affil=Center for Advanced Radiation Sources, The University of Chicago
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=32
cd-vols=
no-issue=12
article-no=
start-page=8903
end-page=8905
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250818
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Mesenteric Route Superior Mesenteric Artery First Approach in Robot-Assisted Pancreatoduodenectomy
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background. The superior mesenteric artery (SMA) approach is crucial for the successful implementation of robot-assisted pancreatoduodenectomy (RPD). Herein, we present a novel technique, the mesenteric route SMA-first approach, for RPD.<br>
Patients and Methods. A 20-year-old woman with a 50 mm intraductal papillary mucinous neoplasm underwent RPD. As the tumor was large and located close to the mesenteric vessels, we developed the mesenteric route SMA-first approach.<br>
Results. Following the mesenteric Kocher maneuver, the mesenteric route SMA-first approach was applied. With appropriate retraction of the pancreatic head, dissection around the mesenteric vessels was performed and their branches were divided. The uncinate process dissection (PL, ph II) was performed via the mesenteric route. This approach facilitated dorsal dissection, particularly around the large tumor. After dissection of the hepatoduodenal ligament, the remaining pancreatic nerve plexus (PL ph I) was dissected. Finally, the pancreas was divided on the superior mesenteric vein, and the specimen was resected. Operative time was 390 min with minimal blood loss.<br>
Conclusions. The mesenteric route SMA-first approach enables uncinate process dissection via the mesenteric route. This technique may be a safe and feasible option for selected patients, such as nonobese individuals with a large pancreatic head tumor near major vessels.
en-copyright=
kn-copyright=

en-aut-name=TakagiKosei
en-aut-sei=Takagi
en-aut-mei=Kosei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ItoAtene
en-aut-sei=Ito
en-aut-mei=Atene
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=FujiTomokazu
en-aut-sei=Fuji
en-aut-mei=Tomokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YasuiKazuya
en-aut-sei=Yasui
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NishiyamaTakeyoshi
en-aut-sei=Nishiyama
en-aut-mei=Takeyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YanagiharaTsubasa
en-aut-sei=Yanagihara
en-aut-mei=Tsubasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=
en-keyword=Robotic pancreaticoduodenectomy
kn-keyword=Robotic pancreaticoduodenectomy
en-keyword=Superior mesenteric artery approach
kn-keyword=Superior mesenteric artery approach
en-keyword=Mesenteric route
kn-keyword=Mesenteric route
END

start-ver=1.4
cd-journal=joma
no-vol=410
cd-vols=
no-issue=1
article-no=
start-page=171
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Robotic distal pancreatectomy using two-surgeon technique (TAKUMI-4): a technical note and initial outcomes
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Purpose With the increasing use of minimally invasive distal pancreatectomy, the use of robotic distal pancreatectomy (RDP) is also increasing worldwide. Standardized surgical protocols are essential for safe implementation of RDP. In this study, we present our surgical protocol and initial outcomes of RDP using “two-surgeon technique”.<br>
Methods Our standard RDP protocol included a two-surgeon technique for cooperation, rationality, and education. Short-term outcomes of RDP were also investigated. This retrospective study included 77 consecutive patients who underwent RDP at our institution between April 2021 and January 2025.<br>
Results The median operative time, estimated blood loss, and postoperative hospital stay were 214 min (interquartile range [IQR], 176?253), 10 mL (IQR, 0?50), and 9 days (IQR, 8?10), respectively. A textbook outcome was achieved in 84.4% of patients. Moreover, superior outcomes of RDP (n?=?77) compared with those of laparoscopic distal pancreatectomy (n?=?62) were confirmed in this study.<br>
Conclusion Using the two-surgeon technique, we successfully standardized and introduced the RDP program. The two-surgeon technique can contribute to the safe introduction of RDP and expansion of the program.
en-copyright=
kn-copyright=

en-aut-name=TakagiKosei
en-aut-sei=Takagi
en-aut-mei=Kosei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FujiTomokazu
en-aut-sei=Fuji
en-aut-mei=Tomokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YasuiKazuya
en-aut-sei=Yasui
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=
en-keyword=Distal pancreatectomy
kn-keyword=Distal pancreatectomy
en-keyword=Robotic surgery: minimally invasive surgery
kn-keyword=Robotic surgery: minimally invasive surgery
en-keyword=Training
kn-keyword=Training
en-keyword=Outcomes
kn-keyword=Outcomes
END

start-ver=1.4
cd-journal=joma
no-vol=39
cd-vols=
no-issue=5
article-no=
start-page=3137
end-page=3145
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250404
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Impact of visceral fat area on surgical difficulty during robotic distal pancreatectomy (TAKUMI-2)
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Difficulty scoring systems (DSS) have been developed to quantify the surgical complexity of laparoscopic distal pancreatectomy (LDP). However, few studies have validated these systems in the context of robotic distal pancreatectomy (RDP). Moreover, the impact of body composition on RDP outcomes remains unexplored. This study aimed to investigate the risk factors of surgical difficulty in RDP, including body composition.<br>
Methods: This retrospective study included 72 consecutive patients who underwent RDP at our institution between April 2021 and October 2024. Using a modified DSS for LDP, patients were divided into three difficulty index groups. The association between the difficulty index and outcomes was investigated. Multivariate analyses were performed to identify risk factors associated with surgical difficulty (prolonged operative time) in RDP.<br>
Results: Patients were classified into three difficulty index groups: low (n?=?28), intermediate (n?=?25), and high (n?=?19). Operative time was significantly associated with the surgical index (P?=?0.01). Moreover, visceral fat area (VFA) was significantly correlated with operative time (r2?=?0.10, P?=?0.008). The multivariate analyses found that VFA (??100 cm2) (odds ratio [OR] 5.03, 95% confidence interval [CI] 1.32?22.4, P?=?0.02), malignancy (OR 4.92, 95% CI 1.50?18.9, P?=?0.01), and pancreatic resection on the portal vein (OR 4.14, 95% CI 1.24?15.9, P?=?0.02) were significant risk factors associated with surgical difficulty.<br>
Conclusion: VFA could be a novel and useful factor for assessing the surgical difficulty associated with RDP.
en-copyright=
kn-copyright=

en-aut-name=TakagiKosei
en-aut-sei=Takagi
en-aut-mei=Kosei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YamadaMotohiko
en-aut-sei=Yamada
en-aut-mei=Motohiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=FujiTomokazu
en-aut-sei=Fuji
en-aut-mei=Tomokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YasuiKazuya
en-aut-sei=Yasui
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NishiyamaTakeyoshi
en-aut-sei=Nishiyama
en-aut-mei=Takeyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NagaiYasuo
en-aut-sei=Nagai
en-aut-mei=Yasuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KanehiraNoriyuki
en-aut-sei=Kanehira
en-aut-mei=Noriyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=
en-keyword=Robotic distal pancreatectomy
kn-keyword=Robotic distal pancreatectomy
en-keyword=Difficulty score
kn-keyword=Difficulty score
en-keyword=Visceral fat area
kn-keyword=Visceral fat area
END

start-ver=1.4
cd-journal=joma
no-vol=8
cd-vols=
no-issue=2
article-no=
start-page=606
end-page=608
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=2025
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Case of Hepatocellular Carcinoma Associated with Hepatic Sarcoidosis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=NagaiYasuo
en-aut-sei=Nagai
en-aut-mei=Yasuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TakagiKosei
en-aut-sei=Takagi
en-aut-mei=Kosei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YasuiKazuya
en-aut-sei=Yasui
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KariyamaKazuya
en-aut-sei=Kariyama
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=FujiTomokazu
en-aut-sei=Fuji
en-aut-mei=Tomokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology, Okayama City Hospital
kn-affil=

affil-num=5
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=
en-keyword=hepatocellular carcinoma
kn-keyword=hepatocellular carcinoma
en-keyword=hepatic sarcoidosis
kn-keyword=hepatic sarcoidosis
en-keyword=peritoneal sarcoidosis
kn-keyword=peritoneal sarcoidosis
END

start-ver=1.4
cd-journal=joma
no-vol=17
cd-vols=
no-issue=2
article-no=
start-page=e79651
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250225
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Gastric Metastasis of Renal Cell Carcinoma Initially Diagnosed by Esophagogastroduodenoscopy
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Here, we report a rare case of renal cell carcinoma (RCC) initially detected as a gastric metastasis. A 58-year-old man with epigastric discomfort underwent esophagogastroduodenoscopy, which revealed a reddish semi-pedunculated lesion with a whitish coating. Biopsy and imaging confirmed clear cell RCC metastasis. Contrast-enhanced computed tomography (CT) revealed a primary renal tumor with pancreatic and lymph node metastases. Despite chemotherapy treatment, the patient died after 10 months. Gastric metastases from RCC, although rare, should be considered in highly vascular gastric lesions with white coatings. Clinicians must be vigilant for metastatic diseases with atypical gastric findings.
en-copyright=
kn-copyright=

en-aut-name=IwamuroMasaya
en-aut-sei=Iwamuro
en-aut-mei=Masaya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KamioTomohiro
en-aut-sei=Kamio
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HirataShoichiro
en-aut-sei=Hirata
en-aut-mei=Shoichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TanakaTakehiro
en-aut-sei=Tanaka
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OtsukaMotoyuki
en-aut-sei=Otsuka
en-aut-mei=Motoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Pathology, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=
en-keyword=clear renal cell carcinoma
kn-keyword=clear renal cell carcinoma
en-keyword=esophagogastroduodenoscopy (egd)
kn-keyword=esophagogastroduodenoscopy (egd)
en-keyword=gastric metastasis
kn-keyword=gastric metastasis
en-keyword=metastatic tumor, renal cell carcinoma (rcc)
kn-keyword=metastatic tumor, renal cell carcinoma (rcc)
END

start-ver=1.4
cd-journal=joma
no-vol=15
cd-vols=
no-issue=5
article-no=
start-page=1877
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260228
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effect of Surgical Procedures for Rheumatoid Forefoot Deformities on Radiographic Foot Length and Width Variations
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: The number of patients with rheumatoid arthritis (RA) undergoing forefoot arthroplasty has increased to better control the disease. Despite patients frequently expressing concerns regarding postoperative foot appearance and footwear-related expectations, no study has investigated postoperative changes in foot length and width in patients with RA. The aim of this study was to evaluate the effect of surgical procedures for rheumatoid forefoot deformities on variations in radiologically determined foot length and width. Methods: In total, 72 feet of 50 women and 3 men (average age: 66.7 years) underwent joint-preserving arthroplasty (n = 33) and arthrodesis of the first metatarsophalangeal joint with shortening osteotomy of the lesser metatarsals or resection arthroplasty of the lesser metatarsal heads (n = 39); procedures were carried out in our institute from August 2013 to February 2020. The mean disease duration was 23.5 years, and the average follow-up period was 17.5 months. Pre- and postoperative hallux valgus angle (HVA), intermetatarsal angle (IMA) of the first and second metatarsals (M1M2A), and IMA of the first and fifth metatarsals (M1M5A) were measured on weightbearing radiographs as well as foot length and width. We also evaluated the correlation between changes in radiographic parameters and variations in radiologically determined foot length and width. Results: Radiologically determined foot width changed significantly from 10.1 cm to 9.7 cm (p < 0.01), while no significant difference was found between pre- and postoperative radiologically determined foot length. HVA, M1M2A, and M1M5A were significantly improved after the surgery (p < 0.01, p < 0.01, and p < 0.01, respectively). A significant negative correlation was found between the variation in radiologically determined foot length and changes in HVA (r = ?0.29, p = 0.02) and M1M5A (r = ?0.23, p < 0.05), while a significant positive correlation was found between the variation in the foot width and changes in HVA (r = 0.34, p < 0.01), M1M2A (r = 0.55, p < 0.01), and M1M5A (r = 0.45, p < 0.01). There were no significant differences between operative procedures regarding variation in radiologically determined foot length and width. Conclusions: Surgical procedure for rheumatoid forefoot deformity improved radiographic parameters and reduced radiographic foot width while maintaining foot length.
en-copyright=
kn-copyright=

en-aut-name=HoritaMasahiro
en-aut-sei=Horita
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KisoYohei
en-aut-sei=Kiso
en-aut-mei=Yohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NasuYoshihisa
en-aut-sei=Nasu
en-aut-mei=Yoshihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakaharaRyuichi
en-aut-sei=Nakahara
en-aut-mei=Ryuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SaigaKenta
en-aut-sei=Saiga
en-aut-mei=Kenta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OzakiToshifumi
en-aut-sei=Ozaki
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NishidaKeiichiro
en-aut-sei=Nishida
en-aut-mei=Keiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Orthopaedic Surgery, Faculty of Medical Development Field, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Orthopaedic Surgery, Kurashiki Sweet Hospital
kn-affil=

affil-num=3
en-affil=Department of Orthopaedic Surgery, Okayama City Hospital
kn-affil=

affil-num=4
en-affil=Department of Musculoskeletal Health Promotion, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Sports Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Locomotive Pain Center, Faculty of Medical Development Field, Okayama University
kn-affil=
en-keyword=forefoot surgery
kn-keyword=forefoot surgery
en-keyword=foot length
kn-keyword=foot length
en-keyword=foot width
kn-keyword=foot width
en-keyword=rheumatoid arthritis
kn-keyword=rheumatoid arthritis
END

start-ver=1.4
cd-journal=joma
no-vol=14
cd-vols=
no-issue=2
article-no=
start-page=e72067
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Oculogyric Crisis During Chronic Aripiprazole Therapy: A Diagnostic Challenge in the Emergency Department
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Oculogyric crisis can occur even during chronic, stable aripiprazole therapy without recent dose escalation. In patients with acute upward eye deviation and an otherwise normal neurologic examination, medication review is key to recognizing drug-induced dystonia and avoiding unnecessary neurologic workup.
en-copyright=
kn-copyright=

en-aut-name=TokiokaKohei
en-aut-sei=Tokioka
en-aut-mei=Kohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NojimaTsuyoshi
en-aut-sei=Nojima
en-aut-mei=Tsuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MatsuoIppei
en-aut-sei=Matsuo
en-aut-mei=Ippei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TsukaharaKohei
en-aut-sei=Tsukahara
en-aut-mei=Kohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NakaoAtsunori
en-aut-sei=Nakao
en-aut-mei=Atsunori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama Universitye, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences Okayama University  Japan
kn-affil=

affil-num=2
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=acute dystonia
kn-keyword=acute dystonia
en-keyword=aripiprazole
kn-keyword=aripiprazole
en-keyword=drug-induced movement disorder
kn-keyword=drug-induced movement disorder
en-keyword=oculogyric crisis
kn-keyword=oculogyric crisis
END

start-ver=1.4
cd-journal=joma
no-vol=19
cd-vols=
no-issue=1
article-no=
start-page=11
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260105
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Association of Wet-Bulb Globe Temperature with heat-related illness hospitalizations in Japan: a time-stratified, case-crossover study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Heat-related illnesses are a serious public health concern and are exacerbated by global warming. Wet-Bulb Globe Temperature (WBGT) is widely used as a heat stress indicator, but its clinical impact remains unclear. This study aimed to investigate the association between hourly variations in WBGT and the incidence of hospitalizations for heat-related illness in Japan using a nationwide database. By incorporating individual-level clinical data and performing stratified analyses, we sought to provide a more granular understanding of how heat exposure affects the risk of heat-related illness requiring hospitalization.<br>
Methods We conducted a time-stratified, case-crossover study using data collected from July to September in 2020 and 2021 in the Heatstroke STUDY registry. The inclusion criteria were patients registered in the Heatstroke STUDY registry, specifically hospitalized patients with heat-related illness who were transported to participating hospitals during the study period. Hourly WBGT values were assigned based on the nearest monitoring station to each hospital. Conditional logistic regression and distributed lag models were used to estimate associations between WBGT and the risk of hospitalization.<br>
Results A total of 1,653 heat-related illness hospitalizations were analyzed. The mean patient age was 67.9 years; 67.6% were male. Each 1 °C increase in WBGT at onset (hospital arrival) was associated with a significantly increased risk of hospitalization (OR 1.10, 95% CI: 1.05?1.15). The cumulative effect over the prior six hours was also significant (OR 1.56, 95% CI: 1.50?1.62). Compared with WBGT?<?25 °C, adjusted ORs were 3.39 (25?27 °C), 8.81 (28?30 °C), and 22.10 (??31 °C). Stratified analyses suggested stronger associations among several subgroups; however, only patients with mental disorders showed statistically significant effect modification, whereas elevated WBGT posed a risk across all groups.<br>
Conclusions Higher WBGT levels were associated with an increased risk of heat-related hospitalization. Although the effect appeared greater in some subgroups, only patients with mental disorders demonstrated statistically significant effect modification, suggesting elevated WBGT confers risk broadly.
en-copyright=
kn-copyright=

en-aut-name=YamamuraYuka
en-aut-sei=Yamamura
en-aut-mei=Yuka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HongoTakashi
en-aut-sei=Hongo
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YumotoTetsuya
en-aut-sei=Yumoto
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SasaiFumiya
en-aut-sei=Sasai
en-aut-mei=Fumiya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TokiokaKohei
en-aut-sei=Tokioka
en-aut-mei=Kohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ObaraTakafumi
en-aut-sei=Obara
en-aut-mei=Takafumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NojimaTsuyoshi
en-aut-sei=Nojima
en-aut-mei=Tsuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KandaJun
en-aut-sei=Kanda
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=YokoboriShoji
en-aut-sei=Yokobori
en-aut-mei=Shoji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NaitoHiromichi
en-aut-sei=Naito
en-aut-mei=Hiromichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=YorifujiTakashi
en-aut-sei=Yorifuji
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=NakaoAtsunori
en-aut-sei=Nakao
en-aut-mei=Atsunori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

affil-num=1
en-affil=Department of Epidemiology, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Epidemiology, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Emergency and Critical Care Medicine, Nippon Medical School Musashikosugi Hospital
kn-affil=

affil-num=9
en-affil=Department of Emergency and Critical Care Medicine, Nippon Medical School
kn-affil=

affil-num=10
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Epidemiology, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=12
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=
en-keyword=Wet-Bulb Globe Temperature
kn-keyword=Wet-Bulb Globe Temperature
en-keyword=Heat stroke
kn-keyword=Heat stroke
en-keyword=Heat related illness
kn-keyword=Heat related illness
en-keyword=Global warming
kn-keyword=Global warming
END

start-ver=1.4
cd-journal=joma
no-vol=17
cd-vols=
no-issue=11
article-no=
start-page=e97962
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251127
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Association of Carboxyhemoglobin With Severity and Outcomes in Hypothermic Patients: A Retrospective Cohort Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Introduction<br>
Carboxyhemoglobin (COHb), an endogenous marker of carbon monoxide production mediated by heme oxygenase-1, may reflect physiological stress responses in critically ill patients. However, its clinical relevance in accidental hypothermia remains unclear.<br>
<br>
Methods<br>
We conducted a single-center retrospective cohort study of adult patients admitted to the emergency ICU with accidental hypothermia between January 1, 2019, and March 31, 2025. Patients were categorized into low- and high-COHb groups based on median COHb levels upon emergency department arrival. Associations between COHb levels, disease severity (Acute Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA) scores), and 28-day mortality were analyzed using regression models adjusted for clinical confounders.<br>
<br>
Results<br>
Among the 88 patients, who had a median admission temperature of 28.7°C, 45 were classified into the low-COHb group and 43 into the high-COHb group, based on a median COHb level of 0.3%. Lower COHb levels on admission were significantly associated with higher APACHE II scores (β = ?4.20; 95% CI, ?7.56 to ?0.85), but not with SOFA scores. Admission and minimum COHb levels were not associated with 28-day mortality. However, higher maximum COHb levels within the first 24 hours were independently associated with lower 28-day mortality (adjusted OR, 0.17; 95% CI, 0.023 to 0.93).<br>
<br>
Conclusions<br>
Lower COHb levels were associated with greater disease severity, and higher maximum COHb levels were associated with lower 28-day mortality. COHb may reflect systemic stress in accidental hypothermia, but its prognostic value appears limited.
en-copyright=
kn-copyright=

en-aut-name=MiyoshiYuya
en-aut-sei=Miyoshi
en-aut-mei=Yuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YumotoTetsuya
en-aut-sei=Yumoto
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HongoTakashi
en-aut-sei=Hongo
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ObaraTakafumi
en-aut-sei=Obara
en-aut-mei=Takafumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NojimaTsuyoshi
en-aut-sei=Nojima
en-aut-mei=Tsuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NaitoHiromichi
en-aut-sei=Naito
en-aut-mei=Hiromichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NakaoAtsunori
en-aut-sei=Nakao
en-aut-mei=Atsunori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=carbon monoxide
kn-keyword=carbon monoxide
en-keyword=carboxyhemoglobin
kn-keyword=carboxyhemoglobin
en-keyword=heme oxygenase
kn-keyword=heme oxygenase
en-keyword=hypothermia
kn-keyword=hypothermia
en-keyword=sepsis
kn-keyword=sepsis
END

start-ver=1.4
cd-journal=joma
no-vol=15
cd-vols=
no-issue=5
article-no=
start-page=372
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260224
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Alpha-Ketoglutarate Drives an Osteogenic and Extracellular Matrix Gene Program in Periodontal Ligament Fibroblasts via Selective Reduction of H3K27me3
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Periodontal disease damages the tissues that support teeth and can ultimately lead to tooth loss, yet effective treatments to regenerate these tissues are still limited. Recent studies have shown that substances produced during normal cellular metabolism can influence how genes are regulated, but their role in periodontal regeneration has not been fully clarified. In this study, we investigated whether alpha-ketoglutarate, a naturally occurring metabolite involved in energy production, could promote periodontal tissue regeneration. We found that alpha-ketoglutarate enhanced bone-related and extracellular matrix-related gene expression in human periodontal ligament cells by reducing a repressive gene-regulatory signal that normally suppresses these genes. Importantly, alpha-ketoglutarate did not broadly alter chromatin accessibility, indicating that its effects were mediated through selective gene regulation. Furthermore, oral administration of alpha-ketoglutarate promoted alveolar bone regeneration and collagen-rich tissue formation in a mouse model of periodontal disease. Because alpha-ketoglutarate is a naturally occurring molecule in the body, these findings suggest that metabolite-based regulation of gene activity may represent a promising and safe approach for periodontal tissue regeneration.
en-copyright=
kn-copyright=

en-aut-name=HasegawaRyu
en-aut-sei=Hasegawa
en-aut-mei=Ryu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SuzukiShigeki
en-aut-sei=Suzuki
en-aut-mei=Shigeki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=FahrezaRahmad Rifqi
en-aut-sei=Fahreza
en-aut-mei=Rahmad Rifqi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TsaiShin-Ho
en-aut-sei=Tsai
en-aut-mei=Shin-Ho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=DaidoujiYoshino
en-aut-sei=Daidouji
en-aut-mei=Yoshino
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OmoriMasato
en-aut-sei=Omori
en-aut-mei=Masato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KajikawaTetsuhiro
en-aut-sei=Kajikawa
en-aut-mei=Tetsuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YamadaSatoru
en-aut-sei=Yamada
en-aut-mei=Satoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Periodontology and Endodontology, Tohoku University Graduate School of Dentistry
kn-affil=

affil-num=2
en-affil=Department of Operative Dentistry, Okayama University Graduate School, Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Periodontology and Endodontology, Tohoku University Graduate School of Dentistry
kn-affil=

affil-num=4
en-affil=Department of Operative Dentistry, Okayama University Graduate School, Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Periodontology and Endodontology, Tohoku University Graduate School of Dentistry
kn-affil=

affil-num=6
en-affil=Department of Periodontology and Endodontology, Tohoku University Graduate School of Dentistry
kn-affil=

affil-num=7
en-affil=Department of Periodontology and Endodontology, Tohoku University Graduate School of Dentistry
kn-affil=

affil-num=8
en-affil=Department of Periodontology and Endodontology, Tohoku University Graduate School of Dentistry
kn-affil=
en-keyword=alpha-ketoglutarate
kn-keyword=alpha-ketoglutarate
en-keyword=periodontal ligament
kn-keyword=periodontal ligament
en-keyword=extracellular matrix
kn-keyword=extracellular matrix
en-keyword=epigenetic regulation
kn-keyword=epigenetic regulation
en-keyword=H3K27me3
kn-keyword=H3K27me3
END

start-ver=1.4
cd-journal=joma
no-vol=18
cd-vols=
no-issue=4
article-no=
start-page=715
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260223
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Antigen Remodeling in Colorectal Cancer: How Radiotherapy and Chemotherapy Enhance Immunotherapy Responsiveness
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Colorectal cancer (CRC) is traditionally considered a “cold tumor” characterized by low immunogenicity and limited responsiveness to immune checkpoint inhibitors (ICIs). However, recent findings reveal that cytotoxic modalities can reprogram this immunologically inert landscape. This review integrates these evolving concepts to guide the optimization of future treatments. Radiotherapy induces extensive DNA double-strand breaks, which may generate de novo mutations through error-prone repair while simultaneously exposing cryptic antigens via increased transcriptional instability, alternative splicing, and enhanced proteasomal processing. Chemoradiation also amplifies epigenetic and epitranscriptomic sources of neoepitope diversity, including RNA editing and stress-induced splicing alterations, expanding the immunopeptidome beyond canonical mutation-driven neoantigens. These changes collectively enhance antigen presentation and facilitate T-cell priming. Chemotherapy further reduces immunosuppressive cell populations and promotes dendritic cell activation, creating a permissive milieu for subsequent immune engagement. Clinically, the VOLTAGE studies demonstrated that long-course chemoradiotherapy can sensitize even mismatch repair?proficient rectal cancers to PD-1 blockade, yielding clinically meaningful pathological responses. In contrast, mismatch repair?deficient rectal tumors may respond completely to ICIs alone. Short-course radiotherapy combined with chemotherapy and ICIs has also shown encouraging activity in the setting of total neoadjuvant therapy. Collectively, these findings support a paradigm in which radiotherapy, chemotherapy, and epigenetic/epitranscriptomic alterations?including RNA editing?act as potent modulators of tumor antigenicity. By expanding the neoantigen repertoire and reshaping the tumor microenvironment, these strategies can transform CRC from a cold tumor into one that is increasingly responsive to immunotherapy.
en-copyright=
kn-copyright=

en-aut-name=MatsumiYuki
en-aut-sei=Matsumi
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ShigeyasuKunitoshi
en-aut-sei=Shigeyasu
en-aut-mei=Kunitoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakahashiToshiaki
en-aut-sei=Takahashi
en-aut-mei=Toshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MoriwakeKazuya
en-aut-sei=Moriwake
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KayanoMasashi
en-aut-sei=Kayano
en-aut-mei=Masashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=
en-keyword=colorectal cancer
kn-keyword=colorectal cancer
en-keyword=immunotherapy
kn-keyword=immunotherapy
en-keyword=radiotherapy
kn-keyword=radiotherapy
en-keyword=chemotherapy
kn-keyword=chemotherapy
en-keyword=neoantigens
kn-keyword=neoantigens
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260221
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Turning pancreatic cancer from cold to hot: the promise of a p53-expressing oncolytic adenovirus (OBP-702)
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Pancreatic cancer remains one of the most lethal malignancies, with limited therapeutic options and poor responsiveness to immune checkpoint inhibitors (ICIs). This resistance is largely attributed to its profoundly immunosuppressive and desmoplastic tumor microenvironment (TME), characterized by low tumor mutational burden, dense stroma, and abundant immunosuppressive cell populations. Therefore, strategies capable of enhancing tumor immunogenicity and overcoming immune evasion are urgently needed. Oncolytic virotherapy is a promising approach, offering not only tumor-selective cytotoxicity, but also potent immunomodulatory effects. Of these agents, Telomelysin (OBP-301, Suratadenoturev), a telomerase-specific oncolytic adenovirus, demonstrated clinical safety but limited efficacy in refractory tumors. To address this challenge, we developed OBP-702, a next-generation, p53-armed, oncolytic adenovirus designed to augment antitumor activity. Preclinical studies have shown that OBP-702 exerts robust cytotoxicity through multiple mechanisms, including p53-mediated apoptosis and autophagy, E1A?E2F1-mediated p21 suppression, and inhibition of oncogenic KRAS pathways. Importantly, OBP-702 induces strong immunogenic cell death, activates dendritic cells, and promotes tumor-specific T-cell responses, effectively converting immunologically “cold” pancreatic tumors into “hot” tumors. OBP-702 also remodels the immunosuppressive TME by reducing granulocyte?macrophage colony-stimulating factor (GM-CSF) secretion, suppressing myeloid-derived suppressor cells (MDSCs), and targeting stromal components, such as cancer-associated fibroblasts (CAFs). These effects contribute to enhanced responses to ICIs and standard chemotherapies. Given its multifaceted antitumor functions and ability to overcome key barriers in pancreatic cancer, OBP-702 represents a highly promising therapeutic candidate. A first-in-human clinical trial evaluating endoscopic ultrasonography-guided intratumoral injection of OBP-702 is currently in preparation, expected to advance clinical translation of this novel virotherapeutic strategy.
en-copyright=
kn-copyright=

en-aut-name=KurodaShinji
en-aut-sei=Kuroda
en-aut-mei=Shinji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TazawaHiroshi
en-aut-sei=Tazawa
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HashimotoMasashi
en-aut-sei=Hashimoto
en-aut-mei=Masashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KanayaNobuhiko
en-aut-sei=Kanaya
en-aut-mei=Nobuhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KakiuchiYoshihiko
en-aut-sei=Kakiuchi
en-aut-mei=Yoshihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KagawaShunsuke
en-aut-sei=Kagawa
en-aut-mei=Shunsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=UrataYasuo
en-aut-sei=Urata
en-aut-mei=Yasuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Oncolys BioPharma Inc
kn-affil=

affil-num=8
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=Oncolytic adenovirus
kn-keyword=Oncolytic adenovirus
en-keyword=p53
kn-keyword=p53
en-keyword=OBP-702
kn-keyword=OBP-702
en-keyword=Immunogenic cell death
kn-keyword=Immunogenic cell death
en-keyword=Tumor microenvironment
kn-keyword=Tumor microenvironment
en-keyword=Pancreatic cancer
kn-keyword=Pancreatic cancer
END

start-ver=1.4
cd-journal=joma
no-vol=15
cd-vols=
no-issue=2
article-no=
start-page=275
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260206
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Study on the Development of an Image Classification System for Urban Sprawl Areas in Japan
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=In Japan, unlike in many other countries, urbanization has progressed while original rural road structures have been retained, leading to distinctive urban sprawl areas with intermingling residential lots and farmland. Currently, much of Japan’s urban areas consist of urban sprawl areas, posing considerable challenges for infrastructure development. However, for such urban sprawl areas in Japan, it is difficult to say that methods have been established to identify their spatial distribution based on quantitative evaluation. Therefore, for this study, we used machine learning to investigate a system that extracts sprawling urban areas from aerial photographs divided into meshes. In the system’s design, we prioritized precision to ensure the reliable detection of urban sprawl areas. Consequently, the accuracy of identifying sprawl areas achieved precision of 0.81, recall of 0.63, and an F-score of 0.71. Examination of the classification results of sprawl areas revealed that most misclassifications occurred near class boundaries. By contrast, areas with particularly high levels of urban sprawl showed few misclassifications.
en-copyright=
kn-copyright=

en-aut-name=HemmiRyota
en-aut-sei=Hemmi
en-aut-mei=Ryota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=UjiharaTakehito
en-aut-sei=Ujihara
en-aut-mei=Takehito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=AndoRyosuke
en-aut-sei=Ando
en-aut-mei=Ryosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HashimotoSeiji
en-aut-sei=Hashimoto
en-aut-mei=Seiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=2
en-affil=Faculty of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=3
en-affil=National Institute for Land and Infrastructure Management, Ministry of Land, Infrastructure Transport and Tourism
kn-affil=

affil-num=4
en-affil=Faculty of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=
en-keyword=image classification
kn-keyword=image classification
en-keyword=machine learning
kn-keyword=machine learning
en-keyword=sprawl
kn-keyword=sprawl
END

start-ver=1.4
cd-journal=joma
no-vol=25
cd-vols=
no-issue=
article-no=
start-page=e5
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=2026
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effects of sagging correction calibration error on radiation therapy equipment using image analysis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Purpose: This study investigates the effect of sagging correction errors on image quality and geometric coordinate accuracy.<br>
Methods: This study utilised the Elekta radiotherapy system, ball bearing (BB), Catphan phantom and MultiMet-WL phantom. Ten distinct flex maps (FMs) were acquired by positioning the BB at the accuracy isocentre and introducing shifts of 0.2, 0.4 and 0.6 mm in the left, table and up directions, respectively. Cone-beam computed tomography images of the Catphan phantom were acquired using 10 FMs. The images were analysed for modulation transfer function (MTF) values and geometric coordinates. Additionally, the Winston?Lutz (W-L) test was conducted under reference couch positions and with a 0.3 mm couch shift.<br>
Results: For the Catphan phantom analysis, the standard deviations of MTF10% across FMs were 0.19. The centre-of-gravity coordinates of the insert exhibited shifts of approximately 0.2, 0.4 and 0.6 mm when comparing reference images to those acquired with the shifted FMs. The results of the W-L test with a 0.3 mm couch shift showed radiation isocentre deviations exceeding 1 mm compared to the reference couch positions.<br>
Conclusions: Minor sagging correction calibration errors did not remarkably impact image quality; however, they altered the geometric coordinates of the image isocentre. These calibration errors decreased the accuracy of off-isocentre positioning.
en-copyright=
kn-copyright=

en-aut-name=FujiiYasushi
en-aut-sei=Fujii
en-aut-mei=Yasushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NakayamaTakahiro
en-aut-sei=Nakayama
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OshitaJunki
en-aut-sei=Oshita
en-aut-mei=Junki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TsunodaAyaka
en-aut-sei=Tsunoda
en-aut-mei=Ayaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SaekiYusuke
en-aut-sei=Saeki
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TanabeYoshinori
en-aut-sei=Tanabe
en-aut-mei=Yoshinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Radiology, Chugoku Central Hospital of the Mutual Aid Association of Public School Teachers
kn-affil=

affil-num=2
en-affil=Department of Radiology, Chugoku Central Hospital of the Mutual Aid Association of Public School Teachers
kn-affil=

affil-num=3
en-affil=Department of Radiology, Chugoku Central Hospital of the Mutual Aid Association of Public School Teachers
kn-affil=

affil-num=4
en-affil=Department of Radiology, Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Radiological Technology, Kawasaki Medical School Hospital
kn-affil=

affil-num=6
en-affil= Faculty of Medicine, Graduate School of Health Sciences, Okayama University
kn-affil=
en-keyword=flex map
kn-keyword=flex map
en-keyword=sagging
kn-keyword=sagging
en-keyword=Winston?Lutz test
kn-keyword=Winston?Lutz test
END

start-ver=1.4
cd-journal=joma
no-vol=17
cd-vols=
no-issue=12
article-no=
start-page=e100138
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251226
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Streptococcal Toxic Shock Syndrome Following Intestinal Obstruction in a Patient With Crohn’s Disease
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Streptococcal toxic shock syndrome (STSS) is a rare, life-threatening complication of invasive group A streptococcal (iGAS) infections. We report the case of a 24-year-old woman with Crohn's disease receiving immunosuppressive therapy who developed STSS following intestinal obstruction. On day 2, she developed fever, altered mental status, hypoxemia, erythema, and hypotension. Chest CT revealed bilateral pulmonary infiltrates, and blood cultures grew emm1-positive M1UK Streptococcus pyogenes, confirming STSS. Early multidisciplinary intervention resulted in rapid recovery without sequelae. This case emphasizes the importance of considering iGAS-induced STSS in septic shock, especially in immunocompromised patients, and highlights the need for prompt recognition and treatment.
en-copyright=
kn-copyright=

en-aut-name=NishioAyano
en-aut-sei=Nishio
en-aut-mei=Ayano
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=IwamuroMasaya
en-aut-sei=Iwamuro
en-aut-mei=Masaya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=InokuchiToshihiro
en-aut-sei=Inokuchi
en-aut-mei=Toshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IshiguroMikako
en-aut-sei=Ishiguro
en-aut-mei=Mikako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=AoyamaYuki
en-aut-sei=Aoyama
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TakaharaMasahiro
en-aut-sei=Takahara
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HiraokaSakiko
en-aut-sei=Hiraoka
en-aut-mei=Sakiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OguniKohei
en-aut-sei=Oguni
en-aut-mei=Kohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HagiyaHideharu
en-aut-sei=Hagiya
en-aut-mei=Hideharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=MatsuokaYuto
en-aut-sei=Matsuoka
en-aut-mei=Yuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KanazawaTomoyuki
en-aut-sei=Kanazawa
en-aut-mei=Tomoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=OtsukaMotoyuki
en-aut-sei=Otsuka
en-aut-mei=Motoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

affil-num=1
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=

affil-num=9
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Anesthesiology and Resuscitology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Anesthesiology and Resuscitology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=12
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=
en-keyword=crohn’s disease (cd)
kn-keyword=crohn’s disease (cd)
en-keyword=group a streptococcus
kn-keyword=group a streptococcus
en-keyword=immunosuppression
kn-keyword=immunosuppression
en-keyword=intestinal obstruction
kn-keyword=intestinal obstruction
en-keyword=streptococcal toxic shock syndrome (stss)
kn-keyword=streptococcal toxic shock syndrome (stss)
END

start-ver=1.4
cd-journal=joma
no-vol=112
cd-vols=
no-issue=2
article-no=
start-page=2301
end-page=2310
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251010
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Total thymectomy is oncologically superior to partial thymectomy in patients with thymic carcinoma: insights from a multicenter real-world data analysis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Although total thymectomy has been the standard surgical approach for thymic epithelial tumors, an increasing number of recent reports suggest that partial thymectomy for early-stage thymomas may yield outcomes comparable to those of total thymectomy. However, whether partial thymectomy is a viable alternative for thymic carcinoma remains unclear.<br>
Materials and methods: A total of 106 patients with thymic carcinoma underwent curative intended resection at 19 institutions between January 2010 and December 2021. Excluding 14 patients with incomplete resection, 92 patients with thymic carcinoma who underwent total (n = 73) or partial thymectomy (n = 19) were compared. Overall survival (OS) and recurrence-free survival (RFS) were analyzed using Kaplan?Meier curves and Cox proportional hazard models. Overlap weighting was applied to adjust for potential confounding factors.<br>
Results: Among patients with clinical stage I disease, 79.3% were upstaged to stage II or higher postoperatively. Unadjusted analyses revealed no statistically significant differences in OS and RFS between the total and partial thymectomy groups, although a trend toward poorer outcomes in the partial thymectomy group was observed. After overlap weighting, partial thymectomy was associated with significantly poorer OS (P = 0.0027) and higher recurrence risk (P < 0.0001). Early postoperative recurrence occurred more frequently in the partial thymectomy group.<br>
Conclusion: Partial thymectomy was associated with significantly worse survival and recurrence outcomes in thymic carcinoma. Given the limitations of preoperative diagnosis, total thymectomy should remain the preferred surgical approach for undiagnosed thymic epithelial tumors to achieve optimal oncologic control and minimize the risk of recurrence.
en-copyright=
kn-copyright=

en-aut-name=HayashiTatsuya
en-aut-sei=Hayashi
en-aut-mei=Tatsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OkazakiMikio
en-aut-sei=Okazaki
en-aut-mei=Mikio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MitsuhashiToshiharu
en-aut-sei=Mitsuhashi
en-aut-mei=Toshiharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YamamotoHidetaka
en-aut-sei=Yamamoto
en-aut-mei=Hidetaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HabuTomohiro
en-aut-sei=Habu
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ShienKazuhiko
en-aut-sei=Shien
en-aut-mei=Kazuhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=SuzawaKen
en-aut-sei=Suzawa
en-aut-mei=Ken
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YamamotoHiromasa
en-aut-sei=Yamamoto
en-aut-mei=Hiromasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OtsukaTomoaki
en-aut-sei=Otsuka
en-aut-mei=Tomoaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=WatanabeMototsugu
en-aut-sei=Watanabe
en-aut-mei=Mototsugu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KurosakiTakeshi
en-aut-sei=Kurosaki
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=YamadaEiji
en-aut-sei=Yamada
en-aut-mei=Eiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=MatsudaEisuke
en-aut-sei=Matsuda
en-aut-mei=Eisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=HayashiTatsurou
en-aut-sei=Hayashi
en-aut-mei=Tatsurou
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=FujiwaraToshiya
en-aut-sei=Fujiwara
en-aut-mei=Toshiya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=HayamaMakio
en-aut-sei=Hayama
en-aut-mei=Makio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=TaoHiroyuki
en-aut-sei=Tao
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=YamaneMasaomi
en-aut-sei=Yamane
en-aut-mei=Masaomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=InokawaHidetoshi
en-aut-sei=Inokawa
en-aut-mei=Hidetoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=HiramiYuji
en-aut-sei=Hirami
en-aut-mei=Yuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=WashioKazuhiro
en-aut-sei=Washio
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=MisaoTakahiko
en-aut-sei=Misao
en-aut-mei=Takahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=YamashitaMotohiro
en-aut-sei=Yamashita
en-aut-mei=Motohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=SanoYoshifumi
en-aut-sei=Sano
en-aut-mei=Yoshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=NakataMasao
en-aut-sei=Nakata
en-aut-mei=Masao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=KawamataOsamu
en-aut-sei=Kawamata
en-aut-mei=Osamu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=ToyookaShinichi
en-aut-sei=Toyooka
en-aut-mei=Shinichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

affil-num=1
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Center of Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Pathology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Okayama University Thoracic Surgery Study Group (OUTSSG)
kn-affil=

affil-num=6
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Okayama University Thoracic Surgery Study Group (OUTSSG)
kn-affil=

affil-num=9
en-affil=Okayama University Thoracic Surgery Study Group (OUTSSG)
kn-affil=

affil-num=10
en-affil=Okayama University Thoracic Surgery Study Group (OUTSSG)
kn-affil=

affil-num=11
en-affil=Okayama University Thoracic Surgery Study Group (OUTSSG)
kn-affil=

affil-num=12
en-affil=Okayama University Thoracic Surgery Study Group (OUTSSG)
kn-affil=

affil-num=13
en-affil=Okayama University Thoracic Surgery Study Group (OUTSSG)
kn-affil=

affil-num=14
en-affil=Okayama University Thoracic Surgery Study Group (OUTSSG)
kn-affil=

affil-num=15
en-affil=Okayama University Thoracic Surgery Study Group (OUTSSG)
kn-affil=

affil-num=16
en-affil=Okayama University Thoracic Surgery Study Group (OUTSSG)
kn-affil=

affil-num=17
en-affil=Okayama University Thoracic Surgery Study Group (OUTSSG)
kn-affil=

affil-num=18
en-affil=Okayama University Thoracic Surgery Study Group (OUTSSG)
kn-affil=

affil-num=19
en-affil=Okayama University Thoracic Surgery Study Group (OUTSSG)
kn-affil=

affil-num=20
en-affil=Okayama University Thoracic Surgery Study Group (OUTSSG)
kn-affil=

affil-num=21
en-affil=Okayama University Thoracic Surgery Study Group (OUTSSG)
kn-affil=

affil-num=22
en-affil=Okayama University Thoracic Surgery Study Group (OUTSSG)
kn-affil=

affil-num=23
en-affil=Okayama University Thoracic Surgery Study Group (OUTSSG)
kn-affil=

affil-num=24
en-affil=Okayama University Thoracic Surgery Study Group (OUTSSG)
kn-affil=

affil-num=25
en-affil=Okayama University Thoracic Surgery Study Group (OUTSSG)
kn-affil=

affil-num=26
en-affil=Okayama University Thoracic Surgery Study Group (OUTSSG)
kn-affil=

affil-num=27
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=partial thymectomy
kn-keyword=partial thymectomy
en-keyword=real-world data analysis
kn-keyword=real-world data analysis
en-keyword=retrospective comparative cohort study
kn-keyword=retrospective comparative cohort study
en-keyword=thymic carcinoma
kn-keyword=thymic carcinoma
en-keyword=thymic epithelial tumors
kn-keyword=thymic epithelial tumors
en-keyword=total thymectomy
kn-keyword=total thymectomy
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260219
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Induction of IL-9-producing CD8+ T cells by ascochlorin derivatives
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background and Purpose: Ascochlorin (ASC) is an antiviral antibiotic from the fermented broth of Ascochyta viciae which exerts an inhibitory effect to cancers. Its impact on immune cells has not been examined. In this study, we obtained ASC derivatives with less cytotoxicity and determined whether they affected T cells, indicating possible immune-mediated antitumour effects.<br>
Experimental Approach: Newly synthesised ASC derivatives were screened for inhibitory effects on T-cell antigen receptor (TCR)-stimulated proliferative responses using murine CD4+ and CD8+ T cells. Two compounds were identified that exhibited >10-fold less toxicity compared with ASC. N184, the less toxic of the two, was analysed for its in vivo antitumour effects, and in vitro effects on CD8+ T-cell proliferation, survival, cytokine production and exhaustion, using microscopy, qPCR and flow cytometry.<br>
Key Results: N184 induced limited IL-9 production in CD8+ T cells following TCR stimulation, thereby improving cell survival. It also enhanced cytokine production in the late phase of proliferation and suppressed the induction of exhaustion. N184 suppressed tumour growth in mice in a CD8+ T cell-dependent manner. The effect was partially prevented by an IL-9-neutralising antibody.<br>
Conclusion and Implications: N184 induces differentiation of IL-9-producing CD8+ T cells in vitro and elicits antitumour immunity in an IL-9-dependent manner.
en-copyright=
kn-copyright=

en-aut-name=ImanoNatsumi
en-aut-sei=Imano
en-aut-mei=Natsumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NishidaMikako
en-aut-sei=Nishida
en-aut-mei=Mikako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TokumasuMiho
en-aut-sei=Tokumasu
en-aut-mei=Miho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ZhaoWeiyang
en-aut-sei=Zhao
en-aut-mei=Weiyang
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YamashitaNahoko
en-aut-sei=Yamashita
en-aut-mei=Nahoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=UdonoHeiichiro
en-aut-sei=Udono
en-aut-mei=Heiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Immunology, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Metabolic Immune Regulation, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Immunology, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Immunology, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Metabolic Immune Regulation, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Metabolic Immune Regulation, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=ascochlorin derivative
kn-keyword=ascochlorin derivative
en-keyword=CD8 positive T lymphocytes
kn-keyword=CD8 positive T lymphocytes
en-keyword=cell survival
kn-keyword=cell survival
en-keyword=IFN-γ
kn-keyword=IFN-γ
en-keyword=interleukin-9
kn-keyword=interleukin-9
en-keyword=Tc9
kn-keyword=Tc9
en-keyword=tumour immunity
kn-keyword=tumour immunity
END

start-ver=1.4
cd-journal=joma
no-vol=15
cd-vols=
no-issue=
article-no=
start-page=1673581
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260107
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Binding of IgA1 and surface-expressed collagen-binding protein of Streptococcus mutans contributes to IgA nephropathy pathogenesis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: The present study was conducted to examine the interaction between collagen-binding protein (Cnm) of Streptococcus mutans and immunoglobulin (IgA) to clarify the possible involvement in IgA nephropathy (IgAN) development.<br>
Methods: The binding of Cnm to human immunoglobulins was examined using an enzyme-linked immunosorbent assay. A nephritis-induced rat model was employed to confirm the localization of Cnm.<br>
Results: IgA1 showed significantly greater binding ability to Cnm than to other bacterial surface proteins, and Cnm showed significantly greater binding ability to IgA1 than to other immunoglobulins. In rats administered Cnm, IgA deposition was observed in the glomerular mesangial region. Furthermore, biotin-labeled Cnm was observed in the same region as IgA deposition in the Cnm group.<br>
Conclusions: Taken together, it is considered that following invasion into the bloodstream, Cnm binds to and forms a complex with IgA1, leading to deposition of IgA1 in renal glomeruli.
en-copyright=
kn-copyright=

en-aut-name=MatsuokaDaiki
en-aut-sei=Matsuoka
en-aut-mei=Daiki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SueharaKana
en-aut-sei=Suehara
en-aut-mei=Kana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NakaShuhei
en-aut-sei=Naka
en-aut-mei=Shuhei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MisakiTaro
en-aut-sei=Misaki
en-aut-mei=Taro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NagasawaYasuyuki
en-aut-sei=Nagasawa
en-aut-mei=Yasuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ItoSeigo
en-aut-sei=Ito
en-aut-mei=Seigo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=SuehiroYuto
en-aut-sei=Suehiro
en-aut-mei=Yuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=NomuraRyota
en-aut-sei=Nomura
en-aut-mei=Ryota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=NakanoKazuhiko
en-aut-sei=Nakano
en-aut-mei=Kazuhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=Matsumoto-NakanoMichiyo
en-aut-sei=Matsumoto-Nakano
en-aut-mei=Michiyo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Pediatric Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Pediatric Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Pediatric Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Division of Nephrology, Seirei Hamamatsu General Hospital
kn-affil=

affil-num=5
en-affil=Department of General Internal Medicine, Hyogo Medical University
kn-affil=

affil-num=6
en-affil=Department of Internal Medicine, Japan Self-Defense Force Iruma Hospital
kn-affil=

affil-num=7
en-affil=Department of Pediatric Dentistry, Graduate School of Dentistry, The University of Osaka
kn-affil=

affil-num=8
en-affil=Department of Pediatric Dentistry, Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=9
en-affil=Department of Pediatric Dentistry, Graduate School of Dentistry, The University of Osaka
kn-affil=

affil-num=10
en-affil=Department of Pediatric Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=bacterial surface proteins
kn-keyword=bacterial surface proteins
en-keyword=collagen-binding protein
kn-keyword=collagen-binding protein
en-keyword=human immunoglobulins
kn-keyword=human immunoglobulins
en-keyword=IgA nephropathy
kn-keyword=IgA nephropathy
en-keyword=Streptococcus mutans
kn-keyword=Streptococcus mutans
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=1
article-no=
start-page=69
end-page=74
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effective Treatment of Advanced Hepatocellular Carcinoma with Extensive Peritoneal Dissemination Using Lenvatinib
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Patients with hepatocellular carcinoma (HCC) and extensive peritoneal dissemination generally have a poor prognosis and are often resistant to systemic therapy. We report the case of a 47-year-old woman with HCC and massive peritoneal dissemination who presented with malignant ascites requiring repeated cell-free and concentrated ascites reinfusion therapy and peritoneovenous shunt placement, as well as malignant pleural effusion requiring pleurodesis. Combined immunotherapy with durvalumab/tremelimumab was initiated;however, disease progression was observed after three treatment courses, prompting a switch to lenvatinib therapy. Two months after initiation of lenvatinib, CT imaging demonstrated complete disappearance of arterial enhancement in the primary hepatic lesion, along with reduction in the size of peritoneal dissemination nodules. Thirteen months after switching to lenvatinib (16 months after the initial diagnosis), the alpha-fetoprotein level continued to decrease, and the disease remained stable under treatment. Despite the extremely high tumor burden, lenvatinib achieved disease stabilization and symptomatic improvement.
en-copyright=
kn-copyright=

en-aut-name=WakatsukiShinya
en-aut-sei=Wakatsuki
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SakamotoShinya
en-aut-sei=Sakamoto
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=UenoAkiko
en-aut-sei=Ueno
en-aut-mei=Akiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NambaTakaomi
en-aut-sei=Namba
en-aut-mei=Takaomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YamamotoYorito
en-aut-sei=Yamamoto
en-aut-mei=Yorito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MatsumotoManabu
en-aut-sei=Matsumoto
en-aut-mei=Manabu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=IwataJun
en-aut-sei=Iwata
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OkabayashiTakehiro
en-aut-sei=Okabayashi
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Obstetrics and Gynecology, Kochi Health Sciences Center
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=3
en-affil=Department of Obstetrics and Gynecology, Kochi Health Sciences Center
kn-affil=

affil-num=4
en-affil=Department of Obstetrics and Gynecology, Kochi Health Sciences Center
kn-affil=

affil-num=5
en-affil=Department of Obstetrics and Gynecology, Kochi Health Sciences Center
kn-affil=

affil-num=6
en-affil=Department of Diagnostic Pathology, Kochi Health Sciences Center
kn-affil=

affil-num=7
en-affil=Department of Diagnostic Pathology, Kochi Health Sciences Center
kn-affil=

affil-num=8
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=
en-keyword=diagnostic laparoscopy
kn-keyword=diagnostic laparoscopy
en-keyword=hepatocellular carcinoma
kn-keyword=hepatocellular carcinoma
en-keyword=peritoneal dissemination
kn-keyword=peritoneal dissemination
en-keyword=lenvatinib
kn-keyword=lenvatinib
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=1
article-no=
start-page=63
end-page=67
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Metastatic Intraocular Tumor Likely from Hepatocellular Carcinoma Mimicking Panuveitis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=A 77-year-old man undergoing treatment for hepatocellular carcinoma (HCC) presented with blurred vision in his right eye, persisting for 2 months. Slit-lamp microscopy and fundus examination revealed inflammatory cells in the anterior chamber, severe vitreous opacities, and retinal vasculitis in the right eye. The patient underwent vitreous surgery with biopsy, and vitreous cytology confirmed a metastatic intraocular tumor originating from the HCC. Radiotherapy was administered to the right eye, with no recurrence of intraocular inflammation observed at 10 months post-irradiation.
en-copyright=
kn-copyright=

en-aut-name=TakasuEri
en-aut-sei=Takasu
en-aut-mei=Eri
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ShiodeYusuke
en-aut-sei=Shiode
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KindoHiroya
en-aut-sei=Kindo
en-aut-mei=Hiroya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KimuraShuhei
en-aut-sei=Kimura
en-aut-mei=Shuhei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HosokawaMio
en-aut-sei=Hosokawa
en-aut-mei=Mio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MatobaRyo
en-aut-sei=Matoba
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KanzakiYuki
en-aut-sei=Kanzaki
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MoritaTetsuro
en-aut-sei=Morita
en-aut-mei=Tetsuro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=AdachiTakuya
en-aut-sei=Adachi
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=OtsukaMotoyuki
en-aut-sei=Otsuka
en-aut-mei=Motoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=MorizaneYuki
en-aut-sei=Morizane
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=metastatic intraocular tumor
kn-keyword=metastatic intraocular tumor
en-keyword=hepatocellular carcinoma
kn-keyword=hepatocellular carcinoma
en-keyword=panuveitis
kn-keyword=panuveitis
en-keyword=uveitis masquerade syndrome
kn-keyword=uveitis masquerade syndrome
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=1
article-no=
start-page=55
end-page=62
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Changes in Prescribing Patterns of Antiviral Drugs before and after Public Coverage Termination among Hospitalized COVID-19 Patients in Regional Hospitals in Japan: A Retrospective, Multicenter Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=In Japan, antiviral agents for COVID-19 were freely available until September 2023 as part of national policy. This study evaluated changes in these agents’ prescribing patterns and the patient outcomes following the policy shift. We conducted a multicenter retrospective study at four hospitals in Japan’s Okayama and Kagawa prefectures from January 2022 to March 2024. The study period was divided into the public-expenditure phase (January 2022 to September 2023) and the post-expenditure phase (October 2023 to March 2024). We extracted the hospitalized patients’ clinical data from the electronic database. The study’s primary outcome was the antiviral prescription rate; the secondary outcome was in-hospital mortality. Among the 302 hospitalized patients (median age 85 years), 52.0% were classified as having a mild condition. Of the patients with mild conditions, 37.7% were diagnosed in outpatient settings prior to hospitalization. During the public-expenditure phase, 47.4% of the patients received antivirals as outpatients, mainly molnupiravir (80.9%). In the post-expenditure period, 80.0% of the patients were prescribed antivirals, mostly molnupiravir (91.7%). The antiviral prescription rate was significantly higher after the policy change. The overall in-hospital mortality was 15.8%, with no significant difference between the two periods (17.0% vs. 10.5%). Despite the termination of government funding, antiviral prescriptions remained frequent at community hospitals located in highly aging regions of western Japan such as Okayama and Kagawa prefectures. Mortality remains high among the elderly, highlighting the need for continued antiviral therapy and booster vaccinations.
en-copyright=
kn-copyright=

en-aut-name=AkazawaHidemasa
en-aut-sei=Akazawa
en-aut-mei=Hidemasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HagiyaHideharu
en-aut-sei=Hagiya
en-aut-mei=Hideharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=FukushimaShinnosuke
en-aut-sei=Fukushima
en-aut-mei=Shinnosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YamamotoShohei
en-aut-sei=Yamamoto
en-aut-mei=Shohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NakanoYasuhiro
en-aut-sei=Nakano
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OtsukaFumio
en-aut-sei=Otsuka
en-aut-mei=Fumio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,
kn-affil=

affil-num=2
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,
kn-affil=

affil-num=5
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,
kn-affil=

affil-num=6
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,
kn-affil=
en-keyword=coronavirus disease 2019
kn-keyword=coronavirus disease 2019
en-keyword=public expenditure
kn-keyword=public expenditure
en-keyword=prescribing pattern
kn-keyword=prescribing pattern
en-keyword=prognosis
kn-keyword=prognosis
en-keyword=Japan
kn-keyword=Japan
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=1
article-no=
start-page=47
end-page=54
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Time Course of the Development and Loss of Delta-9-tetrahydrocannabinol Tolerance: Effects on Hypothermia and Spontaneous Locomotor Activity in Mice
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Deregulation of cannabis use is gradually expanding in Europe and the United States. However, the biological processes driving tolerance to delta-9-tetrahydrocannabinol (Δ9-THC), the main psychoactive component of cannabis, remain unclear. Thus, this study aimed to investigate the mechanisms and time course of tolerance development and loss to Δ9-THC in mice. Male ICR mice (7 weeks old) were administered Δ9-THC once daily for 3 days and then divided into three groups according to the washout period (3-, 10-, and 17-day washout groups). After each washout, changes in body temperature and locomotor activity were measured following re-exposure to Δ9-THC. Furthermore, the mRNA expression levels of CB1 and CB2 receptors in the brain were evaluated using real-time PCR. On day 1, significant hypothermia and reduced spontaneous locomotor activity were observed in the Δ9-THC-treated mice compared with the vehicle-treated mice. Tolerance to the hypothermic and locomotor-suppressing effects of Δ9-THC developed on days 2 and 3, respectively, and dissipated after 3 and 11 days of washout, respectively. These differences in the rates of tolerance development and recovery may reflect distinct underlying mechanisms. No significant changes in receptor mRNA expression were observed. These findings highlight the complexity of Δ9-THC tolerance and its potential implications for long-term cannabis use.
en-copyright=
kn-copyright=

en-aut-name=EguchiYukiomi
en-aut-sei=Eguchi
en-aut-mei=Yukiomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=UshioSoichiro
en-aut-sei=Ushio
en-aut-mei=Soichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=IrieKeiichi
en-aut-sei=Irie
en-aut-mei=Keiichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YamashitaYuta
en-aut-sei=Yamashita
en-aut-mei=Yuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=EguchiMiyu
en-aut-sei=Eguchi
en-aut-mei=Miyu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NakanoTakafumi
en-aut-sei=Nakano
en-aut-mei=Takafumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MishimaKenichi
en-aut-sei=Mishima
en-aut-mei=Kenichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Physiology and Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University
kn-affil=

affil-num=2
en-affil=Department of Emergency and Disaster Medical Pharmacy, Faculty of Pharmaceutical Sciences, Fukuoka University
kn-affil=

affil-num=3
en-affil=Department of Physiology and Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University
kn-affil=

affil-num=4
en-affil=Department of Physiology and Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University
kn-affil=

affil-num=5
en-affil=Department of Emergency and Disaster Medical Pharmacy, Faculty of Pharmaceutical Sciences, Fukuoka University
kn-affil=

affil-num=6
en-affil=Department of Oncology and Infectious Disease Pharmacy, Faculty of Pharmaceutical Sciences, Fukuoka University
kn-affil=

affil-num=7
en-affil=Department of Physiology and Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University
kn-affil=
en-keyword=delta-9-tetrahydrocannabinol
kn-keyword=delta-9-tetrahydrocannabinol
en-keyword=cannabis
kn-keyword=cannabis
en-keyword=tolerance
kn-keyword=tolerance
en-keyword=locomotor
kn-keyword=locomotor
en-keyword=hypothermic
kn-keyword=hypothermic
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=1
article-no=
start-page=39
end-page=46
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Kinesiophobia Is Associated with Disability, Poor Quality of Life, Psychological Morbidity, and Surgery Dissatisfaction in Patients with Lumbar Microdiscetomy: A Cross-Sectional Controlled Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The study aimed to determine the prevalence of kinesiophobia in patients who had undergone lumbar microdiscectomy and to examine its associations with pain intensity, disability, quality of life, depression, anxiety, and satisfaction with surgery. Forty-eight patients with microdiscectomy and 48 healthy controls were enrolled. The Tampa Scale for Kinesiophobia (TSK), Roland-Morris Disability Index (RMDI), Hospital Anxiety and Depression Scale (HADS-A and HADS-D, respectively), and Short Form-36 Health Survey (SF-36) were administered to both groups. The scores of TSK, RMDI, HADS-A, and HADS-D were significantly higher and SF-36 scores were significantly lower in the microdiscectomy than the control group (p<0.001 for all). In the microdiscectomy group, median (min-max) RMDI, HADS-A, and HADS-D scores were 19 (4-34), 10 (0-18), and 9 (0-18), respectively, in kinesiophobic patients, and were significantly higher than 6 (2-20), 3 (0-11), 2.5 (0-11) in non-kinesiophobic patients (all p<0.001). The median (min-max) SF-36 PCS, SF-36 MCS, and VAS scores for surgery satisfaction were 36.5 (8.7-75), 52.1 (11-95), 5, 5 (0-10), respectively, in kinesiophobic patients and were significantly lower than 71 (28-95), 85.5 (9-93), 8.5 (3-10) in non-kinesiophobic patients (all p<0.05). TSK scores were significantly correlated with RMDI, HADS-A, HADS-D, SF-36, and surgery satisfaction scores (all p<0.05). Kinesiophobic patients with lumbar microdiscectomy therefore showed greater disability and psychological morbidity, poorer quality of life, and lower satisfaction with surgery.
en-copyright=
kn-copyright=

en-aut-name=TezelNihal
en-aut-sei=Tezel
en-aut-mei=Nihal
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=CanAsl? Gen?ay
en-aut-sei=Can
en-aut-mei=Asl? Gen?ay
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Department of Physical and Rehabilitation Medicine, Health Sciences University
kn-affil=

affil-num=2
en-affil=Department of Physical and Rehabilitation Medicine, Faculty of Medicine, Ankara Y?ld?r?m Beyaz?t University
kn-affil=
en-keyword=kinesiophobia
kn-keyword=kinesiophobia
en-keyword=microdiscectomy
kn-keyword=microdiscectomy
en-keyword=disability
kn-keyword=disability
en-keyword=quality of life
kn-keyword=quality of life
en-keyword=depression
kn-keyword=depression
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=1
article-no=
start-page=31
end-page=37
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The Preoperative Anterior Pelvic Plane Angle Predicts Cup Anteversion Changes at 1 Year after Total Hip Arthroplasty
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We investigated global alignment changes following total hip arthroplasty (THA) and predictive alignment parameters for increased cup anteversion (CA) by retrospectively analyzing the primary THA data of 75 patients treated at our hospital (49 women, 26 men; age 65.1±5.7 years, BMI 28.3±3.4 kg/m2). Global alignment parameters, i.e., the anterior pelvic plane angle (APPa) and proximal femoral shaft angle (PFSa) and other alignment parameters were measured. CA was evaluated based on the patients’ standing coronal radiographs. ΔCA was defined as the difference in CA from 2 weeks before to 1 year after each THA. We classified the cases as stable (S) (CA < 10°; n=63) and pelvic retroversion (R) (CA ? 10°; n=12) groups. Associations between ΔCA and alignment parameters were evaluated by linear regression and a receiver operating characteristic (ROC) analysis. A significant decrease in the PFSa occurred between the 2-week and 1-year post-THA timepoints (7.8±4.3° vs. 4.2±3.6°, p<0.001), with no notable change in other alignment parameters. At 1-year post-THA, the CA of 12 (16%) patients had increased to 4.5±4.4°. Only the preoperative APPa was positively associated with ΔCA (β=0.165, p=0.020). The ROC analysis revealed that the optimal cut-off value for increased CA in the APPa is 2.1° (area under the curve, 0.700; p=0.020; odds ratio, 4.80). The APPa change predicted increased CA, which emphasizes the importance of the use of preoperative standing radiography for identifying the optimal cup positioning for post-THA changes in CA.
en-copyright=
kn-copyright=

en-aut-name=IshibashiKyota
en-aut-sei=Ishibashi
en-aut-mei=Kyota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OishiHirotaka
en-aut-sei=Oishi
en-aut-mei=Hirotaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ArakiRyo
en-aut-sei=Araki
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KawamuraKosuke
en-aut-sei=Kawamura
en-aut-mei=Kosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SasakiIsamu
en-aut-sei=Sasaki
en-aut-mei=Isamu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=SasakiEiji
en-aut-sei=Sasaki
en-aut-mei=Eiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KamadaHikaru
en-aut-sei=Kamada
en-aut-mei=Hikaru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KogawaMasakazu
en-aut-sei=Kogawa
en-aut-mei=Masakazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TanakaSunao
en-aut-sei=Tanaka
en-aut-mei=Sunao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NumasawaTakuya
en-aut-sei=Numasawa
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=IshibashiYasuyuki
en-aut-sei=Ishibashi
en-aut-mei=Yasuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Orthopedic Surgery, Hachinohe City Hospital
kn-affil=

affil-num=2
en-affil=Department of Orthopedic Surgery, Hachinohe City Hospital
kn-affil=

affil-num=3
en-affil=Department of Orthopedic Surgery, Hachinohe City Hospital
kn-affil=

affil-num=4
en-affil=Department of Orthopedic Surgery, Hachinohe City Hospital
kn-affil=

affil-num=5
en-affil=Department of Orthopedic Surgery, Hachinohe City Hospital
kn-affil=

affil-num=6
en-affil=Department of Orthopedic Surgery, Hirosaki University Graduate School of Medicine
kn-affil=

affil-num=7
en-affil=Department of Orthopedic Surgery, Hachinohe City Hospital
kn-affil=

affil-num=8
en-affil=Department of Orthopedic Surgery, Hachinohe City Hospital
kn-affil=

affil-num=9
en-affil=Department of Orthopedic Surgery, Hachinohe City Hospital
kn-affil=

affil-num=10
en-affil=Department of Orthopedic Surgery, Hachinohe City Hospital
kn-affil=

affil-num=11
en-affil=Department of Orthopedic Surgery, Hirosaki University Graduate School of Medicine
kn-affil=
en-keyword=total hip arthroplasty
kn-keyword=total hip arthroplasty
en-keyword=global alignment
kn-keyword=global alignment
en-keyword=anterior pelvic plane
kn-keyword=anterior pelvic plane
en-keyword=cup anteversion
kn-keyword=cup anteversion
en-keyword=pelvic tilt
kn-keyword=pelvic tilt
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=1
article-no=
start-page=17
end-page=30
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Development of a Stroke Discharge Support Evaluation Scale for Ward Nurses in Acute Care Hospitals
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This study aimed to develop a scale enabling nurses to objectively evaluate their own stroke discharge support, as a basis for enhancing its overall effectiveness. A draft scale was created based on a literature review, and consisted of a 51-item, 5-point Likert-type questionnaire administered to ward nurses engaged in stroke discharge support at acute care hospitals. Factor analysis was performed to refine the scale. Construct validity was assessed using the known-groups method, and reliability was evaluated through internal consistency analysis. The resulting Stroke Discharge Support Evaluation Scale comprises 29 items across 5 factors, each rated on a 5-point Likert scale. Analysis of the data collected from 237 valid responses demonstrated good internal consistency and supported the scale’s construct validity. The Stroke Discharge Support Evaluation Scale is a reliable and valid tool enabling ward nurses in acute care hospitals to evaluate their own stroke discharge support.
en-copyright=
kn-copyright=

en-aut-name=YanoHideki
en-aut-sei=Yano
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TakahataYoko
en-aut-sei=Takahata
en-aut-mei=Yoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YamaguchiTakeshi
en-aut-sei=Yamaguchi
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SaitoShinya
en-aut-sei=Saito
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Department of Nursing, Faculty of Human Health Sciences, Niimi University
kn-affil=

affil-num=2
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Faculty of Nursing, Shikoku University
kn-affil=

affil-num=4
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=
en-keyword=stroke
kn-keyword=stroke
en-keyword=discharge support
kn-keyword=discharge support
en-keyword=scale development
kn-keyword=scale development
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=1
article-no=
start-page=9
end-page=16
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Novel Nomogram that Predicts Chronic Hemodialysis Patients’ Survival Based on Their Sedentary Behavior
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Appropriate treatments for chronic hemodialysis patients are a public health challenge in Japan. Sedentary behavior appears to be closely associated with these patients’ survival. We thus sought to develop a nomogram that predicts survival based on the duration of chronic hemodialysis patients’ sedentary behavior. One hundred twenty-four patients under chronic hemodialysis (73 men, 51 women, age 71.7±11.1 years) were enrolled in this cohort study. The patients wore a triaxial accelerometer that measured both their sedentary behavior, i.e., total sedentary behavior (minutes) and their maximum sedentary bouts (min) on non-hemodialysis days. We obtained the Kaplan-Meier curve and used the log-rank test and a Cox proportional hazards model to evaluate the relationship between the patients’ sedentary behavior and their survival. We also used a Cox proportional hazards model to develop a nomogram for the patients’ 5-year survival rate. Forty-six patients died during the follow-up period. When we stratified the patients by the medians of total sedentary behavior and maximum sedentary bouts, we observed significant between-group differences. After adjustment for confounding factors in a Cox proportional hazards model, total sedentary behavior and maximum sedentary bouts were identified as critical survival factors, and we generated a nomogram using an index of sedentary behavior. Our analysis results demonstrated that sedentary behavior on non-dialysis days was closely associated with the survival of the chronic hemodialysis patients, suggesting that a decrease in sedentary behavior would prolong their survival. The nomogram developed herein based on sedentary behavior may be useful for predicting the outcomes of chronic hemodialysis patients.
en-copyright=
kn-copyright=

en-aut-name=SugaharaKentaro
en-aut-sei=Sugahara
en-aut-mei=Kentaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KondoTakashi
en-aut-sei=Kondo
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MiyatakeNobuyuki
en-aut-sei=Miyatake
en-aut-mei=Nobuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NishiHiroyuki
en-aut-sei=Nishi
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=UjikeKazuhiro
en-aut-sei=Ujike
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KoumotoKiichi
en-aut-sei=Koumoto
en-aut-mei=Kiichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NamioKeiichi
en-aut-sei=Namio
en-aut-mei=Keiichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HishiiShuhei
en-aut-sei=Hishii
en-aut-mei=Shuhei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=KatayamaAkihiko
en-aut-sei=Katayama
en-aut-mei=Akihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=SuzukiHiromi
en-aut-sei=Suzuki
en-aut-mei=Hiromi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=YamamotoYorimasa
en-aut-sei=Yamamoto
en-aut-mei=Yorimasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Hygiene, Faculty of Medicine, Kagawa University
kn-affil=

affil-num=2
en-affil=Innoshima General Hospital
kn-affil=

affil-num=3
en-affil=Department of Hygiene, Faculty of Medicine, Kagawa University
kn-affil=

affil-num=4
en-affil=Innoshima General Hospital
kn-affil=

affil-num=5
en-affil=Innoshima General Hospital
kn-affil=

affil-num=6
en-affil=Innoshima General Hospital
kn-affil=

affil-num=7
en-affil=Department of Hygiene, Faculty of Medicine, Kagawa University
kn-affil=

affil-num=8
en-affil=Department of Hygiene, Faculty of Medicine, Kagawa University
kn-affil=

affil-num=9
en-affil=Faculty of Social Studies, Shikokugakuin University
kn-affil=

affil-num=10
en-affil=Department of Hygiene, Faculty of Medicine, Kagawa University
kn-affil=

affil-num=11
en-affil=Innoshima General Hospital
kn-affil=
en-keyword=nomogram
kn-keyword=nomogram
en-keyword=chronic hemodialysis
kn-keyword=chronic hemodialysis
en-keyword=sedentary behavior
kn-keyword=sedentary behavior
en-keyword=Cox proportional hazards model
kn-keyword=Cox proportional hazards model
en-keyword=Kaplan- Meier curve
kn-keyword=Kaplan- Meier curve
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=1
article-no=
start-page=1
end-page=7
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Usefulness of D-dimer Assay to Confirm the Course of Overt Venous Thromboembolism (VTE) in Cancer Patients
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Venous thromboembolism (VTE) is a serious complication in patients with cancer. In this population, the presence of thrombi is often assessed at cancer diagnosis by measuring D-dimer levels, which have high sensitivity but low specificity for identifying VTE at this clinical time point. However, the usefulness of D-dimer measurement during anticoagulation therapy has not been fully established, despite its widespread use. In this retrospective observational study, we investigated whether D-dimer measurement during anticoagulation therapy in cancer patients could predict overt VTE at follow-up. The study included patients who underwent D-dimer testing and contrast-enhanced computed tomography between 30 and 100 days after initiation of anticoagulation therapy. Eighty-two patients were included: 60 with cancer and 22 without. The diagnostic performance of D-dimer for overt VTE was as follows: sensitivity, 85.7%; specificity, 87.2%; positive predictive value, 78.3%; and negative predictive value, 89.2%. These findings suggest that D-dimer measurement at follow-up has high sensitivity and specificity for overt VTE in cancer patients and may aid in assessing thrombotic status. Clinically, if anticoagulation therapy is continued until D-dimer levels become negative, the absence of overt VTE could be inferred without additional invasive testing.
en-copyright=
kn-copyright=

en-aut-name=YamaokaHidenaru
en-aut-sei=Yamaoka
en-aut-mei=Hidenaru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YoshidaMasashi
en-aut-sei=Yoshida
en-aut-mei=Masashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SarashinaToshihiro
en-aut-sei=Sarashina
en-aut-mei=Toshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=AkagiSatoshi
en-aut-sei=Akagi
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MiyoshiToru
en-aut-sei=Miyoshi
en-aut-mei=Toru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MunemasaMitsuru
en-aut-sei=Munemasa
en-aut-mei=Mitsuru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NakamuraKazufumi
en-aut-sei=Nakamura
en-aut-mei=Kazufumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=ItoHiroshi
en-aut-sei=Ito
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=YuasaShinsuke
en-aut-sei=Yuasa
en-aut-mei=Shinsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Cardiovascular Medicine, IMS Tokyo Katsushika General Hospital
kn-affil=

affil-num=2
en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Seisukai Kuroda Clinic
kn-affil=

affil-num=4
en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Cardiovascular Medicine, Okayama Rosai Hospital
kn-affil=

affil-num=7
en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of General Internal Medicine 3, Kawasaki Medical School General Medical Center
kn-affil=

affil-num=9
en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=D-dimer
kn-keyword=D-dimer
en-keyword=venous
kn-keyword=venous
en-keyword=thromboembolism
kn-keyword=thromboembolism
en-keyword=cancer
kn-keyword=cancer
END

start-ver=1.4
cd-journal=joma
no-vol=153
cd-vols=
no-issue=3
article-no=
start-page=191
end-page=199
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260114
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Impact of Schizophrenia Spectrum Disorders on the Receipt of Invasive and Systemic Therapy for Colorectal Cancer: A Nationwide Multicenter Retrospective Cohort Study in Japan
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Introduction: This study examined treatment disparities for colorectal cancer among patients diagnosed with schizophrenia spectrum disorders (SSD), focusing on invasive treatments and stage-appropriate systemic therapy within a universal healthcare system.<br>
Method: In this nationwide retrospective cohort study (2018?2021), we identified 248,966 colorectal cancer patients, including 2337 diagnosed with SSD, using linked cancer registry and insurance claims data in Japan. The presence of SSD was classified according to ICD-10 codes F20?29. We used multivariable logistic regression to compare the odds of receiving stage-appropriate adjuvant chemotherapy and systemic therapy, as well as the odds of receiving surgical or endoscopic treatments, between the two groups. The analysis adjusted for age, sex, clinical stage, and scores on the Charlson Comorbidity Index and Barthel Index.<br>
Results: The clinical stage distribution at diagnosis for colorectal cancer differed significantly between patients with SSD and those without psychiatric disorders (p?<?0.001). After adjusting for clinical stage and other covariates, patients with SSD demonstrated significantly lower odds of receiving surgical or endoscopic treatment (adjusted odds ratio [aOR], 0.83; 95% CI, 0.73?0.94). The disparities were more pronounced for systemic therapy; patients with SSD had substantially lower odds of receiving adjuvant chemotherapy for stage III disease (aOR, 0.33; 95% CI, 0.26?0.41) and systemic therapy for stage IV disease (aOR, 0.23; 95% CI, 0.17?0.31).<br>
Conclusion: Patients with SSD encounter substantial disparities in accessing standard colorectal cancer care, particularly systemic therapies. These findings highlight the urgent need for interventions to ensure equitable cancer treatment for this vulnerable population.
en-copyright=
kn-copyright=

en-aut-name=FujiwaraMasaki
en-aut-sei=Fujiwara
en-aut-mei=Masaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YamadaYuto
en-aut-sei=Yamada
en-aut-mei=Yuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=IshiiTaisuke
en-aut-sei=Ishii
en-aut-mei=Taisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=WatanabeTomone
en-aut-sei=Watanabe
en-aut-mei=Tomone
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=FujimoriMaiko
en-aut-sei=Fujimori
en-aut-mei=Maiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NakayaNaoki
en-aut-sei=Nakaya
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KawamuraToshihiko
en-aut-sei=Kawamura
en-aut-mei=Toshihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OtsukiKoji
en-aut-sei=Otsuki
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=ShigeyasuKunitoshi
en-aut-sei=Shigeyasu
en-aut-mei=Kunitoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=ShimazuTaichi
en-aut-sei=Shimazu
en-aut-mei=Taichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=HinotsuShiro
en-aut-sei=Hinotsu
en-aut-mei=Shiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=UchitomiYosuke
en-aut-sei=Uchitomi
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=InagakiMasatoshi
en-aut-sei=Inagaki
en-aut-mei=Masatoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

affil-num=1
en-affil=Department of Neuropsychiatry, Medical Development Field, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Division of Health Services Research, National Cancer Center Institute for Cancer Control, National Cancer Center
kn-affil=

affil-num=4
en-affil=Division of Health Services Research, National Cancer Center Institute for Cancer Control, National Cancer Center
kn-affil=

affil-num=5
en-affil=Division of Survivorship Research, National Cancer Center Institute for Cancer Control, National Cancer Center
kn-affil=

affil-num=6
en-affil=Tohoku Medical Megabank Organization, Tohoku University
kn-affil=

affil-num=7
en-affil=Department of Medical Informatics, Shimane University Hospital
kn-affil=

affil-num=8
en-affil=Department of Psychiatry, Faculty of Medicine, Shimane University
kn-affil=

affil-num=9
en-affil=Department of Gastroenterological Surgery, Medical Development Field, Okayama University
kn-affil=

affil-num=10
en-affil=Division of Behavioral Sciences, National Cancer Center Institute for Cancer Control, National Cancer Center
kn-affil=

affil-num=11
en-affil=Department of Biostatistics and Data Management, Sapporo Medical University
kn-affil=

affil-num=12
en-affil=Department of Cancer Survivorship and Digital Medicine, The Jikei University School of Medicine
kn-affil=

affil-num=13
en-affil=Department of Psychiatry, Faculty of Medicine, Shimane University
kn-affil=
en-keyword=colorectal cancer
kn-keyword=colorectal cancer
en-keyword=healthcare disparities
kn-keyword=healthcare disparities
en-keyword=psycho-oncology
kn-keyword=psycho-oncology
en-keyword=schizophrenia spectrum disorders
kn-keyword=schizophrenia spectrum disorders
END

start-ver=1.4
cd-journal=joma
no-vol=15
cd-vols=
no-issue=4
article-no=
start-page=1422
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260211
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Perioperative Ozoralizumab Management for Patients with Rheumatoid Arthritis Who Underwent Orthopaedic Surgery: A Retrospective Case Series
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background/Objectives: Launched in Japan in 2022, ozoralizumab (OZR) is a novel, anti-tumour necrosis factor (TNF)-α inhibitor for treating rheumatoid arthritis (RA) that is refractory to conventional therapies. However, there is a lack of evidence regarding its perioperative management. Methods: This retrospective case series included nine patients with RA who underwent a total of 12 either RA-related (n = 9) or unrelated (n = 3) orthopaedic procedures. We reviewed patient demographics, surgical procedures, perioperative OZR discontinuation periods, and postoperative complications. Results: The mean preoperative OZR discontinuation period was 15.8 days (range, 2?25 days). Sutures were removed at a mean of 12.8 days postoperatively (range, 11?14 days) after adequate wound healing had been confirmed. The mean total discontinuation period was 34.9 days (range, 27?43 days). No cases of surgical site infection (SSI) or delayed wound healing (DWH) were observed during a minimum follow-up period of three months. One patient experienced a disease flare before OZR was restarted. Conclusions: Preoperative OZR discontinuation for up to four weeks appeared to be safe in this cohort. These findings may assist orthopaedic surgeons in determining an appropriate perioperative discontinuation strategy for OZR that minimises SSI and DWH risk while reducing the likelihood of RA flare.
en-copyright=
kn-copyright=

en-aut-name=NishidaKeiichiro
en-aut-sei=Nishida
en-aut-mei=Keiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NasuYoshihisa
en-aut-sei=Nasu
en-aut-mei=Yoshihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HaradaRyozo
en-aut-sei=Harada
en-aut-mei=Ryozo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakaharaRyuichi
en-aut-sei=Nakahara
en-aut-mei=Ryuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HoritaMasahiro
en-aut-sei=Horita
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NatsumedaMasamitsu
en-aut-sei=Natsumeda
en-aut-mei=Masamitsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NaniwaShuichi
en-aut-sei=Naniwa
en-aut-mei=Shuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OzakiToshifumi
en-aut-sei=Ozaki
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Locomotive Pain Center, Faculty of Medical Development Field, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Orthopaedic Surgery, Okayama City Hospital
kn-affil=

affil-num=3
en-affil=Department of Orthopaedic Surgery, Kurashiki Sweet Hospital
kn-affil=

affil-num=4
en-affil=Locomotive Pain Center, Faculty of Medical Development Field, Okayama University
kn-affil=

affil-num=5
en-affil=Locomotive Pain Center, Faculty of Medical Development Field, Okayama University
kn-affil=

affil-num=6
en-affil=Rheumatic Disease Center, Mabi Memorial Hospital
kn-affil=

affil-num=7
en-affil=Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=8
en-affil=Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=delayed wound healing
kn-keyword=delayed wound healing
en-keyword=discontinuation
kn-keyword=discontinuation
en-keyword=ozoralizumab
kn-keyword=ozoralizumab
en-keyword=orthopaedic surgery
kn-keyword=orthopaedic surgery
en-keyword=perioperative management
kn-keyword=perioperative management
en-keyword=rheumatoid arthritis
kn-keyword=rheumatoid arthritis
en-keyword=surgical site infection
kn-keyword=surgical site infection
END

start-ver=1.4
cd-journal=joma
no-vol=14
cd-vols=
no-issue=1
article-no=
start-page=9
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260212
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The Influence of Fluidic Flow Stress on the Development of the Secondary Palate
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Craniofacial development is orchestrated by a finely regulated interplay of numerous genes and signaling pathways. Palatogenesis proceeds through a complex, stepwise process, in which endogenous mechanical stresses within tissues have been implicated. However, the impact of exogenous fluidic flow mechanical stress derived from maternal movement on palatal development remains unclear. In this study, we investigated the effect of exogenous fluidic flow mechanical stress on palatal morphogenesis, focusing on the horizontal outgrowth of palatal shelves after elevation. Palatal tissues dissected from mouse embryos were subjected to organ culture with or without mechanical loading (loaded and unloaded groups, respectively). Stress magnitude was quantified by calculating wave energy, and morphometric and molecular analyses were performed. Compared with the unloaded group, palatal shelves in the loaded group showed significant increases in thickness and volume, accompanied by enhanced cell proliferation, nuclear translocation of YAP and β-catenin, and upregulation of the osteogenic markers Osterix and Osteocalcin. No significant difference in apoptosis was observed. These findings indicate that exogenous mechanical stress promotes cell proliferation and osteogenic differentiation through the Hippo and WNT/β-catenin pathways in palate explants. Our results suggest that moderate maternal movement-induced mechanical stress contributes to normal palatogenesis, providing new insights into the mechanisms underlying cleft palate.
en-copyright=
kn-copyright=

en-aut-name=NagataMasayo
en-aut-sei=Nagata
en-aut-mei=Masayo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HayanoSatoru
en-aut-sei=Hayano
en-aut-mei=Satoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=WangZiyi
en-aut-sei=Wang
en-aut-mei=Ziyi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KosamiTakahiro
en-aut-sei=Kosami
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KamiokaHiroshi
en-aut-sei=Kamioka
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of Orthodontics, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Orthodontics, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Molecular Biology and Biochemistry, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Orthodontics, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Orthodontics, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=mechanical stress
kn-keyword=mechanical stress
en-keyword=palatal development
kn-keyword=palatal development
en-keyword=β-catenin
kn-keyword=β-catenin
en-keyword=YAP
kn-keyword=YAP
END

start-ver=1.4
cd-journal=joma
no-vol=178
cd-vols=
no-issue=1
article-no=
start-page=e70775
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202601
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Reactive Carbonyl Species Mediate Isothiocyanate Signaling Pathway in Arabidopsis thaliana Guard Cells
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Our previous results demonstrated that depletion of glutathione (GSH) rather than elevation of levels of reactive oxygen species (ROS) is highly correlated with the decrease in stomatal aperture induced by isothiocyanates (ITCs), although ROS is considered a key second messenger in stomatal closure, suggesting that another signal component regulates stomatal apertures along with GSH depletion. This study, using Arabidopsis, clarified that reactive carbonyl species (RCS), especially acrolein and 4-hydroxy-(E)-2-nonenal, are determinants of stomatal aperture responses to ITCs. All tested ITCs, allyl isothiocyanate (AITC), sulforaphane (SFN), benzyl isothiocyanate (BITC), and phenethyl isothiocyanate (PEITC), significantly induced stomatal closure, which was inhibited by the RCS scavengers, carnosine and pyridoxamine. The RCS scavengers suppressed ITC-induced depletion of GSH but not elevation of ROS levels. All tested ITCs (AITC, SFN, BITC, and PEITC) increased levels of RCS and non-RCS aldehydes in the epidermal tissues. However, acrolein, 4-hydroxy-(E)-2-nonenal, crotonaldehyde, and (E)-2-pentenal induced stomatal closure at 10 and 100?μM, whereas propionaldehyde, butyraldehyde, and n-pentanal did not at concentrations up to 100?μM. Acrolein and 4-hydroxy-(E)-2-nonenal more effectively induced stomatal closure and GSH depletion than crotonaldehyde and (E)-2-pentenal did. The contents of RCS were more strongly correlated with GSH levels and stomatal closure than with ROS levels. These results suggest that RCS, especially acrolein and 4-hydroxy-(E)-2-nonenal, acts as key regulators of stomatal closure in guard cells in response to ITCs.
en-copyright=
kn-copyright=

en-aut-name=FarzanaSumaiya
en-aut-sei=Farzana
en-aut-mei=Sumaiya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=IslamMd. Moshiul
en-aut-sei=Islam
en-aut-mei=Md. Moshiul
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NakamuraToshiyuki
en-aut-sei=Nakamura
en-aut-mei=Toshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakamuraYoshimasa
en-aut-sei=Nakamura
en-aut-mei=Yoshimasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MunemasaShintaro
en-aut-sei=Munemasa
en-aut-mei=Shintaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ManoJun'ichi
en-aut-sei=Mano
en-aut-mei=Jun'ichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MurataYoshiyuki
en-aut-sei=Murata
en-aut-mei=Yoshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=3
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=4
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=5
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=6
en-affil=Science Research Center, Yamaguchi University
kn-affil=

affil-num=7
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=
en-keyword=arabidopsis
kn-keyword=arabidopsis
en-keyword=GSH depletion
kn-keyword=GSH depletion
en-keyword=isothiocyanate
kn-keyword=isothiocyanate
en-keyword=reactive carbonyl species
kn-keyword=reactive carbonyl species
en-keyword=reactive oxygen species
kn-keyword=reactive oxygen species
END

start-ver=1.4
cd-journal=joma
no-vol=26
cd-vols=
no-issue=12
article-no=
start-page=5742
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250615
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Specific Heat-Killed Lactic Acid Bacteria Enhance Mucosal Aminopeptidase N Activity in the Small Intestine of Aged Mice
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Aminopeptidase N (APN), an enzyme expressed in the small intestinal mucosa, is involved in dietary protein digestion. Previous studies have shown that oral administration of fermented milk containing lactic acid bacteria (LAB) enhances mucosal APN activity in young mice. This study aimed to investigate whether LAB strains stimulate mucosal APN activity in aged mice and to evaluate its relevance to age-related changes in body composition. The underlying molecular mechanisms were also explored in vitro. Experiment 1: Aged C57BL/6J mice were fed diets supplemented with heat-killed LAB strains?Enterococcus faecalis OU-23 (EF), Leuconostoc mesenteroides OU-03 (LM), or Lactiplantibacillus plantarum SNK12 (LP). Compared to the aged Control group, the ileal APN activity was significantly higher in the LP group. LP administration also elevated serum Gla-osteocalcin levels and decreased serum CTX-1 levels. Experiment 2: IEC-6 cells were co-cultured with LP that had been treated with RNase, DNase, or lysozyme. APN activity was significantly lower in cells co-cultured with DNase- or lysozyme-treated LP compared to those co-cultured with untreated LP. A specific LAB strain may enhance mucosal APN activity in the aged intestine, potentially contributing to improved bone metabolism. This effect may be mediated by bacterial DNA and peptidoglycan.
en-copyright=
kn-copyright=

en-aut-name=TsurutaTakeshi
en-aut-sei=Tsuruta
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=WakisakaMami
en-aut-sei=Wakisaka
en-aut-mei=Mami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=WatanabeTakumi
en-aut-sei=Watanabe
en-aut-mei=Takumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NishijimaAoi
en-aut-sei=Nishijima
en-aut-mei=Aoi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=IkedaAkihito
en-aut-sei=Ikeda
en-aut-mei=Akihito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TeraokaMao
en-aut-sei=Teraoka
en-aut-mei=Mao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=WangTianyang
en-aut-sei=Wang
en-aut-mei=Tianyang
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=ChenKuiyi
en-aut-sei=Chen
en-aut-mei=Kuiyi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=NishinoNaoki
en-aut-sei=Nishino
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Faculty of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=2
en-affil=Faculty of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=3
en-affil=Bio-Lab Co., Ltd.
kn-affil=

affil-num=4
en-affil=Faculty of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=5
en-affil=Faculty of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=6
en-affil=Faculty of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=7
en-affil=Faculty of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=8
en-affil=Faculty of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=9
en-affil=Faculty of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=
en-keyword=aging
kn-keyword=aging
en-keyword=aminopeptidase N
kn-keyword=aminopeptidase N
en-keyword=bone metabolism
kn-keyword=bone metabolism
en-keyword=lactic acid bacteria
kn-keyword=lactic acid bacteria
en-keyword=small intestine
kn-keyword=small intestine
END

start-ver=1.4
cd-journal=joma
no-vol=123
cd-vols=
no-issue=6
article-no=
start-page=e2518136123
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260204
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A nuclear CobW/WW-domain factor represses the CO2-concentrating mechanism in the green alga Chlamydomonas reinhardtii
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Microalgae induce a CO2-concentrating mechanism (CCM) to maintain photosynthesis when CO2 is limited. Because this system consumes a substantial portion of photosynthetically generated ATP, its suppression when CO2 levels rise is critical for energy balance, yet the underlying mechanism remains unclear. Here, we identify a nuclear repressor of the CCM in the green alga Chlamydomonas reinhardtii. A pull-down screen for interacting partners of the master activator CCM1/CIA5 revealed an uncharacterized protein that tightly associates with CCM1. This protein, CCM1-binding protein 1 (CBP1), combines a CobW/CobW_C GTP-binding metallochaperone module with a WW-domain characteristic of protein?protein interactions. CBP1 colocalizes and interacts with CCM1 in the nucleus regardless of CO2 conditions. Disruption of CBP1 does not affect growth or CCM induction under CO2 limitation but derepresses 27 of 41 CCM1-dependent low-CO2 inducible genes under high-CO2 conditions. These include the periplasmic and intracellular carbonic anhydrases (CAH1 and LCIB) and inorganic carbon transporters/channels (LCIA, LCI1, BST1, and BST3). Consistently, cbp1 mutants accumulate CAH1 and LCIB proteins and exhibit 40% higher inorganic carbon affinity under high-CO2 conditions; this phenotype is rescued by CBP1 complementation or by acetazolamide treatment. Crucially, cbp1 mutants exhibit significant growth delays under high-CO2 conditions, especially when light is limiting, providing direct evidence that CBP1-mediated repression is essential for energy conservation. Thus, CBP1 prevents unnecessary CCM activity when CO2 is abundant, acting upstream of both transporter/channel and carbonic anhydrase modules. Our findings suggest a regulatory mechanism potentially linking zinc-dependent protein chemistry to CCM gene repression, providing insights into energy-efficient CO2 sensing in aquatic photosynthetic organisms.
en-copyright=
kn-copyright=

en-aut-name=ShimamuraDaisuke
en-aut-sei=Shimamura
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YasudaJunko
en-aut-sei=Yasuda
en-aut-mei=Junko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YamaharaYosuke
en-aut-sei=Yamahara
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakanoHirobumi
en-aut-sei=Nakano
en-aut-mei=Hirobumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OzawaShin-Ichiro
en-aut-sei=Ozawa
en-aut-mei=Shin-Ichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TokutsuRyutaro
en-aut-sei=Tokutsu
en-aut-mei=Ryutaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YamagamiAyumi
en-aut-sei=Yamagami
en-aut-mei=Ayumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MatsushitaTomonao
en-aut-sei=Matsushita
en-aut-mei=Tomonao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TakahashiYuichiro
en-aut-sei=Takahashi
en-aut-mei=Yuichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NakanoTakeshi
en-aut-sei=Nakano
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=FukuzawaHideya
en-aut-sei=Fukuzawa
en-aut-mei=Hideya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=YamanoTakashi
en-aut-sei=Yamano
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

affil-num=1
en-affil=Graduate School of Biostudies, Division of Integrated Life Science, Kyoto University
kn-affil=

affil-num=2
en-affil=Graduate School of Biostudies, Division of Integrated Life Science, Kyoto University
kn-affil=

affil-num=3
en-affil=Graduate School of Biostudies, Division of Integrated Life Science, Kyoto University
kn-affil=

affil-num=4
en-affil=Graduate School of Biostudies, Division of Integrated Life Science, Kyoto University
kn-affil=

affil-num=5
en-affil=Institute of Plant Science and Resources, Okayama University
kn-affil=

affil-num=6
en-affil=Graduate School of Science, Division of Biological Sciences, Kyoto University
kn-affil=

affil-num=7
en-affil=Graduate School of Biostudies, Division of Integrated Life Science, Kyoto University
kn-affil=

affil-num=8
en-affil=Graduate School of Science, Division of Biological Sciences, Kyoto University
kn-affil=

affil-num=9
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=

affil-num=10
en-affil=Graduate School of Biostudies, Division of Integrated Life Science, Kyoto University
kn-affil=

affil-num=11
en-affil=Graduate School of Biostudies, Division of Integrated Life Science, Kyoto University
kn-affil=

affil-num=12
en-affil=Graduate School of Biostudies, Division of Integrated Life Science, Kyoto University
kn-affil=
en-keyword=carbonic anhydrase
kn-keyword=carbonic anhydrase
en-keyword=Chlamydomonas reinhardtii
kn-keyword=Chlamydomonas reinhardtii
en-keyword=CO2-concentrating mechanism
kn-keyword=CO2-concentrating mechanism
en-keyword=photosynthesis
kn-keyword=photosynthesis
en-keyword=pyrenoid
kn-keyword=pyrenoid
END

start-ver=1.4
cd-journal=joma
no-vol=65
cd-vols=
no-issue=4
article-no=
start-page=300
end-page=309
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2013
dt-pub=20130222
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Synthesis of biopterin and related pterin glycosides
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Certain pterins having a hydroxyalkyl side chain at C-6 have been found as glycosidic forms in certain prokaryotes, such as 2′-O-(α-D-glucopyranosyl)biopterin from various kinds of cyanobacteria, and limipterin from a green sulfur photosynthetic bacterium. Synthetic studies on glycosides of biopterin and related pterins have been made in view of the structural proof as well as for closer examination of their biological activities and functions. The syntheses of these natural pterin glycosides have effectively been achieved, mostly through appropriately protected N2-(N,N-dimethylaminomethylene)-3-[2-(4-nitrophenyl)ethyl]pterin derivatives as glycosyl acceptors, and are reviewed here. ? 2013 IUBMB Life 65(4):300?309, 2013.
en-copyright=
kn-copyright=

en-aut-name=HanayaTadashi
en-aut-sei=Hanaya
en-aut-mei=Tadashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YamamotoHiroshi
en-aut-sei=Yamamoto
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Department of Chemistry, Faculty of Science, Okayama University
kn-affil=

affil-num=2
en-affil=School of Pharmacy, Shujitsu University
kn-affil=
en-keyword=pteridine
kn-keyword=pteridine
en-keyword=pterin glycoside
kn-keyword=pterin glycoside
en-keyword=biopterin
kn-keyword=biopterin
en-keyword=ciliapterin
kn-keyword=ciliapterin
en-keyword=neopterin
kn-keyword=neopterin
en-keyword=limipterin
kn-keyword=limipterin
en-keyword=tepidopterin
kn-keyword=tepidopterin
en-keyword=asperopterin-A
kn-keyword=asperopterin-A
en-keyword=protecting group
kn-keyword=protecting group
en-keyword=glycosylation
kn-keyword=glycosylation
END

start-ver=1.4
cd-journal=joma
no-vol=19
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202601
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Clinical efficacy and safety of endoscopic ultrasound-guided ablation therapies for pancreatic neuroendocrine tumors: a systematic review and meta-analysis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Pancreatic neuroendocrine tumors (pNETs) are rare; however, they are increasingly being detected. Although surgical resection remains the standard treatment, its invasiveness has prompted interest in less invasive alternatives, particularly for small non-functional pNETs (NF-pNETs) and insulinomas.<br>
Objectives: To evaluate the clinical efficacy and safety of endoscopic ultrasound-guided ethanol injection (EUS-EI) and radiofrequency ablation (EUS-RFA) for pNETs.<br>
Design: A systematic review and meta-analysis.<br>
Data sources and methods: A literature search of PubMed, MEDLINE, and Google Scholar was conducted (April 2005?April 2025). Studies were eligible if they reported clinical outcomes of EUS-EI or EUS-RFA in adult patients with insulinomas or NF-pNETs. The primary endpoints were clinical success (short-term symptom resolution or radiological response) and adverse event (AE) rates. Data were pooled using a random-effects model.<br>
Results: Twenty-six studies were included in the meta-analysis. For insulinomas, the pooled clinical success rate was 77% (95% confidence interval (CI), 59?88) for EUS-EI and 95% (95% CI, 89?97) for EUS-RFA. The pooled incidence of total AEs was 32% (95% CI, 17?51) for EUS-EI and 25% (95% CI, 15?39) for EUS-RFA. For NF-pNETs, the pooled clinical success rates were 76% (95% CI, 54?90) for EUS-EI and 85% (95% CI, 74?92) for EUS-RFA, and the pooled incidence of total AEs was 27% (95% CI, 20?35) and 26% (95% CI, 17?38), respectively. The most common moderate or severe AEs were pancreatitis in 12 patients (7.6%) after EUS-EI, and pancreatic fluid collection in 4 patients (1.9%) and pancreatic duct stricture in 3 patients (1.4%) after EUS-RFA. One fatal case occurred in a 97-year-old patient following EUS-RFA.<br>
Conclusion: Both EUS-EI and EUS-RFA are effective, relatively safe, and minimally invasive treatment options for pNETs. However, severe AE can occur, and careful patient selection and treatment indication are essential.<br>
Trial registration: Not registered.
en-copyright=
kn-copyright=

en-aut-name=MatsumotoKazuyuki
en-aut-sei=Matsumoto
en-aut-mei=Kazuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FujiiYuki
en-aut-sei=Fujii
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=UchidaDaisuke
en-aut-sei=Uchida
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TakeuchiYasuto
en-aut-sei=Takeuchi
en-aut-mei=Yasuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MitsuhashiToshiharu
en-aut-sei=Mitsuhashi
en-aut-mei=Toshiharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OtsukaMotoyuki
en-aut-sei=Otsuka
en-aut-mei=Motoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=
en-keyword=ablation techniques
kn-keyword=ablation techniques
en-keyword=endoscopic ultrasonography
kn-keyword=endoscopic ultrasonography
en-keyword=ethanol
kn-keyword=ethanol
en-keyword=pancreatic neuroendocrine tumors
kn-keyword=pancreatic neuroendocrine tumors
en-keyword=radiofrequency ablation
kn-keyword=radiofrequency ablation
END

start-ver=1.4
cd-journal=joma
no-vol=62
cd-vols=
no-issue=12
article-no=
start-page=2021
end-page=2029
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202510
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=An Improved Synthesis of a Key Intermediate for Glycosylation of Biopterin and Its Application for the First Synthesis of Microcystbiopterin B
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=A key intermediate for the selective 2′-O-glycosylation of biopterin, N2-(N,N-dimethylaminomethylene)-1′-O-(4-methoxybenzyl)-3-[2-(4-nitrophenyl)ethyl]biopterin (12), was efficiently synthesized via a novel route starting from d-glucose, leading to an improved overall yield. This new pathway involves the preparation of a 5-deoxy-l-arabinose phenylhydrazone derivative (9) as a crucial intermediate in the construction of the pteridine ring. Utilizing compound 12, the first synthesis of microcystbiopterin B (4) was accomplished by glycosylation of 12 with 4,6-di-O-acetyl-2-O-(4-methoxybenzyl)-3-O-methyl-α-d-glucopyranosyl bromide (19) in the presence of silver triflate and tetramethylurea, followed by stepwise deprotection.
en-copyright=
kn-copyright=

en-aut-name=HanayaTadashi
en-aut-sei=Hanaya
en-aut-mei=Tadashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MaedaYuta
en-aut-sei=Maeda
en-aut-mei=Yuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=IwasakiKatsuya
en-aut-sei=Iwasaki
en-aut-mei=Katsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Department of Chemistry, Faculty of Science, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Chemistry, Faculty of Science, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Chemistry, Faculty of Science, Okayama University
kn-affil=
en-keyword=microcystbiopterin B 
kn-keyword=microcystbiopterin B 
en-keyword=pteridine
kn-keyword=pteridine
en-keyword=pterin glycoside
kn-keyword=pterin glycoside
en-keyword=structural identification
kn-keyword=structural identification
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260119
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A retrospective cohort study comparing periodontal regeneration using fibroblast growth factor‐2 versus autologous bone graft
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Fibroblast growth factor-2 (FGF-2) is a novel agent utilized in periodontal regeneration therapy. However, its clinical efficacy compared with autologous bone graft (ABG), a long-established treatment, remains unclear. This study aimed to compare the clinical outcomes of FGF-2 and ABG and to assess the impact of patient background factors on outcomes when using FGF-2.<br>
Methods: We collected the subjects from January 2013 to September 2023. Clinical outcomes included the vertical bone defect improvement rate (VBDIR) and the probing pocket depth improvement (PPDI). Clinical outcomes between the two groups were compared using analysis of covariance (ANCOVA), adjusting for age, sex, smoking history, and hypertension. Additionally, a multilevel linear analysis was performed to assess factors influencing outcomes in FGF-2.<br>
Results: A total of 180 sites from 141 patients (FGF-2: 150 sites; ABG: 30 sites) were evaluated. Both VBDIR and PPDI significantly improved postoperatively in both groups. There were no significant differences in clinical outcomes between FGF-2 and ABG. In FGF-2, smoking history was positively associated, while the preoperative bone defect angle (BDA) was negatively associated with clinical outcomes.<br>
Conclusions: FGF-2 might exhibit clinical outcomes comparable to those of ABG, suggesting it is a clinically viable alternative for vertical bone defects. When using FGF-2, patient-specific factors such as smoking history and preoperative BDA should be considered carefully.<br>
The name in the trial registry: A survey of clinical practice and evaluation of treatment outcomes of periodontal regenerative therapy using REGROTH at Okayama University Hospital
en-copyright=
kn-copyright=

en-aut-name=MatsumotoToshiki
en-aut-sei=Matsumoto
en-aut-mei=Toshiki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NakamuraShin
en-aut-sei=Nakamura
en-aut-mei=Shin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=Ito‐ShinodaYuki
en-aut-sei=Ito‐Shinoda
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SakamotoMai
en-aut-sei=Sakamoto
en-aut-mei=Mai
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=IshiiTakayuki
en-aut-sei=Ishii
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NonomuraYasuki
en-aut-sei=Nonomura
en-aut-mei=Yasuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=IdeguchiHidetaka
en-aut-sei=Ideguchi
en-aut-mei=Hidetaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OkuboKeisuke
en-aut-sei=Okubo
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=Takeuchi‐HatanakaKazu
en-aut-sei=Takeuchi‐Hatanaka
en-aut-mei=Kazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=OmoriKazuhiro
en-aut-sei=Omori
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=YamamotoTadashi
en-aut-sei=Yamamoto
en-aut-mei=Tadashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=TakashibaShogo
en-aut-sei=Takashiba
en-aut-mei=Shogo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

affil-num=1
en-affil=Department of Pathophysiology?Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Pathophysiology?Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Pathophysiology?Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Pathophysiology?Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Pathophysiology?Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Pathophysiology?Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Department of Pathophysiology?Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=8
en-affil=Department of Periodontics and Endodontics, Division of Dentistry, Okayama University Hospital
kn-affil=

affil-num=9
en-affil=Department of Periodontics and Endodontics, Division of Dentistry, Okayama University Hospital
kn-affil=

affil-num=10
en-affil=Department of Pathophysiology?Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=11
en-affil=The Center for Graduate Medical Education (Dental Division), Okayama University Hospital
kn-affil=

affil-num=12
en-affil=Department of Pathophysiology?Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=autologous bone graft
kn-keyword=autologous bone graft
en-keyword=fibroblast growth factor-2
kn-keyword=fibroblast growth factor-2
en-keyword=periodontal pocket
kn-keyword=periodontal pocket
en-keyword=periodontal regeneration
kn-keyword=periodontal regeneration
en-keyword=periodontitis
kn-keyword=periodontitis
en-keyword=vertical bone defect
kn-keyword=vertical bone defect
END

start-ver=1.4
cd-journal=joma
no-vol=11
cd-vols=
no-issue=1
article-no=
start-page=26
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260122
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Osimertinib inhibits the MYLK4-mediated phosphorylation of CDKAL1 to suppress stemness and chemoresistance in rhabdomyosarcoma
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=ItanoTakuto
en-aut-sei=Itano
en-aut-mei=Takuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HuangRongsheng
en-aut-sei=Huang
en-aut-mei=Rongsheng
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OzakiToshifumi
en-aut-sei=Ozaki
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakataEiji
en-aut-sei=Nakata
en-aut-mei=Eiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=FujimuraAtsushi
en-aut-sei=Fujimura
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Cellular Physiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Cellular Physiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=18
cd-vols=
no-issue=1
article-no=
start-page=e102426
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260127
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Central Serous Chorioretinopathy in Parallel With Onset and Relapses of Minimal Change Nephrotic Syndrome: A 28-Year Case Follow-Up
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Central serous chorioretinopathy is an idiopathic disease that manifests as one or several localized, small, dome-shaped serous retinal detachments on fundus examination. The pathophysiology involves fluid leakage from the choroidal capillaries, known as the choriocapillaris, into the subretinal space through sites of damage in the retinal pigment epithelium. This case report discusses the underlying causes of central serous chorioretinopathy-like findings in minimal change nephrotic syndrome.<br>
<br>
The patient was a 33-year-old woman who developed nephrotic syndrome that was confirmed to be minimal change disease by renal biopsy. She experienced two major relapses of nephrotic syndrome at the ages of 36 and 41 years. She also had a minor relapse at the age of 37 years, five months after the first major relapse at the age of 36 years, as well as four additional minor relapses at the ages of 44, 46, 50, and 51 years. The onset of central serous chorioretinopathy-like manifestations, which were localized to the left eye, occurred three months after the initial onset of nephrotic syndrome at the age of 33 years. Two subsequent episodes of relapse of central serous chorioretinopathy-like manifestations were observed in both eyes at intervals of five months and one month, respectively, after major relapses of nephrotic syndrome at the ages of 36 and 41 years. Thereafter, she did not develop further central serous chorioretinopathy-like manifestations.<br>
<br>
She discontinued oral prednisolone at the age of 54 years and experienced no further relapses of nephrotic syndrome through her latest visit at the age of 61 years. She maintained normal renal function and good visual acuity in both eyes. The long-term, consistent temporal association between episodes of central serous chorioretinopathy and the onset and relapses of minimal change nephrotic syndrome is strongly supported by longitudinal clinical observations spanning 28 years. This parallel course suggests a possible shared pathophysiological mechanism or common triggering factors underlying both diseases.
en-copyright=
kn-copyright=

en-aut-name=MatsuoToshihiko
en-aut-sei=Matsuo
en-aut-mei=Toshihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TanakaTakehiro
en-aut-sei=Tanaka
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=WadaJun
en-aut-sei=Wada
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Department of Ophthalmology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Pathology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Nephrology, Rheumatology, Endocrinology, and Metabolism, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=central serous chorioretinopathy
kn-keyword=central serous chorioretinopathy
en-keyword=corticosteroid
kn-keyword=corticosteroid
en-keyword=cyclosporine
kn-keyword=cyclosporine
en-keyword=fluorescein angiography
kn-keyword=fluorescein angiography
en-keyword=minimal change disease
kn-keyword=minimal change disease
en-keyword=minimal change nephrotic syndrome
kn-keyword=minimal change nephrotic syndrome
en-keyword=photoreceptor ellipsoid zone
kn-keyword=photoreceptor ellipsoid zone
en-keyword=renal biopsy
kn-keyword=renal biopsy
en-keyword=steroid-induced retinal pigment epitheliopathy
kn-keyword=steroid-induced retinal pigment epitheliopathy
en-keyword=steroid pulse therapy
kn-keyword=steroid pulse therapy
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260120
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=SPRED2 suppresses the stemness of hepatocellular carcinoma through the p53/miR-506-3p/KLF4 pathway
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Objective: We previously reported that endogenous Sprouty-related, EVH1 domain-containing protein 2 (SPRED2), an inhibitor of the Ras/Raf/ERK-MAPK pathway, controls hepatocellular carcinoma (HCC) cell stemness by downregulating the expression of pluripotency factors, such as Nanog, c-Myc, and KLF4, in an ERK-dependent fashion. However, the exact mechanisms by which SPRED2 regulates HCC cell stemness have not been established.<br>
Methods: Three human HCC cell lines [HepG2 (parental and SPRED2-deficient), HLE, and Hep3B] were used. Cells were transfected to downregulate or overexpress proteins. Western blot and RT-qPCR were used to evaluate the level of protein and mRNA expression. Co-immunoprecipitation and ChIP-qPCR were used to examine protein-protein interactions and the activation of gene transcription. Clinical HCC tissues were also used to validate in vitro data.<br>
Results: KLF4 was identified as the major pluripotency factor responsible for SPRED2-mediated downregulation of HCC cell stemness and KLF4 expression was regulated by miR-506-3p. SPRED2 formed a protein complex with the tumor suppressor (p53) and upregulated miR-506 gene transcription by binding to the promoter region, resulting in subsequent downregulation of KLF4 mRNA expression. There was a negative correlation between KLF4 expression and miR-506-3p and a positive correlation between miR-506-3p expression and SPRED2 in human HCC samples, highlighting the relevance of the study findings.<br>
Conclusions: The current study revealed a novel SPRED2/p53/miR-506-3p/KLF4 axis through which SPRED2 contributes to the suppression of HCC cell stemness and provides a potential new target to prevent HCC progression.
en-copyright=
kn-copyright=

en-aut-name=GaoTong
en-aut-sei=Gao
en-aut-mei=Tong
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ItoSachio
en-aut-sei=Ito
en-aut-mei=Sachio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=Moh-Moh-AungAye
en-aut-sei=Moh-Moh-Aung
en-aut-mei=Aye
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=WangTianyi
en-aut-sei=Wang
en-aut-mei=Tianyi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=FujisawaMasayoshi
en-aut-sei=Fujisawa
en-aut-mei=Masayoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OharaToshiaki
en-aut-sei=Ohara
en-aut-mei=Toshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YoshimuraTeizo
en-aut-sei=Yoshimura
en-aut-mei=Teizo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MatsukawaAkihiro
en-aut-sei=Matsukawa
en-aut-mei=Akihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Pathophysiology and Drug Discovery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=8
en-affil=Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=SPRED2
kn-keyword=SPRED2
en-keyword=p53
kn-keyword=p53
en-keyword=KLF4
kn-keyword=KLF4
en-keyword=miR-506-3p
kn-keyword=miR-506-3p
en-keyword=stemness
kn-keyword=stemness
END

start-ver=1.4
cd-journal=joma
no-vol=15
cd-vols=
no-issue=12
article-no=
start-page=e095428
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202512
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effectiveness of education programme to increase competency of health cadres in Indonesia: a cluster non-randomised controlled trial
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Objectives Health cadres, who assist midwives in supporting pregnant women in community settings, need to enhance their competencies in identifying risk factors and referring high-risk pregnant women to midwives for further care. Since the capabilities of these health cadres are influenced by maternal complications, an educational programme was implemented to strengthen their skills. Therefore, this study aimed to evaluate the competency of health cadres by providing a researcher-developed educational programme.<br>
Design An open-label, cluster non-randomised controlled trial.<br>
Setting and participants Health cadres with at least 1 year of work experience were recruited at six public health centres (PHCs) in Banjarnegara Regency, Indonesia.<br>
Interventions Six PHCs were selected and allocated into intervention group (IG=3 PHCs) and control group (CG=3 PHCs) groups. A total of 133 female health cadres were enrolled across the selected PHCs. At each PHC, a systematic random sampling method was used to select the participants. The researchers and health professionals provided a 3-week period of theoretical and scenario-based simulations to the IG, while the CG received no education.<br>
Outcome measures Researcher-developed questionnaires and checklists were used to assess the knowledge, skills (health assessment, communication, attitude) and confidence. The primary endpoint was competency, a total score of knowledge and skills. The outcome domains were compared between the two groups, and a linear mixed-effect model was used to account for cluster-level variation.<br>
Results A total of 130 (97.7%) completed the study (IG:64, CG:66). The competency score showed significant improvement at endline (CG=49.5?and IG=52.5; p=0.002). The median scores for health assessment skills (CG=12?vs IG=14; p<0.001) and communication skills (CG=7?vs IG=8; p<0.001) were increased in the IG compared with the CG. Mixed-effect model indicated that groups (β (95%?CI) 2.49 (0.57 to 4.41), p=0.012), baseline knowledge (β(95%?CI) 0.73 (0.54 to 0.92), p<0.001) and midline health assessment skills (β (95%?CI) 0.54 (0.25 to 0.82), p<0.001) were significant positive predictors, while age was negatively associated with competency (β (95%?CI) ?0.20 (?0.30 to ?0.10), p<0.001)).<br>
Conclusion Education effectively increased the competency of health cadres. A well-structured education programme is necessary for health cadres to improve and maintain their competencies in monitoring high-risk pregnant women.<br>
Trial registration number NCT06134518.
en-copyright=
kn-copyright=

en-aut-name=SulistyoriniDewie
en-aut-sei=Sulistyorini
en-aut-mei=Dewie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HuqK A T M Ehsanul
en-aut-sei=Huq
en-aut-mei=K A T M Ehsanul
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=BabaitaAbdulfatai Olamilekan
en-aut-sei=Babaita
en-aut-mei=Abdulfatai Olamilekan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=AiveySadia A
en-aut-sei=Aivey
en-aut-mei=Sadia A
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HuiyingGao
en-aut-sei=Huiying
en-aut-mei=Gao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KazawaKana
en-aut-sei=Kazawa
en-aut-mei=Kana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=FukushimaYasuko
en-aut-sei=Fukushima
en-aut-mei=Yasuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KakoMayumi
en-aut-sei=Kako
en-aut-mei=Mayumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MoriyamaMichiko
en-aut-sei=Moriyama
en-aut-mei=Michiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=2
en-affil=Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=3
en-affil=Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=4
en-affil=Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=5
en-affil=Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=6
en-affil=Faculty of Health Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=8
en-affil=Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=9
en-affil=Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=45
cd-vols=
no-issue=1
article-no=
start-page=116781
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202601
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Immunopeptidomics combined with full-length transcriptomics uncovers diverse neoantigens
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Neoantigens are crucial for antitumor immunity and immune checkpoint inhibitor (ICI) efficacy by triggering strong immune responses. However, conventional methods for identifying neoantigens, such as whole-exon sequencing and short-read RNA sequencing (RNA-seq), appear to be insufficient, and the tumor mutational burden cannot sufficiently predict ICI efficacy. In this study, we employed a proteogenomic approach using long-read RNA-seq with Pacific Biosciences Single-Molecule Real-Time Sequencing technology to analyze full-length transcripts in combination with the human leukocyte antigen ligandome. As a result, many neoantigen candidates were identified, which were unregistered in a comprehensive database, including those from non-coding regions. Additionally, we validated the responses of specific T cell receptors (TCRs) to these candidates and identified several pairs of TCRs and neoantigens. These findings highlight the presence of more diverse neoantigens than expected that cannot be identified by conventional methods.
en-copyright=
kn-copyright=

en-aut-name=IshinoTakamasa
en-aut-sei=Ishino
en-aut-mei=Takamasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=WatanabeTomofumi
en-aut-sei=Watanabe
en-aut-mei=Tomofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TokitaSerina
en-aut-sei=Tokita
en-aut-mei=Serina
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=UedaYouki
en-aut-sei=Ueda
en-aut-mei=Youki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KawaseKatsushige
en-aut-sei=Kawase
en-aut-mei=Katsushige
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TakanoYuka
en-aut-sei=Takano
en-aut-mei=Yuka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ThuYin Min
en-aut-sei=Thu
en-aut-mei=Yin Min
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=SuzukiYuta
en-aut-sei=Suzuki
en-aut-mei=Yuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OwaChie
en-aut-sei=Owa
en-aut-mei=Chie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=InozumeTakashi
en-aut-sei=Inozume
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=ZhouWenhao
en-aut-sei=Zhou
en-aut-mei=Wenhao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=NagasakiJoji
en-aut-sei=Nagasaki
en-aut-mei=Joji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=KochinVitaly
en-aut-sei=Kochin
en-aut-mei=Vitaly
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=UenoToshihide
en-aut-sei=Ueno
en-aut-mei=Toshihide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=KojimaShinya
en-aut-sei=Kojima
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=Honobe-TabuchiAkiko
en-aut-sei=Honobe-Tabuchi
en-aut-mei=Akiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=KawamuraTatsuyoshi
en-aut-sei=Kawamura
en-aut-mei=Tatsuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=OhnumaTakehiro
en-aut-sei=Ohnuma
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=MatsuzawaTakamitsu
en-aut-sei=Matsuzawa
en-aut-mei=Takamitsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=KawaharaYu
en-aut-sei=Kawahara
en-aut-mei=Yu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=YamashitaKazuo
en-aut-sei=Yamashita
en-aut-mei=Kazuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=LinJason
en-aut-sei=Lin
en-aut-mei=Jason
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=KosekiJun
en-aut-sei=Koseki
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=NishikawaHiroyoshi
en-aut-sei=Nishikawa
en-aut-mei=Hiroyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=ArakiMotoo
en-aut-sei=Araki
en-aut-mei=Motoo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=KatoNaoya
en-aut-sei=Kato
en-aut-mei=Naoya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=ShimamuraTeppei
en-aut-sei=Shimamura
en-aut-mei=Teppei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=MorishitaShinichi
en-aut-sei=Morishita
en-aut-mei=Shinichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=SuzukiYutaka
en-aut-sei=Suzuki
en-aut-mei=Yutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=ManoHiroyuki
en-aut-sei=Mano
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

en-aut-name=TorigoeToshihiko
en-aut-sei=Torigoe
en-aut-mei=Toshihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=31
ORCID=

en-aut-name=KanasekiTakayuki
en-aut-sei=Kanaseki
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=32
ORCID=

en-aut-name=KawazuMasahito
en-aut-sei=Kawazu
en-aut-mei=Masahito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=33
ORCID=

en-aut-name=TogashiYosuke
en-aut-sei=Togashi
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=34
ORCID=

affil-num=1
en-affil=Department of Tumor Microenvironment, Okayama University, Graduate School of Medicine Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Tumor Microenvironment, Okayama University, Graduate School of Medicine Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Division of Cancer Immunology, Graduate School of Medical and Dental Sciences, Niigata University
kn-affil=

affil-num=4
en-affil=Department of Tumor Microenvironment, Okayama University, Graduate School of Medicine Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Division of Cell Therapy, Chiba Cancer Center Research Institute
kn-affil=

affil-num=6
en-affil=Department of Tumor Microenvironment, Okayama University, Graduate School of Medicine Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Tumor Microenvironment, Okayama University, Graduate School of Medicine Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Computational Biology and Medical Sciences, The University of Tokyo
kn-affil=

affil-num=9
en-affil=Department of Computational Biology and Medical Sciences, The University of Tokyo
kn-affil=

affil-num=10
en-affil=Department of Dermatology, Chiba University Graduate School of Medicine
kn-affil=

affil-num=11
en-affil=Department of Tumor Microenvironment, Okayama University, Graduate School of Medicine Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=12
en-affil=Department of Tumor Microenvironment, Okayama University, Graduate School of Medicine Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=13
en-affil=Department of Immunology, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=14
en-affil=Division of Cellular Signaling, National Cancer Center Research Institute
kn-affil=

affil-num=15
en-affil=Division of Cellular Signaling, National Cancer Center Research Institute
kn-affil=

affil-num=16
en-affil=Department of Dermatology, University of Yamanashi
kn-affil=

affil-num=17
en-affil=Department of Dermatology, University of Yamanashi
kn-affil=

affil-num=18
en-affil=Department of Dermatology, Kumamoto Kenhoku Hospital
kn-affil=

affil-num=19
en-affil=Department of Dermatology, Chiba University Graduate School of Medicine
kn-affil=

affil-num=20
en-affil=Department of Dermatology, Chiba University Graduate School of Medicine
kn-affil=

affil-num=21
en-affil=KOTAI Biotechnologies, Inc
kn-affil=

affil-num=22
en-affil=Division of Cell Therapy, Chiba Cancer Center Research Institute
kn-affil=

affil-num=23
en-affil=Division of Systems Biology, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=24
en-affil=Department of Immunology, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=25
en-affil=Department of Urology, Okayama University, Graduate School of Medicine Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=26
en-affil=Department of Gastroenterology, Graduate School of Medicine, Chiba University
kn-affil=

affil-num=27
en-affil=Division of Systems Biology, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=28
en-affil=Department of Computational Biology and Medical Sciences, The University of Tokyo
kn-affil=

affil-num=29
en-affil=Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo
kn-affil=

affil-num=30
en-affil=Division of Cellular Signaling, National Cancer Center Research Institute
kn-affil=

affil-num=31
en-affil=
kn-affil=

affil-num=32
en-affil=Division of Cancer Immunology, Graduate School of Medical and Dental Sciences, Niigata University
kn-affil=

affil-num=33
en-affil=Division of Cell Therapy, Chiba Cancer Center Research Institute
kn-affil=

affil-num=34
en-affil=Department of Tumor Microenvironment, Okayama University, Graduate School of Medicine Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=cancer immunology
kn-keyword=cancer immunology
en-keyword=neoantigen
kn-keyword=neoantigen
en-keyword=long-read RNA sequencing
kn-keyword=long-read RNA sequencing
en-keyword=HLA ligandome
kn-keyword=HLA ligandome
en-keyword=single-cell RNA sequencing
kn-keyword=single-cell RNA sequencing
en-keyword=single-cell TCR sequencing
kn-keyword=single-cell TCR sequencing
en-keyword=exhausted T cell
kn-keyword=exhausted T cell
END

start-ver=1.4
cd-journal=joma
no-vol=131
cd-vols=
no-issue=1
article-no=
start-page=e2025JB033390
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202601
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Electrical Conductivity of Carbonatite Melts to 20?GPa: Constraints on Partial Melting Atop the 410‐km Discontinuity and in the Lower Mantle Transition Zone
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Deep-origin carbonatite melts are considered to be the products of partial-melting of the oceanic crust in the subduction zones. In this study, we conducted electrical conductivity (EC) measurements on two samples, the composition of which resemble the partial-melting products atop the 410-km discontinuity and in the lower part of the transition zone. The EC of carbonatite melts was investigated using impedance spectroscopy combined with a multi-anvil press up to 20 GPa. Pressure has a great effect on the EC of the carbonatite melts. While the EC dropped overall by 0.6 log unit from 3 to 20 GPa for varying compositions, the pressure effect becomes weaker above 10 GPa. The Hashin-Shtrikman mixing model indicates that melt fraction of 0?0.3 vol% is necessary to account for the EC atop the 410-km discontinuity beneath NE China, north Philippine Sea, north Pacific, and Australian craton. However, this value soars to 1?4.5 vol% for the lower part of the transition zone in the same regions, and further increases to 3.7?7.3 vol% for cold subduction regions if the slab surface temperature is 300 K lower. The difference in the needed melt fraction at different depths implies that the magnitude of partial melting is much larger in the lower part of the mantle transition zone, and it is thus likely to be the main barrier to the recycled carbonates towards the deep interior.
en-copyright=
kn-copyright=

en-aut-name=ZhaoBin
en-aut-sei=Zhao
en-aut-mei=Bin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ZhuJintao
en-aut-sei=Zhu
en-aut-mei=Jintao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ChenQi
en-aut-sei=Chen
en-aut-mei=Qi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YoshinoTakashi
en-aut-sei=Yoshino
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Institute for Planetary Materials, Okayama University
kn-affil=

affil-num=2
en-affil=Institute for Planetary Materials, Okayama University
kn-affil=

affil-num=3
en-affil=Center for Advanced Radiation Sources, University of Chicago
kn-affil=

affil-num=4
en-affil=Institute for Planetary Materials, Okayama University
kn-affil=
en-keyword=carbon
kn-keyword=carbon
en-keyword=carbonatite melts
kn-keyword=carbonatite melts
en-keyword=electrical conductivity
kn-keyword=electrical conductivity
en-keyword=impedance spectroscopy
kn-keyword=impedance spectroscopy
en-keyword=multi-anvil press
kn-keyword=multi-anvil press
END

start-ver=1.4
cd-journal=joma
no-vol=17
cd-vols=
no-issue=12
article-no=
start-page=110594
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251216
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Endoscopic features of oral and pharyngolaryngeal papillomas and their role in distinguishing squamous cell carcinoma
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=BACKGROUND<br>
Oral and pharyngolaryngeal papillomas are occasionally detected during esophagogastroduodenoscopy. However, their endoscopic features have not been sufficiently investigated.<br>
AIM<br>
To distinguish oral and pharyngolaryngeal papillomas from elevated squamous carcinomas, this study examined their endoscopic features.<br>
METHODS<br>
Forty-seven patients with oral or pharyngeal papilloma participated in this study. The endoscopic characteristics of papillomas were identified by focusing on narrowband and blue laser imaging representations.<br>
RESULTS<br>
Papillomas were classified into three patterns based on their endoscopic features: Salmon roe-like polyps, polyps without capillary transparency, and pinecone-like polyps, with salmon roe-like polyps most prevalent (48.9%). We subsequently analyzed features differentiating papillomas and squamous cell carcinomas in the same region and found that squamous cell carcinomas exhibited at least one of the following three features: Uneven or absent lobulated structure, irregular morphology of capillaries, and coexistence of flat lesions. In contrast, papillomas displayed a uniform lobulated structure, homogeneous or non-visible capillaries, and an absence of flat components. When any of these characteristics were present, two endoscopic specialists evaluated the lesions for the diagnosis of squamous cell carcinoma, with sensitivities of 100% and 97.6% and specificities of 68.9% and 93.3%.<br>
CONCLUSION<br>
Understanding distinct endoscopic patterns of oropharyngeal papillomas and squamous cell carcinomas provides valuable guidance to endoscopists performing esophagogastroduodenoscopy.
en-copyright=
kn-copyright=

en-aut-name=IwamuroMasaya
en-aut-sei=Iwamuro
en-aut-mei=Masaya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TanakaTakehiro
en-aut-sei=Tanaka
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HamadaKenta
en-aut-sei=Hamada
en-aut-mei=Kenta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KonoYoshiyasu
en-aut-sei=Kono
en-aut-mei=Yoshiyasu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KawanoSeiji
en-aut-sei=Kawano
en-aut-mei=Seiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KawaharaYoshiro
en-aut-sei=Kawahara
en-aut-mei=Yoshiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=OtsukaMotoyuki
en-aut-sei=Otsuka
en-aut-mei=Motoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Pathology, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Practical Gastrointestinal Endoscopy, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=
en-keyword=Esophagogastroduodenoscopy
kn-keyword=Esophagogastroduodenoscopy
en-keyword=Human papillomavirus
kn-keyword=Human papillomavirus
en-keyword=Laryngeal polyp
kn-keyword=Laryngeal polyp
en-keyword=Papilloma
kn-keyword=Papilloma
en-keyword=Pharyngeal polyp
kn-keyword=Pharyngeal polyp
END

start-ver=1.4
cd-journal=joma
no-vol=16
cd-vols=
no-issue=1
article-no=
start-page=1786
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251221
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Salivary short chain fatty acids serve as biomarkers of periodontal inflammatory burden
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Periodontitis is a chronic inflammatory condition associated with systemic diseases. Early detection and intervention are crucial; however, conventional diagnostic methods require specialized dental procedures. Therefore, we aimed to develop a noninvasive saliva-based screening method that can be easily performed outside dental clinics. This cross-sectional pilot study evaluated three periodontal indices?probing depth, Periodontal Inflamed Surface Area (PISA), and periodontal epithelial surface area?in relation to short-chain fatty acids (SCFAs) and bacterial profiles in the saliva. Saliva samples collected during the day exhibited stronger correlations with periodontal indices than waking time samples, demonstrating a significant association with periodontal pathogens, protease activity, and elevated levels of butyric acid. The diagnostic thresholds for PISA were 300 mm2 and 600 mm2. Multivariate logistic regression and likelihood ratio analyses identified the combination of enzymatic SCFA markers and dipstick-based occult blood or leukocyte detection as a promising biomarker pair. Combining enzymatic SCFA markers with occult blood demonstrated a positive likelihood ratio of 3.4 and a negative likelihood ratio of 0.19 for PISA???600 mm2, with a post-test probability of 77%, sensitivity of 86%, and specificity of 75%. These findings suggest that combining salivary enzymatic and dipstick-based biomarkers provides a simple, cost-effective, and moderately informative screening strategy for periodontitis.
en-copyright=
kn-copyright=

en-aut-name=Takeuchi-HatanakaKazu
en-aut-sei=Takeuchi-Hatanaka
en-aut-mei=Kazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ShirahaseYasushi
en-aut-sei=Shirahase
en-aut-mei=Yasushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YoshidaToshiyuki
en-aut-sei=Yoshida
en-aut-mei=Toshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KonoMari
en-aut-sei=Kono
en-aut-mei=Mari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=ToyaNaoki
en-aut-sei=Toya
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KonishiKenji
en-aut-sei=Konishi
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=OmoriKazuhiro
en-aut-sei=Omori
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TakashibaShogo
en-aut-sei=Takashiba
en-aut-mei=Shogo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Division of Periodontics and Endodontics, Department of Dentistry, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Sysmex Corporation
kn-affil=

affil-num=3
en-affil=Sysmex Corporation
kn-affil=

affil-num=4
en-affil=Sysmex Corporation
kn-affil=

affil-num=5
en-affil=Sysmex Corporation
kn-affil=

affil-num=6
en-affil=Present address: Diagnostics Division, IVD Enzyme Department, Nagase Diagnostics
kn-affil=

affil-num=7
en-affil=Department of Pathophysiology-Periodontal Science, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=8
en-affil=Department of Pathophysiology-Periodontal Science, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=Periodontitis
kn-keyword=Periodontitis
en-keyword=Screening
kn-keyword=Screening
en-keyword=Saliva
kn-keyword=Saliva
en-keyword=Short-chain fatty acid
kn-keyword=Short-chain fatty acid
en-keyword=Periodontal inflamed surface area
kn-keyword=Periodontal inflamed surface area
en-keyword=Crosssectional studies
kn-keyword=Crosssectional studies
END

start-ver=1.4
cd-journal=joma
no-vol=16
cd-vols=
no-issue=
article-no=
start-page=1713471
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251218
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Regulatory considerations for developing phage therapy medicinal products for the treatment of antimicrobial resistant bacterial infections
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Recently, there have been growing expectations that treatment of infections with bacteriophages (phages), viruses which specifically infect bacteria, can be used as a treatment option for antimicrobial resistant bacterial infections. In Europe and the United States, in addition to phage therapy as a form of personalized medicine, development of pre-defined phage therapy medicinal products (PTMPs) is progressing, and clinical trials are underway. From October 2024 to July 2025, the Pharmaceuticals and Medical Devices Agency exchanged opinions on trends and points to consider in drug development of PTMPs used for antimicrobial resistant bacterial infections with external experts. Development of PTMPs for regulatory approval requires quality control strategies, establishment of manufacturing methods, non-clinical evaluations, and clinical trial plans based on the characteristics of the phage. In this document, based on the regulatory and development trends in Europe and the United States, the current considerations on quality, non-clinical evaluation, and clinical trial planning including the Cartagena Act in the development of PTMPs in Japan are summarized. The basic concepts presented here are intended to be applied to antimicrobial resistant bacterial infections targeted by PTMPs but can be mostly applicable to bacterial infections in general. We hope that these findings will further accelerate more active development of PTMPs towards timely patient access to innovative products.
en-copyright=
kn-copyright=

en-aut-name=Fukaya-ShibaAi
en-aut-sei=Fukaya-Shiba
en-aut-mei=Ai
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OgataAkiko
en-aut-sei=Ogata
en-aut-mei=Akiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KuribayashiRyosuke
en-aut-sei=Kuribayashi
en-aut-mei=Ryosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SakuraiAkira
en-aut-sei=Sakurai
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SuzukiKanako
en-aut-sei=Suzuki
en-aut-mei=Kanako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TakadamaShunsuke
en-aut-sei=Takadama
en-aut-mei=Shunsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NishimuraJihei
en-aut-sei=Nishimura
en-aut-mei=Jihei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=UchiyamaJumpei
en-aut-sei=Uchiyama
en-aut-mei=Jumpei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OhgeHiroki
en-aut-sei=Ohge
en-aut-mei=Hiroki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TakeuchiTakamasa
en-aut-sei=Takeuchi
en-aut-mei=Takamasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=TamakiHideyuki
en-aut-sei=Tamaki
en-aut-mei=Hideyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=MatsumotoTetsuya
en-aut-sei=Matsumoto
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=KigaKotaro
en-aut-sei=Kiga
en-aut-mei=Kotaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=IwanoHidetomo
en-aut-sei=Iwano
en-aut-mei=Hidetomo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

affil-num=1
en-affil=Office of Regulatory Science Coordination, Pharmaceuticals and Medical Devices Agency
kn-affil=

affil-num=2
en-affil=Office of Regulatory Science Coordination, Pharmaceuticals and Medical Devices Agency
kn-affil=

affil-num=3
en-affil=Office of Cellular and Tissue-based Products, Pharmaceuticals and Medical Devices Agency
kn-affil=

affil-num=4
en-affil=Office of Cellular and Tissue-based Products, Pharmaceuticals and Medical Devices Agency
kn-affil=

affil-num=5
en-affil=Office of Regulatory Science Coordination, Pharmaceuticals and Medical Devices Agency
kn-affil=

affil-num=6
en-affil=Office of New Drug IV, Pharmaceuticals and Medical Devices Agency
kn-affil=

affil-num=7
en-affil=Office of New Drug IV, Pharmaceuticals and Medical Devices Agency
kn-affil=

affil-num=8
en-affil=Department of Bacteriology, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=9
en-affil=Department of Infectious Diseases, Hiroshima University Hospital
kn-affil=

affil-num=10
en-affil=Pathogen Genomics Center, National Institute of Infectious Diseases, Japan Institute for Health Security
kn-affil=

affil-num=11
en-affil=Biomanufacturing Process Research Center, National Institute of Advanced Industrial Science and Technology
kn-affil=

affil-num=12
en-affil=Department of Infectious Diseases, International University of Health and Welfare
kn-affil=

affil-num=13
en-affil=Department of Drug Development, National Institute of Infectious Diseases, Japan Institute for Health Security
kn-affil=

affil-num=14
en-affil=Laboratory of Veterinary Biochemistry, Rakuno Gakuen University School of Veterinary Medicine
kn-affil=
en-keyword=phage therapy
kn-keyword=phage therapy
en-keyword=bacteriophage
kn-keyword=bacteriophage
en-keyword=antimicrobial resistance (AMR)
kn-keyword=antimicrobial resistance (AMR)
en-keyword=quality considerations
kn-keyword=quality considerations
en-keyword=non-clinical evaluation
kn-keyword=non-clinical evaluation
en-keyword=clinical trial plan
kn-keyword=clinical trial plan
en-keyword=the Cartagena Act
kn-keyword=the Cartagena Act
END

start-ver=1.4
cd-journal=joma
no-vol=18
cd-vols=
no-issue=1
article-no=
start-page=e101143
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260109
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Endoscopic Topical Application (ETA) Therapy for Refractory Overactive Bladder: A First-in-Human Report
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Refractory overactive bladder (OAB) remains a clinical challenge despite established therapies, such as anticholinergics, β3-agonists, and intradetrusor botulinum toxin (BTX). Emerging evidence suggests that sensory mechanisms within the bladder, including those involving the trigone where superficial afferent networks are present, may contribute to persistent urinary urgency and frequency in some patients. Although intradetrusor BTX injection is effective in selected patients, its impact on these superficial pathways may be limited because the injected drug predominantly distributes within the detrusor. Endoscopic topical application (ETA) therapy delivers BTX directly to the trigone under air cystoscopy, potentially providing targeted modulation of sensory hyperexcitability. We report a 72-year-old woman with long-standing refractory OAB who experienced only partial improvement with repeated intradetrusor BTX injections but achieved clinically meaningful symptom relief after ETA therapy. Nocturia, urgency, urgency urinary incontinence, and voided volume were improved, with no complications other than transient postoperative urethral pain. This case suggests that ETA therapy may represent a promising sensory-focused option for refractory OAB.
en-copyright=
kn-copyright=

en-aut-name=SadahiraTakuya
en-aut-sei=Sadahira
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SugiharaMasahiro
en-aut-sei=Sugihara
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MitsuiYosuke
en-aut-sei=Mitsui
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=WatanabeToyohiko
en-aut-sei=Watanabe
en-aut-mei=Toyohiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=ArakiMotoo
en-aut-sei=Araki
en-aut-mei=Motoo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=WatanabeMasami
en-aut-sei=Watanabe
en-aut-mei=Masami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Surgery, Nishi Fukuyama Hospital
kn-affil=

affil-num=3
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=bladder trigone
kn-keyword=bladder trigone
en-keyword=botulinum toxin
kn-keyword=botulinum toxin
en-keyword=endoscopic topical application
kn-keyword=endoscopic topical application
en-keyword=new drug delivery systems
kn-keyword=new drug delivery systems
en-keyword=refractory overactive bladder
kn-keyword=refractory overactive bladder
END

start-ver=1.4
cd-journal=joma
no-vol=35
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202601
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Addition of human platelet lysate to islet culture medium suppresses islet loss and improves transplantation outcomes
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=NoguchiHirofumi
en-aut-sei=Noguchi
en-aut-mei=Hirofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=Miyagi-ShiohiraChika
en-aut-sei=Miyagi-Shiohira
en-aut-mei=Chika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SadahiraTakuya
en-aut-sei=Sadahira
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=WatanabeMasami
en-aut-sei=Watanabe
en-aut-mei=Masami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SaitohIssei
en-aut-sei=Saitoh
en-aut-mei=Issei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of Regenerative Medicine, Graduate School of Medicine, University of the Ryukyus
kn-affil=

affil-num=2
en-affil=Department of Regenerative Medicine, Graduate School of Medicine, University of the Ryukyus
kn-affil=

affil-num=3
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Pediatric Dentistry, Asahi University School of Dentistry
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=2026
cd-vols=
no-issue=1
article-no=
start-page=9991157
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202601
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Knowledge and Attitudes Toward Pain Management Among Nurses in University-Affiliated Hospitals in Western Japan: A Cross-Sectional Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Pain is a major global concern. Nurses’ knowledge and attitudes toward pain management are critical determinants of pain care quality and patient outcomes, making them essential for effective clinical practice.<br>
Objective: This study aimed to assess nurses’ pain management knowledge and attitudes using the Japanese version of the Knowledge and Attitudes Survey Regarding Pain (J-KASRP), applied for the first time in Japan, and to examine how background factors affect these aspects.<br>
Methods: A descriptive, cross-sectional survey was conducted with 1589 nurses in three university-affiliated hospitals in Western Japan. Data were collected using a questionnaire capturing sociodemographic information and the J-KASRP. Descriptive statistics, t-tests, one-way ANOVA, and effect size were used to analyze J-KASRP scores and subdomains. Tukey’s honestly significant difference test was applied for post hoc comparisons across clinical experience patterns.<br>
Results: Of 1001 respondents, 856 valid responses (85.5%) were analyzed. The mean age was 30.1?years (SD?=?8.3), and the mean total correct response rate for the J-KASRP was 59.8%; only 1.3% scored ??80%. Cancer-related pain had the lowest J-KASRP subdomain score (42.5%, SD = 20.3%). Higher total J-KASRP scores were found for those with a higher level of education, prior clinical pain education, and recent opioid administration experience (all p < 0.001, effect size > 0.2). In an exploratory pattern analysis, regardless of education level, respondents with both education and opioid administering experience had the highest total and pharmacology subdomains’ scores. No significant differences in cancer-related pain subdomain were observed across patterns of clinical experiences.<br>
Conclusions: This first application of the J-KASRP in Japan revealed that nurses’ pain management knowledge and attitudes need to be strengthened, especially for cancer-related pain and opioid pharmacology. The study findings highlight the importance of pain management strengthening education and training to enhance nurses’ evidence-based knowledge and clinical competence.
en-copyright=
kn-copyright=

en-aut-name=XiMengyao
en-aut-sei=Xi
en-aut-mei=Mengyao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KajiwaraYuki
en-aut-sei=Kajiwara
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HiramatsuTakako
en-aut-sei=Hiramatsu
en-aut-mei=Takako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MorimotoMichiko
en-aut-sei=Morimoto
en-aut-mei=Michiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Graduate School of Health Sciences, Okayama University,
kn-affil=

affil-num=2
en-affil=Faculty of Health Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Nursing, Kawasaki Medical School Hospital
kn-affil=

affil-num=4
en-affil=Faculty of Health Sciences, Okayama University
kn-affil=
en-keyword=knowledge andattitudes
kn-keyword=knowledge andattitudes
en-keyword=nurses
kn-keyword=nurses
en-keyword=painmanagement
kn-keyword=painmanagement
END

start-ver=1.4
cd-journal=joma
no-vol=12
cd-vols=
no-issue=1
article-no=
start-page=16
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251229
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=FluoNeRF: Fluorescent Novel-View Synthesis Under Novel Light Source Colors and Spectra
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Synthesizing photo-realistic images of a scene from arbitrary viewpoints and under arbitrary lighting environments is one of the important research topics in computer vision and graphics. In this paper, we propose a method for synthesizing photo-realistic images of a scene with fluorescent objects from novel viewpoints and under novel lighting colors and spectra. In general, fluorescent materials absorb light with certain wavelengths and then emit light with longer wavelengths than the absorbed ones, in contrast to reflective materials, which preserve wavelengths of light. Therefore, we cannot reproduce the colors of fluorescent objects under arbitrary lighting colors by combining conventional view synthesis techniques with the white balance adjustment of the RGB channels. Accordingly, we extend the novel-view synthesis based on the neural radiance fields by incorporating the superposition principle of light; our proposed method captures a sparse set of images of a scene from varying viewpoints and under varying lighting colors or spectra with active lighting systems such as a color display or a multi-spectral light stage and then synthesizes photo-realistic images of the scene without explicitly modeling its geometric and photometric models. We conducted a number of experiments using real images captured with an LCD and confirmed that our method works better than the existing methods. Moreover, we showed that the extension of our method using more than three primary colors with a light stage enables us to reproduce the colors of fluorescent objects under common light sources.
en-copyright=
kn-copyright=

en-aut-name=ShiLin
en-aut-sei=Shi
en-aut-mei=Lin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MatsufujiKengo
en-aut-sei=Matsufuji
en-aut-mei=Kengo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YoshidaMichitaka
en-aut-sei=Yoshida
en-aut-mei=Michitaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KawaharaRyo
en-aut-sei=Kawahara
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OkabeTakahiro
en-aut-sei=Okabe
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of Artificial Intelligence, Kyushu Institute of Technology
kn-affil=

affil-num=2
en-affil=Department of Artificial Intelligence, Kyushu Institute of Technology
kn-affil=

affil-num=3
en-affil=Department of Computer Science, Okayama University
kn-affil=

affil-num=4
en-affil=Graduate School of Informatics, Kyoto University
kn-affil=

affil-num=5
en-affil=Department of Computer Science, Okayama University
kn-affil=
en-keyword=novel-view synthesis
kn-keyword=novel-view synthesis
en-keyword=neural radiance fields
kn-keyword=neural radiance fields
en-keyword=relighting
kn-keyword=relighting
en-keyword=superposition principle
kn-keyword=superposition principle
en-keyword=fluorescence
kn-keyword=fluorescence
en-keyword=Stokes shift
kn-keyword=Stokes shift
END

start-ver=1.4
cd-journal=joma
no-vol=18
cd-vols=
no-issue=1
article-no=
start-page=e70066
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202501
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Procedural Transhiatal Approach for the Thoracic Para‐Aortic Lymph Node: A Case Report
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The thoracic posterior para-aortic lymph node (TPAN) is classified as an extra-regional lymph node in esophageal cancer, with metastasis indicating poor prognosis. However, some cases with suspected TPAN metastasis may benefit from esophagectomy with lymph node dissection, including TPAN. This report presents the case of a 58-year-old man with upper thoracic esophageal squamous cell carcinoma and suspected simultaneous TPAN metastasis who underwent neoadjuvant chemotherapy followed by thoracoscopic subtotal esophagectomy and procedural transhiatal TPAN dissection. This transhiatal approach provided direct access to the lymph node without additional thoracic incisions, ensuring safe resection in coordination with the assistant and following anatomical landmarks systematically. Pathological examination showed a false-positive TPAN finding, though the patient later developed distant recurrence. Compared with conventional approaches, this transhiatal technique allows for procedural and reproducible lymphadenectomy while minimizing respiratory burden. This case highlights the feasibility of a transhiatal approach for TPAN dissection.
en-copyright=
kn-copyright=

en-aut-name=HashimotoMasashi
en-aut-sei=Hashimoto
en-aut-mei=Masashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NomaKazuhiro
en-aut-sei=Noma
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakedaYasushige
en-aut-sei=Takeda
en-aut-mei=Yasushige
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MatsumotoHijiri
en-aut-sei=Matsumoto
en-aut-mei=Hijiri
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KawasakiKento
en-aut-sei=Kawasaki
en-aut-mei=Kento
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KunitomoTomoyoshi
en-aut-sei=Kunitomo
en-aut-mei=Tomoyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MaedaNaoaki
en-aut-sei=Maeda
en-aut-mei=Naoaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TanabeShunsuke
en-aut-sei=Tanabe
en-aut-mei=Shunsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=112aoP
kn-keyword=112aoP
en-keyword=esophageal cancer
kn-keyword=esophageal cancer
en-keyword=thoracic posterior para-aortic lymph node
kn-keyword=thoracic posterior para-aortic lymph node
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=2
article-no=
start-page=129
end-page=130
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251231
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Exposure-induced mediator?outcome confounders in causal mediation: implications and visualisation
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=SuzukiEtsuji
en-aut-sei=Suzuki
en-aut-mei=Etsuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ShinozakiTomohiro
en-aut-sei=Shinozaki
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YamamotoEiji
en-aut-sei=Yamamoto
en-aut-mei=Eiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Interfaculty Initiative in Information Studies, the University of Tokyo
kn-affil=

affil-num=3
en-affil=Okayama University of Science
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=13
cd-vols=
no-issue=4
article-no=
start-page=1041
end-page=1054
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250904
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Asian Subgroup Analysis of Patients in the Phase 2 DeLLphi-301 Study of Tarlatamab for Previously Treated Small Cell Lung Cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Introduction: Tarlatamab is a bispecific T-cell engager (BiTE?) immunotherapy that binds delta-like ligand 3 on the surface of small cell lung cancer (SCLC) cells and CD3 on T cells, facilitating T cell-mediated cancer cell lysis. In the primary analysis of the phase 2 DeLLphi-301 study (NCT05060016), tarlatamab showed a favourable benefit-to-risk profile with durable objective responses and promising survival outcomes in patients with previously treated SCLC. Here, phase 2 data for the Asia region subgroup are presented.<br>
Methods: Patients with previously treated, advanced SCLC received 10 mg tarlatamab every 2 weeks. The primary endpoint was objective response rate (ORR) by blinded independent central review (RECIST version 1.1). Key secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival (OS) and safety. The present analysis includes patients enrolled at sites in Asia.<br>
Results: A total of 43 patients were enrolled at sites in Asia. ORR was 46.3% (95% confidence interval [CI], 30.7?62.6) and median DOR was 7.2 months (95% CI 3.9 to not estimable). The median follow-up was 16.6 months for PFS and 21.2 months for OS. Median PFS was 5.4 months (95% CI 3.0?8.1) and median OS was 19.0 months (95% CI 11.4 to not estimable). The most common treatment-emergent adverse event (AE) was cytokine release syndrome (48.8%), and all such events were grade 1 or 2. There were no discontinuations due to treatment-related AEs.<br>
Conclusions: Tarlatamab demonstrated durable responses and promising survival outcomes with a manageable safety profile in this post hoc analysis of patients from Asia with previously treated SCLC.<br>
Trial Registration: ClinicalTrials.gov, NCT05060016.
en-copyright=
kn-copyright=

en-aut-name=AhnMyung-Ju
en-aut-sei=Ahn
en-aut-mei=Myung-Ju
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ChoByoung Chul
en-aut-sei=Cho
en-aut-mei=Byoung Chul
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OhashiKadoaki
en-aut-sei=Ohashi
en-aut-mei=Kadoaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IzumiHiroki
en-aut-sei=Izumi
en-aut-mei=Hiroki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=LeeJong-Seok
en-aut-sei=Lee
en-aut-mei=Jong-Seok
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HanJi-Youn
en-aut-sei=Han
en-aut-mei=Ji-Youn
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ChiangChi-Lu
en-aut-sei=Chiang
en-aut-mei=Chi-Lu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HuangShuang
en-aut-sei=Huang
en-aut-mei=Shuang
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HamidiAli
en-aut-sei=Hamidi
en-aut-mei=Ali
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=MukherjeeSujoy
en-aut-sei=Mukherjee
en-aut-mei=Sujoy
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=XuKrista Lin
en-aut-sei=Xu
en-aut-mei=Krista Lin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=AkamatsuHiraoki
en-aut-sei=Akamatsu
en-aut-mei=Hiraoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

affil-num=1
en-affil=Hematology-Oncology Department, Samsung Medical Center (SMC), Sungkyunkwan University School of Medicine
kn-affil=

affil-num=2
en-affil=Medical Oncology Department-501, ABMRC, Yonsei University
kn-affil=

affil-num=3
en-affil=Department of Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Thoracic Oncology, National Cancer Center Hospital East
kn-affil=

affil-num=5
en-affil=Hematology/Oncology, Seoul National University Bundang Hospital
kn-affil=

affil-num=6
en-affil=Center for Lung Cancer, National Cancer Center-Graduate School of Cancer Science and Policy
kn-affil=

affil-num=7
en-affil=Department of Chest Medicine, Taipei Veterans General Hospital
kn-affil=

affil-num=8
en-affil=Amgen Inc.
kn-affil=

affil-num=9
en-affil=Amgen Inc.
kn-affil=

affil-num=10
en-affil=Amgen Inc.
kn-affil=

affil-num=11
en-affil=Amgen Asia Pacific Pte. Ltd.
kn-affil=

affil-num=12
en-affil=Internal Medicine III, Wakayama Medical University
kn-affil=
en-keyword=Small cell lung cancer (SCLC)
kn-keyword=Small cell lung cancer (SCLC)
en-keyword=Tarlatamab
kn-keyword=Tarlatamab
en-keyword=DLL3
kn-keyword=DLL3
en-keyword=Bispecific T-cell engager
kn-keyword=Bispecific T-cell engager
en-keyword=Asian patients
kn-keyword=Asian patients
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251117
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Daytime Bladder Control Status in Toddlerhood Is Associated With Subsequent Bedwetting in Preschool Years: A Nationwide Cohort Study of Over 30?000 Japanese Children
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Objectives: Nocturnal enuresis is common in early childhood. While daytime bladder control typically precedes nighttime continence, the temporal relationship between early daytime bladder control and subsequent bedwetting remains unclear. We investigated whether daytime bladder control status at age 2.5?years?as indicated by diaper use?is associated with bedwetting at age 4.5?years in a Japanese nationwide cohort.<br>
Methods: We analyzed data from the Japanese Longitudinal Survey of Newborns in the 21st Century (2010 cohort). Daytime bladder control was assessed at age 2.5?years through caregiver-reported diaper use, and bedwetting frequency at age 4.5?years through parental questionnaires. Modified Poisson regression estimated risk ratios (RRs), adjusting for birth-related factors, socioeconomic status, daycare attendance, and developmental milestones.<br>
Results: Among 32?168 children, 26?651 (82.8%) still used diapers at 2.5?years. Bedwetting prevalence at 4.5?years was 42.2%: 34.5% in children who achieved daytime bladder control at 2.5?years versus 43.9% in those still using diapers. After multivariable adjustment, incomplete daytime bladder control at 2.5?years was associated with higher bedwetting risk (adjusted RR 1.25; 95% CI, 1.20?1.31). Multinomial regression revealed dose?response relationships: odds ratios 1.41 (95% CI, 1.30?1.52) for “sometimes” and 1.58 (95% CI, 1.42?1.77) for “often” bedwetting.<br>
Conclusions: Daytime bladder control status at 2.5?years was associated with a 25% increased bedwetting risk at 4.5?years. This association likely reflects individual differences in bladder control maturation rather than causal effects. While daytime bladder control may serve as a developmental marker, its validity as an intervention target remains unestablished.
en-copyright=
kn-copyright=

en-aut-name=MoriwakeTakatoshi
en-aut-sei=Moriwake
en-aut-mei=Takatoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MatsumotoNaomi
en-aut-sei=Matsumoto
en-aut-mei=Naomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TominagaYusuke
en-aut-sei=Tominaga
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=UraguchiKensuke
en-aut-sei=Uraguchi
en-aut-mei=Kensuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KobayashiTomoko
en-aut-sei=Kobayashi
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TsuboiIchiro
en-aut-sei=Tsuboi
en-aut-mei=Ichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YoshinagaKasumi
en-aut-sei=Yoshinaga
en-aut-mei=Kasumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YamanoiTomoaki
en-aut-sei=Yamanoi
en-aut-mei=Tomoaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=KawadaTatsushi
en-aut-sei=Kawada
en-aut-mei=Tatsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=SadahiraTakuya
en-aut-sei=Sadahira
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KatayamaSatoshi
en-aut-sei=Katayama
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=IwataTakehiro
en-aut-sei=Iwata
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=NishimuraShingo
en-aut-sei=Nishimura
en-aut-mei=Shingo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=BekkuKensuke
en-aut-sei=Bekku
en-aut-mei=Kensuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=EdamuraKohei
en-aut-sei=Edamura
en-aut-mei=Kohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=TakaoSoshi
en-aut-sei=Takao
en-aut-mei=Soshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=YorifujiTakashi
en-aut-sei=Yorifuji
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=ArakiMotoo
en-aut-sei=Araki
en-aut-mei=Motoo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

affil-num=1
en-affil=Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=8
en-affil=Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=9
en-affil=Department of Urology Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University  Okayama Japan
kn-affil=

affil-num=10
en-affil=Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=11
en-affil=Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=12
en-affil=Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=13
en-affil=Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=14
en-affil=Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=15
en-affil=Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=16
en-affil=Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=17
en-affil=Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=18
en-affil=Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=bedwetting
kn-keyword=bedwetting
en-keyword=cohort study
kn-keyword=cohort study
en-keyword=daytime bladder control
kn-keyword=daytime bladder control
en-keyword=nocturnal enuresis
kn-keyword=nocturnal enuresis
END

start-ver=1.4
cd-journal=joma
no-vol=13
cd-vols=
no-issue=12
article-no=
start-page=e71586
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251130
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Experience and Insight Into Genetic Diagnosis of Infective Aortic Aneurysm
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Culture-negative infected aneurysms possibly occur in various clinical situations, including prior antibiotic exposure. Accurate microbial identification is crucial for an optimal antimicrobial strategy. 16S ribosomal RNA gene sequence analysis would provide a useful tool for precise bacterial identification.
en-copyright=
kn-copyright=

en-aut-name=FukushimaShinnosuke
en-aut-sei=Fukushima
en-aut-mei=Shinnosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HagiyaHideharu
en-aut-sei=Hagiya
en-aut-mei=Hideharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=FujimoriTakumi
en-aut-sei=Fujimori
en-aut-mei=Takumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IioKoji
en-aut-sei=Iio
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Microbiology Division, Clinical Laboratory, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Microbiology Division, Clinical Laboratory, Okayama University Hospital
kn-affil=
en-keyword=16S rRNA
kn-keyword=16S rRNA
en-keyword=culture-negative
kn-keyword=culture-negative
en-keyword=Enterobacter hormaechei
kn-keyword=Enterobacter hormaechei
en-keyword=infected aneurysm
kn-keyword=infected aneurysm
END

start-ver=1.4
cd-journal=joma
no-vol=190
cd-vols=
no-issue=6
article-no=
start-page=90
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250922
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Prognostic Value of Serum (1→3)-β-D-Glucan Levels in Patients with Candidemia Stratified by Compliance with Candida Bundle: A Multicenter Retrospective Cohort Study (2016?2023)
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Candidemia is a severe systemic infection with a high mortality risk. While β-D-glucan (BDG) serves as a diagnostic biomarker, its prognostic value in candidemia, particularly in association with Candida bundle compliance, remains unclear.<br>
Methods In this retrospective multicenter cohort study, we evaluated 96 patients with candidemia across nine Japanese hospitals between 2016 and 2023. Candida bundle compliance was assessed using five key components: central venous catheter removal within 24 h of diagnosis, appropriate initial antifungal therapy, ophthalmologic examination, follow-up blood cultures until clearance, and antifungal therapy for at least two weeks post-clearance. Analyses stratified patients by serum BDG status (positive/negative) and compliance with the Candida bundle (high: 4?5 points; low: 0?3 points). The primary outcome was 30-day mortality, and the secondary outcome was defined as endophthalmitis incidence.<br>
Results Of 96 eligible patients with candidemia, 70 (72.9%) were BDG-positive and 26 (27.1%) were BDG-negative. The overall 30-day mortality was 17.7%. Among BDG-positive patients, 15 (21.4%) died, while 2 (7.7%) died in BDG-negative cohorts (p?=?0.09). Serum BDG positivity demonstrated a statistically significant association with decreased survival rates in the low bundle adherence group (p?=?0.02), whereas this correlation was not observed among patients in the high-compliance cohort (p?=?0.66). Endophthalmitis occurred in 25.0% of patients, without significant correlation to serum BDG status. C. albicans was associated with a significantly higher incidence of endophthalmitis compared with non-albicans species (45.7% vs. 8.9%).<br>
Conclusions Serum BDG positivity potentially correlates with worse survival in candidemia, particularly in patients with low bundle compliance. This emphasizes the importance of adherence to standardized Candida management protocols for optimizing patient outcomes.
en-copyright=
kn-copyright=

en-aut-name=AkazawaHidemasa
en-aut-sei=Akazawa
en-aut-mei=Hidemasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FukushimaShinnosuke
en-aut-sei=Fukushima
en-aut-mei=Shinnosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HiguchiToshie
en-aut-sei=Higuchi
en-aut-mei=Toshie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MiyoshiTomoko
en-aut-sei=Miyoshi
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NakanoYasuhiro
en-aut-sei=Nakano
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=IioKoji
en-aut-sei=Iio
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=AkamatsuYukinobu
en-aut-sei=Akamatsu
en-aut-mei=Yukinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HarukiYuto
en-aut-sei=Haruki
en-aut-mei=Yuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=IwamotoYoshitaka
en-aut-sei=Iwamoto
en-aut-mei=Yoshitaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TanakaShuichi
en-aut-sei=Tanaka
en-aut-mei=Shuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=FujisatoShun
en-aut-sei=Fujisato
en-aut-mei=Shun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=AkoSoichiro
en-aut-sei=Ako
en-aut-mei=Soichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=HagiyaHideharu
en-aut-sei=Hagiya
en-aut-mei=Hideharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

affil-num=1
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of General Internal Medicine, Okayama Red Cross Hospital
kn-affil=

affil-num=4
en-affil=Center for Medical Education and Internationalization, Kyoto University Graduate School of Medicine
kn-affil=

affil-num=5
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Microbiology Division, Clinical Laboratory, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Department of General Medicine, Tottori Municipal Hospital
kn-affil=

affil-num=8
en-affil=Department of Pharmacy, Tsuyama Chuo Hospital
kn-affil=

affil-num=9
en-affil=Department of General Medicine, NHO Okayama Medical Center
kn-affil=

affil-num=10
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Pharmacy, Okayama Rousai Hospital
kn-affil=

affil-num=12
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=13
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=
en-keyword=Candidemia
kn-keyword=Candidemia
en-keyword=Prognosis
kn-keyword=Prognosis
en-keyword=β-D-glucan
kn-keyword=β-D-glucan
en-keyword=Candida bundle
kn-keyword=Candida bundle
en-keyword=Endophthalmitis
kn-keyword=Endophthalmitis
END

start-ver=1.4
cd-journal=joma
no-vol=6
cd-vols=
no-issue=1
article-no=
start-page=100026
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202502
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Severe Intracranial Infection
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=FukushimaShinnosuke
en-aut-sei=Fukushima
en-aut-mei=Shinnosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FujimoriTakumi
en-aut-sei=Fujimori
en-aut-mei=Takumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=IioKoji
en-aut-sei=Iio
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HagiyaHideharu
en-aut-sei=Hagiya
en-aut-mei=Hideharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Microbiology Division, Clinical Laboratory, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Microbiology Division, Clinical Laboratory, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=
en-keyword=bloodstream infection
kn-keyword=bloodstream infection
en-keyword=brain abscess
kn-keyword=brain abscess
en-keyword=mixed infection
kn-keyword=mixed infection
END

start-ver=1.4
cd-journal=joma
no-vol=30
cd-vols=
no-issue=7
article-no=
start-page=oyaf201
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202507
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Pharmacovigilance study for the identification of mogamulizumab-induced immune-related adverse events using a real-world database
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Mogamulizumab is a humanized anti-CCR4 monoclonal antibody used for relapsed/refractory adult T-cell leukemia, cutaneous T-cell lymphoma, and/or S?zary syndrome. Reports of immune-related adverse events (irAEs) in these patients are increasing, and the association between irAEs and mogamulizumab remains to be elucidated. This study aimed to evaluate the association between mogamulizumab and immune-related adverse events (irAEs), as well as to characterize the irAEs associated with mogamulizumab using data from a large-scale spontaneous reporting system.<br>
Methods: We performed an exploratory hypothesis-generating analysis of patients from 1967 to September 2023 using VigiBase, a World Health Organization spontaneous adverse event reporting system database. We performed a disproportionality analysis and determined the reporting odds ratios and information components between the drugs of interest and each irAE.<br>
Results: Mogamulizumab was associated with some irAEs, including myocarditis, severe cutaneous adverse reactions, hepatitis, and myositis. Mogamulizumab exhibited significantly higher reporting rates of these 4 irAEs compared to the anticancer agents other than mogamulizumab. Conversely, the reporting rate of other irAEs, including endocrine autoimmune diseases induced by immune checkpoint inhibitors, was not significant in patients who received mogamulizumab.<br>
Conclusions: Mogamulizumab is associated with irAEs, including myocarditis, severe cutaneous adverse reactions, hepatitis, and myositis.
en-copyright=
kn-copyright=

en-aut-name=MiyataKoji
en-aut-sei=Miyata
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=Izawa-IshizawaYuki
en-aut-sei=Izawa-Ishizawa
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NiimuraTakahiro
en-aut-sei=Niimura
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YoshiokaToshihiko
en-aut-sei=Yoshioka
en-aut-mei=Toshihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HyodoMizusa
en-aut-sei=Hyodo
en-aut-mei=Mizusa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ItokazuShuto
en-aut-sei=Itokazu
en-aut-mei=Shuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MiyataTatsumi
en-aut-sei=Miyata
en-aut-mei=Tatsumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=AizawaFuka
en-aut-sei=Aizawa
en-aut-mei=Fuka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=YagiKenta
en-aut-sei=Yagi
en-aut-mei=Kenta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KawadaKei
en-aut-sei=Kawada
en-aut-mei=Kei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=HamanoHirofumi
en-aut-sei=Hamano
en-aut-mei=Hirofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=GodaMitsuhiro
en-aut-sei=Goda
en-aut-mei=Mitsuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=IshizawaKeisuke
en-aut-sei=Ishizawa
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

affil-num=1
en-affil=Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University
kn-affil=

affil-num=2
en-affil=Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University
kn-affil=

affil-num=3
en-affil=Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University
kn-affil=

affil-num=4
en-affil=Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University
kn-affil=

affil-num=5
en-affil=Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University
kn-affil=

affil-num=6
en-affil=Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University
kn-affil=

affil-num=7
en-affil=Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University
kn-affil=

affil-num=8
en-affil=Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University
kn-affil=

affil-num=9
en-affil=Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University
kn-affil=

affil-num=10
en-affil=Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University
kn-affil=

affil-num=11
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=

affil-num=12
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=

affil-num=13
en-affil=Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University
kn-affil=

affil-num=14
en-affil=Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University
kn-affil=
en-keyword=irAEs
kn-keyword=irAEs
en-keyword=mogamulizumab
kn-keyword=mogamulizumab
en-keyword=VigiBase
kn-keyword=VigiBase
en-keyword=disproportionality analysis
kn-keyword=disproportionality analysis
en-keyword=s?zary syndrome
kn-keyword=s?zary syndrome
END

start-ver=1.4
cd-journal=joma
no-vol=5
cd-vols=
no-issue=2
article-no=
start-page=100820
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=2026
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Feasibility and Diagnostic Utility of Mucosal T-Cell Flow Cytometry for Intestinal Graft-Versus-Host Disease
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background and Aims: Timely diagnosis of intestinal complications after hematopoietic stem cell transplantation (HSCT), including graft-versus-host disease (GVHD), transplant-associated thrombotic microangiopathy, and cytomegalovirus infection, is essential for appropriate management. This study evaluated whether mucosal T-cell profiling from endoscopic biopsies could support the diagnosis of these post-transplant conditions.<br>
Methods: We prospectively analyzed 58 intestinal biopsy specimens from 21 post-HSCT patients. Paired samples were obtained from the stomach and duodenum during upper endoscopy and from the ileum and large intestine during colonoscopy. Lymphocytes were isolated from each specimen and analyzed using flow cytometry. These data were integrated with those of a previously collected cohort (35 patients, 51 samples) for comparative immunophenotypic analysis across histologically defined groups.<br>
Results: Duodenal biopsies yielded more lymphocytes than did gastric biopsies (mean ± standard deviation: 532 ± 823 vs 233 ± 392 cells; P = .070), with comparable yields between the ileum and colon. Among 41 evaluable cases, the CD56+:CD3+ ratio was significantly lower in patients with GVHD (5.5 ± 2.2%) than in those with nonspecific or no inflammation (28.4 ± 16.3%; P = .006). A cutoff value of <11% provided 85.7% sensitivity and 83.3% specificity for diagnosing GVHD (area under the curve = 0.91).<br>
Conclusion: Mucosal T-cell profiling using endoscopic biopsies is feasible and may aid in the diagnosis of GVHD after HSCT. A decreased CD56+:CD3+ ratio is a promising marker for distinguishing GVHD from other post-transplant intestinal conditions.
en-copyright=
kn-copyright=

en-aut-name=IwamuroMasaya
en-aut-sei=Iwamuro
en-aut-mei=Masaya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KondoTakumi
en-aut-sei=Kondo
en-aut-mei=Takumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=EnnishiDaisuke
en-aut-sei=Ennishi
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=FujiiNobuharu
en-aut-sei=Fujii
en-aut-mei=Nobuharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HiramatsuMai
en-aut-sei=Hiramatsu
en-aut-mei=Mai
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HirabataAraki
en-aut-sei=Hirabata
en-aut-mei=Araki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TakahashiTakahide
en-aut-sei=Takahashi
en-aut-mei=Takahide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TanakaTakehiro
en-aut-sei=Tanaka
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MaedaYoshinobu
en-aut-sei=Maeda
en-aut-mei=Yoshinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=OtsukaMotoyuki
en-aut-sei=Otsuka
en-aut-mei=Motoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Division of Medical Support, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Division of Medical Support, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Division of Medical Support, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=
en-keyword=cytomegalovirus infection
kn-keyword=cytomegalovirus infection
en-keyword=flow cytometry
kn-keyword=flow cytometry
en-keyword=graft-versus-host disease
kn-keyword=graft-versus-host disease
en-keyword=hematopoietic stem cell transplantation
kn-keyword=hematopoietic stem cell transplantation
en-keyword=T lymphocytes
kn-keyword=T lymphocytes
END

start-ver=1.4
cd-journal=joma
no-vol=15
cd-vols=
no-issue=1
article-no=
start-page=376
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260104
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Oral Health-Related Quality of Life and Self-Reported Oral Health Status Are Associated with Change in Self-Reported Depression Status: A Cohort Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background/Objectives: Oral health-related quality of life (OHRQoL) may influence mental health outcomes, yet longitudinal evidence on its association with depression remains limited. This study aimed to examine whether oral health status and OHRQoL are associated with a change in self-reported depression status among adults in Japan. Methods: We analyzed data from the Japan COVID-19 and Society Internet Survey (JACSIS), conducted in 2022 and 2023. A total of 15,068 participants aged ?20 years without depression at baseline were included. Depression status was identified by self-reported measures between the two survey waves. Logistic regression models estimated odds ratios (ORs) and 95% confidence intervals (CIs) for change in self-reported depression status in relation to OHRQoL and oral health status, adjusting for sociodemographic and behavioral factors. Results: During follow-up, 218 participants (1.45%) reported a change in self-reported depression status. Poorer OHRQoL was significantly associated with a change in self-reported depression status (OR: 1.018; 95% CI: 1.001?1.036; p = 0.039). Additional risk factors included younger age (OR: 0.974; 95% CI: 0.964?0.985), participation in hobbies and cultural activities (OR: 2.224; 95% CI: 1.498?3.302), habitual use of sleeping pills or anxiolytics (current use OR: 3.512; 95% CI: 2.267?5.442), increased loneliness (OR: 1.217; 95% CI: 1.140?1.299), lower life satisfaction (OR: 0.900; 95% CI: 0.836?0.969), and poor self-rated health (OR: 2.921; 95% CI: 1.810?4.715). Conclusions: Impaired OHRQoL was associated with a change in self-reported depression status, potentially through psychosocial mechanisms. These findings suggest that oral health and OHRQoL may be relevant factors to consider in integrated oral and mental health approaches in clinical practice.
en-copyright=
kn-copyright=

en-aut-name=TakeuchiNoriko
en-aut-sei=Takeuchi
en-aut-mei=Noriko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MaruyamaTakayuki
en-aut-sei=Maruyama
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ToyamaNaoki
en-aut-sei=Toyama
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KatsubeYuzuki
en-aut-sei=Katsube
en-aut-mei=Yuzuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TabuchiTakahiro
en-aut-sei=Tabuchi
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=EkuniDaisuke
en-aut-sei=Ekuni
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Preventive Dentistry, Division of Dentistry, Medical Development Field, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Preventive Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Preventive Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Dental School, Okayama University
kn-affil=

affil-num=5
en-affil=Division of Epidemiology, School of Public Health, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=6
en-affil=Department of Preventive Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=oral health-related quality of life
kn-keyword=oral health-related quality of life
en-keyword=depression status
kn-keyword=depression status
en-keyword=cohort study
kn-keyword=cohort study
END

start-ver=1.4
cd-journal=joma
no-vol=16
cd-vols=
no-issue=1
article-no=
start-page=45
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260105
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Magnetic Detection of Cancer Cells Using Tumor-Homing Peptide-Modified Magnetic Nanoparticles
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Magnetic nanoparticles (MNPs) provide a platform for target detection because of their magnetic responsiveness to alternating magnetic fields (AMFs). We developed a detection method using MNPs modified with tumor-homing peptides (THPs), PL1 and PL3, which selectively bind to protein components enriched in malignant tissues. THP-MNPs were synthesized using maleimide-PEG-NHS linkers and characterized using transmission electron microscopy. Human glioblastoma cancer U87MG and normal tissue-derived HEK293 cells were incubated with THP-MNPs, and the magnetic signals were measured using a high-temperature superconducting quantum interference device (SQUID) magnetometer under an AMF (1.06 kHz). Dark-field microscopy confirmed the preferential binding of THP-MNPs to U87MG cells. In the absence of cells, THP-MNPs exhibited AMF-dependent signal enhancement, which correlated with particle size reduction due to THP release. This increase was completely suppressed in the presence of U87MG cells, indicating a strong THP-mediated interaction. PL3-MNPs exhibited superior discrimination between malignant and non-malignant cells. These results demonstrate that SQUID-based magnetic measurements using THP-MNPs enable rapid and label-free cancer cell detection.
en-copyright=
kn-copyright=

en-aut-name=ZhouShengli
en-aut-sei=Zhou
en-aut-mei=Shengli
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FurutaniYuji
en-aut-sei=Furutani
en-aut-mei=Yuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YamashitaKei
en-aut-sei=Yamashita
en-aut-mei=Kei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KakoSakuya
en-aut-sei=Kako
en-aut-mei=Sakuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=WatanabeKazunori
en-aut-sei=Watanabe
en-aut-mei=Kazunori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KiwaToshihiko
en-aut-sei=Kiwa
en-aut-mei=Toshihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=OhtsukiTakashi
en-aut-sei=Ohtsuki
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=

affil-num=7
en-affil=Department of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=
en-keyword=magnetic nanoparticle
kn-keyword=magnetic nanoparticle
en-keyword=tumor-homing peptide
kn-keyword=tumor-homing peptide
en-keyword=superconducting quantum interference devices
kn-keyword=superconducting quantum interference devices
END

start-ver=1.4
cd-journal=joma
no-vol=32
cd-vols=
no-issue=6
article-no=
start-page=1405
end-page=1416
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251012
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Clinical significance on switching CDK4/6 inhibitors among 13,284 patients with metastatic breast cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Recent clinical trials have shown that switching to a combination therapy of a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) and endocrine therapy (ET) prolongs progression-free survival (PFS) compared with ET monotherapy. Reports indicate that abemaciclib provides benefits regardless of the PIK3CA mutation status; however, its clinical benefits remain insufficient. This study aimed to evaluate the clinical significance of switching CDK4/6i?+?ET in a large real-world cohort. Using a medical database, we identified 13,284 patients with hormone receptor?positive/human epidermal growth factor receptor 2?negative advanced breast cancer who received CDK4/6i?+?ET between 2008 and 2022. Patients were categorized into five groups based on their first- and second-line therapy patterns. We compared the median time to discontinuation (TTD) among the groups. In patients who switched from one CDK4/6i?+?ET to another CDK4/6i?+?ET, the second-line TTD and total TTD of first- and second-line therapies (n?=?542) were significantly longer than those in patients who switched from CDK4/6i?+?ET to ET monotherapy (n?=?490) (the second-line TTD: 11.2 vs. 4.9 months, p?<?0.01; total TTD: 25.1 vs. 20.5 months, p?<?0.01). The order of palbociclib and abemaciclib administration did not significantly affect the second-line or total TTD in patients who switched from one CDK4/6i?+?ET to another CDK4/6i?+?ET. Switching from one CDK4/6i?+?ET to another CDK4/6i?+?ET resulted in a significantly longer TTD than switching to ET monotherapy. Considering the phase III clinical trial results of capivasertib, switching to CDK4/6i?+?ET is a viable therapeutic option regardless of the PIK3CA mutation status.
en-copyright=
kn-copyright=

en-aut-name=NishinaTakuya
en-aut-sei=Nishina
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TaniokaMaki
en-aut-sei=Tanioka
en-aut-mei=Maki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakadaKenji
en-aut-sei=Takada
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TsukiokiTakahiro
en-aut-sei=Tsukioki
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TakahashiYuko
en-aut-sei=Takahashi
en-aut-mei=Yuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ShienTadahiko
en-aut-sei=Shien
en-aut-mei=Tadahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ToyookaShinichi
en-aut-sei=Toyooka
en-aut-mei=Shinichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Medical AI Project, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=Cyclin-dependent kinase 4/6 inhibitors
kn-keyword=Cyclin-dependent kinase 4/6 inhibitors
en-keyword=Endocrine therapy
kn-keyword=Endocrine therapy
en-keyword=HR-positive/HER2-negative advanced breast cancer 
kn-keyword=HR-positive/HER2-negative advanced breast cancer 
en-keyword=Progression-free survival
kn-keyword=Progression-free survival
en-keyword=Time to discontinuation
kn-keyword=Time to discontinuation
END

start-ver=1.4
cd-journal=joma
no-vol=69
cd-vols=
no-issue=12
article-no=
start-page=e00740-25
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251210
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Genomic portrayal of emerging carbapenem-resistant El Tor variant Vibrio cholerae O1
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The escalating prevalence of carbapenem-resistant (CR) enteric pathogens elicits significant challenges to public health management and effective antimicrobial therapy. While carbapenem resistance is rare in Vibrio cholerae O1 (VC), the recent emergence of CR strains reveals a concerning shift in their antimicrobial resistance (AMR) landscape. This study aims to characterize the resistance mechanisms in newly identified El Tor CRVC isolated from cholera patients in Gujarat, India during 2019. Fifty VC isolates were screened for major virulence-associated genes along with the determination of their antibiotic resistance profiles using Kirby-Bauer disk diffusion and MIC assays. Whole-genome sequencing (WGS) was employed to investigate the underlying mechanisms of CR. All the isolates exhibited hypervirulent Haitian alleles of major virulence genes and AMR profiles of typical multidrug resistance (MDR). Strikingly, 12% (6/50) of them were resistant to carbapenems and other antibiotics. Molecular analysis revealed that these CR isolates were clonally related and harbored a 142 kbp IncA/C type conjugative mega-plasmid with several AMR encoding genes, including blaNDM-1, that can be easily transferred to other bacterial species and confer donor AMR patterns. The plasmid’s competence for horizontal gene transfer presents a significant risk of dissemination to other enteric pathogens and thereby may complicate the treatment. This finding emphasizes the urgent need for enhanced genomic surveillance and robust antimicrobial stewardship programs aimed at curbing the spread of CRVC strains and mitigating their impact on cholera treatment and containment strategies.
en-copyright=
kn-copyright=

en-aut-name=ShawSreeja
en-aut-sei=Shaw
en-aut-mei=Sreeja
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=PragasamAgila Kumari
en-aut-sei=Pragasam
en-aut-mei=Agila Kumari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ChowdhuryGoutam
en-aut-sei=Chowdhury
en-aut-mei=Goutam
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SamantaProsenjit
en-aut-sei=Samanta
en-aut-mei=Prosenjit
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=RoyDeboleena
en-aut-sei=Roy
en-aut-mei=Deboleena
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=GhoshDebjani
en-aut-sei=Ghosh
en-aut-mei=Debjani
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=RamamurthyThandavarayan
en-aut-sei=Ramamurthy
en-aut-mei=Thandavarayan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KariaJigna
en-aut-sei=Karia
en-aut-mei=Jigna
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=NinamaGovind
en-aut-sei=Ninama
en-aut-mei=Govind
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=MiyoshiShin-ichi
en-aut-sei=Miyoshi
en-aut-mei=Shin-ichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=AkedaYukihiro
en-aut-sei=Akeda
en-aut-mei=Yukihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=KoleyHemanta
en-aut-sei=Koley
en-aut-mei=Hemanta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=MukhopadhyayAsish Kumar
en-aut-sei=Mukhopadhyay
en-aut-mei=Asish Kumar
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

affil-num=1
en-affil=ICMR-National Institute for Research in Bacterial Infections
kn-affil=

affil-num=2
en-affil=V. Ramalingaswami Bhawan, Indian Council of Medical Research
kn-affil=

affil-num=3
en-affil=ICMR-National Institute for Research in Bacterial Infections
kn-affil=

affil-num=4
en-affil=ICMR-National Institute for Research in Bacterial Infections
kn-affil=

affil-num=5
en-affil=ICMR-National Institute for Research in Bacterial Infections
kn-affil=

affil-num=6
en-affil=ICMR-National Institute for Research in Bacterial Infections
kn-affil=

affil-num=7
en-affil=ICMR-National Institute for Research in Bacterial Infections
kn-affil=

affil-num=8
en-affil=Medical College Baroda
kn-affil=

affil-num=9
en-affil=Medical College Baroda
kn-affil=

affil-num=10
en-affil=Okayama University
kn-affil=

affil-num=11
en-affil=National Institute of Infectious Diseases
kn-affil=

affil-num=12
en-affil=ICMR-National Institute for Research in Bacterial Infections
kn-affil=

affil-num=13
en-affil=ICMR-National Institute for Research in Bacterial Infections
kn-affil=
en-keyword=antimicrobial resistance
kn-keyword=antimicrobial resistance
en-keyword=Vibrio cholerae
kn-keyword=Vibrio cholerae
en-keyword=blaNDM-1
kn-keyword=blaNDM-1
en-keyword=carbapenem resistance
kn-keyword=carbapenem resistance
en-keyword=horizontal gene transfer
kn-keyword=horizontal gene transfer
en-keyword=IncA/C plasmid
kn-keyword=IncA/C plasmid
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=1
article-no=
start-page=10
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251218
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Gut microbial metabolite butyrate boosts p53-expressing telomerase-specific oncolytic adenovirus efficacy by enhancing infectivity and activating MHC-I/cGAS-STING
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The gut microbiota plays an essential role in regulating host immunity, and its metabolites such as butyrate exert immunomodulatory effects by acting as histone deacetylase inhibitors. Oncolytic virotherapy has emerged as a promising approach for cancer treatment, and we have developed OBP-702, a telomerase-specific oncolytic adenovirus that expresses p53 and elicits strong systemic antitumor responses. In this study, the potential synergy between butyrate and OBP-702 was investigated in colorectal cancer models. Using human and murine colorectal carcinoma cell lines, butyrate was found to directly enhance the infectivity of OBP-702 by upregulating CAR and integrins, thereby promoting apoptosis and autophagy in tumor cells. In addition, butyrate indirectly boosted systemic antitumor immunity by upregulating MHC-I expression through activation of the cGAS-STING pathway and enhancing CD8?+?T cell recruitment via CXCL10 secretion. These findings were supported by in vivo experiments using CT26 subcutaneous, bilateral, and orthotopic tumor models, in which the combination of oral butyrate and intratumoral OBP-702 administration produced synergistic antitumor effects. These results highlight the therapeutic potential of integrating gut microbial metabolites with oncolytic virotherapy as a novel immunotherapeutic strategy for colorectal cancer.
en-copyright=
kn-copyright=

en-aut-name=SakamotoMasaki
en-aut-sei=Sakamoto
en-aut-mei=Masaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KurodaShinji
en-aut-sei=Kuroda
en-aut-mei=Shinji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KatayamaTetsuya
en-aut-sei=Katayama
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MikaneYu
en-aut-sei=Mikane
en-aut-mei=Yu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HanzawaShunya
en-aut-sei=Hanzawa
en-aut-mei=Shunya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KadowakiDaisuke
en-aut-sei=Kadowaki
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YoshidaYusuke
en-aut-sei=Yoshida
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HamadaYuki
en-aut-sei=Hamada
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=SugimotoRyoma
en-aut-sei=Sugimoto
en-aut-mei=Ryoma
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=YagiChiaki
en-aut-sei=Yagi
en-aut-mei=Chiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=HashimotoMasashi
en-aut-sei=Hashimoto
en-aut-mei=Masashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=KanayaNobuhiko
en-aut-sei=Kanaya
en-aut-mei=Nobuhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=KakiuchiYoshihiko
en-aut-sei=Kakiuchi
en-aut-mei=Yoshihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=KikuchiSatoru
en-aut-sei=Kikuchi
en-aut-mei=Satoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=ShigeyasuKunitoshi
en-aut-sei=Shigeyasu
en-aut-mei=Kunitoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=TazawaHiroshi
en-aut-sei=Tazawa
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=KagawaShunsuke
en-aut-sei=Kagawa
en-aut-mei=Shunsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=UrataYasuo
en-aut-sei=Urata
en-aut-mei=Yasuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=12
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=13
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=14
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=15
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=16
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=17
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=18
en-affil=Oncolys BioPharma, Inc.
kn-affil=

affil-num=19
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=Butyrate
kn-keyword=Butyrate
en-keyword=Oncolytic adenovirus
kn-keyword=Oncolytic adenovirus
en-keyword=MHC-I
kn-keyword=MHC-I
en-keyword=CD8 + T cells
kn-keyword=CD8 + T cells
en-keyword=Cancer immunotherapy
kn-keyword=Cancer immunotherapy
END

start-ver=1.4
cd-journal=joma
no-vol=137
cd-vols=
no-issue=3
article-no=
start-page=95
end-page=97
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The 2024 Incentive Award of the Okayama Medical Association in Cardiovascular and Pulmonary Research (2024 Sunada Prize)
kn-title=令和６年度岡山医学会賞　胸部・循環研究奨励賞（砂田賞）
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=KawanaShinichi
en-aut-sei=Kawana
en-aut-mei=Shinichi
kn-aut-name=川名伸一
kn-aut-sei=川名
kn-aut-mei=伸一
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=岡山大学大学院医歯薬学総合研究科 呼吸器・乳腺内分泌外科学
END

start-ver=1.4
cd-journal=joma
no-vol=137
cd-vols=
no-issue=3
article-no=
start-page=92
end-page=94
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The 2024 Incentive Award of the Okayama Medical Association in General Medical Science (2024 Yuuki Prize)
kn-title=令和６年度岡山医学会賞　総合研究奨励賞（結城賞）
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=YumotoTetsuya
en-aut-sei=Yumoto
en-aut-mei=Tetsuya
kn-aut-name=湯本哲也
kn-aut-sei=湯本
kn-aut-mei=哲也
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Department of Emergency, Critical Care and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=岡山大学大学院医歯薬学総合研究科　救命救急・災害医学
END

start-ver=1.4
cd-journal=joma
no-vol=137
cd-vols=
no-issue=3
article-no=
start-page=89
end-page=91
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=The 2024 Incentive Award of the Okayama Medical Association in Cancer Research (2024 Hayashibara Prize and Yamada Prize)
kn-title=令和６年度岡山医学会賞　がん研究奨励賞（林原賞・山田賞）
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=TakihiraShota
en-aut-sei=Takihira
en-aut-mei=Shota
kn-aut-name=�逡ｽ将太
kn-aut-sei=�逡ｽ
kn-aut-mei=将太
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=岡山大学大学院医歯薬学総合研究科　整形外科学
END

start-ver=1.4
cd-journal=joma
no-vol=695
cd-vols=
no-issue=
article-no=
start-page=123031
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202511
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Flash vaporization and migration of iodine in the oceanic plate subduction zone
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Crustal fluids in subduction zones, such as subsurface aquifers, submarine seeps, and gas hydrate waters, are often rich in iodine (I2) and methane (CH4). Large-scale aquifers in the Kanto subduction zone, where the Pacific Plate (PAC) and the Philippine Sea Plate (PHS) are subducting, also exhibit high concentrations of I2 and CH4. However, the origin and behavior of I2 in the subduction zone are unclear, and its coexistence with CH4 remains unresolved. To investigate this, we compiled the I2 phase diagram under high-pressure and high-temperature (P?T) conditions to predict its physicochemical properties in the subduction zone. We then applied the P?T paths of subducted PAC and PHS sediments to the I2 phase diagram. Our findings reveal that I2 can exist as a liquid in the young and hot PHS subduction zone. Transient decompressions during earthquake ruptures can cause liquid iodine to flash-vaporize and be expelled from subducted sediments. Along with I2, thermogenic CH4 and hydrogen (H2) generated in the subducted sediments are also released and transported upward, likely by slab-dehydrated fluids. Additionally, H2 may enhance microbial CH4 production through hydrogenotrophic methanogenesis. In subduction zones of young and hot oceanic plates such as the PHS, crustal fluids are enriched in I2 and coexist with CH4 owing to the simultaneous expulsion of I2, CH4, and H2 from the same subducted sediments and their migration via deep fluids. Large subsurface aquifers can act as traps and reservoirs for migrating I2 and CH4, forming large-scale I2 and CH4 deposits.
en-copyright=
kn-copyright=

en-aut-name=SuzukiNoriyuki
en-aut-sei=Suzuki
en-aut-mei=Noriyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KamedaJun
en-aut-sei=Kameda
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=AmoMiki
en-aut-sei=Amo
en-aut-mei=Miki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Department of Earth and Planetary Sciences, Faculty of Science, Hokkaido University
kn-affil=

affil-num=2
en-affil=Institute for Planetary Materials, Okayama University
kn-affil=

affil-num=3
en-affil=Geology and Geophysics Division, Technology Department, Japan Organization for Metals and Energy Security
kn-affil=
en-keyword=Iodine circulation
kn-keyword=Iodine circulation
en-keyword=Flash vaporization
kn-keyword=Flash vaporization
en-keyword=Microbial methane
kn-keyword=Microbial methane
en-keyword=Thermogenic methane
kn-keyword=Thermogenic methane
en-keyword=Thermogenic hydrogen
kn-keyword=Thermogenic hydrogen
en-keyword=Subducted sediments
kn-keyword=Subducted sediments
END

start-ver=1.4
cd-journal=joma
no-vol=27
cd-vols=
no-issue=8
article-no=
start-page=938
end-page=943
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202508
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Clinical outcomes of Japanese patients treated with out-of-specification tisagenlecleucel in a phase 3b trial
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: The final manufactured tisagenlecleucel product should meet the commercial product release specifications to ensure the quality in terms of safety, purity, identity, and potency. However, it may occasionally fail to meet these specifications due to the nature of patient-derived cells with variable properties as starting material and the complex manufacturing process. The final product that does not meet at least one of the commercial release specifications is referred to as “out-of-specification” (OOS). However, the benefit-risk profile of OOS tisagenlecleucel has not yet been fully elucidated.<br>
Aims: To evaluate the safety and efficacy of OOS tisagenlecleucel in Japanese patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) and B-cell acute lymphoblastic leukemia (B-ALL).<br>
Methods: This is a single-arm, open-label, multicenter phase 3b study (NCT04094311). Patients consistent with label indication were enrolled and followed-up for 3 months.<br>
Results: Of the 29 patients enrolled between December 2019 and May 2022 across 13 qualified sites in Japan, 28 received tisagenlecleucel, and of these, 23 had r/r DLBCL and 5 had r/r B-ALL. The primary reasons for OOS were low cell viability (15 of 24 batches) and low dose (8 of 23 batches) tisagenlecleucel in the r/r DLBCL group, and high dose (4 of 5 batches) in the r/r B-ALL group. In patients with r/r DLBCL, the grade 3 or 4 cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome occurred in 3 and 1 patients, respectively. Response assessments were performed for 15 of 23 patients with r/r DLBCL: 6 achieved a complete response, and 1 achieved a partial response as the best response within 3 months.<br>
Conclusions: Despite the limited patient sample size, our findings affirm that the infusion of OOS tisagenlecleucel is a viable option, with no observed increase in toxicity and outcomes comparable to those of in-specification products in clinical and real-world studies.
en-copyright=
kn-copyright=

en-aut-name=KatoKoji
en-aut-sei=Kato
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KatoJun
en-aut-sei=Kato
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=GotoHideki
en-aut-sei=Goto
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KobayashiTakeshi
en-aut-sei=Kobayashi
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TakahashiYoshiyuki
en-aut-sei=Takahashi
en-aut-mei=Yoshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=SakaidaEmiko
en-aut-sei=Sakaida
en-aut-mei=Emiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HiramatsuHidefumi
en-aut-sei=Hiramatsu
en-aut-mei=Hidefumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YamamotoMasahide
en-aut-sei=Yamamoto
en-aut-mei=Masahide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=YoshiharaSatoshi
en-aut-sei=Yoshihara
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=AndoJun
en-aut-sei=Ando
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KohKatsuyoshi
en-aut-sei=Koh
en-aut-mei=Katsuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=FukushimaKentaro
en-aut-sei=Fukushima
en-aut-mei=Kentaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=IwamotoFumiko
en-aut-sei=Iwamoto
en-aut-mei=Fumiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=TiwariRanjan
en-aut-sei=Tiwari
en-aut-mei=Ranjan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=FujiiNobuharu
en-aut-sei=Fujii
en-aut-mei=Nobuharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

affil-num=1
en-affil=Department of Hematology, Oncology, and Cardiovascular Medicine, Kyushu University Hospital
kn-affil=

affil-num=2
en-affil=Division of Hematology, Department of Medicine, Keio University School of Medicine
kn-affil=

affil-num=3
en-affil=Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital
kn-affil=

affil-num=4
en-affil=Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
kn-affil=

affil-num=5
en-affil=Department of Pediatrics, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=6
en-affil=Department of Hematology, Chiba University Hospital
kn-affil=

affil-num=7
en-affil=Department of Pediatrics, Graduate School of Medicine, Kyoto University
kn-affil=

affil-num=8
en-affil=Department of Hematology, Institute of Science Tokyo Hospital
kn-affil=

affil-num=9
en-affil=Department of Hematology, Hyogo Medical University Hospital
kn-affil=

affil-num=10
en-affil=Department of Cell Therapy and Transfusion Medicine, Juntendo University Graduate School of Medicine
kn-affil=

affil-num=11
en-affil=Department of Hematology/Oncology, Saitama Children’s Medical Center
kn-affil=

affil-num=12
en-affil=Department of Hematology and Oncology, Osaka University Graduate School of Medicine
kn-affil=

affil-num=13
en-affil=Medical Affairs, Novartis Pharma K.K.
kn-affil=

affil-num=14
en-affil=Development Advance Quantitative Sciences, Novartis Healthcare Private Limited
kn-affil=

affil-num=15
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=
en-keyword=CAR-T
kn-keyword=CAR-T
en-keyword=DLBCL
kn-keyword=DLBCL
en-keyword=Out-of-specification
kn-keyword=Out-of-specification
en-keyword=Safety
kn-keyword=Safety
en-keyword=Tisagenlecleucel
kn-keyword=Tisagenlecleucel
END

start-ver=1.4
cd-journal=joma
no-vol=74
cd-vols=
no-issue=1
article-no=
start-page=263
end-page=267
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=2025
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Improvement of anodic oxide film characteristics of Al-Cu alloy by refinement of IMCs with large-area electron beam irradiation
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Al-Cu alloy has been widely applied to automobile products due to its light weight and high strength, but pitting corrosion easily occurs due to intermetallic compounds (IMCs) in Al-Cu alloy. Anodizing process has been conventionally performed to improve the corrosion resistance of Al-Cu alloy surface. However, IMCs in Al-Cu alloy lead to defects in anodic oxide film. In this study, refinement of IMCs in Al-Cu alloy surface by large-area EB irradiation was proposed. Experimental results show that reflectance and corrosion resistance of anodic oxide film formed on Al-Cu alloy surface are improved by refinement of IMCs with the EB irradiation.
en-copyright=
kn-copyright=

en-aut-name=ShinonagaT.
en-aut-sei=Shinonaga
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SebeA.
en-aut-sei=Sebe
en-aut-mei=A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TaniguchiM.
en-aut-sei=Taniguchi
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=FujiiT.
en-aut-sei=Fujii
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OkadaA.
en-aut-sei=Okada
en-aut-mei=A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Faculty of Environmental, Life, Natural Science & Technology, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Environmental, Life, Natural Science & Technology, Okayama University
kn-affil=

affil-num=3
en-affil=Shimano Research Laboratories, R&D Strategy Dept., SHIMANO INC.
kn-affil=

affil-num=4
en-affil=Shimano Research Laboratories, R&D Strategy Dept., SHIMANO INC.
kn-affil=

affil-num=5
en-affil=Faculty of Environmental, Life, Natural Science & Technology, Okayama University
kn-affil=
en-keyword=Electron beam
kn-keyword=Electron beam
en-keyword=aluminum
kn-keyword=aluminum
en-keyword=anodic oxide film
kn-keyword=anodic oxide film
END

start-ver=1.4
cd-journal=joma
no-vol=10
cd-vols=
no-issue=11
article-no=
start-page=105889
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202511
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Association between adjuvant chemotherapy and outcomes in resected locoregional recurrence of hormone receptor-positive HER2-negative breast cancer: a multi-institutional retrospective study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: To evaluate the association of adjuvant chemotherapy and prognosis for locoregional recurrence (LRR) in hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative subtype breast cancer.<br>
Patients and methods: We carried out a multi-institutional retrospective cohort study in patients with breast cancer who developed HR-positive HER2-negative LRR. Patients who underwent curative surgery for LRR between 2014 and 2018 were categorized based on whether they received adjuvant chemotherapy for LRR (CTx versus no-CTx). Invasive disease-free survival (iDFS) was evaluated between the groups by Cox proportional hazards analysis. The primary analysis used a double-robust Cox model incorporating inverse probability of treatment weighting, and a sensitivity analysis using propensity score matching was also carried out.<br>
Results: A total of 958 patients were included. The median time from the primary surgery to LRR diagnosis was 9.5 years (interquartile range 3.1-10.1 years). There were 235 patients (25%) in the CTx group and 722 (75%) in the no-CTx group. Among all patients, the 5-year iDFS rate was 75.4% [95% confidence interval (CI) 72.4% to 78.2%]. Multivariate analysis showed better iDFS in the CTx group (hazard ratio 0.70, 95% CI 0.49-0.99, P = 0.045). Sensitivity analysis supported these findings. Subgroup analyses showed that the CTx group had better iDFS in cases with non-ipsilateral breast tumor recurrence (IBTR), recurrences during adjuvant endocrine therapy for primary breast cancer, and without perioperative chemotherapy for primary breast cancer. Secondary analysis showed no significant difference with a worse trend toward overall survival in the CTx group with multivariate Cox proportional hazards analysis.<br>
Conclusion: Adjuvant chemotherapy for HR-positive HER2-negative LRR was associated with better iDFS, particularly in cases of non-IBTR, recurrences during adjuvant endocrine therapy, and no prior perioperative chemotherapy for their primary tumor. However, the retrospective design and inability to distinguish true recurrences from new primary tumors in IBTR warrant cautious interpretation.
en-copyright=
kn-copyright=

en-aut-name=OzakiY.
en-aut-sei=Ozaki
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TokudaE.
en-aut-sei=Tokuda
en-aut-mei=E.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SagaraY.
en-aut-sei=Sagara
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HaraF.
en-aut-sei=Hara
en-aut-mei=F.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SasadaS.
en-aut-sei=Sasada
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=SawakiM.
en-aut-sei=Sawaki
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KanbayashiC.
en-aut-sei=Kanbayashi
en-aut-mei=C.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YamanakaT.
en-aut-sei=Yamanaka
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OnishiT.
en-aut-sei=Onishi
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=FujikiY.
en-aut-sei=Fujiki
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=SutoA.
en-aut-sei=Suto
en-aut-mei=A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=TakahashiY.
en-aut-sei=Takahashi
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=TokunagaE.
en-aut-sei=Tokunaga
en-aut-mei=E.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=ArugaT.
en-aut-sei=Aruga
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=NakamuraR.
en-aut-sei=Nakamura
en-aut-mei=R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=FujisawaT.
en-aut-sei=Fujisawa
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=SajiS.
en-aut-sei=Saji
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=IwataH.
en-aut-sei=Iwata
en-aut-mei=H.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=ShienT.
en-aut-sei=Shien
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

affil-num=1
en-affil=Department of Breast Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research
kn-affil=

affil-num=2
en-affil=Department of Medical Oncology, Fukushima Medical University
kn-affil=

affil-num=3
en-affil=Department of Breast Surgery, Social Medical Corporation Hakuaikai Sagara Hospital
kn-affil=

affil-num=4
en-affil=Department of Breast Oncology, Aichi Cancer Center Hospital
kn-affil=

affil-num=5
en-affil=Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University
kn-affil=

affil-num=6
en-affil=Department of Breast Oncology, Aichi Cancer Center Hospital
kn-affil=

affil-num=7
en-affil=Department of Breast Oncology, Niigata Cancer Center Hospital
kn-affil=

affil-num=8
en-affil=Department of Breast Surgery and Oncology, Kanagawa Cancer Center
kn-affil=

affil-num=9
en-affil=Department of Breast Oncology, National Cancer Center Hospital East
kn-affil=

affil-num=10
en-affil=Department of Breast Surgery, Social Medical Corporation Hakuaikai Sagara Hospital
kn-affil=

affil-num=11
en-affil=Department of Breast Oncology, National Cancer Center Hospital
kn-affil=

affil-num=12
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=13
en-affil=Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center
kn-affil=

affil-num=14
en-affil=Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
kn-affil=

affil-num=15
en-affil=Division of Breast Surgery, Chiba Cancer Center
kn-affil=

affil-num=16
en-affil=Department of Breast Oncology, Gunma Prefectural Cancer Center
kn-affil=

affil-num=17
en-affil=Department of Medical Oncology, Fukushima Medical University
kn-affil=

affil-num=18
en-affil=Department of Advanced Clinical Research and Development, Nagoya City University
kn-affil=

affil-num=19
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=
en-keyword=breast cancer
kn-keyword=breast cancer
en-keyword=locoregional recurrence
kn-keyword=locoregional recurrence
en-keyword=adjuvant chemotherapy
kn-keyword=adjuvant chemotherapy
en-keyword=inverse probability of treatment weighting
kn-keyword=inverse probability of treatment weighting
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251222
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Suppression of Na+ Uptake Via Apoplastic Flow by Chitosan in Rice
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Purpose: Chitosan enhances tolerance to salinity in rice. Apoplastic flow plays a crucial role in the accumulation of sodium (Na+) in rice under salinity. This study investigated the effects of exogenous chitosan on apoplastic flow and Na+ uptake in NaCl-treated rice seedlings. Methods: We employed an apoplastic tracer, trisodium salt of 8-hydroxy-1,3,6-pyrenetrisulphonic acid (PTS), in order to evaluate apoplastic flow in rice (Oryza sativa L., cv. Nipponbare) seedlings that were hydroponically grown in the solution containing NaCl (0 and 25 mM), and chitosan (0 mg L??1, 10 mg L??1, and 50 mg L??1). Results: Application of 25 mM NaCl significantly increased PTS uptake and Na+ content in shoots but did not affect K+ content, resulting in a lower K+/Na+ ratio although 25 mM NaCl did not affect the seedling growth. The application of chitosan suppressed Na+-enhanced PTS uptake and Na+ accumulation in shoots without affecting the K+ content, which led to a higher K+/Na+ ratio. Moreover, chitosan did not affect the reducing sugar content or electrical conductivity in the solution containing NaCl. Conclusions: These results suggest that application of chitosan suppressed Na+-enhanced apoplastic flow to reduce Na+ uptake in rice seedlings.
en-copyright=
kn-copyright=

en-aut-name=ZhaoMaoxiang
en-aut-sei=Zhao
en-aut-mei=Maoxiang
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=GalibMd. Asadulla Al
en-aut-sei=Galib
en-aut-mei=Md. Asadulla Al
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NakamuraToshiyuki
en-aut-sei=Nakamura
en-aut-mei=Toshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakamuraYoshimasa
en-aut-sei=Nakamura
en-aut-mei=Yoshimasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HiraiYoshihiko
en-aut-sei=Hirai
en-aut-mei=Yoshihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NakashimaYoshitaka
en-aut-sei=Nakashima
en-aut-mei=Yoshitaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MunemasaShintaro
en-aut-sei=Munemasa
en-aut-mei=Shintaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MoriIzumi C.
en-aut-sei=Mori
en-aut-mei=Izumi C.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MurataYoshiyuki
en-aut-sei=Murata
en-aut-mei=Yoshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=3
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=4
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=5
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=6
en-affil=
kn-affil=

affil-num=7
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=8
en-affil=Institute of Plant Science and Resources, Okayama University
kn-affil=

affil-num=9
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=
en-keyword=Rice ? Salinity
kn-keyword=Rice ? Salinity
en-keyword=Apoplastic flow
kn-keyword=Apoplastic flow
en-keyword=Trisodium-8-hydroxy-1,3,6-pyrenetrisulphonic acid
kn-keyword=Trisodium-8-hydroxy-1,3,6-pyrenetrisulphonic acid
en-keyword=Chitosan
kn-keyword=Chitosan
END

start-ver=1.4
cd-journal=joma
no-vol=16
cd-vols=
no-issue=
article-no=
start-page=1666999
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251114
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Activation of the pentose phosphate pathway by microcurrent stimulation mediates antioxidant effects in inflammation-stimulated macrophages
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Introduction: Excessive inflammatory responses in macrophages lead to increased oxidative stress, and the excessive production of reactive oxygen species (ROS) causes tissue damage, contributing to the development of chronic diseases and tissue deterioration. Therefore, controlling the inflammatory response and ROS production is crucial for human health. Electrical stimulation (ES) has been shown to have antioxidant and anti-inflammatory effects on macrophages. However, the key pathway underlying these effects remains unclear.<br>
Methods: In this study, ES was applied to Lipopolysaccharide (LPS)-stimulated macrophages, and the production of ROS and 8?hydroxy?2′?deoxyguanosine (8-OHdG), inflammatory cytokine expression, and intracellular metabolites were analyzed in a glucose-6-phosphate dehydrogenase (G6PD) knockdown experiment, the rate-limiting enzyme of the Pentose Phosphate Pathway(PPP).<br>
Results: ES significantly increased sedoheptulose 7-phosphate (S7P), an intermediate metabolite in PPP, and reduced ROS and 8-OHdG production and the expression of inflammatory cytokines in LPS-stimulated macrophages. Meanwhile, ES did not exert antioxidant effects in G6PD-knockdown macrophages.<br>
Discussion: These findings indicate that the antioxidant effects of ES are mediated by PPP in LPS-stimulated macrophages.
en-copyright=
kn-copyright=

en-aut-name=UemuraMikiko
en-aut-sei=Uemura
en-aut-mei=Mikiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MaeshigeNoriaki
en-aut-sei=Maeshige
en-aut-mei=Noriaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YamaguchiAtomu
en-aut-sei=Yamaguchi
en-aut-mei=Atomu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MaXiaoqi
en-aut-sei=Ma
en-aut-mei=Xiaoqi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=FuYunfei
en-aut-sei=Fu
en-aut-mei=Yunfei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=InoueTaketo
en-aut-sei=Inoue
en-aut-mei=Taketo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MatsudaMami
en-aut-sei=Matsuda
en-aut-mei=Mami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=NishimuraYuya
en-aut-sei=Nishimura
en-aut-mei=Yuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HasunumaTomohisa
en-aut-sei=Hasunuma
en-aut-mei=Tomohisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=WangJi
en-aut-sei=Wang
en-aut-mei=Ji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KondoHiroyo
en-aut-sei=Kondo
en-aut-mei=Hiroyo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=FujinoHidemi
en-aut-sei=Fujino
en-aut-mei=Hidemi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

affil-num=1
en-affil=Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences
kn-affil=

affil-num=2
en-affil=Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences
kn-affil=

affil-num=3
en-affil=Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences
kn-affil=

affil-num=4
en-affil=Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences
kn-affil=

affil-num=5
en-affil=Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences
kn-affil=

affil-num=6
en-affil=Assisted Reproductive Technology Center, Okayama University
kn-affil=

affil-num=7
en-affil=Graduate School of Science, Technology and Innovation, Kobe University
kn-affil=

affil-num=8
en-affil=Graduate School of Science, Technology and Innovation, Kobe University
kn-affil=

affil-num=9
en-affil=Graduate School of Science, Technology and Innovation, Kobe University
kn-affil=

affil-num=10
en-affil=Department of Toxicology and Sanitary Chemistry, School of Public Health, Capital Medical University
kn-affil=

affil-num=11
en-affil=Department of Nutrition, Faculty of Health and Nutrition, Shubun University
kn-affil=

affil-num=12
en-affil=Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences
kn-affil=
en-keyword=microcurrent stimulation
kn-keyword=microcurrent stimulation
en-keyword=pentose phosphate pathway (PPP)
kn-keyword=pentose phosphate pathway (PPP)
en-keyword=NADPH
kn-keyword=NADPH
en-keyword=oxidative stress
kn-keyword=oxidative stress
en-keyword=macrophage
kn-keyword=macrophage
en-keyword=glucose metabolism
kn-keyword=glucose metabolism
END

start-ver=1.4
cd-journal=joma
no-vol=19
cd-vols=
no-issue=1
article-no=
start-page=e70157
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202501
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Subspace-Guided Feature Reconstruction for Unsupervised Anomaly Localization
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Unsupervised anomaly localization aims to identify anomalous regions that deviate from normal sample patterns. Most recent methods perform feature matching or reconstruction for the target sample with pre-trained deep neural networks. However, they still struggle to address challenging anomalies because the deep embeddings stored in the memory bank can be less powerful and informative. Specifically, prior methods often overly rely on the finite resources stored in the memory bank, which leads to low robustness to unseen targets. In this paper, we propose a novel subspace-guided feature reconstruction framework to pursue adaptive feature approximation for anomaly localization. It first learns to construct low-dimensional subspaces from the given nominal samples, and then learns to reconstruct the given deep target embedding by linearly combining the subspace basis vectors using the self-expressive model. Our core is that, despite the limited resources in the memory bank, the out-of-bank features can be alternatively “mimicked” to adaptively model the target. Moreover, we propose a sampling method that leverages the sparsity of subspaces and allows the feature reconstruction to depend only on a small resource subset, contributing to less memory overhead. Extensive experiments on three benchmark datasets demonstrate that our approach generally achieves state-of-the-art anomaly localization performance.
en-copyright=
kn-copyright=

en-aut-name=HottaKatsuya
en-aut-sei=Hotta
en-aut-mei=Katsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ZhangChao
en-aut-sei=Zhang
en-aut-mei=Chao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HagiharaYoshihiro
en-aut-sei=Hagihara
en-aut-mei=Yoshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=AkashiTakuya
en-aut-sei=Akashi
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Iwate University
kn-affil=

affil-num=2
en-affil=University of Toyama
kn-affil=

affil-num=3
en-affil=Iwate University
kn-affil=

affil-num=4
en-affil=Okayama University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251117
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Genomic Profiling of Pediatric Solid Tumors With a Dual DNA/RNA Panel: JCCG-TOP2 Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=To develop an optimized genomic medicine platform for pediatric cancers, a nationwide cancer genome profiling project was conducted from January 2022 to February 2023 in collaboration with the Japan Children's Cancer Group. This prospective observational study analyzed matched blood and FFPE tumor samples from patients aged 0?29?years with solid tumors. Genomic analysis used the TOP2 hybrid capture?enrichment system, targeting 737 and 455 genes in the DNA and RNA panels, along with allele-specific genome copy number alterations. A total of 210 patients from 50 institutions were enrolled across Japan (median age, 8?years; range, 0?25). Of these, 154 (77%) were enrolled at diagnosis or during/after initial treatment and 56 (27%) at disease progression or relapse. The TOP2 findings had great benefits in clarifying the diagnosis of pediatric solid tumors. Among the 204 patients with genomic results, 147 (72%) had potentially actionable findings, including diagnostic, prognostic, and therapeutic findings in 111 (54%), 61 (30%), and 64 (31%), respectively. Oncogenic fusions were noted in 45 (23%) patients. A copy number alteration was identified in at least one genomic region in 170 (83%) patients. Two patients exhibited a high tumor mutation burden. Seventeen (8%) patients harbored a germline pathogenic/likely pathogenic variant in cancer-predisposing genes. This study highlighted the feasibility of implementing a nationwide precision medicine platform and the clinical utility of the TOP2 system for pediatric cancers. The results support the integration of genomic data into the standard clinical care of pediatric patients with cancer, both at diagnosis and at relapse.
en-copyright=
kn-copyright=

en-aut-name=TaoKayoko
en-aut-sei=Tao
en-aut-mei=Kayoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YoshiokaTakako
en-aut-sei=Yoshioka
en-aut-mei=Takako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KatoMiho
en-aut-sei=Kato
en-aut-mei=Miho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KomatsuKazuyuki
en-aut-sei=Komatsu
en-aut-mei=Kazuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TsujimotoShinichi
en-aut-sei=Tsujimoto
en-aut-mei=Shinichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=SakamotoKenichi
en-aut-sei=Sakamoto
en-aut-mei=Kenichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TanimuraKazuki
en-aut-sei=Tanimura
en-aut-mei=Kazuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=SugiyamaMinako
en-aut-sei=Sugiyama
en-aut-mei=Minako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=SekiguchiMasahiro
en-aut-sei=Sekiguchi
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NakanoYoshiko
en-aut-sei=Nakano
en-aut-mei=Yoshiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=OtaniYoshihiro
en-aut-sei=Otani
en-aut-mei=Yoshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=YatabeYasushi
en-aut-sei=Yatabe
en-aut-mei=Yasushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=YoshidaAkihiko
en-aut-sei=Yoshida
en-aut-mei=Akihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=OkitaHajime
en-aut-sei=Okita
en-aut-mei=Hajime
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=HiratoJunko
en-aut-sei=Hirato
en-aut-mei=Junko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=KohashiKenichi
en-aut-sei=Kohashi
en-aut-mei=Kenichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=TanakaYukichi
en-aut-sei=Tanaka
en-aut-mei=Yukichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=KohsakaShinji
en-aut-sei=Kohsaka
en-aut-mei=Shinji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=KuboTakashi
en-aut-sei=Kubo
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=SunamiKuniko
en-aut-sei=Sunami
en-aut-mei=Kuniko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=HirataMakoto
en-aut-sei=Hirata
en-aut-mei=Makoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=TsutsumiShuichi
en-aut-sei=Tsutsumi
en-aut-mei=Shuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=AburataniHiroyuki
en-aut-sei=Aburatani
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=KohKatsuyoshi
en-aut-sei=Koh
en-aut-mei=Katsuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=HirayamaMasahiro
en-aut-sei=Hirayama
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=KarakawaShuhei
en-aut-sei=Karakawa
en-aut-mei=Shuhei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=TerashitaYukayo
en-aut-sei=Terashita
en-aut-mei=Yukayo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=FujisakiHiroyuki
en-aut-sei=Fujisaki
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=YagiTakeshi
en-aut-sei=Yagi
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=YonedaAkihiro
en-aut-sei=Yoneda
en-aut-mei=Akihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

en-aut-name=MochizukiShinji
en-aut-sei=Mochizuki
en-aut-mei=Shinji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=31
ORCID=

en-aut-name=ShichinoHiroyuki
en-aut-sei=Shichino
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=32
ORCID=

en-aut-name=SuzukiTatsuya
en-aut-sei=Suzuki
en-aut-mei=Tatsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=33
ORCID=

en-aut-name=TakimotoTetsuya
en-aut-sei=Takimoto
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=34
ORCID=

en-aut-name=IchimuraKoichi
en-aut-sei=Ichimura
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=35
ORCID=

en-aut-name=OgawaChitose
en-aut-sei=Ogawa
en-aut-mei=Chitose
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=36
ORCID=

en-aut-name=MatsumotoKimikazu
en-aut-sei=Matsumoto
en-aut-mei=Kimikazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=37
ORCID=

en-aut-name=IchikawaHitoshi
en-aut-sei=Ichikawa
en-aut-mei=Hitoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=38
ORCID=

en-aut-name=KatoMotohiro
en-aut-sei=Kato
en-aut-mei=Motohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=39
ORCID=

affil-num=1
en-affil=Department of Pediatrics, National Cancer Center Hospital
kn-affil=

affil-num=2
en-affil=Department of Pathology, National Center for Child Health and Development
kn-affil=

affil-num=3
en-affil=Department of Childhood Cancer Data Management, National Center for Child Health and Development
kn-affil=

affil-num=4
en-affil=Department of Pediatrics, Hamamatsu University School of Medicine
kn-affil=

affil-num=5
en-affil=Department of Pediatrics, Yokohama City University
kn-affil=

affil-num=6
en-affil=Department of Pediatrics, Shinshu University School of Medicine
kn-affil=

affil-num=7
en-affil=Department of Pediatrics, National Cancer Center Hospital
kn-affil=

affil-num=8
en-affil=Department of Pediatrics, National Cancer Center Hospital
kn-affil=

affil-num=9
en-affil=Department of Pediatrics, The University of Tokyo
kn-affil=

affil-num=10
en-affil=Department of Pediatrics, The University of Tokyo
kn-affil=

affil-num=11
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=12
en-affil=Department of Diagnostic Pathology, National Cancer Center Hospital
kn-affil=

affil-num=13
en-affil=Department of Diagnostic Pathology, National Cancer Center Hospital
kn-affil=

affil-num=14
en-affil=Department of Pathology, Keio University School of Medicine
kn-affil=

affil-num=15
en-affil=Department of Pathology, Public Tomioka General Hospital
kn-affil=

affil-num=16
en-affil=Department of Pathology, Graduate School of Medicine, Osaka Metropolitan University
kn-affil=

affil-num=17
en-affil=Department of Pathology, Kanagawa Children's Medical Center
kn-affil=

affil-num=18
en-affil=Division of Cellular Signaling, National Cancer Center Research Institute
kn-affil=

affil-num=19
en-affil=Department of Clinical Genomics, National Cancer Center Research Institute
kn-affil=

affil-num=20
en-affil=Department of Laboratory Medicine, National Cancer Center Hospital
kn-affil=

affil-num=21
en-affil=Department of Genetic Medicine and Services, National Cancer Center Hospital
kn-affil=

affil-num=22
en-affil=Genome Science & Medicine Division, Research Center of Advanced Science and Technology, The University of Tokyo
kn-affil=

affil-num=23
en-affil=Genome Science & Medicine Division, Research Center of Advanced Science and Technology, The University of Tokyo
kn-affil=

affil-num=24
en-affil=Department of Hematology and Oncology, Saitama Children's Medical Center
kn-affil=

affil-num=25
en-affil=Department of Pediatrics, Mie University Graduate School of Medicine
kn-affil=

affil-num=26
en-affil=Department of Pediatrics, Hiroshima University Hospital
kn-affil=

affil-num=27
en-affil=Department of Pediatrics, Hokkaido University Hospital
kn-affil=

affil-num=28
en-affil=Department of Pediatric Hematology and Oncology, Osaka City General Hospital
kn-affil=

affil-num=29
en-affil=Okinawa Prefectural Nanbu Medical Center & Children's Medical Center
kn-affil=

affil-num=30
en-affil=Department of Pediatric Surgery, National Center for Child Health and Development
kn-affil=

affil-num=31
en-affil=Department of Pediatrics, National Center for Global Health and Medicine, Japan Institute for Health Security
kn-affil=

affil-num=32
en-affil=Department of Pediatrics, National Center for Global Health and Medicine, Japan Institute for Health Security
kn-affil=

affil-num=33
en-affil=Department of Hematology, National Cancer Center Hospital
kn-affil=

affil-num=34
en-affil=Department of Childhood Cancer Data Management, National Center for Child Health and Development
kn-affil=

affil-num=35
en-affil=Department of Pathology, Kyorin University Faculty of Medicine
kn-affil=

affil-num=36
en-affil=Department of Pediatrics, National Cancer Center Hospital
kn-affil=

affil-num=37
en-affil=Children's Cancer Center National Center for Child Health and Development
kn-affil=

affil-num=38
en-affil=Department of Clinical Genomics, National Cancer Center Research Institute
kn-affil=

affil-num=39
en-affil=Department of Pediatrics, The University of Tokyo
kn-affil=
en-keyword=genomic medicine
kn-keyword=genomic medicine
en-keyword=integrative diagnosis
kn-keyword=integrative diagnosis
en-keyword=molecularly targeted therapy
kn-keyword=molecularly targeted therapy
en-keyword=multigene panel
kn-keyword=multigene panel
en-keyword=pediatric cancers
kn-keyword=pediatric cancers
END

start-ver=1.4
cd-journal=joma
no-vol=38
cd-vols=
no-issue=2
article-no=
start-page=222
end-page=225
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250104
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Ethical Use of Cadaveric Images in Anatomical Textbooks, Atlases, and Journals: A Consensus Response From Authors and Editors
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Nowadays, consent to use donor bodies for medical education and research is obtained from the body donors and their families before the donation. Recently, the International Federation of Associations of Anatomists (IFAA) published guidelines that could restrict the appearance of cadaveric images in commercial anatomical resources such as textbooks and other educational products. These guidelines state that the donor must expressly consent to using such images for this purpose. Cadaveric photos and drawings made from dissections of cadavers have been used in anatomy textbooks and atlases for hundreds of years. They are invaluable for anatomy students and clinical/surgical practitioners. The IFAA guidelines should not restrict the use of those older books; to do so would infringe the rights of those seeking knowledge from these resources. As the images in such textbooks and atlases are anonymized and are used for teaching and research, and the donors and their families are informed about this before the donation, we believe no additional consent is needed. It is impossible to separate educational from “commercial” usage entirely in any situation, e.g., publications from publishers and the use of cadavers in medical schools. Therefore, our best efforts to avoid unethical use of cadaveric images by following traditional consent processes are still needed so that more people will reap the benefits from them. As senior textbook/atlas authors/editors from over 10 countries, we believe that using cadaveric images in anatomy textbooks is appropriate, and no additional consent should be necessary. Such usage falls within the good faith of professionals using these invaluable gifts.
en-copyright=
kn-copyright=

en-aut-name=IwanagaJoe
en-aut-sei=Iwanaga
en-aut-mei=Joe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KimHee‐Jin
en-aut-sei=Kim
en-aut-mei=Hee‐Jin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=AkitaKeiichi
en-aut-sei=Akita
en-aut-mei=Keiichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=LoganBari M.
en-aut-sei=Logan
en-aut-mei=Bari M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HutchingsRalph T.
en-aut-sei=Hutchings
en-aut-mei=Ralph T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OttoneNicol?s
en-aut-sei=Ottone
en-aut-mei=Nicol?s
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NonakaYoichi
en-aut-sei=Nonaka
en-aut-mei=Yoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=AnandMahindra
en-aut-sei=Anand
en-aut-mei=Mahindra
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=BurnsDanny
en-aut-sei=Burns
en-aut-mei=Danny
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=SinghVishram
en-aut-sei=Singh
en-aut-mei=Vishram
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=Peris‐CeldaMaria
en-aut-sei=Peris‐Celda
en-aut-mei=Maria
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=Martinez‐SorianoFrancisco
en-aut-sei=Martinez‐Soriano
en-aut-mei=Francisco
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=ApaydinNihal
en-aut-sei=Apaydin
en-aut-mei=Nihal
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=HannaAmgad
en-aut-sei=Hanna
en-aut-mei=Amgad
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=YoshiokaNobutaka
en-aut-sei=Yoshioka
en-aut-mei=Nobutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=Fernandez‐MirandaJuan
en-aut-sei=Fernandez‐Miranda
en-aut-mei=Juan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=HurMi‐Sun
en-aut-sei=Hur
en-aut-mei=Mi‐Sun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=ShojaMohammadali M.
en-aut-sei=Shoja
en-aut-mei=Mohammadali M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=SaremiFarhood
en-aut-sei=Saremi
en-aut-mei=Farhood
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=ReinaFrancisco
en-aut-sei=Reina
en-aut-mei=Francisco
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=TabiraYoko
en-aut-sei=Tabira
en-aut-mei=Yoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=CarreraAnna
en-aut-sei=Carrera
en-aut-mei=Anna
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=SprattJonathan D.
en-aut-sei=Spratt
en-aut-mei=Jonathan D.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=HoS. Yen
en-aut-sei=Ho
en-aut-mei=S. Yen
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=MoriShumpei
en-aut-sei=Mori
en-aut-mei=Shumpei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=KomuneNoritaka
en-aut-sei=Komune
en-aut-mei=Noritaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=WatanabeKoichi
en-aut-sei=Watanabe
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=Prats‐GalinoAlberto
en-aut-sei=Prats‐Galino
en-aut-mei=Alberto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=De Andr?sJose
en-aut-sei=De Andr?s
en-aut-mei=Jose
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=ReinaMiguel Angel
en-aut-sei=Reina
en-aut-mei=Miguel Angel
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

en-aut-name=AbrahamsPeter H.
en-aut-sei=Abrahams
en-aut-mei=Peter H.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=31
ORCID=

en-aut-name=AndersonRobert H.
en-aut-sei=Anderson
en-aut-mei=Robert H.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=32
ORCID=

en-aut-name=IbaragiSoichiro
en-aut-sei=Ibaragi
en-aut-mei=Soichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=33
ORCID=

en-aut-name=LoukasMarios
en-aut-sei=Loukas
en-aut-mei=Marios
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=34
ORCID=

en-aut-name=TubbsR. Shane
en-aut-sei=Tubbs
en-aut-mei=R. Shane
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=35
ORCID=

affil-num=1
en-affil=Department of Neurosurgery, Tulane University School of Medicine
kn-affil=

affil-num=2
en-affil=Division in Anatomy & Development Biology, Department of Oral Biology, Yonsei University College of Dentistry
kn-affil=

affil-num=3
en-affil=Department of Clinical Anatomy, Tokyo Medical and Dental University (TMDU)
kn-affil=

affil-num=4
en-affil=UK
kn-affil=

affil-num=5
en-affil=UK
kn-affil=

affil-num=6
en-affil=Department of Integral Adult Dentistry, Center for Research in Dental Sciences (CICO), Dental School, Universidad de La Frontera
kn-affil=

affil-num=7
en-affil=Department of Neurosurgery, Tokai University School of Medicine
kn-affil=

affil-num=8
en-affil=Department of Anatomy, Rama Medical College & Research Centre
kn-affil=

affil-num=9
en-affil=Department of Anatomical Sciences, School of Medicine, St. George's University
kn-affil=

affil-num=10
en-affil=Department of Anatomy, Kasturba Medical College Mangalore, Manipal Academy of Higher Education
kn-affil=

affil-num=11
en-affil=Department of Neurologic Surgery, Mayo Clinic
kn-affil=

affil-num=12
en-affil=Department of Anatomy, University of Valencia
kn-affil=

affil-num=13
en-affil=Department of Anatomy, Faculty of Medicine, Ankara University
kn-affil=

affil-num=14
en-affil=Department of Neurological Surgery, University of Wisconsin
kn-affil=

affil-num=15
en-affil=Department of Neuroplastic and Reconstructive Surgery Social Medical Corporation Kotobukikai Tominaga Hospital
kn-affil=

affil-num=16
en-affil=Department of Neurosurgery, Stanford University School of Medicine
kn-affil=

affil-num=17
en-affil=Department of Anatomy, Daegu Catholic University School of Medicine
kn-affil=

affil-num=18
en-affil=Department of Medical Education, Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University (NSU) 
kn-affil=

affil-num=19
en-affil=Department of Radiological Sciences, David Geffen School of Medicine at UCLA, Ronald Reagan UCLA Medical Center 
kn-affil=

affil-num=20
en-affil=Medical Sciences Department, Faculty of Medicine, Clinical Anatomy, Embryology and Neuroscience Research Group, University of Girona
kn-affil=

affil-num=21
en-affil=Division of Gross and Clinical Anatomy, Department of Anatomy, Kurume University School of Medicine
kn-affil=

affil-num=22
en-affil=Medical Sciences Department, Faculty of Medicine, Clinical Anatomy, Embryology and Neuroscience Research Group, University of Girona
kn-affil=

affil-num=23
en-affil=University Hospital of North Durham
kn-affil=

affil-num=24
en-affil=Cardiac Morphology, Royal Brompton & Harefield Hospitals
kn-affil=

affil-num=25
en-affil=University of California Los Angeles (UCLA) Cardiac Arrhythmia Center, Cardiovascular and Interventional Programs, UCLA Health System, David Geffen School of Medicine at UCLA 
kn-affil=

affil-num=26
en-affil=Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University
kn-affil=

affil-num=27
en-affil=Division of Gross and Clinical Anatomy, Department of Anatomy, Kurume University School of Medicine
kn-affil=

affil-num=28
en-affil=Laboratory of Surgical NeuroAnatomy (LSNA), director of the Body Donation and Dissection Rooms Service, Faculty of Medicine and Health of Science, University of Barcelona
kn-affil=

affil-num=29
en-affil=Surgery Specialties Department, University of Valencia
kn-affil=

affil-num=30
en-affil=CEU‐San‐Pablo University School of Medicine
kn-affil=

affil-num=31
en-affil=Warwick Medical School
kn-affil=

affil-num=32
en-affil=Biosciences Institute, Newcastle University
kn-affil=

affil-num=33
en-affil=Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=34
en-affil=Department of Anatomical Sciences, School of Medicine, St. George's University
kn-affil=

affil-num=35
en-affil=Department of Neurosurgery, Tulane University School of Medicine
kn-affil=
en-keyword=anatomy
kn-keyword=anatomy
en-keyword=cadaver
kn-keyword=cadaver
en-keyword=commercial
kn-keyword=commercial
en-keyword=consent
kn-keyword=consent
en-keyword=dissection
kn-keyword=dissection
en-keyword=donors
kn-keyword=donors
en-keyword=medical education
kn-keyword=medical education
en-keyword=medical ethics
kn-keyword=medical ethics
en-keyword=publishing
kn-keyword=publishing
END

start-ver=1.4
cd-journal=joma
no-vol=17
cd-vols=
no-issue=12
article-no=
start-page=e100045
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251225
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Sequential Bilateral Central Retinal Vein Occlusion With Differential Long-Term Outcomes Following Cardiac Surgery
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Bilateral central retinal vein occlusion (CRVO) is rare and is associated with systemic diseases such as hypertension, diabetes, dyslipidemia, and coagulopathy. In this study, we showed that the sequential development of bilateral CRVO in an elderly patient was related to increased venous pressure in the right heart system. A 71-year-old man developed CRVO in the right eye, and one year later, he developed CRVO in the left eye. He had undergone pacemaker implantation for sick sinus syndrome 10 years earlier and had started hemodialysis three months prior for chronic renal failure, probably caused by hypertensive nephrosclerosis. The right CRVO resulted in neovascular glaucoma and loss of light perception despite intensive treatment with panretinal laser photocoagulation, intravitreal bevacizumab injection, and additional laser therapy. In contrast, the left CRVO remained at an impending stage, was treated only with panretinal laser photocoagulation, and had a favorable outcome for 11 years until his death. In retrospect, half a year after the onset of left CRVO, the patient underwent open-heart surgery to repair aortic, mitral, and tricuspid valve regurgitation through aortic valve replacement, mitral valve annuloplasty, and tricuspid valve annuloplasty, respectively. Based on the temporal sequence of events, elevated venous pressure due to right heart dysfunction may have contributed to the poor outcome of the right CRVO, whereas improvement of venous stasis after cardiac surgery may have led to the better long-term outcome of the left CRVO. Venous stasis in the right heart system should therefore be considered an underlying factor in the development of bilateral CRVO.
en-copyright=
kn-copyright=

en-aut-name=MatsuoToshihiko
en-aut-sei=Matsuo
en-aut-mei=Toshihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MasudaZenichi
en-aut-sei=Masuda
en-aut-mei=Zenichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SugiyamaHiroki
en-aut-sei=Sugiyama
en-aut-mei=Hiroki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakamuraKazufumi
en-aut-sei=Nakamura
en-aut-mei=Kazufumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Ophthalmology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Cardiovascular Surgery, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Cardiovascular Medicine, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Cardiovascular Medicine and Center for Advanced Heart Failure, Okayama University Hospital
kn-affil=
en-keyword=aortic valve regurgitation
kn-keyword=aortic valve regurgitation
en-keyword=aortic valve replacement
kn-keyword=aortic valve replacement
en-keyword=bevacizumab
kn-keyword=bevacizumab
en-keyword=bilateral central retinal vein occlusion
kn-keyword=bilateral central retinal vein occlusion
en-keyword=intravitreal injection
kn-keyword=intravitreal injection
en-keyword=mitral valve annuloplasty
kn-keyword=mitral valve annuloplasty
en-keyword=mitral valve regurgitation
kn-keyword=mitral valve regurgitation
en-keyword=panretinal laser photocoagulation
kn-keyword=panretinal laser photocoagulation
en-keyword=tricuspid valve annuloplasty
kn-keyword=tricuspid valve annuloplasty
en-keyword=tricuspid valve regurgitation
kn-keyword=tricuspid valve regurgitation
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251114
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Dorsolateral Cervical Cord T2 Hyperintensity in KIF1C-Related Disease (Spastic Paraplegia 58): Two Long-Duration Cases
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Pathogenic variants in KIF1C cause Spastic Paraplegia 58 (SPG58), typically presenting with cerebellar ataxia and spastic paraparesis. We report two unrelated patients with spastic paraparesis, cerebellar ataxia, and tremor. Whole-exome sequence analysis identified novel homozygous variants in the motor domain of KIF1C (NM_006612.6): c.921G>A (p.Trp307Ter) and c.607C>T (p.Arg203Trp). In addition to the canonical brain MRI showing leukoencephalopathy with posterior dominance and hyperintensity along the corticospinal tracts, both patients showed symmetric T2 hyperintensity confined to the lateral and dorsal columns of the cervical cord. Given the long disease durations (22 and 51?years), these findings may represent late-emerging or previously overlooked spinal cord involvement and broaden the neuroradiological spectrum of SPG58.
en-copyright=
kn-copyright=

en-aut-name=MitsutakeAkihiko
en-aut-sei=Mitsutake
en-aut-mei=Akihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OsakiMasao
en-aut-sei=Osaki
en-aut-mei=Masao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MatsukawaTakashi
en-aut-sei=Matsukawa
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=OsakoMiho
en-aut-sei=Osako
en-aut-mei=Miho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TakeuchiChisen
en-aut-sei=Takeuchi
en-aut-mei=Chisen
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=IshiuraHiroyuki
en-aut-sei=Ishiura
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MitsuiJun
en-aut-sei=Mitsui
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KurokawaRyo
en-aut-sei=Kurokawa
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MoriHarushi
en-aut-sei=Mori
en-aut-mei=Harushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TakahashiYuji
en-aut-sei=Takahashi
en-aut-mei=Yuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=GotoJun
en-aut-sei=Goto
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=TsujiShoji
en-aut-sei=Tsuji
en-aut-mei=Shoji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=TodaTatsushi
en-aut-sei=Toda
en-aut-mei=Tatsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

affil-num=1
en-affil=Department of Neurology, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=2
en-affil=Department of Neurology, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=3
en-affil=Department of Neurology, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=4
en-affil=Department of Neurology, Tokyo Metropolitan Kita Medical and Rehabilitation Center for the Disabled
kn-affil=

affil-num=5
en-affil=Department of Neurology, Tokyo Metropolitan Kita Medical and Rehabilitation Center for the Disabled
kn-affil=

affil-num=6
en-affil=Department of Neurology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Precision Medicine Neurology, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=8
en-affil=Department of Radiology, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=9
en-affil=Department of Radiology, School of Medicine, Jichi Medical University
kn-affil=

affil-num=10
en-affil=Department of Neurology, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=11
en-affil=Department of Neurology, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=12
en-affil=Institute of Medical Genomics, International University of Health and Welfare
kn-affil=

affil-num=13
en-affil=Department of Neurology, Graduate School of Medicine, The University of Tokyo
kn-affil=
en-keyword=cerebellar ataxia
kn-keyword=cerebellar ataxia
en-keyword=hereditary spastic paraplegia
kn-keyword=hereditary spastic paraplegia
en-keyword=KIF1C
kn-keyword=KIF1C
en-keyword=leukoencephalopathy
kn-keyword=leukoencephalopathy
END

start-ver=1.4
cd-journal=joma
no-vol=63
cd-vols=
no-issue=13
article-no=
start-page=1863
end-page=1872
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240701
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Activated CD4+ T Cell Proportion in the Peripheral Blood Correlates with the Duration of Cytokine Release Syndrome and Predicts Clinical Outcome after Chimeric Antigen Receptor T Cell Therapy
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Objective Chimeric antigen receptor (CAR) T cell therapy is an emerging and effective therapy for relapsed or refractory diffuse large B cell lymphoma (R/R DLBCL). The characteristic toxicities of CAR T cell therapy include cytokine release syndrome (CRS) and prolonged cytopenia. We investigated the factors associated with these complications after CAR T cell therapy by analyzing lymphocyte subsets following CAR T cell infusion.<br>
Methods We retrospectively analyzed peripheral blood samples on days 7, 14, and 28 after tisagenlecleucel (tisa-cel) infusion by flow cytometry at our institution between June 2020 and September 2022.<br>
Patients Thirty-five patients with R/R DLBCL who received tisa-cel therapy were included.<br>
Results A flow cytometry-based analysis of blood samples from these patients revealed that the proportion of CD4+CD25+CD127+ T cells (hereafter referred to as "activated CD4+ T cells" ) among the total CD4+ T cells on day 7 after tisa-cel infusion correlated with the duration of CRS (r=0.79, p<0.01). In addition, a prognostic analysis of the overall survival (OS) using time-dependent receiver operating characteristic curves indicated a significantly more favorable OS and progression-free survival of patients with a proportion of activated CD4+ T cells among the total CD4+ T cells <0.73 (p=0.01, and p<0.01, respectively).<br>
Conclusion These results suggest that the proportion of activated CD4+ T cells on day 7 after tisa-cel infusion correlates with the CRS duration and predicts clinical outcomes after CAR T cell therapy. Further studies with a larger number of patients are required to validate these observations.
en-copyright=
kn-copyright=

en-aut-name=KitamuraWataru
en-aut-sei=Kitamura
en-aut-mei=Wataru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=AsadaNoboru
en-aut-sei=Asada
en-aut-mei=Noboru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=IkegawaShuntaro
en-aut-sei=Ikegawa
en-aut-mei=Shuntaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=FujiwaraHideaki
en-aut-sei=Fujiwara
en-aut-mei=Hideaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KamoiChihiro
en-aut-sei=Kamoi
en-aut-mei=Chihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=EnnishiDaisuke
en-aut-sei=Ennishi
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NishimoriHisakazu
en-aut-sei=Nishimori
en-aut-mei=Hisakazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=FujiiKeiko
en-aut-sei=Fujii
en-aut-mei=Keiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=FujiiNobuharu
en-aut-sei=Fujii
en-aut-mei=Nobuharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=MatsuokaKen-ichi
en-aut-sei=Matsuoka
en-aut-mei=Ken-ichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=MaedaYoshinobu
en-aut-sei=Maeda
en-aut-mei=Yoshinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Hematology and Oncology, Okayama University Hospital, Japan
kn-affil=

affil-num=4
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Center for Comprehensive Genomic Medicine, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Division of Clinical Laboratory, Okayama University Hospital
kn-affil=

affil-num=9
en-affil=Division of Blood Transfusion, Okayama University Hospital
kn-affil=

affil-num=10
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=11
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=
en-keyword=chimeric antigen receptor T cell therapy
kn-keyword=chimeric antigen receptor T cell therapy
en-keyword=diffuse large B cell lymphoma
kn-keyword=diffuse large B cell lymphoma
en-keyword=flow cytometry
kn-keyword=flow cytometry
en-keyword=cytokine release syndrome
kn-keyword=cytokine release syndrome
en-keyword=prolonged cytopenia
kn-keyword=prolonged cytopenia
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=2
article-no=
start-page=346
end-page=141
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251223
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Judicial Doctrine on Freedom of Occupation in Japan
kn-title=職業選択の自由に関する判例法理
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=ItoT. 
en-aut-sei=Ito
en-aut-mei=T. 
kn-aut-name=伊藤健
kn-aut-sei=伊藤
kn-aut-mei=健
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学学術研究院社会文化科学学域
END

start-ver=1.4
cd-journal=joma
no-vol=19
cd-vols=
no-issue=4
article-no=
start-page=e70051
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Interaction between nuclear‐translocated cellular communication network factor 2 and purine‐rich box 1 regulates the expression of fibrosis‐related genes
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Cellular communication network factor 2 (CCN2) with a nuclear localization signal-like peptide is known to promote fibrosis. However, translocation of CCN2 into the nucleus and its role in fibrosis remain unclear. We hypothesized that nuclear-translocated CCN2 is associated with purine-rich box 1 (PU.1), which is a transcription factor regulating the differentiation of myofibroblasts. Western blot analysis of the cytoplasmic and nuclear fractions of cell lysate and immunofluorescence analysis revealed that CCN2 was detectable in both the cytoplasm and nuclei of murine fibroblastic NIH3T3 cells. Additionally, chromatin immunoprecipitation (IP)-PCR and an electrophoretic mobility shift assay revealed that recombinant CCN2 protein bound to the regulatory region of Spi1, which encodes PU.1. Furthermore, IP-Western blot analysis showed that CCN2 interacted with PU.1. Finally, the forced expression of both Ccn2 and Spi1 significantly promoted the production of angiotensin II, and increased fibrosis-related molecules, such as Col1a1 and Acta2, at the gene and protein levels. These findings indicate that CCN2 translocated to the nucleus interacts with PU.1 and that the complex promotes the markers of myofibroblast differentiation, suggesting that CCN2 plays an important role in fibrosis via cooperation with PU.1, as a transcription co-factor.
en-copyright=
kn-copyright=

en-aut-name=NguyenXuan Thi
en-aut-sei=Nguyen
en-aut-mei=Xuan Thi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KubotaSatoshi
en-aut-sei=Kubota
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakigawaMasaharu
en-aut-sei=Takigawa
en-aut-mei=Masaharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NishidaTakashi
en-aut-sei=Nishida
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Department of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Advanced Research Center for Oral and Craniofacial Sciences, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences  Okayama Japan
kn-affil=

affil-num=4
en-affil=Department of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=cellular communication network factor 2 (CCN2)
kn-keyword=cellular communication network factor 2 (CCN2)
en-keyword=fibrosis
kn-keyword=fibrosis
en-keyword=myofibroblast
kn-keyword=myofibroblast
en-keyword=purine‐rich box 1 (PU.1)
kn-keyword=purine‐rich box 1 (PU.1)
en-keyword=transcription co‐factor
kn-keyword=transcription co‐factor
END

start-ver=1.4
cd-journal=joma
no-vol=37
cd-vols=
no-issue=6
article-no=
start-page=1392
end-page=1399
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251220
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Directed Poisoning Attacks on FRIT in Adaptive Cruise Control
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Recent advances in connected-vehicle technologies have enabled the large-scale collection of driving data, facilitating the deployment of data-driven control schemes. Although these methods offer advantages by eliminating the need for explicit modeling, they also introduce vulnerabilities due to their reliance on stored data. This study investigates a class of targeted data poisoning attacks on fictitious reference iterative tuning, a widely used data-driven controller tuning approach. We present a method that allows an adversary to influence closed-loop dynamics by manipulating the training data so that the resulting controller behavior matches a maliciously defined reference response. This strategy differs from conventional poisoning attacks, which aim only to the degrade control performance. Instead, it enables deliberate alteration of control characteristics such as overshoot and convergence time. The proposed attack is formulated as a constrained optimization problem under bounded tampering signals. Through a numerical study involving adaptive cruise control with stop functionality, we show that minor data modifications, indistinguishable from sensor noise, can cause significant degradation in control behavior. These findings highlight the need for robust security mechanisms in data-driven control implementation.
en-copyright=
kn-copyright=

en-aut-name=IkezakiTaichi
en-aut-sei=Ikezaki
en-aut-mei=Taichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SawadaKenji
en-aut-sei=Sawada
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KanekoOsamu
en-aut-sei=Kaneko
en-aut-mei=Osamu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Faculty of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate school of Mechanical Engineering, The University of Osaka
kn-affil=

affil-num=3
en-affil=Graduate School of Informatics and Engineering, The University of Electro-Communications
kn-affil=
en-keyword=cyberattack
kn-keyword=cyberattack
en-keyword=data-driven control
kn-keyword=data-driven control
en-keyword=cruise control
kn-keyword=cruise control
en-keyword=FRIT
kn-keyword=FRIT
en-keyword=poisoning attack
kn-keyword=poisoning attack
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=6
article-no=
start-page=469
end-page=474
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202512
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Ileus Tube-Related Intussusception: A Case Report and Review of 80 Previously Reported Cases
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We report a rare case of ileus tube-related intussusception in an adult. A 56-year-old man with adhesive bowel obstruction was treated with a nasointestinal ileus tube. Although his condition initially improved, persistent abdominal pain led to the diagnosis of intussusception via CT imaging. Manual repositioning of the tube resolved the intussusception without the need for bowel resection. A review of 80 previously reported cases of ileus tube-associated intussusception (total 81 cases, 95 lesions) highlighted the timing of onset, treatment strategies, and precautions. Early detection and diagnosis are crucial to prevent severe complications and preserve bowel function.
en-copyright=
kn-copyright=

en-aut-name=TsujiiTeruyuki
en-aut-sei=Tsujii
en-aut-mei=Teruyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MatsudaTatsuo
en-aut-sei=Matsuda
en-aut-mei=Tatsuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KimuraYuji
en-aut-sei=Kimura
en-aut-mei=Yuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KatsubeRyoichi
en-aut-sei=Katsube
en-aut-mei=Ryoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=IwadouHironori
en-aut-sei=Iwadou
en-aut-mei=Hironori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FunabikiSadami
en-aut-sei=Funabiki
en-aut-mei=Sadami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KamikawaYasuaki
en-aut-sei=Kamikawa
en-aut-mei=Yasuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MatsudaTadakazu
en-aut-sei=Matsuda
en-aut-mei=Tadakazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Surgery, Matsuda Hospital
kn-affil=

affil-num=2
en-affil=Department of Surgery, Matsuda Hospital
kn-affil=

affil-num=3
en-affil=Department of Surgery, Matsuda Hospital
kn-affil=

affil-num=4
en-affil=Department of Surgery, Matsuda Hospital
kn-affil=

affil-num=5
en-affil=Department of Surgery, Matsuda Hospital
kn-affil=

affil-num=6
en-affil=Department of Surgery, Matsuda Hospital
kn-affil=

affil-num=7
en-affil=Department of Surgery, Matsuda Hospital
kn-affil=

affil-num=8
en-affil=Department of Surgery, Matsuda Hospital
kn-affil=
en-keyword=nasointestinal ileus tube
kn-keyword=nasointestinal ileus tube
en-keyword=intussusception
kn-keyword=intussusception
en-keyword=small bowel obstruction
kn-keyword=small bowel obstruction
en-keyword=enterectomy
kn-keyword=enterectomy
en-keyword=conservative treatment
kn-keyword=conservative treatment
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=6
article-no=
start-page=463
end-page=468
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202512
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=MRI Images of a Case of Adenocarcinoma, Human Papillomavirus-Independent, Mesonephric Type, of the Uterine Cervix
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We present a case of a woman in her 70s who was diagnosed with mesonephric adenocarcinoma of the uterine cervix, following biopsy and surgery. Preoperative MRI revealed a 7-cm, well-defined circumferential cervical mass with left lateral wall predominance, bulging into the uterine cavity and vagina. The lesion showed intermediate signal intensity on T2-weighted images, diffusion restriction, and early contrast enhancement weaker than that of the myometrium, followed by washout on contrast-enhanced imaging. The circumferential growth pattern with the lateral wall predominance and its imaging characteristics may suggest this rare entity be routinely included in the differential diagnosis of cervical cancers.
en-copyright=
kn-copyright=

en-aut-name=AsanoYudai
en-aut-sei=Asano
en-aut-mei=Yudai
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NishiharaChika
en-aut-sei=Nishihara
en-aut-mei=Chika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KitayamaTakahiro
en-aut-sei=Kitayama
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=OkawaNanako
en-aut-sei=Okawa
en-aut-mei=Nanako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MakimotoSatoko
en-aut-sei=Makimoto
en-aut-mei=Satoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HigakiFumiyo
en-aut-sei=Higaki
en-aut-mei=Fumiyo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KojimaKatsuhide
en-aut-sei=Kojima
en-aut-mei=Katsuhide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=SugiharaHanako
en-aut-sei=Sugihara
en-aut-mei=Hanako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=IdaNaoyuki
en-aut-sei=Ida
en-aut-mei=Naoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=YanaiHiroyuki
en-aut-sei=Yanai
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=HirakiTakao
en-aut-sei=Hiraki
en-aut-mei=Takao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Department of Obstetrics and Gynecology, Okayama University Hospital
kn-affil=

affil-num=9
en-affil=Department of Obstetrics and Gynecology, Okayama University Hospital
kn-affil=

affil-num=10
en-affil=Department of Pathology, Okayama University Hospital
kn-affil=

affil-num=11
en-affil=Department of Radiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=mesonephric adenocarcinoma
kn-keyword=mesonephric adenocarcinoma
en-keyword=cervical cancer
kn-keyword=cervical cancer
en-keyword=MRI imaging characteristics
kn-keyword=MRI imaging characteristics
en-keyword=HPV-independent adenocarcinoma
kn-keyword=HPV-independent adenocarcinoma
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=6
article-no=
start-page=457
end-page=461
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202512
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Exacerbation of Proteinuria in a Patient with Beh?et’s Disease and IgA Nephropathy Following Colchicine Discontinuation
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This case involves a 23-year-old male who was diagnosed with Beh?et’s disease 5 years ago and managed with colchicine. Two months ago, he underwent renal biopsy due to abnormal urinalysis and kidney dysfunction, leading to a diagnosis of IgA nephropathy. He subsequently underwent tonsillectomy followed by glucocorticoid pulse therapy. However, after the tonsillectomy, discontinuing colchicine led to increased proteinuria, despite the glucocorticoid pulse therapy. Upon reintroducing colchicine, urinary protein excretion decreased, achieving incomplete remission. These findings suggest that colchicine may be effective in decreasing proteinuria in patients with Beh?et’s disease complicated by IgA nephropathy.
en-copyright=
kn-copyright=

en-aut-name=AsakawaTomohiko
en-aut-sei=Asakawa
en-aut-mei=Tomohiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=UchidaHaruhito A.
en-aut-sei=Uchida
en-aut-mei=Haruhito A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KatayamaYu
en-aut-sei=Katayama
en-aut-mei=Yu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SakurabuYoshimasa
en-aut-sei=Sakurabu
en-aut-mei=Yoshimasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KatayamaKatsuyoshi
en-aut-sei=Katayama
en-aut-mei=Katsuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OnishiYasuhiro
en-aut-sei=Onishi
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=Matsuoka-UchiyamaNatsumi
en-aut-sei=Matsuoka-Uchiyama
en-aut-mei=Natsumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TakeuchiHidemi
en-aut-sei=Takeuchi
en-aut-mei=Hidemi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TanakaKeiko
en-aut-sei=Tanaka
en-aut-mei=Keiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TsujiKenji
en-aut-sei=Tsuji
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=UmebayashiRyoko
en-aut-sei=Umebayashi
en-aut-mei=Ryoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=TakemotoRika
en-aut-sei=Takemoto
en-aut-mei=Rika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=WadaJun
en-aut-sei=Wada
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

affil-num=1
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=12
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=13
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=Beh?et’s disease
kn-keyword=Beh?et’s disease
en-keyword=IgA nephropathy
kn-keyword=IgA nephropathy
en-keyword=colchicine
kn-keyword=colchicine
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=6
article-no=
start-page=451
end-page=455
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202512
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Recurrence of FVIII Inhibitor during Surgery in a Patient with Severe Hemophilia A Receiving Emicizumab Prophylaxis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Emicizumab, a bispecific monoclonal antibody, benefits patients with severe hemophilia A. It alters laboratory assessments of coagulation activity, requiring anti-idiotype monoclonal antibodies for accurate monitoring. A 64-year-old man, receiving emicizumab regularly, was admitted for laminoplasty. We planned to use FVIII replacement during the perioperative period after confirming the disappearance of inhibitors, monitoring coagulation activity with anti-idiotype monoclonal antibodies. Activated partial thromboplastin time was prolonged on postoperative day 2, prompting an immediate switch to eptacog alfa. The patient recovered without bleeding. This case underscores the necessity of anti-idiotype monoclonal antibodies for accurate monitoring.
en-copyright=
kn-copyright=

en-aut-name=HagiharaMoe
en-aut-sei=Hagihara
en-aut-mei=Moe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SeikeKeisuke
en-aut-sei=Seike
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HayashinoKenta
en-aut-sei=Hayashino
en-aut-mei=Kenta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YasuharaTakao
en-aut-sei=Yasuhara
en-aut-mei=Takao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KinKyohei
en-aut-sei=Kin
en-aut-mei=Kyohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HirataYuichi
en-aut-sei=Hirata
en-aut-mei=Yuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KobayashiHiroki
en-aut-sei=Kobayashi
en-aut-mei=Hiroki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KitamuraWataru
en-aut-sei=Kitamura
en-aut-mei=Wataru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=FujiwaraHideaki
en-aut-sei=Fujiwara
en-aut-mei=Hideaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=AsadaNoboru
en-aut-sei=Asada
en-aut-mei=Noboru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=FujiiNobuharu
en-aut-sei=Fujii
en-aut-mei=Nobuharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=MaedaYoshinobu
en-aut-sei=Maeda
en-aut-mei=Yoshinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

affil-num=1
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Neurological Surgery, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Neurological Surgery, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Neurological Surgery, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=9
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=10
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=11
en-affil=Division of Transfusion and Cell Therapy, Okayama University Hospital
kn-affil=

affil-num=12
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=
en-keyword=emicizumab
kn-keyword=emicizumab
en-keyword=eptacog alfa
kn-keyword=eptacog alfa
en-keyword=hemophilia A
kn-keyword=hemophilia A
en-keyword=inhibitor
kn-keyword=inhibitor
en-keyword=anti-idiotype monoclonal antibodies to emicizumab
kn-keyword=anti-idiotype monoclonal antibodies to emicizumab
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=6
article-no=
start-page=445
end-page=449
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202512
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Perioperative Team Management Was Beneficially Associated with Prolonged Postoperative Hospital Stays after Long Lower-Abdominal Surgeries
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Our hospital began a PERIO program (perioperative patient management by a multi-disciplinary team from multiple departments) in 2016 to improve patient outcomes. We retrospectively analyzed the clinical effects of the PERIO program regarding the postoperative hospital stay (PHS) in the patients aged ? 18 years who underwent long lower-abdominal surgery at our hospital during the period April 2019 to March 2023. We excluded the cases of patients whose general anesthesia use was < 8 h, those for whom another surgery was performed simultaneously at another site, and emergency surgeries. The outcome was prolonged PHS, defined as exceeding the scheduled number of days specified in the patient’s clinical pathway. Among the 480 patients, prolonged PHS was observed for 270 patients (56.3%). In a multivariate logistic regression using advanced age, sex, high-risk general state, surgery requiring colon resection, serious adverse events (SAEs), and PERIO use, the following were associated with prolonged PHS: advance age (odds ratio [OR] 4.91, 95% confidence interval [CI]: 2.68-8.99, p=0.01), surgery requiring colon resection (OR 4.91, 95%CI: 2.68-8.99, p<0.001), SAE (OR 18.7, 95%CI: 7.22-48.2, p<0.001), and PERIO (OR 0.25, 95%CI: 0.13-0.47, p<0.001). The use of the PERIO program was thus beneficially associated with PHS after long lower-abdominal surgery.
en-copyright=
kn-copyright=

en-aut-name=MatsumiJunya
en-aut-sei=Matsumi
en-aut-mei=Junya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Department of Anesthesiology and Intensive Care Medicine, National Cancer Center Hospital
kn-affil=
en-keyword=hospital stay
kn-keyword=hospital stay
en-keyword=ERAS
kn-keyword=ERAS
en-keyword=surgery
kn-keyword=surgery
en-keyword=cancer
kn-keyword=cancer
en-keyword=perioperative management
kn-keyword=perioperative management
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=6
article-no=
start-page=431
end-page=436
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202512
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Association of Weekend Admission and In-Hospital Mortality in Adult Patients with Acute Myeloid Leukemia in Japan
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The effect of weekend admission on patient mortality has been investigated in several therapeutic areas, including acute myeloid leukemia (AML), but the investigations’ results are controversial. We evaluated the relationship between in-hospital mortality and weekend admission in adult patients with AML in Japan by conducting a retrospective observational study using administrative data from 144 acute care hospitals from which patients were discharged between April 2014 and March 2019. The primary endpoint was in-hospital mortality, compared between weekend and weekday admissions. Among the 1,340 eligible patients, 11% (150) were admitted during a weekend. The in-hospital mortality rates of the patients admitted during weekends and those admitted on a weekday were 28% (42/150) and 17% (204/1190), respectively. After an adjustment for covariates, weekend admission was associated with a significantly higher risk of in-hospital mortality than weekday admission (HR 1.70, 95%CI: 1.20-2.40; p=0.003). However, such an association was not observed in patients treated in a bio-clean room (HR 1.26, 95%CI: 0.65-2.42). Our results demonstrate that for patients with AML, weekend admission was independently associated with a higher risk of death during hospitalization. An appropriate system is necessary for these patients.
en-copyright=
kn-copyright=

en-aut-name=InoueTakahiro
en-aut-sei=Inoue
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KuwabaraHiroyo
en-aut-sei=Kuwabara
en-aut-mei=Hiroyo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YamamotoKoh
en-aut-sei=Yamamoto
en-aut-mei=Koh
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Healthcare Management Research Center, Chiba University Hospital
kn-affil=

affil-num=2
en-affil=Healthcare Management Research Center, Chiba University Hospital
kn-affil=

affil-num=3
en-affil=Department of Hematology, Yokohama City Minato Red Cross Hospital
kn-affil=
en-keyword=acute leukemia
kn-keyword=acute leukemia
en-keyword=weekend admission
kn-keyword=weekend admission
en-keyword=in-hospital mortality
kn-keyword=in-hospital mortality
en-keyword=bio-clean room
kn-keyword=bio-clean room
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=6
article-no=
start-page=421
end-page=429
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202512
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effects of Thoron Inhalation and Cyclosporin A Treatment on Dextran Sulfate Sodium-Induced Oxidative Damage in Mice
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Radon (222Rn; Rn) and thoron (220Rn; Tn) inhalation have been reported to enhance antioxidant activity in various organs. However, the effects of Tn on the colon have not been investigated. This study aimed to clarify the effects of Tn inhalation, alone and in combination with cyclosporin A (CsA), on dextran sulfate sodium (DSS)-induced colitis, and the accompanying oxidative stress, in mice. Male BALB/c mice were subjected to continuous 8-day Tn inhalation (c-Tn, 533±128 Bq/m3) or alternate-day Tn inhalation over the same period (f-Tn, 577±63Bq/m3), followed by treatment with 3% DSS and either CsA or vehicle for 7 days. Although the disease activity index (DAI) decreased significantly by day 2 in the c-Tn group, scores remained significantly higher than those in the f-Tn group. In the c-Tn group, superoxide dismutase and catalase activity in the colon were significantly elevated compared with those in sham controls. Thus, DSS-induced damage was effectively inhibited in the earlier stages by the c-Tn mode of inhalation than by the f-Tn mode. These findings suggest that continuous Tn inhalation more effectively attenuated early colitis symptoms than alternate-day inhalation, potentially through upregulation of antioxidant defenses. Tn and CsA showed no combined effects.
en-copyright=
kn-copyright=

en-aut-name=TanakaAyumi
en-aut-sei=Tanaka
en-aut-mei=Ayumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NaoeShota
en-aut-sei=Naoe
en-aut-mei=Shota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakenakaReiju
en-aut-sei=Takenaka
en-aut-mei=Reiju
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KanzakiNorie
en-aut-sei=Kanzaki
en-aut-mei=Norie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SakodaAkihiro
en-aut-sei=Sakoda
en-aut-mei=Akihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YamaokaKiyonori
en-aut-sei=Yamaoka
en-aut-mei=Kiyonori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KataokaTakahiro
en-aut-sei=Kataoka
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Ningyo-toge Environmental Engineering Center, Japan Atomic Energy Agency
kn-affil=

affil-num=5
en-affil=Ningyo-toge Environmental Engineering Center, Japan Atomic Energy Agency
kn-affil=

affil-num=6
en-affil=Faculty of Health Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Faculty of Health Sciences, Okayama University
kn-affil=
en-keyword=thoron
kn-keyword=thoron
en-keyword=DSS
kn-keyword=DSS
en-keyword=antioxidant activity
kn-keyword=antioxidant activity
en-keyword=CsA
kn-keyword=CsA
en-keyword=colon
kn-keyword=colon
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=6
article-no=
start-page=413
end-page=419
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202512
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=COVID-19 and the Risks of Migraine and Headache: A Mendelian Randomization Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Several observational studies suggested that migraine headache attacks were associated with coronavirus disease 2019 (COVID-19). We investigated genetic causal links between COVID-19 phenotypes and the development of headache and migraine, including migraine with aura (MA) and migraine without aura (MO). We conducted a two-sample Mendelian randomization (MR) analysis to estimate the genetic association in European populations. The inverse-variance weighted (IVW) method was used as the main approach in the MR analyses, together with weighted median and MR-Egger methods. We also performed a series of sensitivity tests to assess the robustness of the MR results. The MR results demonstrated that COVID-19 severity, hospitalization, and susceptibility had no causal effect on the risks of headache, migraine, MA, or MO. No horizontal pleiotropy was detected, and the results were robust as supported by the sensitivity analysis findings. Our analyses identified no casual effect of COVID-19 severity, hospitalization, or susceptibility on the risks of headache or migraine in European populations.
en-copyright=
kn-copyright=

en-aut-name=JiangZhiyun
en-aut-sei=Jiang
en-aut-mei=Zhiyun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=XiYing
en-aut-sei=Xi
en-aut-mei=Ying
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University
kn-affil=

affil-num=2
en-affil=Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University
kn-affil=
en-keyword=headache
kn-keyword=headache
en-keyword=migraine
kn-keyword=migraine
en-keyword=Mendelian randomization
kn-keyword=Mendelian randomization
en-keyword=COVID-19
kn-keyword=COVID-19
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=6
article-no=
start-page=405
end-page=412
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202512
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration in Patients Aged 85 or Older
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We investigated the treatment outcomes of patients aged ?85 years with neovascular age-related macular degeneration (nAMD) who received anti-vascular endothelial growth factor (anti-VEGF) therapy using either treat-and-extend (TAE) or pro re nata (PRN) regimens for 1 year in real-world clinical practice. Eighty-five eyes from 85 patients were included. Among them, types 1, 2, and 3 macular neovascularization and polypoidal choroidal vasculopathy were present in 27.1%, 17.6%, 18.8%, and 36.5%, respectively. TAE and PRN regimens were used in 43.5% and 56.5% of patients, respectively. At baseline, the PRN group was older and had worse best-corrected visual acuity (BCVA), greater central retinal thickness, and more intraretinal fluid than the TAE group. In the TAE group, the mean number of injections was 7.6, BCVA improved significantly, and all retinal fluid rates decreased. In the PRN group, the mean number of injections was 3.9, BCVA remained unchanged, and the rates of macular fibrosis and atrophy increased. No serious adverse events were observed in either group. Anti-VEGF therapy was safe for patients aged ? 85 years with nAMD, and the TAE regimen effectively improved BCVA in this population. BCVA remained unchanged in the PRN-treated patients, with baseline disease severity and/or undertreatment potentially influencing the outcomes.
en-copyright=
kn-copyright=

en-aut-name=OuchiChihiro
en-aut-sei=Ouchi
en-aut-mei=Chihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=Morizane HosokawaMio
en-aut-sei=Morizane Hosokawa
en-aut-mei=Mio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KimuraShuhei
en-aut-sei=Kimura
en-aut-mei=Shuhei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ShiodeYusuke
en-aut-sei=Shiode
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MatobaRyo
en-aut-sei=Matoba
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MoritaTetsuro
en-aut-sei=Morita
en-aut-mei=Tetsuro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MorizaneYuki
en-aut-sei=Morizane
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=anti-vascular endothelial growth factor therapy
kn-keyword=anti-vascular endothelial growth factor therapy
en-keyword=neovascular age-related macular degeneration
kn-keyword=neovascular age-related macular degeneration
en-keyword=age
kn-keyword=age
en-keyword=treat-and-extend
kn-keyword=treat-and-extend
en-keyword=pro re nata
kn-keyword=pro re nata
END

start-ver=1.4
cd-journal=joma
no-vol=19
cd-vols=
no-issue=
article-no=
start-page=1599114
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250519
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effects of visual spatial frequency on audiovisual interaction: an event-related potential study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Spatial frequency is a fundamental characteristic of visual signals that modulates the audiovisual integration behavior, but the neural mechanisms underlying spatial frequency are not well established. In the present study, the high temporal resolution of event-related potentials was used to investigate how visual spatial frequency modulates audiovisual integration. A visual orientation discrimination task was used, and the spatial frequency of visual stimuli was manipulated under three conditions. Results showed that the influence of visual spatial frequency on audiovisual integration is a dynamic process. The earliest audiovisual integration occurred over the left temporal-occipital regions in the early sensory stage (60?90?ms) for high spatial frequency conditions but was absent for low and middle spatial frequency conditions. In addition, audiovisual integration over fronto-central regions was delayed as spatial frequency increased (from 230?260?ms to 260?320?ms). The integration effect was also observed over parietal and occipital regions at 350?380?ms, and its strength gradually decreased at higher spatial frequencies. These discrepancies in the temporal and spatial distributions of audiovisual integration imply that the role of spatial frequency varies between early sensory and late cognitive stages. The findings of this study offer the first neural demonstration that spatial frequency modulates audiovisual integration, thus providing a basis for studying complex multisensory integration, especially in semantic and emotional domains.
en-copyright=
kn-copyright=

en-aut-name=WuFengxia
en-aut-sei=Wu
en-aut-mei=Fengxia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=RenYanna
en-aut-sei=Ren
en-aut-mei=Yanna
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HaoTengfei
en-aut-sei=Hao
en-aut-mei=Tengfei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YangJingjing
en-aut-sei=Yang
en-aut-mei=Jingjing
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=WuQiong
en-aut-sei=Wu
en-aut-mei=Qiong
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YangJiajia
en-aut-sei=Yang
en-aut-mei=Jiajia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=WangMeng
en-aut-sei=Wang
en-aut-mei=Meng
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=School of Artificial Intelligence, Changchun University of Science and Technology
kn-affil=

affil-num=2
en-affil=Department of Psychology, College of Humanities and Management, Guizhou University of Traditional Chinese Medicine
kn-affil=

affil-num=3
en-affil=School of Artificial Intelligence, Changchun University of Science and Technology
kn-affil=

affil-num=4
en-affil=School of Artificial Intelligence, Changchun University of Science and Technology
kn-affil=

affil-num=5
en-affil=Department of Psychology, Suzhou University of Science and Technology
kn-affil=

affil-num=6
en-affil=Cognitive Neuroscience Laboratory, Graduate School of Natural Science and Technology, Okayama University
kn-affil=

affil-num=7
en-affil=School of Artificial Intelligence, Changchun University of Science and Technology
kn-affil=
en-keyword=spatial frequency
kn-keyword=spatial frequency
en-keyword=visual orientation discrimination
kn-keyword=visual orientation discrimination
en-keyword=audiovisual integration
kn-keyword=audiovisual integration
en-keyword=early sensory stage
kn-keyword=early sensory stage
en-keyword=late cognitive stage
kn-keyword=late cognitive stage
en-keyword=event-related potentials
kn-keyword=event-related potentials
END

start-ver=1.4
cd-journal=joma
no-vol=30
cd-vols=
no-issue=8
article-no=
start-page=1537
end-page=1544
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250528
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Phase-Ib dose-finding and pharmacokinetic trial of metformin combined with nivolumab for refractory/recurrent solid tumors
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Our previous findings showed that the addition of metformin to nivolumab resulted in remarkable tumor regression and increased the number of tumor-infiltrating T cells in mouse models. Therefore, we conducted a phase Ib study using combination therapy with nivolumab and metformin in patients with refractory/recurrent solid tumors.<br>
Methods This study consisted of two parts: 1, evaluating the maximum tolerated dose (MTD), safety, pharmacokinetics in solid tumors, and 2, principally investigating the safety at the recommended dose limited to thoracic and pancreatic cancers. Metformin and nivolumab were administered orally at doses of 750?2,250 mg/day and biweekly at a fixed intravenous dose of 3 mg/kg, respectively. Dose-limiting toxicity was evaluated within the first 4 weeks. Both metformin and nivolumab were continued until disease progression or discontinued because of toxicity.<br>
Results In total, 17 and 24 patients were enrolled in parts 1 and 2, respectively. One patient experienced increased pancreatic enzyme levels (grade 4) and lactic acidosis (grade 3). No Grade 5 adverse events were observed. MTD was not reached up to 2,250 mg/day of metformin, 2,250 mg/day was selected for part 2. An objective response was observed in 4 of 41 patients. One-year progression-free and overall survival rates were 9.8% and 56.8%, respectively. Two patients remained alive without disease progression for more than three years.<br>
Conclusions Nivolumab and metformin combination therapy was well-tolerated and showed preliminary signals of efficacy in a subset of patients. Further verification of the underlying mechanism in cases where treatment is effective is required.<br>
Trial registration numbers UMIN registration number 000028405 https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031915.
en-copyright=
kn-copyright=

en-aut-name=KuboToshio
en-aut-sei=Kubo
en-aut-mei=Toshio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KatoHironari
en-aut-sei=Kato
en-aut-mei=Hironari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HoriguchiShigeru
en-aut-sei=Horiguchi
en-aut-mei=Shigeru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KozukiToshiyuki
en-aut-sei=Kozuki
en-aut-mei=Toshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=AsagiAkinori
en-aut-sei=Asagi
en-aut-mei=Akinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YoshidaMichihiro
en-aut-sei=Yoshida
en-aut-mei=Michihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=UdonoHeiichiro
en-aut-sei=Udono
en-aut-mei=Heiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KiuraKatsuyuki
en-aut-sei=Kiura
en-aut-mei=Katsuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HottaKatsuyuki
en-aut-sei=Hotta
en-aut-mei=Katsuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Thoracic Oncology and Medicine, NHO Shikoku Cancer Center
kn-affil=

affil-num=5
en-affil=Department of Gastrointestinal Medical Oncology, NHO Shikoku Cancer Center
kn-affil=

affil-num=6
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=9
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=
en-keyword=Pancreatic cancer
kn-keyword=Pancreatic cancer
en-keyword=Thoracic tumors
kn-keyword=Thoracic tumors
en-keyword=Phase Ib
kn-keyword=Phase Ib
en-keyword=Anti-PD-1 antibody
kn-keyword=Anti-PD-1 antibody
en-keyword=Nivolumab
kn-keyword=Nivolumab
en-keyword=Metformin
kn-keyword=Metformin
END

start-ver=1.4
cd-journal=joma
no-vol=64
cd-vols=
no-issue=13
article-no=
start-page=e202419624
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250129
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Conduction Band and Defect Engineering for the Prominent Visible‐Light Responsive Photocatalysts
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Controlling trap depth is crucial to improve photocatalytic activity, but designing such crystal structures has been challenging. In this study, we discovered that in 2D materials like BiOCl and Bi4NbO8Cl, composed of interleaved [Bi2O2]2+ and Cl- slabs, the trap depth can be controlled by manipulating the slab stacking structure. In BiOCl, oxygen vacancies (VO) create deep electron traps, while chlorine vacancies (VCl) produce shallow traps. The depth is determined by the coordination around anion vacancies: VO forms strong σ bonds with Bi-6p dangling bonds below the conduction band minimum (CBM), while those around Cl are parallel, forming weak π-bonding. The strong re-hybridization makes the trap depth deeper. In Bi4NbO8Cl, VCl also creates shallow traps, but VO does not produce deep traps although Bi-6p orbitals are also forming strong σ bonding. This difference is attributed to the difference of the energy level of CBM. In both cases, the CBM consists of Bi-6p orbitals extending into the Cl layers. However, these orbitals are isolated in BiOCl, but those in Bi4NbO8Cl are bonded with each other between neighboring [Bi2O2]2+ layers. This unique bonding-based CBM prevents the formation of deep electron traps, and significantly enhances H2 evolution activity by prolonging the lifetime of highly reactive free electrons.
en-copyright=
kn-copyright=

en-aut-name=YamakataAkira
en-aut-sei=Yamakata
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KatoKosaku
en-aut-sei=Kato
en-aut-mei=Kosaku
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OgawaTakafumi
en-aut-sei=Ogawa
en-aut-mei=Takafumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=OgawaKanta
en-aut-sei=Ogawa
en-aut-mei=Kanta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OgawaMakoto
en-aut-sei=Ogawa
en-aut-mei=Makoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KatoDaichi
en-aut-sei=Kato
en-aut-mei=Daichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ZhongChengchao
en-aut-sei=Zhong
en-aut-mei=Chengchao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KuwabaraAkihide
en-aut-sei=Kuwabara
en-aut-mei=Akihide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=AbeRyu
en-aut-sei=Abe
en-aut-mei=Ryu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KageyamaHiroshi
en-aut-sei=Kageyama
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Graduate School of Natural Science and Technology, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Natural Science and Technology, Okayama University
kn-affil=

affil-num=3
en-affil=Nanostructures Research Laboratory, Japan Fine Ceramics Center 
kn-affil=

affil-num=4
en-affil=Department of Energy and Hydrocarbon Chemistry Graduate School of Engineering, Kyoto University
kn-affil=

affil-num=5
en-affil=Department of Energy and Hydrocarbon Chemistry Graduate School of Engineering, Kyoto University
kn-affil=

affil-num=6
en-affil=Department of Energy and Hydrocarbon Chemistry Graduate School of Engineering, Kyoto University
kn-affil=

affil-num=7
en-affil=Department of Energy and Hydrocarbon Chemistry Graduate School of Engineering, Kyoto University
kn-affil=

affil-num=8
en-affil=Nanostructures Research Laboratory, Japan Fine Ceramics Center
kn-affil=

affil-num=9
en-affil=Department of Energy and Hydrocarbon Chemistry Graduate School of Engineering, Kyoto University
kn-affil=

affil-num=10
en-affil=Department of Energy and Hydrocarbon Chemistry Graduate School of Engineering, Kyoto University
kn-affil=
en-keyword=photocatalysis
kn-keyword=photocatalysis
en-keyword=defects
kn-keyword=defects
en-keyword=charge trapping
kn-keyword=charge trapping
en-keyword=recombination
kn-keyword=recombination
en-keyword=time-resolved spectroscopy
kn-keyword=time-resolved spectroscopy
END

start-ver=1.4
cd-journal=joma
no-vol=23
cd-vols=
no-issue=1
article-no=
start-page=1387
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251208
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Tumor marker?guided precision BNCT for CA19-9?positive cancers: a new paradigm in molecularly targeted chemoradiation therapy
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Boron neutron capture therapy (BNCT) is a molecularly targeted chemoradiation modality that relies on boron delivery agents such as p-borophenylalanine (BPA), which require LAT1 (L-type amino acid transporter 1) for tumor uptake. However, the limited efficacy of BPA in LAT1-low tumors restricts its therapeutic scope. To address this limitation, we developed a tumor marker?guided BNCT strategy targeting cancers overexpressing the clinically validated glycan biomarker CA19-9.<br>
Methods: We conducted transcriptomic analyses using The Cancer Genome Atlas (TCGA) datasets to identify LAT1-low cancers with high CA19-9 expression. These analyses revealed elevated expression of fucosyltransferase 3 (FUT3), which underlies CA19-9 biosynthesis, in pancreatic, biliary, and ovarian malignancies. Based on this, we synthesized a novel boron compound, fucose-BSH, designed to selectively accumulate in CA19-9?positive tumors. We evaluated its physicochemical properties, pharmacokinetics, biodistribution, and antitumor efficacy in cell lines and xenograft models, comparing its performance to that of BPA.<br>
Results: Fucose-BSH demonstrated significantly greater boron uptake in CA19-9?positive cell lines (AsPC-1, Panc 04.03, HuCCT-1, HSKTC, OVISE) compared to CA19-9?negative PANC-1. In HuCCT-1 xenografts, boron accumulation reached 36.2 ppm with a tumor/normal tissue ratio of 2.1, outperforming BPA. Upon neutron irradiation, fucose-BSH?mediated BNCT achieved?>?80% tumor growth inhibition. Notably, fucose-BSH retained therapeutic efficacy in LAT1-deficient models where BPA was ineffective, confirming LAT1-independent targeting.<br>
Conclusions: This study establishes a novel precision BNCT approach by leveraging CA19-9 as a tumor-selective glycan marker for boron delivery. Fucose-BSH offers a promising platform for expanding BNCT to previously inaccessible LAT1-low malignancies, including pancreatic, biliary, and ovarian cancers. These findings provide a clinically actionable strategy for tumor marker?driven chemoradiation and lay the foundation for translational application in BNCT. This strategy has the potential to support companion diagnostic development and precision stratification in ongoing and future BNCT clinical trials.<br>
Translational Relevance: Malignancies with elevated CA19-9 expression, such as pancreatic, biliary, and ovarian cancers, are associated with poor prognosis and limited response to current therapies. This study presents a tumor marker?guided strategy for boron neutron capture therapy (BNCT) by leveraging CA19-9 glycan biology to enable selective tumor targeting via fucose-BSH, a novel boron compound. Through transcriptomic data mining and preclinical validation, fucose-BSH demonstrated LAT1-independent boron delivery, potent BNCT-mediated cytotoxicity, and tumor-specific accumulation in CA19-9?positive models. These findings support a precision chemoradiation approach that addresses a critical gap in BNCT applicability, offering a clinically actionable pathway for patient stratification and therapeutic development in CA19-9?expressing cancers.
en-copyright=
kn-copyright=

en-aut-name=KanehiraNoriyuki
en-aut-sei=Kanehira
en-aut-mei=Noriyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TeraishiFuminori
en-aut-sei=Teraishi
en-aut-mei=Fuminori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TajimaTomoyuki
en-aut-sei=Tajima
en-aut-mei=Tomoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=OsoneTatsunori
en-aut-sei=Osone
en-aut-mei=Tatsunori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=GotohKazuyoshi
en-aut-sei=Gotoh
en-aut-mei=Kazuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FujimotoTakuya
en-aut-sei=Fujimoto
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=SakuraiYoshinori
en-aut-sei=Sakurai
en-aut-mei=Yoshinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KondoNatsuko
en-aut-sei=Kondo
en-aut-mei=Natsuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=NagahisaNarikazu
en-aut-sei=Nagahisa
en-aut-mei=Narikazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KameiKaoru
en-aut-sei=Kamei
en-aut-mei=Kaoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=FujitaTaiga
en-aut-sei=Fujita
en-aut-mei=Taiga
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=MoriharaAkira
en-aut-sei=Morihara
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=TakaguchiYutaka
en-aut-sei=Takaguchi
en-aut-mei=Yutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=KitamatsuMizuki
en-aut-sei=Kitamatsu
en-aut-mei=Mizuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=TakaradaTakeshi
en-aut-sei=Takarada
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=ShigeyasuKunitoshi
en-aut-sei=Shigeyasu
en-aut-mei=Kunitoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=SuzukiMinoru
en-aut-sei=Suzuki
en-aut-mei=Minoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=MichiueHiroyuki
en-aut-sei=Michiue
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Regenerative Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Medical Laboratory Science, Okayama University Graduate School of Health Sciences
kn-affil=

affil-num=6
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Institute for Integrated Radiation and Nuclear Science, Kyoto University
kn-affil=

affil-num=8
en-affil=Institute for Integrated Radiation and Nuclear Science, Kyoto University
kn-affil=

affil-num=9
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=11
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=12
en-affil=Graduate School of Environmental, Life Science, Okayama University
kn-affil=

affil-num=13
en-affil=Faculty of Sustainable Design, Department of Material Design and Engineering, University of Toyama
kn-affil=

affil-num=14
en-affil=Department of Applied Chemistry, Kindai University
kn-affil=

affil-num=15
en-affil=Department of Regenerative Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=16
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=17
en-affil=Institute for Integrated Radiation and Nuclear Science, Kyoto University
kn-affil=

affil-num=18
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=19
en-affil=Neutron Therapy Research Center, Okayama University
kn-affil=
en-keyword=Boron neutron capture therapy (BNCT)
kn-keyword=Boron neutron capture therapy (BNCT)
en-keyword=Precision BNCT
kn-keyword=Precision BNCT
en-keyword=Fucose-conjugated medicine
kn-keyword=Fucose-conjugated medicine
en-keyword=CA19-9
kn-keyword=CA19-9
en-keyword=Drug discovery
kn-keyword=Drug discovery
END

start-ver=1.4
cd-journal=joma
no-vol=13
cd-vols=
no-issue=12
article-no=
start-page=577
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251203
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effects of miR-128-3p on Renal Inflammation in a Rat Periodontitis Model
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Objectives: The study aim was to investigate the effects of extracellular vesicles (EVs) derived miR-128-3p on renal inflammation using a rat periodontitis model. Methods: Ten-week-old male Wistar rats were divided into two groups: a control (n = 8) and a lipopolysaccharides (LPS) group (n = 8). The LPS group received LPS (Porphyromonas gingivalis) injection in the gingiva for 7 days. At the end of the experiment, plasma, gingival tissue, and kidney samples were collected. Hematoxylin and eosin staining was performed to evaluate the glomerular tissue injury score. Bioinformatic analysis was conducted to identify potential target genes of miR-128-3p. The reverse transcription-quantitative polymerase chain reaction was performed to evaluate miR-128-3p, inflammatory, pro-inflammatory cytokine, chemokine and predicting gene’s expression. The control and LPS groups were compared using Welch’s t-test. p-values < 0.05 were considered to indicate statistical significance. Results: The kidney glomerular tissue injury score was significantly higher in the LPS than in the control group. miR-128-3p expression in the LPS group was significantly higher in the gingival tissue and plasma. mRNAs (interleukin [IL]-1β, tumor necrosis factor [TNF]-α, C-X3-C motif chemokine ligand 1 [CX3CL1], and C-X-C motif chemokine ligand 7 [CXCL7]) expression was higher in the kidney of the LPS group. The potential target genes of activin A receptor type I (Acvr1), ribosomal protein S6 kinase B1 (Rps6kb1), and transforming growth factor beta receptor type 1 (Tgfbr1) were significantly lower in the kidneys of the LPS group. Conclusions: EVs-derived miR-128-3p in LPS induced periodontitis may cause kidney inflammation which may be mediated by, Rps6kb1, Tgfbr1, and Acvr1.
en-copyright=
kn-copyright=

en-aut-name=NurhamimMohammad
en-aut-sei=Nurhamim
en-aut-mei=Mohammad
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ZhangYixuan
en-aut-sei=Zhang
en-aut-mei=Yixuan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NakaharaMomoko
en-aut-sei=Nakahara
en-aut-mei=Momoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=FukuharaDaiki
en-aut-sei=Fukuhara
en-aut-mei=Daiki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NagashimaYosei
en-aut-sei=Nagashima
en-aut-mei=Yosei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MaruyamaTakayuki
en-aut-sei=Maruyama
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MoritaManabu
en-aut-sei=Morita
en-aut-mei=Manabu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=EkuniDaisuke
en-aut-sei=Ekuni
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Preventive Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Preventive Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Preventive Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Preventive Dentistry, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Preventive Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Preventive Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Department of Oral Health, Takarazuka University of Medical and Health Care
kn-affil=

affil-num=8
en-affil=Department of Preventive Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=extracellular vesicles
kn-keyword=extracellular vesicles
en-keyword=miR-128-3p
kn-keyword=miR-128-3p
en-keyword=mRNA
kn-keyword=mRNA
en-keyword=inflammation
kn-keyword=inflammation
en-keyword=periodontitis
kn-keyword=periodontitis
en-keyword=renal inflammation
kn-keyword=renal inflammation
en-keyword=lipopolysaccharide
kn-keyword=lipopolysaccharide
END

start-ver=1.4
cd-journal=joma
no-vol=6
cd-vols=
no-issue=1
article-no=
start-page=e70144
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250616
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Japanese Multi‐Institution Study of Success Rates of Wire‐Guided Biliary Cannulation During Endoscopic Retrograde Cholangiopancreatography in Relation to Guidewire tip Length (JMIT Study) (With Video)
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Objective: Wire-guided cannulation (WGC) reportedly increases the successful biliary cannulation rate and reduces the risk of post-endoscopic retrograde cholangiopancreatography pancreatitis. Currently, various types of guidewires are available. However, the effect of the length of flexible-tip guidewires on the success rate of biliary cannulation under WGC and the rate of adverse events, especially post-endoscopic retrograde cholangiopancreatography pancreatitis, is unclear. The aim of this study was to compare the influence of long-tapered and short-tapered tips of a 0.025-inch guidewire on outcomes in primary selective biliary cannulation.<br>
Methods: Consecutive patients who underwent biliary access under endoscopic retrograde cholangiopancreatography guidance using WGC at 27 high-volume centers in Japan were enrolled in this prospective registration study. The primary outcome was the technical success rate of biliary cannulation. The secondary outcomes were the rates of adverse events, biliary cannulation time, and number of guidewire insertions into the pancreatic duct.<br>
Results: A total of 530 patients underwent biliary cannulation for biliary disease with native papilla between April 2021 and December 2023. The technical success rate of biliary cannulation was 86.1% (161/187) in the long-tip group and 84.3% (289/343) in the short-tip group, indicating no significant differences between the two groups. Although the frequency of post-endoscopic retrograde cholangiopancreatography was not significantly different, the successful biliary cannulation rate without guidewire mis-insertion into the main pancreatic duct was significantly higher in the long tip group (64.7%, 121/187) compared with the short tip group (54.2%, 186/343p = 0.02).<br>
Conclusions: In conclusion, WGC using long-tip guidewires might reduce the risk of guidewire insertion into the main pancreatic duct.
en-copyright=
kn-copyright=

en-aut-name=OguraTakeshi
en-aut-sei=Ogura
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TanisakaYuki
en-aut-sei=Tanisaka
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SekineMasanari
en-aut-sei=Sekine
en-aut-mei=Masanari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KobayashiKatsumasa
en-aut-sei=Kobayashi
en-aut-mei=Katsumasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MaruyamaHirotsugu
en-aut-sei=Maruyama
en-aut-mei=Hirotsugu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HiraiShinji
en-aut-sei=Hirai
en-aut-mei=Shinji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ShiomiHideyuki
en-aut-sei=Shiomi
en-aut-mei=Hideyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=ShigekawaMinoru
en-aut-sei=Shigekawa
en-aut-mei=Minoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=KuwataniMasaki
en-aut-sei=Kuwatani
en-aut-mei=Masaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=IkezawaKenji
en-aut-sei=Ikezawa
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=ItonagaMasahiro
en-aut-sei=Itonaga
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=TakenakaMamoru
en-aut-sei=Takenaka
en-aut-mei=Mamoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=HijiokaSusumu
en-aut-sei=Hijioka
en-aut-mei=Susumu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=IkeuraTsukasa
en-aut-sei=Ikeura
en-aut-mei=Tsukasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=DoiShinpei
en-aut-sei=Doi
en-aut-mei=Shinpei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=FujimoriNao
en-aut-sei=Fujimori
en-aut-mei=Nao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=KoizumiKazuya
en-aut-sei=Koizumi
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=NakaiYousuke
en-aut-sei=Nakai
en-aut-mei=Yousuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=InoueTadahisa
en-aut-sei=Inoue
en-aut-mei=Tadahisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=MukaiShuntaro
en-aut-sei=Mukai
en-aut-mei=Shuntaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=MatsumotoKazuyuki
en-aut-sei=Matsumoto
en-aut-mei=Kazuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=MinamiRyuki
en-aut-sei=Minami
en-aut-mei=Ryuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=MandaiKoichiro
en-aut-sei=Mandai
en-aut-mei=Koichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=MatsudaAtsuhiro
en-aut-sei=Matsuda
en-aut-mei=Atsuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=IwashitaTakuji
en-aut-sei=Iwashita
en-aut-mei=Takuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=KawashimaHiroki
en-aut-sei=Kawashima
en-aut-mei=Hiroki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=ItoiTakao
en-aut-sei=Itoi
en-aut-mei=Takao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

affil-num=1
en-affil=Endoscopy Center, Osaka Medical and Pharmaceutical University
kn-affil=

affil-num=2
en-affil=Gastroenterology, Saitama Medical University International Medical Center
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology Jichi Medical University, Saitama Medical Center
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology, Tokyo Metropolitan Bokutoh Hospital
kn-affil=

affil-num=5
en-affil=Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University
kn-affil=

affil-num=6
en-affil=Department of Medicine, Division of Gastroenterology, Kurume University School of Medicine
kn-affil=

affil-num=7
en-affil=Department of Gastroenterology, Division of Hepatobiliary and Pancreatic Diseases, Hyogo Medical University
kn-affil=

affil-num=8
en-affil=Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine
kn-affil=

affil-num=9
en-affil=Department of Gastroenterology and Hepatology, Hokkaido University Hospital
kn-affil=

affil-num=10
en-affil=Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute
kn-affil=

affil-num=11
en-affil=Second Department of Internal Medicine, Wakayama Medical University
kn-affil=

affil-num=12
en-affil=Department of Gastroenterology and Hepatology, Faculty of Medicine, Kindai University
kn-affil=

affil-num=13
en-affil=Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital
kn-affil=

affil-num=14
en-affil=Third Department of Internal Medicine, Kansai Medical University
kn-affil=

affil-num=15
en-affil=Department of Gastroenterology, Teikyo University Mizonokuchi Hospital
kn-affil=

affil-num=16
en-affil=Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University
kn-affil=

affil-num=17
en-affil=Department of Gastroenterology, Medicine Center, Shonan Kamakura General Hospital
kn-affil=

affil-num=18
en-affil=Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=19
en-affil=Department of Gastroenterology, Aichi Medical University
kn-affil=

affil-num=20
en-affil=Department of Gastroenterology and Hepatology, Tokyo Medical University
kn-affil=

affil-num=21
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=22
en-affil=Department of Gastroenterology, Tenri Hospital
kn-affil=

affil-num=23
en-affil=Department of Gastroenterology, Kyoto Second Red Cross Hospital
kn-affil=

affil-num=24
en-affil=Department of Internal Medicine, Toyama Prefectural Central Hospital
kn-affil=

affil-num=25
en-affil=First Department of Internal Medicine, Gifu University Hospital
kn-affil=

affil-num=26
en-affil=Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=27
en-affil=Department of Gastroenterology and Hepatology, Tokyo Medical University
kn-affil=
en-keyword=ERCP
kn-keyword=ERCP
en-keyword=guidewire
kn-keyword=guidewire
en-keyword=pancreatitis
kn-keyword=pancreatitis
en-keyword=post-ERCP pancreatitis
kn-keyword=post-ERCP pancreatitis
en-keyword=wire-guided cannulation
kn-keyword=wire-guided cannulation
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251127
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=EUS-Guided Versus Percutaneous Transhepatic Drainage of Liver Abscesses: A Multicenter Endohepatology Study in Western Japan (EPIC-LA Study)
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Objective: Percutaneous transhepatic liver abscess drainage (PTAD) and endoscopic ultrasound-guided liver abscess drainage (EUS-LAD) have several limitations. Recently, because of technical improvements in echoendoscope maneuvers, EUS-guided access for the right hepatic lobe has been reported. The aim of this multicenter, retrospective study was to compare clinical outcomes of PTAD and EUS-LAD including the right hepatic lobe in West Japan.<br>
Method: This retrospective, multicenter study included consecutive patients with liver abscesses between January 2019 and November 2024. The primary outcome in this study was the clinical success rate compared between EUS-LAD and PTAD.<br>
Results: During the study period, 1012 consecutive patients developed liver abscesses. Of them, 734 patients were excluded, 43 underwent EUS-LAD and 235 patients underwent PTAD. After propensity score-matched analysis, the clinical success rate was significantly higher in the EUS-LAD group (97.7%, 42/43) than in the PTAD group (79.1%, 34/43) (p?=?0.007). After a propensity score-matched analysis, 25 patients were included in each group. The clinical success rate was significantly higher in the EUS-LAD group (100%, 25/25) than in the PTAD group (84%, 21/25) (p?=?0.037). Adverse events were also significantly higher in the PTAD group (16%, 5/25) than in the EUS-LAD group (p?=?0.025). In addition, the median length of hospital stay was significantly shorter in the EUS-LAD group (15?days) than in the PTAD group (22?days) (p?=?0.005).<br>
Conclusions: EUS-LAD using a metal stent might be one of the options, but further randomized, controlled trials are needed.
en-copyright=
kn-copyright=

en-aut-name=OguraTakeshi
en-aut-sei=Ogura
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KurodaTaira
en-aut-sei=Kuroda
en-aut-mei=Taira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MatsuuraTakanori
en-aut-sei=Matsuura
en-aut-mei=Takanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KitadaiJun
en-aut-sei=Kitadai
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KitagawaKoh
en-aut-sei=Kitagawa
en-aut-mei=Koh
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ItonagaMasahiro
en-aut-sei=Itonaga
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TakeshitaKotaro
en-aut-sei=Takeshita
en-aut-mei=Kotaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MatsumoriTomoaki
en-aut-sei=Matsumori
en-aut-mei=Tomoaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=EmoriTomoya
en-aut-sei=Emori
en-aut-mei=Tomoya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TakenakaMamoru
en-aut-sei=Takenaka
en-aut-mei=Mamoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=ImaiHajime
en-aut-sei=Imai
en-aut-mei=Hajime
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=MandaiKoichiro
en-aut-sei=Mandai
en-aut-mei=Koichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=ShintaniShuhei
en-aut-sei=Shintani
en-aut-mei=Shuhei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=FujimoriNao
en-aut-sei=Fujimori
en-aut-mei=Nao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=ShiomiHideyuki
en-aut-sei=Shiomi
en-aut-mei=Hideyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=AsadaMasanori
en-aut-sei=Asada
en-aut-mei=Masanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=SagamiRyota
en-aut-sei=Sagami
en-aut-mei=Ryota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=MaruyamaHirotsugu
en-aut-sei=Maruyama
en-aut-mei=Hirotsugu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=IkeuraTsukasa
en-aut-sei=Ikeura
en-aut-mei=Tsukasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=ShimataniMasaaki
en-aut-sei=Shimatani
en-aut-mei=Masaaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=NishikioriHidefumi
en-aut-sei=Nishikiori
en-aut-mei=Hidefumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=MatsumotoKazuyuki
en-aut-sei=Matsumoto
en-aut-mei=Kazuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=KokubuMasahito
en-aut-sei=Kokubu
en-aut-mei=Masahito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=KamadaHideki
en-aut-sei=Kamada
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=IshidaYusuke
en-aut-sei=Ishida
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=HakodaAkitoshi
en-aut-sei=Hakoda
en-aut-mei=Akitoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=KitanoMasayuki
en-aut-sei=Kitano
en-aut-mei=Masayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

affil-num=1
en-affil=Pancreatobiliary Advanced Medical Center, Osaka Medical and Pharmaceutical University Hospital
kn-affil=

affil-num=2
en-affil=Gastroenterology Center, Ehime Prefectural Hospital
kn-affil=

affil-num=3
en-affil=Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine
kn-affil=

affil-num=4
en-affil=Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine
kn-affil=

affil-num=5
en-affil=Department of Gastroenterology, Nara Medical University
kn-affil=

affil-num=6
en-affil=Second Department of Internal Medicine, Wakayama Medical University
kn-affil=

affil-num=7
en-affil=Department of Gastroenterology, Tane General Hospital
kn-affil=

affil-num=8
en-affil=Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine
kn-affil=

affil-num=9
en-affil=Department of Gastroenterology, Wakayama Rosai Hospital
kn-affil=

affil-num=10
en-affil=Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine Graduate School of Medical Sciences
kn-affil=

affil-num=11
en-affil=Department of Gastroenterology, Okanami General Hospital
kn-affil=

affil-num=12
en-affil=Department of Gastroenterology, Kyoto Second Red Cross Hospital
kn-affil=

affil-num=13
en-affil=Department of Gastroenterology, Shiga University of Medical Science
kn-affil=

affil-num=14
en-affil=Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University
kn-affil=

affil-num=15
en-affil=Division of Hepatobiliary and Pancreatic Diseases, Department of Gastroenterology, Hyogo Medical University
kn-affil=

affil-num=16
en-affil=Department of Gastroenterology and Hepatology, Japanese Red Cross Osaka Hospital
kn-affil=

affil-num=17
en-affil=Department of Gastroenterology, Faculty of Medicine, Oita University
kn-affil=

affil-num=18
en-affil=Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University
kn-affil=

affil-num=19
en-affil=Division of Gastroenterology and Hepatology, Kansai Medical University Hospital
kn-affil=

affil-num=20
en-affil=Department of Gastroenterology and Hepatology, Kansai Medical University Medical Center
kn-affil=

affil-num=21
en-affil=Department of Gastroenterology, Oita San-ai Medical Center
kn-affil=

affil-num=22
en-affil=Department of Endoscopy, Okayama University Hospital
kn-affil=

affil-num=23
en-affil=Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine
kn-affil=

affil-num=24
en-affil=Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University
kn-affil=

affil-num=25
en-affil=Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University
kn-affil=

affil-num=26
en-affil=2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University
kn-affil=

affil-num=27
en-affil=Second Department of Internal Medicine, Wakayama Medical University
kn-affil=
en-keyword=drainage
kn-keyword=drainage
en-keyword=endoscopic ultrasound-guided liver abscess drainage
kn-keyword=endoscopic ultrasound-guided liver abscess drainage
en-keyword=EUS
kn-keyword=EUS
en-keyword=liver abscess
kn-keyword=liver abscess
en-keyword=percutaneous transhepatic liver abscess drainage
kn-keyword=percutaneous transhepatic liver abscess drainage
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251118
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Mortality and cancer risk in patients with chronic pancreatitis in japan: insights into the importance of surveillance for pancreatic cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background/Objective: Since the 2010s, Japan’s national health insurance system has covered key management for chronic pancreatitis (CP), including pancreatic enzyme replacement therapy. These therapies are expected to improve long-term prognosis; however, recent data are lacking. This study aimed to clarify the updated cancer risk and mortality among patients with CP in Japan.<br>
Methods: We conducted a multicenter, retrospective cohort study on 1,110 patients with CP treated at 28 institutions in 2011. Standardized incidence ratios (SIRs) and standardized mortality ratios (SMRs) were calculated for comorbidities. Factors associated with the development of malignancy and overall survival were analyzed.<br>
Results: Patients with CP had an elevated SIR of 1.62 (95% confidence interval [CI], 1.43?1.83) for malignancy, with the highest risk observed for pancreatic cancer (SIR?=?6.44 [95% CI, 4.64?8.90]). During follow-up, 143 patients (12.9%) died, most frequently from malignancy (47.5%). The SMR was elevated in all patients with CP (SMR?=?1.20 [95% CI, 1.01?1.42]) and in those with alcohol-related CP (SMR?=?1.49 [95% CI, 1.23?1.81]) but not in those with alcohol-unrelated CP. Pancreatic cancer was identified as the strongest factor associated with overall survival (hazard ratio, 48.92 in multivariate analysis). Overall survival of the patients with pancreatic cancer was significantly longer in those who underwent regular examinations for CP at least every three months (P?=?0.011).<br>
Conclusions: Patients with alcohol-related CP have higher mortality than the general population in Japan. Pancreatic cancer remains a crucial prognostic factor in patients with CP. Regular surveillance for pancreatic cancer is important to improve their prognosis.
en-copyright=
kn-copyright=

en-aut-name=MatsumotoRyotaro
en-aut-sei=Matsumoto
en-aut-mei=Ryotaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KikutaKazuhiro
en-aut-sei=Kikuta
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakikawaTetsuya
en-aut-sei=Takikawa
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakaiYousuke
en-aut-sei=Nakai
en-aut-mei=Yousuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TakenakaMamoru
en-aut-sei=Takenaka
en-aut-mei=Mamoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OkiKentaro
en-aut-sei=Oki
en-aut-mei=Kentaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=OhnoEizaburo
en-aut-sei=Ohno
en-aut-mei=Eizaburo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=ItoKen
en-aut-sei=Ito
en-aut-mei=Ken
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=FujimoriNao
en-aut-sei=Fujimori
en-aut-mei=Nao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KatanumaAkio
en-aut-sei=Katanuma
en-aut-mei=Akio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=MasudaAtsuhiro
en-aut-sei=Masuda
en-aut-mei=Atsuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=HoriYasuki
en-aut-sei=Hori
en-aut-mei=Yasuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=IkeuraTsukasa
en-aut-sei=Ikeura
en-aut-mei=Tsukasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=SuzukiRei
en-aut-sei=Suzuki
en-aut-mei=Rei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=YamamotoSatoshi
en-aut-sei=Yamamoto
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=SogameYoshio
en-aut-sei=Sogame
en-aut-mei=Yoshio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=KawashimaHiroki
en-aut-sei=Kawashima
en-aut-mei=Hiroki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=ItoTetsuhide
en-aut-sei=Ito
en-aut-mei=Tetsuhide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=OkuwakiKosuke
en-aut-sei=Okuwaki
en-aut-mei=Kosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=ItoiTakao
en-aut-sei=Itoi
en-aut-mei=Takao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=TakayamaYukiko
en-aut-sei=Takayama
en-aut-mei=Yukiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=NakamuraAkira
en-aut-sei=Nakamura
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=TeraiShuji
en-aut-sei=Terai
en-aut-mei=Shuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=MatsumotoKazuyuki
en-aut-sei=Matsumoto
en-aut-mei=Kazuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=KuwataniMasaki
en-aut-sei=Kuwatani
en-aut-mei=Masaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=KishiwadaMasashi
en-aut-sei=Kishiwada
en-aut-mei=Masashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=ShigekawaMinoru
en-aut-sei=Shigekawa
en-aut-mei=Minoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=MatsumoriTomoaki
en-aut-sei=Matsumori
en-aut-mei=Tomoaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=InatomiOsamu
en-aut-sei=Inatomi
en-aut-mei=Osamu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=HattaWaku
en-aut-sei=Hatta
en-aut-mei=Waku
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

en-aut-name=IrisawaAtsushi
en-aut-sei=Irisawa
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=31
ORCID=

en-aut-name=UnnoMichiaki
en-aut-sei=Unno
en-aut-mei=Michiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=32
ORCID=

en-aut-name=TakeyamaYoshifumi
en-aut-sei=Takeyama
en-aut-mei=Yoshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=33
ORCID=

en-aut-name=MasamuneAtsushi
en-aut-sei=Masamune
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=34
ORCID=

en-aut-name=Japan Pancreatitis Study Group for Chronic Pancreatitis
en-aut-sei=Japan Pancreatitis Study Group for Chronic Pancreatitis
en-aut-mei=
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=35
ORCID=

affil-num=1
en-affil=Division of Gastroenterology, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=2
en-affil=Division of Gastroenterology, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=3
en-affil=Division of Gastroenterology, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=5
en-affil=Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine
kn-affil=

affil-num=6
en-affil=Department of Gastroenterology and Hepatology, Kurashiki Central Hospital
kn-affil=

affil-num=7
en-affil=Department of Gastroenterology and Hepatology, Fujita Health University School of Medicine
kn-affil=

affil-num=8
en-affil=Division of Gastroenterology and Hepatology, Toho University Omori Medical Center
kn-affil=

affil-num=9
en-affil=Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University
kn-affil=

affil-num=10
en-affil=Center for Gastroenterology, Teine-Keijinkai Hospital
kn-affil=

affil-num=11
en-affil=Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine
kn-affil=

affil-num=12
en-affil=Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences
kn-affil=

affil-num=13
en-affil=Department of Gastroenterology and Hepatology, Kansai Medical University
kn-affil=

affil-num=14
en-affil=Department of Gastroenterology, Fukushima Medical University School of Medicine
kn-affil=

affil-num=15
en-affil=Department of Gastroenterology, Fujita Health University Bantane Hospital
kn-affil=

affil-num=16
en-affil=Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine
kn-affil=

affil-num=17
en-affil=Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=18
en-affil=Neuroendocrine Tumor Centre, Fukuoka Sanno Hospital, International University of Health and Welfare
kn-affil=

affil-num=19
en-affil=Department of Gastroenterology, Kitasato University School of Medicine
kn-affil=

affil-num=20
en-affil=Department of Gastroenterology and Hepatology, Tokyo Medical University
kn-affil=

affil-num=21
en-affil=Department of Internal Medicine, Institute of Gastroenterology, Tokyo Women’s Medical University
kn-affil=

affil-num=22
en-affil=Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine
kn-affil=

affil-num=23
en-affil=Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University
kn-affil=

affil-num=24
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=25
en-affil=Department of Gastroenterology and Hepatology, Hokkaido University Hospital
kn-affil=

affil-num=26
en-affil=Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine
kn-affil=

affil-num=27
en-affil=Department of Gastroenterology and Hepatology, The University of Osaka Graduate School of Medicine
kn-affil=

affil-num=28
en-affil=Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine
kn-affil=

affil-num=29
en-affil=Department of Medicine, Shiga University of Medical Science
kn-affil=

affil-num=30
en-affil=Division of Gastroenterology, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=31
en-affil=Department of Gastroenterology, Dokkyo Medical University School of Medicine
kn-affil=

affil-num=32
en-affil=Department of Surgery, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=33
en-affil=Department of Surgery, Kindai University Faculty of Medicine
kn-affil=

affil-num=34
en-affil=Division of Gastroenterology, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=35
en-affil=
kn-affil=
en-keyword=Alcohol
kn-keyword=Alcohol
en-keyword=Chronic pancreatitis
kn-keyword=Chronic pancreatitis
en-keyword=Pancreatic cancer
kn-keyword=Pancreatic cancer
en-keyword=Pancreatitis
kn-keyword=Pancreatitis
en-keyword=Smoking
kn-keyword=Smoking
END

start-ver=1.4
cd-journal=joma
no-vol=14
cd-vols=
no-issue=10
article-no=
start-page=715
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241012
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Photocatalytic Ammonia Decomposition Using Dye-Encapsulated Single-Walled Carbon Nanotubes
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The photocatalytic decomposition of ammonia to produce N2 and H2 was achieved using single-walled carbon nanotube (SWCNT) nanohybrids. The physical modification of ferrocene-dye-encapsulated CNTs by amphiphilic C60-dendron yielded nanohybrids with a dye/CNT/C60 coaxial heterojunction. Upon irradiation with visible light, an aqueous solution of NH3 and dye@CNT/C60-dendron nanohybrids produced both N2 and H2 in a stoichiometric ratio of 1/3. The action spectra of this reaction clearly demonstrated that the encapsulated dye acted as the photosensitizer, exhibiting an apparent quantum yield (AQY) of 0.22% at 510 nm (the λmax of the dye). This study reports the first example of dye-sensitized ammonia decomposition and provides a new avenue for developing efficient and sustainable photocatalytic hydrogen production systems.
en-copyright=
kn-copyright=

en-aut-name=TajimaTomoyuki
en-aut-sei=Tajima
en-aut-mei=Tomoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YanoKotone
en-aut-sei=Yano
en-aut-mei=Kotone
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MukaiKazushi
en-aut-sei=Mukai
en-aut-mei=Kazushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TakaguchiYutaka
en-aut-sei=Takaguchi
en-aut-mei=Yutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Materials Design and Engineering, University of Toyama
kn-affil=

affil-num=4
en-affil=Department of Materials Design and Engineering, University of Toyama
kn-affil=
en-keyword=photocatalyst
kn-keyword=photocatalyst
en-keyword=ammonia decomposition
kn-keyword=ammonia decomposition
en-keyword=dye sensitization
kn-keyword=dye sensitization
en-keyword=hydrogen evolution
kn-keyword=hydrogen evolution
en-keyword=carbon nanotube
kn-keyword=carbon nanotube
en-keyword=fullerene
kn-keyword=fullerene
END

start-ver=1.4
cd-journal=joma
no-vol=32
cd-vols=
no-issue=2
article-no=
start-page=103274
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Optimization of the reconstruction kernel for temporal bone imaging using photon-counting detector CT: A combined physical and visual evaluation
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Introduction: Photon-counting detector CT (PCD-CT) offers superior spatial resolution and noise characteristics compared to conventional CT. However, optimal reconstruction parameters for temporal bone imaging, especially kernel selection, remain unclear. This study aimed to identify the optimal reconstruction kernel using both objective physical image quality metrics and subjective expert assessments.<br>
Methods: In phantom experiments, the system performance function (SPF) based on the task-based transfer function (TTF) and noise power spectrum (NPS) was calculated across 11 reconstruction kernels (Hr60?Hr98). Based on the results of the physical evaluation and clinical considerations from clinical practice, a subset of kernels was selected for visual assessment. For clinical images, two diagnostic radiologists evaluated three fine anatomical structures (i.e., stapes footplate, incudomalleolar joint, and cochlea) and overall image quality using both a ranking method and a 5-point Likert scale.<br>
Results: TTF analysis indicated that Hr96 had the highest spatial resolution, while Hr60 showed the lowest noise in the NPS. SPF analysis identified Hr72 as providing the optimal balance between resolution and noise. Visual assessment using four reconstruction kernels (Hr60, Hr72, Hr76, and Hr84) showed that Hr76 consistently received the highest preference for overall image quality and visualization of fine structures. Statistically significant differences were observed among the kernels, with Hr60 consistently rated the lowest (p < 0.05).<br>
Conclusion: The kernel Hr76 was found suitable for middle and inner ear diagnoses using PCD-CT, providing a good balance between spatial resolution and image noise. This finding provides a foundation for standardized reconstruction protocols in high-resolution temporal bone imaging.<br>
Implications for practice: These findings support the use of Hr76 as a standard kernel for high-resolution temporal bone imaging and may contribute to protocol optimization in clinical PCD-CT practice.
en-copyright=
kn-copyright=

en-aut-name=NishiiS.
en-aut-sei=Nishii
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=AsaharaT.
en-aut-sei=Asahara
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MorimitsuY.
en-aut-sei=Morimitsu
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KajisakiS.
en-aut-sei=Kajisaki
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=AkagiN.
en-aut-sei=Akagi
en-aut-mei=N.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HondaM.
en-aut-sei=Honda
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HayashiH.
en-aut-sei=Hayashi
en-aut-mei=H.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=SugayaA.
en-aut-sei=Sugaya
en-aut-mei=A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MunetomoK.
en-aut-sei=Munetomo
en-aut-mei=K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=HigakiF.
en-aut-sei=Higaki
en-aut-mei=F.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=HirakiT.
en-aut-sei=Hiraki
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=IguchiT.
en-aut-sei=Iguchi
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

affil-num=1
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Radiological Technology, Faculty of Health Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Division of Radiological Technology, Medical Support Department, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Division of Radiological Technology, Medical Support Department, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Division of Radiological Technology, Medical Support Department, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Division of Radiological Technology, Medical Support Department, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=College of Transdisciplinary Sciences for Innovation, Kanazawa University
kn-affil=

affil-num=8
en-affil=Department of Otolaryngology, Head & Neck Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=9
en-affil=Department of Radiology, Medical Development Field, Okayama University
kn-affil=

affil-num=10
en-affil=Department of Radiology, Medical Development Field, Okayama University
kn-affil=

affil-num=11
en-affil=Department of Radiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=12
en-affil=Department of Radiological Technology, Faculty of Health Sciences, Okayama University
kn-affil=
en-keyword=Photon-counting CT
kn-keyword=Photon-counting CT
en-keyword=Temporal bone imaging
kn-keyword=Temporal bone imaging
en-keyword=Reconstruction kernel
kn-keyword=Reconstruction kernel
en-keyword=Image quality
kn-keyword=Image quality
END

start-ver=1.4
cd-journal=joma
no-vol=3
cd-vols=
no-issue=
article-no=
start-page=28
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202412
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Airway management during sedation for dental treatment in people with intellectual disabilities: a review
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The oral health of people with intellectual disabilities remains poor due to a complex combination of physical and social problems, and often requires invasive dental treatment. However, it can be difficult to obtain their cooperation for dental treatment because they may not fully understand the need for treatment or may experience high levels of anxiety due to lack of understanding and/or sensory aversions to stimuli present in the dental environment, and behavioral management is often necessary during such treatment. Sedation is a very useful patient management method for dental treatment for people with intellectual disabilities; however, the dental treatment-related sedation of people with intellectual disabilities has different characteristics to the dental treatment-related sedation of others or other procedure-related sedation. For example, deep sedation is required for behavioral management; drug interactions between the patient’s regular medications, such as antiepileptic and antipsychotic drugs, and anesthetics may make the depth of sedation deeper; and the prevalence rate of obesity is higher among people with intellectual disabilities. The fact that the patient is in the supine position with their mouth open also makes airway management during sedation for dental treatment more difficult. It is therefore imperative that airway management during dental treatment for people with intellectual disabilities be conducted with the utmost precision and vigilance. Various attempts have been made to improve airway management during such sedation, and new technologies, such as capnography, nasal high-flow systems, and acoustic respiration monitors, may help. The objective of this review is to enhance comprehension of the attributes of airway management in dental sedation for people with intellectual disabilities and to properly understand the usefulness of the techniques that have been attempted thus far to ensure safer and more secure airway management for this population. The ultimate goal is to provide them with safe and secure medical care and improve their health outcomes.
en-copyright=
kn-copyright=

en-aut-name=HiguchiHitoshi
en-aut-sei=Higuchi
en-aut-mei=Hitoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NishiokaYukiko
en-aut-sei=Nishioka
en-aut-mei=Yukiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MiyakeSaki
en-aut-sei=Miyake
en-aut-mei=Saki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MiyawakiTakuya
en-aut-sei=Miyawaki
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Department of Dental Anesthesiology, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Dental Anesthesiology, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Dental Anesthesiology and Special Care Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Dental Anesthesiology and Special Care Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=Dentistry
kn-keyword=Dentistry
en-keyword=sedation
kn-keyword=sedation
en-keyword=airway management
kn-keyword=airway management
en-keyword=people with intellectual disabilities
kn-keyword=people with intellectual disabilities
END

start-ver=1.4
cd-journal=joma
no-vol=15
cd-vols=
no-issue=2
article-no=
start-page=191
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250219
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Palladium-Catalyzed Decarbonylative Nucleophilic Halogenation of Acid Anhydrides
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=In this study, we developed a palladium-catalyzed decarbonylative nucleophilic halogenation reaction using inexpensive and readily available acid anhydrides as substrates. This approach effectively circumvents the instability of acyl chlorides and the low reactivity of acyl fluorides. The Pd/Xantphos catalyst system exhibited excellent compatibility with the thermodynamically and kinetically challenging reductive elimination of C?X bonds (X = I, Br, and Cl) from Pd(II) intermediates. Notably, for electron-donating substrates, adopting an open system significantly improved the reaction efficiency. The positive effect of the open system may be due to the reversible nature of CO insertion and deinsertion, which helps direct the reaction toward the desired pathway by allowing the generated CO to exit the reaction system. Mechanistic studies suggest that the reaction proceeds through a highly reactive acyl halide intermediate, followed by a unimolecular fragment coupling (UFC) pathway via decarbonylation or an alternative pathway involving the formation of an activated anionic palladate complex in the presence of lithium halide.
en-copyright=
kn-copyright=

en-aut-name=TianTian
en-aut-sei=Tian
en-aut-mei=Tian
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=UeiShuhei
en-aut-sei=Uei
en-aut-mei=Shuhei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YanWeidan
en-aut-sei=Yan
en-aut-mei=Weidan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NishiharaYasushi
en-aut-sei=Nishihara
en-aut-mei=Yasushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Graduate School of Natural Science and Technology, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Chemistry, Faculty of Science, Okayama University
kn-affil=

affil-num=3
en-affil=Graduate School of Natural Science and Technology, Okayama University
kn-affil=

affil-num=4
en-affil=Research Institute for Interdisciplinary Science (RIIS), Okayama University
kn-affil=
en-keyword=reductive elimination of C?X bond
kn-keyword=reductive elimination of C?X bond
en-keyword=nucleophilic halogenation
kn-keyword=nucleophilic halogenation
en-keyword=unimolecular fragment coupling (UFC)
kn-keyword=unimolecular fragment coupling (UFC)
en-keyword=acid anhydrides
kn-keyword=acid anhydrides
en-keyword=aryl halides
kn-keyword=aryl halides
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=e21664
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251014
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Biologically-Architected Wear and Damage-Resistant Nanoparticle Coating From the Radular Teeth of Cryptochiton stelleri
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Nature utilizes simple building blocks to construct mechanically robust materials that demonstrate superior performance under extreme conditions. These exquisite structures result from the controlled synthesis and hierarchical assembly of nanoscale organic and mineral components that have provided critical evolutionary advantages to ensure survival. One such example is the ultrahard radular teeth found in mollusks, which are used to scrape against rock to feed on algae. Here, it is reported that the leading edges of these teeth consist of a wear-resistant coating that is comprised of densely packed ?65 nm magnetic nanoparticles integrated within an organic matrix of chitin and protein. These mesocrystalline magnetite-based structures are assembled from smaller, highly aligned nanocrystals with inter/intracrystalline organics introduced during the crystallization process. Nanomechanical testing reveals that this multi-scale, nano-architected coating has a combination of increased hardness and a slight decrease in modulus versus geologic magnetite provides the surface of the chiton tooth with superior abrasion resistance. The mesocrystalline structures fracture at primary domain interfaces, corroborated by computational models, providing significant toughening to the tooth under extreme contact stresses. The design features revealed provide insight for the design and fabrication of next-generation advanced wear- and impact-resistant coatings for tooling, machinery, wind turbines, armor, etc.
en-copyright=
kn-copyright=

en-aut-name=WangTaifeng
en-aut-sei=Wang
en-aut-mei=Taifeng
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ChenYu
en-aut-sei=Chen
en-aut-mei=Yu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SarmientoEzra
en-aut-sei=Sarmiento
en-aut-mei=Ezra
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HaoTaige
en-aut-sei=Hao
en-aut-mei=Taige
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=ArakakiAtsushi
en-aut-sei=Arakaki
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NemotoMichiko
en-aut-sei=Nemoto
en-aut-mei=Michiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ZavattieriPablo
en-aut-sei=Zavattieri
en-aut-mei=Pablo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KisailusDavid
en-aut-sei=Kisailus
en-aut-mei=David
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Materials Science and Engineering, University of California
kn-affil=

affil-num=2
en-affil=Lyles School of Civil and Construction Engineering, Purdue University
kn-affil=

affil-num=3
en-affil=Department of Materials Science and Engineering, University of California
kn-affil=

affil-num=4
en-affil=Materials and Manufacturing Technologies Program, University of California
kn-affil=

affil-num=5
en-affil=Division of Biotechnology and Life Science, Institute of Engineering, Tokyo University of Agriculture and Technology 
kn-affil=

affil-num=6
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=7
en-affil=Lyles School of Civil and Construction Engineering, Purdue University
kn-affil=

affil-num=8
en-affil=Department of Materials Science and Engineering, University of California
kn-affil=
en-keyword=biomineralization
kn-keyword=biomineralization
en-keyword=coatings
kn-keyword=coatings
en-keyword=damage tolerance
kn-keyword=damage tolerance
en-keyword=magnetite
kn-keyword=magnetite
en-keyword=mesocrystals
kn-keyword=mesocrystals
END

start-ver=1.4
cd-journal=joma
no-vol=20
cd-vols=
no-issue=8
article-no=
start-page=e0328792
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250814
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Risk stratification for the prediction of skeletal-related events in patients with castration-resistant prostate cancer with bone metastases
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Skeletal-related events (SREs) are common in patients with bone metastases from castration-resistant prostate cancer (CRPC). Despite advances in prostate cancer treatment, clinically validated predictive models for SREs in CRPC patients with bone metastases remain elusive. This gap in prognostic tools hinders optimal patient management and treatment planning for this high-risk population. This study aimed to develop a prediction model for SRE by investigating potential risk factors and classifying them into different groups. This model can be used to identify patients at high risk of SREs who need close follow-up. Between 2004 and 2013, 68 male patients with bone metastases from CRPC who were treated at our institute were evaluated for survival without SREs and survival without SREs of the spinal cord. The study analyzed clinical data at enrollment to identify risk factors for initial and spinal SREs. Multivariate analysis revealed that a high count of metastatic vertebrae, along with visceral or lymph node metastases, were significant risk factors. Patients were categorized into four subgroups based on the number of vertebral metastases and presence of visceral or lymph node metastases: 1) extensive vertebral and both types of metastases, 2) extensive vertebral without additional metastases, 3) some vertebral with other metastases, 4) some vertebral without additional metastases. The first SRE and spinal SRE occurred significantly sooner in the first subgroup compared to others. Incidence rates at 12 months for the first SRE were 56%, 40%, 27%, and 5%, and for the first spinal SRE were 47%, 40%, 27%, and 0% respectively. Patients with extensive vertebral and additional metastases require vigilant monitoring to mitigate SREs.
en-copyright=
kn-copyright=

en-aut-name=HamadaMasanori
en-aut-sei=Hamada
en-aut-mei=Masanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NakataEiji
en-aut-sei=Nakata
en-aut-mei=Eiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NakaharaRyuichi
en-aut-sei=Nakahara
en-aut-mei=Ryuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SugiharaShinsuke
en-aut-sei=Sugihara
en-aut-mei=Shinsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KatayamaHaruyoshi
en-aut-sei=Katayama
en-aut-mei=Haruyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ItanoTakuto
en-aut-sei=Itano
en-aut-mei=Takuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=InoueTomohiro
en-aut-sei=Inoue
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TakihiraShota
en-aut-sei=Takihira
en-aut-mei=Shota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=AkezakiYoshiteru
en-aut-sei=Akezaki
en-aut-mei=Yoshiteru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=OzakiToshifumi
en-aut-sei=Ozaki
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=
kn-affil=

affil-num=2
en-affil=
kn-affil=

affil-num=3
en-affil=
kn-affil=

affil-num=4
en-affil=
kn-affil=

affil-num=5
en-affil=
kn-affil=

affil-num=6
en-affil=
kn-affil=

affil-num=7
en-affil=
kn-affil=

affil-num=8
en-affil=
kn-affil=

affil-num=9
en-affil=
kn-affil=

affil-num=10
en-affil=
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=17
cd-vols=
no-issue=10
article-no=
start-page=e95695
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251029
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Association of Use of GRADE, Protocol Registration, and Journal Impact Factor With Reporting and Methodological Quality of Systematic Reviews Published in Rehabilitation Journals: A Meta-Epidemiological Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This study aimed to identify factors associated with the reporting and methodological quality of systematic reviews (SRs) published in rehabilitation journals. We conducted a meta-epidemiological study as a secondary analysis of a previous study. The study protocol was registered in the Open Science Framework. We analyzed 219 SRs from rehabilitation journals published since 2020. We assessed reporting quality using the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) 2020 and methodological quality using A MeaSurement Tool to Assess systematic Reviews (AMSTAR) 2. Multiple linear regression and Spearman's correlation were used to identify factors associated with quality, including Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach and the Journal Impact Factor (JIF). Multivariate analysis revealed PRISMA 2020 adherence was significantly associated with use of GRADE (β = 4.33; 95% confidence interval (CI): 3.24-5.42), protocol registration (β = 3.40; 95% CI: 2.32-4.47), and the JIF (2023) (β = 0.69; 95% CI: 0.42-0.95). AMSTAR 2 adherence was also significantly associated with use of GRADE (β = 2.52; 95% CI: 1.88-3.17), protocol registration (β = 2.07; 95% CI: 1.44-2.70), and the JIF (2023) (β = 0.29; 95% CI: 0.14-0.45). Weak positive correlations were observed between the JIF (2023) and both PRISMA 2020 and AMSTAR 2 adherence (ρ = 0.27 and ρ = 0.22, respectively; both P < 0.01). It should be noted that these findings reflect associations and do not imply causality. To enhance the quality of SRs in rehabilitation, researchers should prioritize adherence to PRISMA 2020, particularly the use of GRADE and protocol registration, which this study identified as key associated factors.
en-copyright=
kn-copyright=

en-aut-name=TsugeTakahiro
en-aut-sei=Tsuge
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YamamotoNorio
en-aut-sei=Yamamoto
en-aut-mei=Norio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TomitaYosuke
en-aut-sei=Tomita
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HagiyamaAkikazu
en-aut-sei=Hagiyama
en-aut-mei=Akikazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=ShiratsuchiDaijo
en-aut-sei=Shiratsuchi
en-aut-mei=Daijo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OkamuraMasatsugu
en-aut-sei=Okamura
en-aut-mei=Masatsugu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KanekoTakao
en-aut-sei=Kaneko
en-aut-mei=Takao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=SuzukiKosuke
en-aut-sei=Suzuki
en-aut-mei=Kosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=NakashimaYuki
en-aut-sei=Nakashima
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TaitoShunsuke
en-aut-sei=Taito
en-aut-mei=Shunsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=YorifujiTakashi
en-aut-sei=Yorifuji
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Systematic Reviewers, Scientific Research WorkS Peer Support Group (SRWS-PSG)
kn-affil=

affil-num=3
en-affil=Physical Therapy, Faculty of Health Care, Takasaki University of Health and Welfare
kn-affil=

affil-num=4
en-affil=Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Physical Therapy, School of Health Sciences, Faculty of Medicine, Kagoshima University
kn-affil=

affil-num=6
en-affil=Systematic Reviewers, Scientific Research WorkS Peer Support Group (SRWS-PSG)
kn-affil=

affil-num=7
en-affil=Rehabilitation, Yamagata Prefectural Central Hospital
kn-affil=

affil-num=8
en-affil=Rehabilitation, Yamagata Saisei Hospital
kn-affil=

affil-num=9
en-affil=Systematic Reviewers, Scientific Research WorkS Peer Support Group (SRWS-PSG)
kn-affil=

affil-num=10
en-affil=Systematic Reviewers, Scientific Research WorkS Peer Support Group (SRWS-PSG)
kn-affil=

affil-num=11
en-affil=Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=citation
kn-keyword=citation
en-keyword=grade
kn-keyword=grade
en-keyword=journal impact factor
kn-keyword=journal impact factor
en-keyword=methodological and reporting quality
kn-keyword=methodological and reporting quality
en-keyword=prisma
kn-keyword=prisma
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=e00463-25
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251128
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Analysis of the drug target of the anti-tuberculosis compound OCT313: phosphotransacetylase is a potential drug target for anti-mycobacterial agents
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Tuberculosis (TB) is one of the most common infectious diseases caused by bacteria worldwide. The increasing prevalence of multidrug-resistant TB (MDR-TB) and latent TB infection (LTBI) has intensified the global TB burden. Therefore, the development of new drugs for MDR-TB and LTBI is urgently required. We have reported that the derivative of dithiocarbamate sugar derivative, 2-acetamido-2-deoxy-β-D-glucopyranosyl N,N-dimethyldithiocarbamate (OCT313), exhibits anti-mycobacterial activity against MDR-MTB. Here, we identified the target of OCT313. In experimentally generated OCT313-resistant bacteria, adenine at position 1,092 in the metabolic enzyme phosphotransacetylase (PTA) gene was replaced with cytosine. This mutation is a nonsynonymous mutation that converts methionine to leucine at position 365 in the PTA protein. OCT313 inhibited the enzymatic activity of recombinant wild-type PTA, but not of the mutant PTA (M365L). PTA is an enzyme that produces acetyl-coenzyme A (acetyl-CoA) from acetyl phosphate and CoA and is involved in metabolic pathways; therefore, it was expected to also be active against dormant Mycobacterium tuberculosis bacilli. OCT313 exhibits antibacterial activity in the Wayne model of dormancy using Mycobacterium bovis BCG, and overexpression of PTA in OCT313-resistant bacilli restored sensitivity to OCT313. Collectively, the target of OCT313 is PTA, and OCT313 is a promising antimicrobial candidate for MDR-TB and LTBI.
en-copyright=
kn-copyright=

en-aut-name=TakiiTakemasa
en-aut-sei=Takii
en-aut-mei=Takemasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HasegawaTomohiro
en-aut-sei=Hasegawa
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ItohSaotomo
en-aut-sei=Itoh
en-aut-mei=Saotomo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MaedaShinji
en-aut-sei=Maeda
en-aut-mei=Shinji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=WadaTakayuki
en-aut-sei=Wada
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HoritaYasuhiro
en-aut-sei=Horita
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NishiyamaAkihito
en-aut-sei=Nishiyama
en-aut-mei=Akihito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MatsumotoSohkichi
en-aut-sei=Matsumoto
en-aut-mei=Sohkichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OharaNaoya
en-aut-sei=Ohara
en-aut-mei=Naoya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KimishimaAoi
en-aut-sei=Kimishima
en-aut-mei=Aoi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=AsamiYukihiro
en-aut-sei=Asami
en-aut-mei=Yukihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=HidaShigeaki
en-aut-sei=Hida
en-aut-mei=Shigeaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=OnozakiKikuo
en-aut-sei=Onozaki
en-aut-mei=Kikuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

affil-num=1
en-affil=Department of Mycobacterium Reference and Research, the Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association
kn-affil=

affil-num=2
en-affil=Department of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University
kn-affil=

affil-num=3
en-affil=Department of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University
kn-affil=

affil-num=4
en-affil=Graduate School of Pharmaceutical Sciences, Hokkaido University of Sciences
kn-affil=

affil-num=5
en-affil=Department of Microbiology, Graduate School of Human Life and Ecology, Osaka Metropolitan University
kn-affil=

affil-num=6
en-affil=Department of Clinical Pharmaceutics, Graduate School of Medical Sciences, Nagoya City University
kn-affil=

affil-num=7
en-affil=Department of Bacteriology, Niigata University School of Medicine
kn-affil=

affil-num=8
en-affil=Department of Bacteriology, Niigata University School of Medicine
kn-affil=

affil-num=9
en-affil=Department of Oral Microbiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=10
en-affil=Laboratory of Applied Microbial Chemistry, ?mura Satoshi Memorial Institute, Kitasato University
kn-affil=

affil-num=11
en-affil=Laboratory of Applied Microbial Chemistry, ?mura Satoshi Memorial Institute, Kitasato University
kn-affil=

affil-num=12
en-affil=Department of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University
kn-affil=

affil-num=13
en-affil=Department of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University
kn-affil=
en-keyword=phosphotransacetylase
kn-keyword=phosphotransacetylase
en-keyword=acetyl coenzyme A
kn-keyword=acetyl coenzyme A
en-keyword=dithiocarbamate
kn-keyword=dithiocarbamate
en-keyword=N-acetyl glucosamine
kn-keyword=N-acetyl glucosamine
en-keyword=anti-mycobacterial agents
kn-keyword=anti-mycobacterial agents
en-keyword=latent tuberculosis infection
kn-keyword=latent tuberculosis infection
END

start-ver=1.4
cd-journal=joma
no-vol=15
cd-vols=
no-issue=1
article-no=
start-page=40522
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251118
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Long intervals between repetitive concussions reduce risk of cognitive impairment and limit microglial activation, astrogliosis, and tauopathy in adolescent rats
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Although previous studies have demonstrated the effects of concussions do not accumulate as the time interval between injuries increases, little is known about the relationship between this interval and the effects of repetitive concussions. The objective of this study is to explore the relationship between the time interval and changes in behavior and histology following repetitive concussions. Male adolescent rats received concussions by weight drop and were randomly assigned to one of five experimental groups, receiving concussions three times either daily, every other day, once per week, once every 2 weeks, or receiving sham procedures. Only rats that received daily concussions exhibited cognitive impairment, while the other groups did not. No groups showed motor or anxiety-like impairments. Histological analysis revealed accumulation of microglia, as well as astrogliosis, in the prefrontal cortex, corpus callosum, dentate gyrus, and cornu Ammonis 1 region of the hippocampus in rats subjected to daily concussions. Accumulation of phosphorylated tau was also observed in the prefrontal cortex and cornu Ammonis 1. Longer intervals between concussions may reduce the risk of cognitive impairment and limit microglial activation, astrogliosis, and phosphorylated tau accumulation. These findings may help guide decisions on the appropriate timing for return to play in humans.
en-copyright=
kn-copyright=

en-aut-name=HirataYuichi
en-aut-sei=Hirata
en-aut-mei=Yuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KinKyohei
en-aut-sei=Kin
en-aut-mei=Kyohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NagaseTakayuki
en-aut-sei=Nagase
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SasakiTatsuya
en-aut-sei=Sasaki
en-aut-mei=Tatsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SasadaSusumu
en-aut-sei=Sasada
en-aut-mei=Susumu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=SugaharaChiaki
en-aut-sei=Sugahara
en-aut-mei=Chiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HirayamaTakahiro
en-aut-sei=Hirayama
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KawaiKoji
en-aut-sei=Kawai
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TanimotoShun
en-aut-sei=Tanimoto
en-aut-mei=Shun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=MiyakeHayato
en-aut-sei=Miyake
en-aut-mei=Hayato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=SaijoTomoya
en-aut-sei=Saijo
en-aut-mei=Tomoya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=NaitoHiromichi
en-aut-sei=Naito
en-aut-mei=Hiromichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=MasaiKaori
en-aut-sei=Masai
en-aut-mei=Kaori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=YasuharaTakao
en-aut-sei=Yasuhara
en-aut-mei=Takao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=TanakaShota
en-aut-sei=Tanaka
en-aut-mei=Shota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

affil-num=1
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital
kn-affil=

affil-num=9
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital
kn-affil=

affil-num=10
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital
kn-affil=

affil-num=11
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital
kn-affil=

affil-num=12
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University Hospital
kn-affil=

affil-num=13
en-affil=Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=14
en-affil=Yasuhara Clinic
kn-affil=

affil-num=15
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital
kn-affil=
en-keyword=Concussion
kn-keyword=Concussion
en-keyword=Return to play
kn-keyword=Return to play
en-keyword=Sports-related head injury
kn-keyword=Sports-related head injury
en-keyword=Microglia
kn-keyword=Microglia
en-keyword=Astrocyte
kn-keyword=Astrocyte
en-keyword=Tauopathy
kn-keyword=Tauopathy
END

start-ver=1.4
cd-journal=joma
no-vol=27
cd-vols=
no-issue=1
article-no=
start-page=219
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251121
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Does perioperative discontinuation of anti-rheumatic drugs increase postoperative complications in orthopedic surgery for rheumatoid arthritis?
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Objective This study aimed to investigate whether discontinuation of biological or targeted synthetic antirheumatic disease-modifying drugs (bDMARDs or tsDMARDs) influences the incidence of postoperative complications in patients with rheumatoid arthritis (RA) undergoing orthopedic surgery.<br>
Methods A retrospective multicenter cohort study including patients receiving bDMARDs or tsDMARDs who underwent orthopedic surgery was conducted. Data collected encompassed the duration of drug discontinuation and postoperative adverse events, such as delayed wound healing, surgical site infection (SSI), disease flare-ups, and mortality. The association between drug discontinuation and these outcomes was analyzed. Multivariate analyses were conducted to identify potential risk factors for these events.<br>
Results A total of 2,060 cases were initially enrolled. After applying inclusion and exclusion criteria, data from 1,953 patients were analyzed. No significant differences were observed between the groups regarding delayed wound healing, SSI, or mortality. However, the incidence of disease flare-ups was substantially higher in the drug discontinuation group and in the interleukin (IL)-6 inhibitor group. Multivariate analysis identified that tumor necrosis factor α and IL-6 inhibitor use was associated with a higher risk of delayed wound healing relative to T-cell function modifiers.<br>
Conclusion In orthopedic surgery for patients with RA, maintaining the standard or the half of administration interval of bDMARD appears safe in the preoperative period. However, the drug discontinuation may increase the risk of postoperative flare-ups, particularly with IL-6 inhibitors. In addition, T-cell function modifiers may be associated with a lower risk of delayed wound healing, suggesting their safety profile in this context.
en-copyright=
kn-copyright=

en-aut-name=ItoHiromu
en-aut-sei=Ito
en-aut-mei=Hiromu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=IshikawaHajime
en-aut-sei=Ishikawa
en-aut-mei=Hajime
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TsujiShigeyoshi
en-aut-sei=Tsuji
en-aut-mei=Shigeyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakayamaMasanori
en-aut-sei=Nakayama
en-aut-mei=Masanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NishidaKeiichiro
en-aut-sei=Nishida
en-aut-mei=Keiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MochizukiTakeshi
en-aut-sei=Mochizuki
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=EbinaKosuke
en-aut-sei=Ebina
en-aut-mei=Kosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KojimaToshihisa
en-aut-sei=Kojima
en-aut-mei=Toshihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MatsumotoTakumi
en-aut-sei=Matsumoto
en-aut-mei=Takumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KubotaAyako
en-aut-sei=Kubota
en-aut-mei=Ayako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=NakajimaArata
en-aut-sei=Nakajima
en-aut-mei=Arata
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=KanekoAtsushi
en-aut-sei=Kaneko
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=MatsushitaIsao
en-aut-sei=Matsushita
en-aut-mei=Isao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=HaraRyota
en-aut-sei=Hara
en-aut-mei=Ryota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=SakurabaKoji
en-aut-sei=Sakuraba
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=AkasakiYukio
en-aut-sei=Akasaki
en-aut-mei=Yukio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=MatsubaraTsukasa
en-aut-sei=Matsubara
en-aut-mei=Tsukasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=MochidaYuichi
en-aut-sei=Mochida
en-aut-mei=Yuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=KanbeKatsuaki
en-aut-sei=Kanbe
en-aut-mei=Katsuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=NakagawaNatsuko
en-aut-sei=Nakagawa
en-aut-mei=Natsuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=MurataKoichi
en-aut-sei=Murata
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=MomoharaShigeki
en-aut-sei=Momohara
en-aut-mei=Shigeki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

affil-num=1
en-affil=Department of Orthopaedic Surgery, Kurashiki Central Hospital
kn-affil=

affil-num=2
en-affil=Department of Rheumatology, Niigata Rheumatic Center
kn-affil=

affil-num=3
en-affil=Department of Orthopaedic Surgery, Osaka Minami Medical Center
kn-affil=

affil-num=4
en-affil=Department of Orthopaedic Surgery, International University of Health and Welfare
kn-affil=

affil-num=5
en-affil=Locomotive Pain Center, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Orthopaedic Surgery, Kamagaya General Hospital
kn-affil=

affil-num=7
en-affil=Department of Orthopaedic Surgery, Osaka University Faculty of Medicine Graduate School of Medicine
kn-affil=

affil-num=8
en-affil=Department of Orthopaedic Surgery, Nagoya University Hospital
kn-affil=

affil-num=9
en-affil=Department of Orthopaedic Surgery, University of Tokyo
kn-affil=

affil-num=10
en-affil=Department of Orthopaedic Surgery, Toho University Omori Medical Center
kn-affil=

affil-num=11
en-affil=Department of Orthopaedic Surgery and Rehabilitation, Toho University Sakura Medical Center
kn-affil=

affil-num=12
en-affil=Department of Orthopaedic Surgery, Nagoya Medical Center
kn-affil=

affil-num=13
en-affil=Department of Rehabilitation Medicine, Kanazawa Medical University
kn-affil=

affil-num=14
en-affil=The Center for Rheumatic Diseases, Nara Medical University
kn-affil=

affil-num=15
en-affil=Department of Orthopaedic Surgery, Kyushu Medical Center
kn-affil=

affil-num=16
en-affil=Department of Orthopaedic Surgery, Kyushu University
kn-affil=

affil-num=17
en-affil=Department of Orthopaedic Surgery, Matsubara Mayflower Hospital
kn-affil=

affil-num=18
en-affil=Department of Orthopaedic Surgery, Yokohama City University Medical Center
kn-affil=

affil-num=19
en-affil=Department of Orthopaedic Surgery, Nippori Orthopaedics and Rheumatic Clinic
kn-affil=

affil-num=20
en-affil=Department of Orthopaedic Surgery, Kakogawa Medical Center
kn-affil=

affil-num=21
en-affil=Department of Orthopaedic Surgery, Kyoto University Graduate School of Medicine
kn-affil=

affil-num=22
en-affil=Endowed Course for Advanced Therapy for Musculoskeletal Disorders, Keio University School of Medicine
kn-affil=
en-keyword=Rheumatoid arthritis
kn-keyword=Rheumatoid arthritis
en-keyword=Orthopaedic surgery
kn-keyword=Orthopaedic surgery
en-keyword=DMARD
kn-keyword=DMARD
en-keyword=Perioperative complications
kn-keyword=Perioperative complications
END

start-ver=1.4
cd-journal=joma
no-vol=26
cd-vols=
no-issue=19
article-no=
start-page=9630
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251002
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Critical Requirement of Senescence-Associated CCN3 Expression in CD44-Positive Stem Cells for Osteoarthritis Progression
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Osteoarthritis (OA) is a degenerative joint disease characterized by progressive cartilage breakdown, synovial inflammation, and subchondral bone remodeling. Previous studies have shown that cellular communication network factor 3 (CCN3) expression increases with age in cartilage, and its overexpression promotes OA-like changes by inducing senescence-associated secretory phenotypes. This study aimed to investigate the effect of Ccn3 knockout (KO) on OA development using a murine OA model. Destabilization of the medial meniscus (DMM) surgery was performed in wild-type (WT) and Ccn3-KO mice. Histological scoring and staining were used to assess cartilage degeneration and proteoglycan loss. Gene and protein expressions of catabolic enzyme (Mmp9), hypertrophic chondrocyte marker (Col10a1), senescence marker, and cyclin-dependent kinase inhibitor 1A (Cdkn1a) were evaluated. Single-cell RNA sequencing (scRNA-seq) data from WT and Sox9-deficient cartilage were reanalyzed to identify Ccn3+ progenitor populations. Immunofluorescence staining assessed CD44 and Ki67 expression in articular cartilage. The effects of Ccn3 knockdown on IL-1β-induced Mmp13 and Adamts5 expression in chondrocytes were examined in vitro. Ccn3 KO mice exhibited reduced cartilage degradation and catabolic gene expression compared with WT mice post-DMM. scRNA-seq revealed enriched Ccn3-Cd44 double-positive cells in osteoblast progenitor, synovial mesenchymal stem cell, and mesenchymal stem cell clusters. Immunofluorescence showed increased CCN3+/CD44+ cells in femoral and tibial cartilage and meniscus. Ki67+ cells were significantly increased in DMM-treated Ccn3 KO cartilage, mostly CD44+. In vitro Ccn3 knockdown attenuated IL-1β-induced Mmp13 and Adamts5 expressions in chondrocytes. Ccn3 contributes to OA pathogenesis by promoting matrix degradation, inducing hypertrophic changes, and restricting progenitor cell proliferation, highlighting Ccn3 as a potential therapeutic target for OA.
en-copyright=
kn-copyright=

en-aut-name=HabumugishaJanvier
en-aut-sei=Habumugisha
en-aut-mei=Janvier
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OkudaRyuichiro
en-aut-sei=Okuda
en-aut-mei=Ryuichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HiroseKazuki
en-aut-sei=Hirose
en-aut-mei=Kazuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KuwaharaMiho
en-aut-sei=Kuwahara
en-aut-mei=Miho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=WangZiyi
en-aut-sei=Wang
en-aut-mei=Ziyi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OnoMitsuaki
en-aut-sei=Ono
en-aut-mei=Mitsuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KamiokaHiroshi
en-aut-sei=Kamioka
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KubotaSatoshi
en-aut-sei=Kubota
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HattoriTakako
en-aut-sei=Hattori
en-aut-mei=Takako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Molecular Biology and Biochemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Oral Rehabilitation and Regenerative Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Orthodontics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=articular
kn-keyword=articular
en-keyword=cartilage
kn-keyword=cartilage
en-keyword=mesenchymal stem cells
kn-keyword=mesenchymal stem cells
en-keyword=nephroblastoma overexpressed protein
kn-keyword=nephroblastoma overexpressed protein
en-keyword=osteoarthritis
kn-keyword=osteoarthritis
END

start-ver=1.4
cd-journal=joma
no-vol=14
cd-vols=
no-issue=12
article-no=
start-page=1455
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251203
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Roles of ROS and NO in Plant Responses to Individual and Combined Salt Stress and Waterlogging
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=During the climate change era, plants are increasingly exposed to multiple environmental challenges occurring simultaneously or sequentially. Among these, salt stress and waterlogging are two major factors that severely constrain crop productivity worldwide and often occur together. To survive under such conditions, plants have evolved sophisticated systems to scavenge harmful levels of reactive oxygen species (ROS). Despite their cytotoxic potential, ROS also act as key signaling molecules that interact with nitric oxide (NO), Ca2+, protein kinases, ion homeostasis pathways, and plant hormones. These signaling and acclimatory mechanisms are closely associated with the functions of energy-regulating organelles?chloroplasts and mitochondria?which are major sources of ROS under both individual and combined stresses. While many of these responses are shared between salt stress, waterlogging and their combination, it is likely that specific signaling mechanisms are uniquely activated when both stresses occur together?mechanisms that cannot be inferred from responses to each stress alone. Such specificity may depend on precise coordination among organelle-derived signals and the tight regulation of their cross-communication. Within this network, ROS and NO likely serve as central hubs, fine-tuning the integration of multiple signaling pathways that enable plants to adapt to complex and fluctuating stress environments.
en-copyright=
kn-copyright=

en-aut-name=AneeTaufika Islam
en-aut-sei=Anee
en-aut-mei=Taufika Islam
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SewelamNasser A.
en-aut-sei=Sewelam
en-aut-mei=Nasser A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=BautistaNonnatus S.
en-aut-sei=Bautista
en-aut-mei=Nonnatus S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HirayamaTakashi
en-aut-sei=Hirayama
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SuzukiNobuhiro
en-aut-sei=Suzuki
en-aut-mei=Nobuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of Materials and Life Sciences, Faculty of Science and Technology, Sophia University
kn-affil=

affil-num=2
en-affil=Botany Department, Faculty of Science, Tanta University
kn-affil=

affil-num=3
en-affil=Institute of Biological Sciences, College of Arts and Sciences, University of the Philippines Los Ba?os
kn-affil=

affil-num=4
en-affil=Institute of Plant Science and Resources, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Materials and Life Sciences, Faculty of Science and Technology, Sophia University
kn-affil=
en-keyword=chloroplasts
kn-keyword=chloroplasts
en-keyword=mitochondria
kn-keyword=mitochondria
en-keyword=nitric oxide (NO)
kn-keyword=nitric oxide (NO)
en-keyword=reactive oxygen species (ROS)
kn-keyword=reactive oxygen species (ROS)
en-keyword=salt stress
kn-keyword=salt stress
en-keyword=stress combination waterlogging
kn-keyword=stress combination waterlogging
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251127
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Avoiding splenectomy in splenic sclerosing angiomatoid nodular transformation through endoscopic ultrasound-guided tissue acquisition: a 36-month follow-up case report
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=A 48-mm splenic mass was incidentally discovered in a 78-year-old man upon computed tomography. Follow-up imaging at 12 months revealed enlargement to 60 mm, prompting endoscopic ultrasound-guided tissue acquisition with a 22-gauge needle. Histopathological analysis confirmed that it was a sclerosing angiomatoid nodular transformation. The patient was asymptomatic and had no hematologic abnormalities; therefore, splenectomy was not performed. After biopsy, the lesion regressed from 60 mm to 46 mm, possibly owing to hematoma formation or vascular disruption, and remained stable during 36 months of follow-up. Although splenectomy has been performed in most reported cases of sclerosing angiomatoid nodular transformation because of diagnostic uncertainty, a few recent reports have demonstrated that sclerosing angiomatoid nodular transformation can be diagnosed by endoscopic ultrasound-guided tissue acquisition, thereby avoiding splenectomy. This case highlights the diagnostic utility of endoscopic ultrasound-guided tissue acquisition and supports spleen-preserving management for biopsy-proven sclerosing angiomatoid nodular transformation.
en-copyright=
kn-copyright=

en-aut-name=OkuyamaTakaki
en-aut-sei=Okuyama
en-aut-mei=Takaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MatsumotoKazuyuki
en-aut-sei=Matsumoto
en-aut-mei=Kazuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MorimotoKosaku
en-aut-sei=Morimoto
en-aut-mei=Kosaku
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KimuraShogo
en-aut-sei=Kimura
en-aut-mei=Shogo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MiyakeTakayoshi
en-aut-sei=Miyake
en-aut-mei=Takayoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=SatomiTakuya
en-aut-sei=Satomi
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TakeiKensuke
en-aut-sei=Takei
en-aut-mei=Kensuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=InoueShogo
en-aut-sei=Inoue
en-aut-mei=Shogo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TakenakaRyuta
en-aut-sei=Takenaka
en-aut-mei=Ryuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Internal Medicine, Tsuyama Chuo Hospital
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Internal Medicine, Tsuyama Chuo Hospital
kn-affil=

affil-num=4
en-affil=Department of Internal Medicine, Tsuyama Chuo Hospital
kn-affil=

affil-num=5
en-affil=Department of Pathology, Tsuyama Chuo Hospital
kn-affil=

affil-num=6
en-affil=Department of Internal Medicine, Tsuyama Chuo Hospital
kn-affil=

affil-num=7
en-affil=Department of Internal Medicine, Tsuyama Chuo Hospital
kn-affil=

affil-num=8
en-affil=Department of Internal Medicine, Tsuyama Chuo Hospital
kn-affil=

affil-num=9
en-affil=Department of Internal Medicine, Tsuyama Chuo Hospital
kn-affil=
en-keyword=Sclerosing angiomatoid nodular transformation
kn-keyword=Sclerosing angiomatoid nodular transformation
en-keyword=Spleen
kn-keyword=Spleen
en-keyword=Endoscopic ultrasound-guided tissue acquisition
kn-keyword=Endoscopic ultrasound-guided tissue acquisition
en-keyword=Conservative management
kn-keyword=Conservative management
en-keyword=Biopsy
kn-keyword=Biopsy
END

start-ver=1.4
cd-journal=joma
no-vol=64
cd-vols=
no-issue=6
article-no=
start-page=104265
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202512
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Novel leukocytapheresis method using highly concentrated sodium citrate solution for the manufacturing of tisagenlecleucel
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=For the manufacturing of tisagenlecleucel (tisa-cel) requires the non-mobilized mononuclear cell collection (MNC). CD3+ cell collection is performed using the same protocol as autologous peripheral blood stem cell harvest (auto-PBSCH), but this procedure necessitates the same target CD3+ cell yields regardless of age or body weight, which may take several days especially in pediatric and small female patients with low white blood cell counts. We previously demonstrated a novel method using highly concentration sodium citrate (HSC), which reduced the need for an anticoagulant (AC) solution and shortened the procedure time in auto-PBSCH. This novel method was expected to offer advantages for smaller patients, prompting us to investigate its application in leukocytapheresis for the manufacturing of tisa-cel. We retrospectively analyzed consecutive leukocytapheresis data obtained using Spectra Optia continuous MNC mode between November 2022 and June 2024 at our institution (n?=?9). In six of nine patients, pre-leukocytapheresis CD3+ cell counts were less than 500 /μL, but all could obtain the target CD3+ cell yields in one day upon processing blood volume adjustment. When we compared patients who had received CD3+ cell collection using normal-concentration sodium citrate (NSC) as our previously reported using propensity score-matched pair analysis, the total AC solution volume was significantly lower (1168 vs. 316?mL, p?<?0.001) and procedure time was significantly shorter (254 vs. 228?min, p?=?0.04) in the HSC group compared to the NSC group. In conclusion, this procedure was also useful for non-mobilized MNC. Our findings warrant validation in a larger patient cohort.
en-copyright=
kn-copyright=

en-aut-name=KitamuraWataru
en-aut-sei=Kitamura
en-aut-mei=Wataru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FujiiKeiko
en-aut-sei=Fujii
en-aut-mei=Keiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=AbeMasaya
en-aut-sei=Abe
en-aut-mei=Masaya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IkeuchiKazuhiro
en-aut-sei=Ikeuchi
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=WashioKana
en-aut-sei=Washio
en-aut-mei=Kana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OtsukaFumio
en-aut-sei=Otsuka
en-aut-mei=Fumio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MaedaYoshinobu
en-aut-sei=Maeda
en-aut-mei=Yoshinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=FujiiNobuharu
en-aut-sei=Fujii
en-aut-mei=Nobuharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Pediatrics, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Division of Clinical Laboratory, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=
en-keyword=Chimeric antigen receptor T cell therapy
kn-keyword=Chimeric antigen receptor T cell therapy
en-keyword=Anticoagulant
kn-keyword=Anticoagulant
en-keyword=Acid citrate dextrose solution A
kn-keyword=Acid citrate dextrose solution A
en-keyword=Highly concentrated sodium citrate
kn-keyword=Highly concentrated sodium citrate
END

start-ver=1.4
cd-journal=joma
no-vol=17
cd-vols=
no-issue=8
article-no=
start-page=e90112
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250814
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Conversion to Hip Arthroplasty After Internal Fixation Failure in an Intertrochanteric Femoral Fracture: A Case Report
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Intertrochanteric femoral fractures are mainly managed by internal fixation. However, failures such as over-telescoping, cut-out, nonunion, or implant failure can occur, especially in osteoporotic elderly patients. We report the case of a patient in whom we performed artificial hip replacement surgery after fixation failure following internal fixation of an intertrochanteric femoral fracture. We report the case of an 85-year-old woman who sustained a left intertrochanteric femoral fracture treated with a dynamic hip screw (DHS). One week postoperatively, radiographs revealed over-telescoping of the lag screw. The patient did not complain of pain, but she underwent conversion to cemented bipolar hemiarthroplasty under general anesthesia. One possible cause of over-telescoping of the lag screw after surgery was that the longitudinal fracture line in the calcar of the proximal bone fragment, as seen in the initial CT image, may have extended horizontally at the neck level. During surgery, a fracture at the same site caused the anterior medial fragment to fail, resulting in a coronal shear fracture and fixation failure. When a longitudinal fracture line is observed in the calcar of the proximal fragment, it is necessary to keep in mind that it may extend horizontally at the neck level.
en-copyright=
kn-copyright=

en-aut-name=FukuokaShiro
en-aut-sei=Fukuoka
en-aut-mei=Shiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=InoueTomoo
en-aut-sei=Inoue
en-aut-mei=Tomoo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakahashiMotoki
en-aut-sei=Takahashi
en-aut-mei=Motoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KawasakiKeisuke
en-aut-sei=Kawasaki
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OzakiToshifumi
en-aut-sei=Ozaki
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of Orthopedics, Kagawa Prefectural Central Hospital
kn-affil=

affil-num=2
en-affil=Department of Orthopedics, Kagawa Prefectural Central Hospital
kn-affil=

affil-num=3
en-affil=Department of Orthopedics, Kagawa Prefectural Central Hospital
kn-affil=

affil-num=4
en-affil=Department of Orthopedic Surgery, Kagawa Prefectural Central Hospital
kn-affil=

affil-num=5
en-affil=Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
kn-affil=
en-keyword=arthroplasty
kn-keyword=arthroplasty
en-keyword=coronal shear fracture
kn-keyword=coronal shear fracture
en-keyword=double jaws sign
kn-keyword=double jaws sign
en-keyword=fixation failure
kn-keyword=fixation failure
en-keyword=intertrochanteric femoral fracture
kn-keyword=intertrochanteric femoral fracture
END

start-ver=1.4
cd-journal=joma
no-vol=17
cd-vols=
no-issue=3
article-no=
start-page=e80656
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250316
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Case of Charcot Spine Arthropathy at the Lumbosacral Level in a Patient With Ankylosis of the Spine
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Charcot spinal arthropathy, a rare refractory progressive disease, is characterized by symptoms such as pain, deformity, and neurological impairment, which can significantly reduce functional ability, quality of life, and life expectancy. We report a case of Charcot spine at the L5/S1 level with long segment ankylosis to the L5 vertebra. We first performed thorough debridement via a posterior approach. We used antibiotic-containing cement as a spacer to fill the dead space, facilitating the second surgery approach. In the second surgery, transdiscal screws, which have a low profile and strong force, were used as anchors, and bulk bone harvested from both iliac bones was grafted to the intervertebral space. The lumbosacral alignment was kyphotic, and the patient could sit and move independently. Disimpaction was impossible, and a stoma had to be created.
en-copyright=
kn-copyright=

en-aut-name=OdaYoshiaki
en-aut-sei=Oda
en-aut-mei=Yoshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=UotaniKoji
en-aut-sei=Uotani
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TetsunagaTomoko
en-aut-sei=Tetsunaga
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ShinoharaKensuke
en-aut-sei=Shinohara
en-aut-mei=Kensuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OzakiToshifumi
en-aut-sei=Ozaki
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of Orthopedic Surgery, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Musculoskeletal Traumatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Orthopedic Surgery, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Orthopedic Surgery, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Orthopedic Surgery, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=ankylosing spine
kn-keyword=ankylosing spine
en-keyword=charcot spine
kn-keyword=charcot spine
en-keyword=charcot spine arthropathy
kn-keyword=charcot spine arthropathy
en-keyword=lumbosacral segment
kn-keyword=lumbosacral segment
en-keyword=paraplegia
kn-keyword=paraplegia
en-keyword=transdiscal screw
kn-keyword=transdiscal screw
END

start-ver=1.4
cd-journal=joma
no-vol=17
cd-vols=
no-issue=1
article-no=
start-page=e77632
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250118
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Mid-term Clinical and Radiographic Outcomes of the Actis Total Hip System: A Retrospective Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Introduction<br>
Implant technology for total hip arthroplasty (THA) was developed to improve hip function and patient satisfaction. Actis (DePuy Synthes, Warsaw, IN, USA) is a short fit-and-fill titanium stem, with a medial-collared and triple-taper (MCTT) geometry, that is fully coated with hydroxyapatite (HA). We evaluated the radiographic and clinical outcomes of the Actis Total Hip System during a mean follow-up of five years.<br>
Patients and methods<br>
We retrospectively analyzed data from 80 patients (14 male and 66 female, mean age: 65 ± 8.4 years) who underwent primary THA using Actis stems (anterolateral approach, 60 hips; posterior approach, 20 hips). Radiographs were obtained postoperatively and at the time of the final examination. Radiographic assessments included the alignment of the femoral stem, spot welds, stress shielding, cortical hypertrophy, subsidence (>2 mm), radiolucent line, pedestal formation, Dorr type, canal fill ratio (CFR), and stem fixation. Clinical evaluation included the Japanese Orthopaedic Association Hip-Disease Evaluation Questionnaire (JHEQ) and Harris Hip Score (HHS).<br>
Results<br>
The mean follow-up period was 64.0 ± 6.0 months. No significant differences were observed in the alignment of the femoral components between approaches. Of the 80 hips, 53 (66.3%) showed radiographic signs of stem osseointegration, predominantly in the mid-distal region of the stem at the final follow-up. Multiple logistic regression analysis revealed that younger age and a higher CFR (20 mm proximal to the lesser trochanter) were associated with the presence of spot welds. Mild stress shielding occurred in 25 hips (31.3%), and no patient experienced severe stress shielding. All stems were fixed by bone on growth. The JHEQ and HHS significantly improved at the final assessment.<br>
Conclusion<br>
At the five-year follow-up, patients who received the Actis Total Hip System during THA had good radiographic and clinical outcomes.<br>
en-copyright=
kn-copyright=

en-aut-name=MasadaYasutaka
en-aut-sei=Masada
en-aut-mei=Yasutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TetsunagaTomonori
en-aut-sei=Tetsunaga
en-aut-mei=Tomonori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YamadaKazuki
en-aut-sei=Yamada
en-aut-mei=Kazuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KouraTakashi
en-aut-sei=Koura
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=InoueTomohiro
en-aut-sei=Inoue
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OkudaRyuichiro
en-aut-sei=Okuda
en-aut-mei=Ryuichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TetsunagaTomoko
en-aut-sei=Tetsunaga
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YokoyamaYusuke
en-aut-sei=Yokoyama
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OkazakiYuki
en-aut-sei=Okazaki
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=OzakiToshifumi
en-aut-sei=Ozaki
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Medical Materials for Musculoskeletal Reconstruction, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Musculoskeletal Health Promotion, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Medical Materials for Musculoskeletal Reconstruction, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Medical Materials for Musculoskeletal Reconstruction, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Medical Materials for Musculoskeletal Reconstruction, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Department of Orthopaedic Surgery, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Department of Orthopaedic Surgery, Okayama University Hospital
kn-affil=

affil-num=9
en-affil=Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=10
en-affil=Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=actis
kn-keyword=actis
en-keyword=hydroxyapatite
kn-keyword=hydroxyapatite
en-keyword=mid-term outcome
kn-keyword=mid-term outcome
en-keyword=spot welds
kn-keyword=spot welds
en-keyword=stem
kn-keyword=stem
en-keyword=total hip arthroplasty
kn-keyword=total hip arthroplasty
END

start-ver=1.4
cd-journal=joma
no-vol=145
cd-vols=
no-issue=1
article-no=
start-page=373
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250715
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Changes in the anatomical positions of the femoral nerve and artery in the lateral and supine positions: a multicenter retrospective study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Introduction Femoral nerve palsy and femoral artery injury are serious complications of total hip arthroplasty. However, few studies have compared the anatomical positions of these structures in different patient positions. This study aimed to compare the anatomical positions of the femoral nerve and artery in the lateral and supine positions.<br>
Materials and methods This multicenter retrospective study included 111 patients who underwent lateral and supine computed tomography (CT) from 2016 to 2023. CT images were reconstructed in the anterior pelvic plane. The horizontal distance from the anterior margin of the acetabulum to the femoral nerve (Distance N) and femoral artery (Distance A) was measured. The difference in Distance N between the two positions (ΔLateral?supine Distance N) was calculated by subtracting the supine value from the lateral value.<br>
Results The average Distance N was 26.5?±?5.1 mm in the lateral position and 21.1?±?4.4 mm in the supine position, with the nerve located significantly closer to the acetabulum in the supine position (P?<?0.001). Similarly, the average Distance A was 26.8?±?5.4 mm in the lateral position and 20.4?±?4.9 mm in the supine position (P?<?0.001). Multiple regression analysis showed that Distance N in the lateral position was significantly shorter in female patients and those with low body weight. In addition, low body weight correlated with a smaller ΔLateral?supine Distance N.<br>
Conclusions The femoral nerve and artery are located closer to the anterior margin of the acetabulum in the supine position than in the lateral position. Low body weight was an independent predictor of shorter Distance N in both positions and a smaller ΔLateral?supine Distance N. These findings underscore the importance of considering patient positioning during total hip arthroplasty, particularly in patients with low body weight, to reduce neurovascular risks.
en-copyright=
kn-copyright=

en-aut-name=OkudaRyuichiro
en-aut-sei=Okuda
en-aut-mei=Ryuichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TetsunagaTomonori
en-aut-sei=Tetsunaga
en-aut-mei=Tomonori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YamadaKazuki
en-aut-sei=Yamada
en-aut-mei=Kazuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TetsunagaTomoko
en-aut-sei=Tetsunaga
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KouraTakashi
en-aut-sei=Koura
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=InoueTomohiro
en-aut-sei=Inoue
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MasadaYasutaka
en-aut-sei=Masada
en-aut-mei=Yasutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YamamotoTetsuya
en-aut-sei=Yamamoto
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MatsumotoShin
en-aut-sei=Matsumoto
en-aut-mei=Shin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=IkumaHisanori
en-aut-sei=Ikuma
en-aut-mei=Hisanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KomatsubaraTadashi
en-aut-sei=Komatsubara
en-aut-mei=Tadashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=OkazakiYuki
en-aut-sei=Okazaki
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=OzakiToshifumi
en-aut-sei=Ozaki
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

affil-num=1
en-affil=Department of Orthopaedic Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=2
en-affil=Department of Musculoskeletal Health Promotion, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Medical Materials for Musculoskeletal Reconstruction, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Sports Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Orthopaedic Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=6
en-affil=Department of Orthopaedic Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=7
en-affil=Department of Orthopaedic Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=8
en-affil=Department of Orthopaedic Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=9
en-affil=Department of Orthopaedic Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=10
en-affil=Department of Orthopaedic Surgery, Kagawa Prefectural Central Hospital
kn-affil=

affil-num=11
en-affil=Department of Orthopaedic Surgery, Okayama Rosai Hospital
kn-affil=

affil-num=12
en-affil=Department of Orthopaedic Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=13
en-affil=Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=Total hip arthroplasty
kn-keyword=Total hip arthroplasty
en-keyword=Femoral artery
kn-keyword=Femoral artery
en-keyword=Femoral nerve
kn-keyword=Femoral nerve
en-keyword=Computed tomography
kn-keyword=Computed tomography
en-keyword=Lateral position
kn-keyword=Lateral position
en-keyword=Supine position
kn-keyword=Supine position
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=小胞型グルタミン酸輸送体3はポドサイトにおけるグルタミン酸を用いた細胞間シグナル伝達に関与する
kn-title=Vesicular Glutamate Transporter 3 Is Involved in Glutamatergic Signalling in Podocytes
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=NISHIINaoko
en-aut-sei=NISHII
en-aut-mei=Naoko
kn-aut-name=西井尚子
kn-aut-sei=西井
kn-aut-mei=尚子
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=急性鶏コクシジウム症感染早期におけるγδ T細胞の機能的役割に関する研究
kn-title=Studies on the functional roles of γδ T cells in the early phase of acute avian coccidiosis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=LE VIET QUAN
en-aut-sei=LE VIET QUAN
en-aut-mei=
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=岡山大学大学院環境生命科学研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=CaF2結晶ホスト中におけるトリウム229アイソマー状態のX線誘起消光
kn-title=The X-ray induced quenching of the thorium-229 isomer states in a CaF2 crystal host
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=GuanMing
en-aut-sei=Guan
en-aut-mei=Ming
kn-aut-name=管明
kn-aut-sei=管
kn-aut-mei=明
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Natural Science and Technology, Okayama university
kn-affil=岡山大学大学院自然科学研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=リン酸カルシウム共沈殿を活用した消化管内カドミウム除去
kn-title=Co-precipitating calcium phosphate as oral detoxification of cadmium
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=BIKHARUDINAHMAD
en-aut-sei=BIKHARUDIN
en-aut-mei=AHMAD
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=垂直的骨格パターンの異なる成人における軟口蓋および気道内腔寸法に基づく上気道容積の臨床的予測モデル
kn-title=Clinical Prediction Models for Upper Airway Volume Based on Soft Palate and Airway Lumen Dimensions in Adults With Varying Vertical Skeletal Patterns
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=HABUMUGISHA JANVIER
en-aut-sei=HABUMUGISHA JANVIER
en-aut-mei=
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=歯小?と歯根膜の細胞が高分化型口腔扁平上皮癌の骨浸潤におよぼす影響
kn-title=Impacts of Dental Follicle Cells and Periodontal Ligament Cells on the Bone Invasion of Well-Differentiated Oral Squamous Cell Carcinoma
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=CHANGANQI
en-aut-sei=CHANG
en-aut-mei=ANQI
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=COVID-19罹患後症状における血糖測定の予後への影響：日本での後方視的研究
kn-title=Importance of Blood Glucose Measurement for Predicting the Prognosis of Long COVID：A Retrospective Study in Japan
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=YOKOYAMASho
en-aut-sei=YOKOYAMA
en-aut-mei=Sho
kn-aut-name=横山将
kn-aut-sei=横山
kn-aut-mei=将
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=ブドウ球菌巨大ファージS6由来エンドライシンS6_ORF93のリンカー短縮変異体における生産性、溶菌活性および冷所保存性の検討
kn-title=Examination of yield, bacteriolytic activity and cold storage of linker deletion mutants based on endolysin S6_ORF93 derived from Staphylococcus giant bacteriophage S6
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=MUNETOMOSosuke
en-aut-sei=MUNETOMO
en-aut-mei=Sosuke
kn-aut-name=宗友荘介
kn-aut-sei=宗友
kn-aut-mei=荘介
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Treg細胞の高い抗原性は、Treg細胞における高いPD-1発現を介してPD-1ブロック療法に対する抵抗性を与える
kn-title=High Antigenicity for Treg Cells Confers Resistance to PD-1 Blockade Therapy via High PD-1 Expression in Treg Cells
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=MATSUURAHiroaki
en-aut-sei=MATSUURA
en-aut-mei=Hiroaki
kn-aut-name=松浦宏昌
kn-aut-sei=松浦
kn-aut-mei=宏昌
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=体細胞変異による腫瘍浸潤リンパ球の活性化
kn-title=Somatic mutations in tumor-infiltrating lymphocytes impact on antitumor immunity?
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=MUKOHARAFumiaki
en-aut-sei=MUKOHARA
en-aut-mei=Fumiaki
kn-aut-name=向原史晃
kn-aut-sei=向原
kn-aut-mei=史晃
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=小腸腺癌における相同組換え修復遺伝子変異のゲノムプロファイルと臨床的影響
kn-title=Genomic landscape and clinical impact of homologous recombination repair gene mutation in small bowel adenocarcinoma
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=OZATOToshiki
en-aut-sei=OZATO
en-aut-mei=Toshiki
kn-aut-name=大里俊樹
kn-aut-sei=大里
kn-aut-mei=俊樹
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Japanese title：食道扁平上皮癌の予後因子としての特異的形態を有する腫瘍微小血管
kn-title=Tumor microvessels with specific morphology as a prognostic factor in esophageal squamous cell carcinoma
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=HNIN THIDA TUN
en-aut-sei=HNIN THIDA TUN
en-aut-mei=
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=活動性食欲不振モデルマウスにおける前頭前野および海馬におけるペリニューロナルネットおよびパルブアルブミン介在ニューロンの変化、および血中コルチコステロンとの相関性
kn-title=Alteration of perineuronal nets and parvalbumin interneurons in prefrontal cortex and hippocampus, and correlation with blood corticosterone in activity-based anorexia model mice
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=NGUYEN DUY HOANG
en-aut-sei=NGUYEN DUY HOANG
en-aut-mei=
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=膵癌において腫瘍関連線維芽細胞の影響を受けた好中球はIL-8を介して腫瘍促進的なはたらきを行う
kn-title=Cancer?associated fibroblasts promote pro?tumor functions of neutrophils in pancreatic cancer via IL?8: potential suppression by pirfenidon
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=YAGITomohiko
en-aut-sei=YAGI
en-aut-mei=Tomohiko
kn-aut-name=八木朝彦
kn-aut-sei=八木
kn-aut-mei=朝彦
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=ADAR1高発現の腫瘍関連マクロファージは化学療法を誘導しており、治療標的となる可能性がある
kn-title=ADAR1-high tumor-associated macrophages induce drug resistance and are therapeutic targets in colorectal cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=OTSUKI (UMEDA)Hibiki
en-aut-sei=OTSUKI (UMEDA)
en-aut-mei=Hibiki
kn-aut-name=大槻（梅田）響
kn-aut-sei=大槻（梅田）
kn-aut-mei=響
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=EGFRとMETを標的とする二重特異性抗体であるアミバンタマブのALK融合遺伝子陽性非小細胞肺癌細胞株に対する有効性
kn-title=Efficacy of amivantamab, a bi-specific antibody targeting EGFR and MET, in ALK-rearranged non-small-cell lung cancer cell lines
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=NISHITatsuya
en-aut-sei=NISHI
en-aut-mei=Tatsuya
kn-aut-name=西達也
kn-aut-sei=西
kn-aut-mei=達也
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=HIF-PH阻害剤はT細胞に擬似低酸素状態を誘導し、抗腫瘍免疫応答を増強することでマイクロサテライト安定型大腸癌の増殖を抑制する
kn-title=HIF‐PH inhibitors induce pseudohypoxia in T cells and suppress the growth of microsatellite stable colorectal cancer by enhancing antitumor immune responses
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=CHENYUEHUA
en-aut-sei=CHEN
en-aut-mei=YUEHUA
kn-aut-name=?悦?
kn-aut-sei=?
kn-aut-mei=悦?
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=突発性難聴に対するサルベージ療法としてのステロイド鼓室内注入の応用
kn-title=Application of intratympanic steroid injection as salvage therapy for idiopathic sudden sensorineural hearing loss
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=KOMATSUBARAYasutoshi
en-aut-sei=KOMATSUBARA
en-aut-mei=Yasutoshi
kn-aut-name=小松原靖聡
kn-aut-sei=小松原
kn-aut-mei=靖聡
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=関連線維芽細胞が誘導するインターロイキン6を標的とした胃癌腹膜転移に対する新規治療戦略
kn-title=Novel treatment strategy targeting interleukin-6 induced by cancer associated fibroblasts for peritoneal metastasis of gastric cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=MITSUIEma
en-aut-sei=MITSUI
en-aut-mei=Ema
kn-aut-name=光井恵麻
kn-aut-sei=光井
kn-aut-mei=恵麻
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=中枢神経原発リンパ腫における形質芽細胞様リンパ腫細胞のシングルセル並びに空間解析
kn-title=Single-cell and spatial characterization of plasmablast-like lymphoma cells in primary central nervous system lymphoma
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=KOBAYASHIHiroki
en-aut-sei=KOBAYASHI
en-aut-mei=Hiroki
kn-aut-name=小林宏紀
kn-aut-sei=小林
kn-aut-mei=宏紀
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=抗石灰化グルタールアルデヒド処置を施した三次元培養軟骨組織の物理的特性の評価と加工
kn-title=Evaluation and processing of physical properties of anti-calcified glutaraldehyde-treated three-dimensional cultured cartilage tissues
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=KITAGUCHIYohei
en-aut-sei=KITAGUCHI
en-aut-mei=Yohei
kn-aut-name=北口陽平
kn-aut-sei=北口
kn-aut-mei=陽平
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=3つの非侵襲的マーカーの組み合わせによるクローン病における内視鏡的寛解の効果的な診断
kn-title=Efficient diagnosis for endoscopic remission in Crohn’s diseases by the combination of three non-invasive markers
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=TAKEIKensuke
en-aut-sei=TAKEI
en-aut-mei=Kensuke
kn-aut-name=竹井健介
kn-aut-sei=竹井
kn-aut-mei=健介
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=経口タクロリムスによる導入療法は、血清アルブミン値が低いにもかかわらず、チオプリン未投与の難治性潰瘍性大腸炎患者に長期的な利益をもたらす
kn-title=Induction Therapy With Oral Tacrolimus Provides Long-Term Benefit in Thiopurine-Na?ve Refractory Ulcerative Colitis Patients Despite Low Serum Albumin Levels
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=IGAWAShoko
en-aut-sei=IGAWA
en-aut-mei=Shoko
kn-aut-name=井川翔子
kn-aut-sei=井川
kn-aut-mei=翔子
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=骨肉腫細胞由来CCL2による腫瘍関連マクロファージ集積を介した肺転移促進機序
kn-title=Osteosarcoma cell?derived CCL2 facilitates lung metastasis via accumulation of tumor-associated macrophages
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=KONDOHiroya
en-aut-sei=KONDO
en-aut-mei=Hiroya
kn-aut-name=近藤宏也
kn-aut-sei=近藤
kn-aut-mei=宏也
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=乳幼児期のBMI変化と学童期喘息有症率の関係：性別と喘息フェノタイプによる分類
kn-title=Changes in body mass index during early childhood on school-age asthma prevalence classified by phenotypes and sex
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=YABUUCHIToshihiko
en-aut-sei=YABUUCHI
en-aut-mei=Toshihiko
kn-aut-name=籔内俊彦
kn-aut-sei=籔内
kn-aut-mei=俊彦
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=血管新生を誘導した皮下組織への膵島移植による生着率および機能の改善：マウスモデルによる検討
kn-title=Grafting Islets to a Prevascularized Subcutaneous Site to Improve Transplant Survival and Function: A Mouse Model
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=OKADATsuyoshi
en-aut-sei=OKADA
en-aut-mei=Tsuyoshi
kn-aut-name=岡田剛
kn-aut-sei=岡田
kn-aut-mei=剛
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=日本の高齢者における聴力検査と補聴器装用に影響を与える要因の探索： 難聴と認知症の関連を認識することの意義
kn-title=Exploring factors influencing the hearing test and hearing aid adoption among Japanese older adults: Implications of recognizing the hearing loss?dementia relationship
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=FUKUMASUIchiro
en-aut-sei=FUKUMASU
en-aut-mei=Ichiro
kn-aut-name=福増一郎
kn-aut-sei=福増
kn-aut-mei=一郎
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=LRP4とAgrinは軟骨変性によって調節されヒト関節軟骨細胞におけるβ-カテニンシグナル伝達に関与する
kn-title=LRP4 and Agrin Are Modulated by Cartilage Degeneration and Involved in β-Catenin Signaling in Human Articular Chondrocytes
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=NANIWAShuichi
en-aut-sei=NANIWA
en-aut-mei=Shuichi
kn-aut-name=浪花崇一
kn-aut-sei=浪花
kn-aut-mei=崇一
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=出生順位が小児アレルギー疾患に及ぼす影響： 日本における全国出生コホート
kn-title=Impact of Birth Order on Paediatric Allergic Diseases: A National Birth Cohort in Japan
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=KOBAYASHIMitsuro
en-aut-sei=KOBAYASHI
en-aut-mei=Mitsuro
kn-aut-name=小林光郎
kn-aut-sei=小林
kn-aut-mei=光郎
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=潰瘍性大腸炎において血清ロイシンリッチ α2 グリコプロテインの変化は内視鏡的および組織学的活動性の変化を予測し得るマーカーである
kn-title=Changes of leucine-rich alpha 2 glycoprotein could be a marker of changes of endoscopic and histologic activity of ulcerative colitis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=AOYAMAYuki
en-aut-sei=AOYAMA
en-aut-mei=Yuki
kn-aut-name=青山祐樹
kn-aut-sei=青山
kn-aut-mei=祐樹
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=慢性外傷性脳症の再現性および定量的モデル：反復性の非出血性および非挫傷性の軽度外傷性脳損傷ラットは、ミクログリアの活性化、アストログリア症、およびタウオパチーを伴い行動障害を引き起こす
kn-title=Repeated non-hemorrhagic and non-contusional mild traumatic brain injury in rats elicits behavioral impairment with microglial activation, astrogliosis, and tauopathy: Reproducible and quantitative model of chronic traumatic encephalopathy
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=SUGAHARAChiaki
en-aut-sei=SUGAHARA
en-aut-mei=Chiaki
kn-aut-name=菅原千明
kn-aut-sei=菅原
kn-aut-mei=千明
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=61
cd-vols=
no-issue=6
article-no=
start-page=973
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250524
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Accuracy Verification of a Computed Tomography-Based Navigation System for Total Hip Arthroplasty in Severe Hip Dysplasia: A Simulation Study Using 3D-Printed Bone Models of Crowe Types II, III, and IV
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background and Objective: The use of computed tomography (CT)-based navigation systems has been shown to improve surgical accuracy in total hip arthroplasty. However, there is limited literature available about the application of CT-based navigation systems in severe hip dysplasia. This study aimed to evaluate the accuracy of a CT-based navigation system in patients with severe hip dysplasia using three-dimensional (3D)-printed bone models. Methods: 3D-printed bone models were generated from CT data of patients with severe hip dysplasia (Crowe type II, 10 hips; type III, 10 hips; and type IV, 10 hips). The accuracy of automatic segmentation, success rate, point-matching accuracy across different registration methods, and deviation values at reference points after registration were assessed. Results: For the combined cohort of Crowe II, III, and IV cases (n = 30), the Dice Similarity Coefficient and Jaccard Index were 0.99 ± 0.01 and 0.98 ± 0.02, respectively. These values indicate a high level of segmentation accuracy. The “Matching with true and false acetabulum + iliac crest” method achieved a 100% success rate across all groups, with mean deviations of 0.08 ± 0.28 mm in the Crowe II group, 0.12 ± 0.33 mm in the Crowe III group, and 0.14 ± 0.50 mm in the Crowe IV group (p = 0.572). In the Crowe IV group, the anterior superior iliac spine deviation was significantly lower using the “Matching with true and false acetabulum + iliac crest” method compared to the “Matching with true and false acetabulum” method (0.28 ± 0.49 mm vs. 3.29 ± 2.56 mm, p < 0.05). Conclusions: This study demonstrated the high accuracy of automatic AI-based segmentation, with a Dice Similarity Coefficient of 0.99 ± 0.01 and a Jaccard Index of 0.98 ± 0.02 in the combined cohort of Crowe type II, III, and IV cases (n = 30). The matching success rate was 100%, with additional points on the iliac crest, which improved matching accuracy and reduced deviations, depending on the case.
en-copyright=
kn-copyright=

en-aut-name=OkudaRyuichiro
en-aut-sei=Okuda
en-aut-mei=Ryuichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TetsunagaTomonori
en-aut-sei=Tetsunaga
en-aut-mei=Tomonori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YamadaKazuki
en-aut-sei=Yamada
en-aut-mei=Kazuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TetsunagaTomoko
en-aut-sei=Tetsunaga
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KouraTakashi
en-aut-sei=Koura
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=InoueTomohiro
en-aut-sei=Inoue
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MasadaYasutaka
en-aut-sei=Masada
en-aut-mei=Yasutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OkazakiYuki
en-aut-sei=Okazaki
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OzakiToshifumi
en-aut-sei=Ozaki
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Musculoskeletal Health Promotion, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Orthopaedic Surgery, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Sports Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=total hip arthroplasty
kn-keyword=total hip arthroplasty
en-keyword=CT-based navigation
kn-keyword=CT-based navigation
en-keyword=bone model
kn-keyword=bone model
en-keyword=artificial intelligence
kn-keyword=artificial intelligence
en-keyword=Ortoma Treatment Solution
kn-keyword=Ortoma Treatment Solution
END

start-ver=1.4
cd-journal=joma
no-vol=17
cd-vols=
no-issue=4
article-no=
start-page=e83089
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250427
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Subcutaneous and Periorbital Emphysema Following a Dental Procedure
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Subcutaneous emphysema following dental procedures is rare. We present the case of a young, healthy woman who was transferred from a dental clinic to our emergency department due to sudden swelling of the left orbit immediately after a dental procedure involving the use of the dental air and water syringe. The diagnosis of subcutaneous facial emphysema was made based on the patient's history, physical examination, and computed tomography imaging. The patient received prophylactic amoxicillin, and the lesion resolved completely in one week. Prompt clinical suspicion and a thorough evaluation of the signs and symptoms, including a detailed clinical history, are crucial for diagnosing subcutaneous emphysema following a dental procedure.
en-copyright=
kn-copyright=

en-aut-name=ObaraTakafumi
en-aut-sei=Obara
en-aut-mei=Takafumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NojimaTsuyoshi
en-aut-sei=Nojima
en-aut-mei=Tsuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NakatsujiKazuki
en-aut-sei=Nakatsuji
en-aut-mei=Kazuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HongoTakashi
en-aut-sei=Hongo
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YumotoTetsuya
en-aut-sei=Yumoto
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NakaoAtsunori
en-aut-sei=Nakao
en-aut-mei=Atsunori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences Okayama University
kn-affil=

affil-num=2
en-affil=Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences Okayama University
kn-affil=

affil-num=3
en-affil=Department of Oral and Maxillofacial Reconstructive Surgery, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences Okayama University
kn-affil=

affil-num=5
en-affil=Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences Okayama University
kn-affil=

affil-num=6
en-affil=Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences Okayama University
kn-affil=
en-keyword=air pressure
kn-keyword=air pressure
en-keyword=antibiotic prophylaxis
kn-keyword=antibiotic prophylaxis
en-keyword=dental procedures
kn-keyword=dental procedures
en-keyword=operative
kn-keyword=operative
en-keyword=subcutaneous emphysema
kn-keyword=subcutaneous emphysema
END

start-ver=1.4
cd-journal=joma
no-vol=16
cd-vols=
no-issue=6
article-no=
start-page=1100
end-page=1111
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250327
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Relation between obesity and health disorders as revealed by the J-ORBIT clinical information collection system directly linked to electronic medical records (J-ORBIT 1)
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Aims/Introduction: Obesity triggers various health disorders, but information on these disorders in real-world settings remains limited. To address this knowledge gap, we developed a database directly linked to electronic medical records (EMRs). We here present the baseline data for this database, designated Japan Obesity Research Based on electronIc healTh Records (J-ORBIT).<br>
Materials and Methods: Individuals with obesity disease diagnosed according to the criteria of the Japan Society for the Study of Obesity were registered in J-ORBIT from seven medical centers in Japan. We analyzed the relationship between body mass index (BMI), clinical characteristics, and the prevalence of obesity-related health disorders in this cohort.<br>
Results: Data were obtained from 1,169 individuals, with a mean (±SD) age of 56.9?±?15.3?years and a BMI of 31.4?±?6.1?kg/m2. The prevalence of health disorders varied substantially across BMI categories, with a higher BMI being associated with an increased prevalence of hyperuricemia or gout, obstructive sleep apnea syndrome or obesity hypoventilation syndrome, musculoskeletal disorders, and obesity-related kidney disease, as well as with a higher frequency of both a family history of obesity and of a history of childhood obesity. Among individuals with a BMI of ?25?kg/m2, the prevalence of hypertension and dyslipidemia did not increase with BMI, whereas that of glucose intolerance decreased with increasing BMI.<br>
Conclusions: The J-ORBIT system, which collects clinical data in real time directly from EMRs, has the potential to provide insight into obesity and its associated health conditions, thereby contributing to improved care of affected individuals.
en-copyright=
kn-copyright=

en-aut-name=NishikageSeiji
en-aut-sei=Nishikage
en-aut-mei=Seiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HirotaYushi
en-aut-sei=Hirota
en-aut-mei=Yushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NakagawaYasushi
en-aut-sei=Nakagawa
en-aut-mei=Yasushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IshiiMasamichi
en-aut-sei=Ishii
en-aut-mei=Masamichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OhsugiMitsuru
en-aut-sei=Ohsugi
en-aut-mei=Mitsuru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MaedaEiichi
en-aut-sei=Maeda
en-aut-mei=Eiichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YoshimuraKai
en-aut-sei=Yoshimura
en-aut-mei=Kai
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YamamotoAkane
en-aut-sei=Yamamoto
en-aut-mei=Akane
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TakayoshiTomofumi
en-aut-sei=Takayoshi
en-aut-mei=Tomofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KatoTakehiro
en-aut-sei=Kato
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=YabeDaisuke
en-aut-sei=Yabe
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=MatsuhisaMunehide
en-aut-sei=Matsuhisa
en-aut-mei=Munehide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=EguchiJun
en-aut-sei=Eguchi
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=WadaJun
en-aut-sei=Wada
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=FujitaYukihiro
en-aut-sei=Fujita
en-aut-mei=Yukihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=KumeShinji
en-aut-sei=Kume
en-aut-mei=Shinji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=MaegawaHiroshi
en-aut-sei=Maegawa
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=MiyakeKana
en-aut-sei=Miyake
en-aut-mei=Kana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=ShojimaNobuhiro
en-aut-sei=Shojima
en-aut-mei=Nobuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=YamauchiToshimasa
en-aut-sei=Yamauchi
en-aut-mei=Toshimasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=YokoteKoutaro
en-aut-sei=Yokote
en-aut-mei=Koutaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=UekiKohjiro
en-aut-sei=Ueki
en-aut-mei=Kohjiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=MiyoKengo
en-aut-sei=Miyo
en-aut-mei=Kengo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=OgawaWataru
en-aut-sei=Ogawa
en-aut-mei=Wataru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

affil-num=1
en-affil=Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine
kn-affil=

affil-num=2
en-affil=Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine
kn-affil=

affil-num=3
en-affil=Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine
kn-affil=

affil-num=4
en-affil=Center for Medical Informatics Intelligence, National Center for Global Health and Medicine
kn-affil=

affil-num=5
en-affil=Diabetes and Metabolism Information Center, Research Institute, National Center for Global Health and Medicine
kn-affil=

affil-num=6
en-affil=Division of Medical Informatics, Department of Internal Medicine, Kobe University Graduate School of Medicine
kn-affil=

affil-num=7
en-affil=Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine
kn-affil=

affil-num=8
en-affil=Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine
kn-affil=

affil-num=9
en-affil=Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine
kn-affil=

affil-num=10
en-affil=Department of Diabetes, Endocrinology, and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine
kn-affil=

affil-num=11
en-affil=Department of Diabetes, Endocrinology, and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine
kn-affil=

affil-num=12
en-affil=Diabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences, Tokushima University
kn-affil=

affil-num=13
en-affil=Department of Nephrology, Rheumatology, Endocrinology, and Metabolism, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=14
en-affil=Department of Nephrology, Rheumatology, Endocrinology, and Metabolism, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=15
en-affil=Department of Medicine, Shiga University of Medical Science
kn-affil=

affil-num=16
en-affil=Department of Medicine, Shiga University of Medical Science
kn-affil=

affil-num=17
en-affil=Department of Medicine, Shiga University of Medical Science
kn-affil=

affil-num=18
en-affil=Department of Diabetes and Metabolic Disease, The University of Tokyo Graduate School of Medicine
kn-affil=

affil-num=19
en-affil=Department of Diabetes and Metabolic Disease, The University of Tokyo Graduate School of Medicine
kn-affil=

affil-num=20
en-affil=Department of Diabetes and Metabolic Disease, The University of Tokyo Graduate School of Medicine
kn-affil=

affil-num=21
en-affil=Chiba University
kn-affil=

affil-num=22
en-affil=Diabetes Research Center, Research Institute, National Center for Global Health and Medicine
kn-affil=

affil-num=23
en-affil=Center for Medical Informatics Intelligence, National Center for Global Health and Medicine
kn-affil=

affil-num=24
en-affil=Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine
kn-affil=
en-keyword=Body mass index
kn-keyword=Body mass index
en-keyword=Electronic medical records
kn-keyword=Electronic medical records
en-keyword=Obesity
kn-keyword=Obesity
END

start-ver=1.4
cd-journal=joma
no-vol=15
cd-vols=
no-issue=1
article-no=
start-page=5762
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250217
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Hypoglycemia and hyperinsulinemia induced by phenolic uremic toxins in CKD and DKD patients
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Patients with end-stage renal disease have lower fasting plasma glucose and HbA1c levels, with significantly higher insulin levels. For a long time, it has been believed that this higher insulin level in renal failure is due to decreased insulin clearance caused by reduced renal function. However, here we reported that accumulation of the gut microbiota-derived uremic toxin, phenyl sulfate (PS) in the renal failure, increased insulin secretion from the pancreas by enhanced glucose-stimulated insulin secretion. Other endogenous sulfides compounds which accumulated as in the renal failure also increased glucose-stimulated insulin secretion from β?-cell. With RNA-seq analyses and gene knock down, we demonstrated that insulin secretion evoked by PS was mediated by Ddah2. In addition, we also found that PS increased insulin resistance through lncRNA expression and Erk phosphorylation in the adipocytes. To confirm the relationship between PS and glucose metabolism in human, we recruited 2 clinical cohort studies (DKD and CKD) including 462 patients, and found that there was a weak negative correlation between PS and HbA1c. Because these trials did not measure fasting insulin level, we alternatively used the urinary C-peptide/creatinine ratio (UCPCR) as an indicator of insulin resistance. We found that PS may induce insulin resistance in patients with eGFR?<?60 mL/min/1.73 m2. These data suggest that the accumulation of uremic toxins modulates glucose metabolism and induced insulin resistance in CKD and DKD patients. Considering HbA1c as a reflection of chronic hyperglycemia and UCPCR as a reflection of chronic hyperinsulinemia, our findings indicate that PS is negatively associated with hyperglycemia independent of CKD, and positively associated with hyperinsulinemia in DKD patients.
en-copyright=
kn-copyright=

en-aut-name=TonguYoshiyasu
en-aut-sei=Tongu
en-aut-mei=Yoshiyasu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KasaharaTomoko
en-aut-sei=Kasahara
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=AkiyamaYasutoshi
en-aut-sei=Akiyama
en-aut-mei=Yasutoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SuzukiTakehiro
en-aut-sei=Suzuki
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HoHsin-Jung
en-aut-sei=Ho
en-aut-mei=Hsin-Jung
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MatsumotoYotaro
en-aut-sei=Matsumoto
en-aut-mei=Yotaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KujiraiRyota
en-aut-sei=Kujirai
en-aut-mei=Ryota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KikuchiKoichi
en-aut-sei=Kikuchi
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=NataKoji
en-aut-sei=Nata
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KanzakiMakoto
en-aut-sei=Kanzaki
en-aut-mei=Makoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=SuzukiKenshin
en-aut-sei=Suzuki
en-aut-mei=Kenshin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=WatanabeShun
en-aut-sei=Watanabe
en-aut-mei=Shun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=KawabeChiharu
en-aut-sei=Kawabe
en-aut-mei=Chiharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=MiyataYui
en-aut-sei=Miyata
en-aut-mei=Yui
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=ItaiShun
en-aut-sei=Itai
en-aut-mei=Shun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=ToyoharaTakafumi
en-aut-sei=Toyohara
en-aut-mei=Takafumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=SuzukiChitose
en-aut-sei=Suzuki
en-aut-mei=Chitose
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=TanakaTetsuhiro
en-aut-sei=Tanaka
en-aut-mei=Tetsuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=WadaJun
en-aut-sei=Wada
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=TomiokaYoshihisa
en-aut-sei=Tomioka
en-aut-mei=Yoshihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=AbeTakaaki
en-aut-sei=Abe
en-aut-mei=Takaaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

affil-num=1
en-affil=Tohoku University School of Medicine
kn-affil=

affil-num=2
en-affil=Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=3
en-affil=Laboratory of Oncology, Pharmacy Practice and Sciences, Tohoku University Graduate School of Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=5
en-affil=Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=6
en-affil=Laboratory of Oncology, Pharmacy Practice and Sciences, Tohoku University Graduate School of Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Laboratory of Oncology, Pharmacy Practice and Sciences, Tohoku University Graduate School of Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=9
en-affil=Department of Medical Biochemistry, School of Pharmacy, Iwate Medical University
kn-affil=

affil-num=10
en-affil=Department of Biomedical Engineering, Tohoku University
kn-affil=

affil-num=11
en-affil=Tohoku University School of Medicine
kn-affil=

affil-num=12
en-affil=Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=13
en-affil=Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=14
en-affil=Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=15
en-affil=Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=16
en-affil=Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=17
en-affil=Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=18
en-affil=Division of Nephrology, Endocrinology, and Vascular Medicine, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=19
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=20
en-affil=Laboratory of Oncology, Pharmacy Practice and Sciences, Tohoku University Graduate School of Pharmaceutical Sciences
kn-affil=

affil-num=21
en-affil=Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine
kn-affil=
en-keyword=CKD, DKD, Phenyl sulfate, Uremic toxin, Insulin secretion, Insulin resistance, Gut microbiota
kn-keyword=CKD, DKD, Phenyl sulfate, Uremic toxin, Insulin secretion, Insulin resistance, Gut microbiota
END

start-ver=1.4
cd-journal=joma
no-vol=16
cd-vols=
no-issue=
article-no=
start-page=1568338
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250807
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A pilot transcriptomic study of a novel multitargeted BRT regimen for anti?MDA5 antibody-positive dermatomyositis: improving survival over conventional therapy
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis (MDA5-DM) is associated with severe outcomes, primarily due to rapidly progressive interstitial lung disease (RP-ILD), which is often refractory to standard therapies such as calcineurin inhibitors (e.g., tacrolimus) combined with cyclophosphamide (TC-Tx). This study evaluated the efficacy of a novel multitargeted regimen combining baricitinib, rituximab, and tacrolimus (BRT-Tx) in improving survival outcomes for MDA5-DM patients with poor prognostic factors.<br>
Methods: Fourteen MDA5-DM patients with multiple adverse prognostic factors were studied. Seven received the BRT-Tx regimen, and the remaining seven, previously treated with TC-Tx, served as historical controls. Twelve-month survival was assessed. Transcriptome analysis was performed for six patients (BRT=3, TC=3), beginning with cluster analysis to evaluate whether changes in peripheral blood gene expression varied according to treatment or prognosis. Gene ontology analysis characterized expression profiles in survivors and distinguished treatment effects. Alterations in the type I, II, and III interferon signatures were also assessed.<br>
Results: In the TC-Tx group, four of seven patients succumbed to RP-ILD, whereas all seven BRT-Tx patients survived the 12-month observation period. Only one BRT-Tx patient required combined rescue therapies, including plasma exchange, and one case of unexplained limbic encephalitis (LE) occurred. Cytomegalovirus reactivation was observed in both groups (BRT: 5/7; TC: 6/7). Transcriptomic analysis revealed no treatment-specific clustering of differentially expressed genes (DEGs) before and after therapy. However, survivors and nonsurvivors formed distinct clusters, with survivors showing significant posttreatment suppression of B-cell-related gene expression. Moreover, interferon signature scores were significantly lower after treatment in survivors than in nonsurvivors. BRT-Tx effectively suppressed B-cell-mediated immune responses and maintained a low interferon signature, while TC-Tx resulted in nonspecific gene suppression, and in nonsurvivors, an elevated interferon signature was observed.<br>
Conclusion: BRT-Tx has the potential to improve survival in MDA5-DM patients by effectively targeting hyperactive immune pathways. The combination of rituximab and tacrolimus is expected to disrupt B-cell?T-cell interactions and reduce autoantibody production, whereas baricitinib may suppress both IFN and GM-CSF signaling, regulating excessive autoimmunity mediated by cells such as macrophages. Unlike TC-Tx, BRT-Tx avoids cyclophosphamide-associated risks such as infertility and secondary malignancies. Future randomized controlled trials are warranted to validate its efficacy and safety.
en-copyright=
kn-copyright=

en-aut-name=TokunagaMoe
en-aut-sei=Tokunaga
en-aut-mei=Moe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NakaiYu
en-aut-sei=Nakai
en-aut-mei=Yu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SatoYoshiharu
en-aut-sei=Sato
en-aut-mei=Yoshiharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HiratsukaMitori
en-aut-sei=Hiratsuka
en-aut-mei=Mitori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MatsumotoYoshinori
en-aut-sei=Matsumoto
en-aut-mei=Yoshinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NakatsueTakeshi
en-aut-sei=Nakatsue
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=SaekiTakako
en-aut-sei=Saeki
en-aut-mei=Takako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=UmayaharaTakatsune
en-aut-sei=Umayahara
en-aut-mei=Takatsune
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=WadaJun
en-aut-sei=Wada
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KoyamaYoshinobu
en-aut-sei=Koyama
en-aut-mei=Yoshinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Division of Rheumatology, Center for Autoimmune Diseases, Japanese Red Cross Okayama Hospital
kn-affil=

affil-num=3
en-affil=DNA Chip Research Inc., Medical Laboratory
kn-affil=

affil-num=4
en-affil=DNA Chip Research Inc., Medical Laboratory
kn-affil=

affil-num=5
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Division of Rheumatology and Nephrology, Department of Internal Medicine, Nagaoka Red Cross Hospital
kn-affil=

affil-num=7
en-affil=Division of Rheumatology and Nephrology, Department of Internal Medicine, Nagaoka Red Cross Hospital
kn-affil=

affil-num=8
en-affil=Division of Dermatology, Center for Autoimmune Diseases, Japanese Red Cross Okayama Hospital
kn-affil=

affil-num=9
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Division of Rheumatology, Center for Autoimmune Diseases, Japanese Red Cross Okayama Hospital
kn-affil=
en-keyword=anti-MDA5 antibody-positive dermatomyositis (MDA5-DM)
kn-keyword=anti-MDA5 antibody-positive dermatomyositis (MDA5-DM)
en-keyword=JAK inhibitor
kn-keyword=JAK inhibitor
en-keyword=baricitinib
kn-keyword=baricitinib
en-keyword=rituximab
kn-keyword=rituximab
en-keyword=multitargeted treatment
kn-keyword=multitargeted treatment
en-keyword=IFN signature
kn-keyword=IFN signature
en-keyword=transcriptome analysis
kn-keyword=transcriptome analysis
END

start-ver=1.4
cd-journal=joma
no-vol=14
cd-vols=
no-issue=1
article-no=
start-page=27481
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241111
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Association between proteinuria and mineral metabolism disorders in chronic kidney disease: the Japan chronic kidney disease database extension (J-CKD-DB-Ex)
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Chronic kidney disease-mineral and bone disorder (CKD-MBD) are recognized as a systemic disease affecting the prognosis of patients with CKD. Proper management of CKD-MBD is important to improve the prognosis of patients with CKD. Although proteinuria is recognized as a poor prognostic factor in these patients, few reports have examined its association with CKD-MBD. We examined the association between proteinuria and CKD-MBD using data from the Japan Chronic Kidney Disease Database Extension (J-CKD-DB-Ex). Among the patients registered in the J-CKD-DB-Ex, 30,977 with CKD stages G2?G5 who had serum creatinine, albumin, calcium, and phosphate concentrations measured at least once and urinalysis performed were included. The patients were divided into four groups (negative, 1+, 2+, and 3+) according to the degree of proteinuria. The association between proteinuria and CKD-MBD was examined by a logistic regression analysis. In a model adjusted for age, sex, diabetes, and the estimated glomerular filtration rate (eGFR), the odds ratio of the 3?+?group compared with the negative group significantly increased to 2.67 (95% confidence interval, 2.29?3.13) for hyperphosphatemia, 2.68 (1.94?3.71) for hypocalcemia, and 1.56 (1.24?1.98) for hypomagnesemia. Proteinuria is associated with hyperphosphatemia, hypocalcemia, and hypomagnesemia in patients with CKD independently of eGFR.
en-copyright=
kn-copyright=

en-aut-name=ShimamotoSho
en-aut-sei=Shimamoto
en-aut-mei=Sho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NakaharaTakako
en-aut-sei=Nakahara
en-aut-mei=Takako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YamadaShunsuke
en-aut-sei=Yamada
en-aut-mei=Shunsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NagasuHajime
en-aut-sei=Nagasu
en-aut-mei=Hajime
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KishiSeiji
en-aut-sei=Kishi
en-aut-mei=Seiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NakashimaNaoki
en-aut-sei=Nakashima
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TsuruyaKazuhiko
en-aut-sei=Tsuruya
en-aut-mei=Kazuhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OkadaHirokazu
en-aut-sei=Okada
en-aut-mei=Hirokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TamuraKouichi
en-aut-sei=Tamura
en-aut-mei=Kouichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NaritaIchiei
en-aut-sei=Narita
en-aut-mei=Ichiei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=MaruyamaShoichi
en-aut-sei=Maruyama
en-aut-mei=Shoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=YanoYuichiro
en-aut-sei=Yano
en-aut-mei=Yuichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=YokooTakashi
en-aut-sei=Yokoo
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=WadaTakashi
en-aut-sei=Wada
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=WadaJun
en-aut-sei=Wada
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=KandaEiichiro
en-aut-sei=Kanda
en-aut-mei=Eiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=KataokaHiromi
en-aut-sei=Kataoka
en-aut-mei=Hiromi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=NangakuMasaomi
en-aut-sei=Nangaku
en-aut-mei=Masaomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=KashiharaNaoki
en-aut-sei=Kashihara
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=NakanoToshiaki
en-aut-sei=Nakano
en-aut-mei=Toshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

affil-num=1
en-affil=Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University
kn-affil=

affil-num=2
en-affil=Department of Medical Technology, Faculty of Health Science and Technology, Kawasaki University of Medical Welfare
kn-affil=

affil-num=3
en-affil=Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University
kn-affil=

affil-num=4
en-affil=Department of Nephrology and Hypertension, Kawasaki Medical School
kn-affil=

affil-num=5
en-affil=Department of Nephrology and Hypertension, Kawasaki Medical School
kn-affil=

affil-num=6
en-affil=Department of Medical Informatics, Graduate School of Medical Science, Kyushu University
kn-affil=

affil-num=7
en-affil=Department of Nephrology, Nara Medical University
kn-affil=

affil-num=8
en-affil=Department of Nephrology, Faculty of Medicine, Saitama Medical University
kn-affil=

affil-num=9
en-affil=Department of Medical Science and Cardiorenal Medicine, Graduate School of Medicine, Yokohama City University
kn-affil=

affil-num=10
en-affil=Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences
kn-affil=

affil-num=11
en-affil=Department of Nephrology, Nagoya University Graduate School of Medicine
kn-affil=

affil-num=12
en-affil=Department of General Medicine, Juntendo University Faculty of Medicine
kn-affil=

affil-num=13
en-affil=Division of Kidney and Hypertension, Department of Internal Medicine, Jikei University School of Medicine
kn-affil=

affil-num=14
en-affil=Department of Nephrology and Rheumatology, Kanazawa University
kn-affil=

affil-num=15
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
kn-affil=

affil-num=16
en-affil=Department of Health Data Science, Kawasaki Medical School
kn-affil=

affil-num=17
en-affil=Department of Medical Technology, Faculty of Health Science and Technology, Kawasaki University of Medical Welfare
kn-affil=

affil-num=18
en-affil=Division of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine
kn-affil=

affil-num=19
en-affil=Department of Nephrology and Hypertension, Kawasaki Medical School
kn-affil=

affil-num=20
en-affil=Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University
kn-affil=
en-keyword=CKD-MBD
kn-keyword=CKD-MBD
en-keyword=Proteinuria
kn-keyword=Proteinuria
en-keyword=Hyperphosphatemia
kn-keyword=Hyperphosphatemia
en-keyword=Hypocalcemia
kn-keyword=Hypocalcemia
en-keyword=Hypomagnesemia
kn-keyword=Hypomagnesemia
en-keyword=J-CKD-DB-Ex
kn-keyword=J-CKD-DB-Ex
END